<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Kaletra, INN-lopinavir, ritonavir</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
@font-face
	{font-family:Goudy;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Garamond-Italic;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:DIN-Bold;}
@font-face
	{font-family:"CG Times \(W1\)";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"HelveticaNeue Condensed";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@HGMaruGothicMPRO";}
@font-face
	{font-family:CourierStd;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EFPPNA+TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@TimesNewRoman";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-name:"Heading 1\,D70AR\,Info rubrik 1\,titel 1";
	mso-style-link:"Heading 1 Char\,D70AR Char\,Info rubrik 1 Char\,titel 1 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h2
	{margin-top:0in;
	margin-right:63.7pt;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-31.3pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:center;
	line-height:12.0pt;
	page-break-after:avoid;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:30.0pt;
	text-indent:-30.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
h5
	{mso-style-name:"Heading 5\,DO NOT USE";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	text-decoration:underline;}
h6
	{margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{margin:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:24.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:48.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:84.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:96.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.5in;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:24.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:48.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:84.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:96.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	text-indent:-12.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	line-height:12.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:27.0pt;
	text-indent:-9.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{margin:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-align:justify;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	background:navy;
	font-size:10.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS",sans-serif;}
address
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{margin:0in;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char\,D70AR Char\,Info rubrik 1 Char\,titel 1 Char";
	mso-style-link:"Heading 1\,D70AR\,Info rubrik 1\,titel 1";
	font-weight:bold;}
p.EMEANormal, li.EMEANormal, div.EMEANormal
	{mso-style-name:"EMEA Normal";
	mso-style-link:"EMEA Normal Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.EMEANormalChar
	{mso-style-name:"EMEA Normal Char";
	mso-style-link:"EMEA Normal";}
p.EMEATitle, li.EMEATitle, div.EMEATitle
	{mso-style-name:"EMEA Title";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading1, li.EMEAHeading1, div.EMEAHeading1
	{mso-style-name:"EMEA Heading 1";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading1Para1, li.EMEAHeading1Para1, div.EMEAHeading1Para1
	{mso-style-name:"EMEA Heading 1 Para 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeading2SPC, li.EMEAHeading2SPC, div.EMEAHeading2SPC
	{mso-style-name:"EMEA Heading 2 SPC";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.EMEAHeading2SPCEmpty, li.EMEAHeading2SPCEmpty, div.EMEAHeading2SPCEmpty
	{mso-style-name:"EMEA Heading 2 SPC Empty";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.EMEAHeadingUI, li.EMEAHeadingUI, div.EMEAHeadingUI
	{mso-style-name:"EMEA Heading UI";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;
	text-decoration:underline;}
p.EMEAHeadingItalic, li.EMEAHeadingItalic, div.EMEAHeadingItalic
	{mso-style-name:"EMEA Heading Italic";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.EMEAHeadingUnderline, li.EMEAHeadingUnderline, div.EMEAHeadingUnderline
	{mso-style-name:"EMEA Heading Underline";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-decoration:underline;}
p.EMEABullet, li.EMEABullet, div.EMEABullet
	{mso-style-name:"EMEA Bullet";
	mso-style-link:"EMEA Bullet Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.45pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.EMEABulletChar
	{mso-style-name:"EMEA Bullet Char";
	mso-style-link:"EMEA Bullet";}
p.Considrant, li.Considrant, div.Considrant
	{mso-style-name:Considrant;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-align:justify;
	text-indent:-35.45pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAHeadingLeaflet, li.EMEAHeadingLeaflet, div.EMEAHeadingLeaflet
	{mso-style-name:"EMEA Heading Leaflet";
	margin-top:5.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
p.EMEAHeadingBoxedEmpty, li.EMEAHeadingBoxedEmpty, div.EMEAHeadingBoxedEmpty
	{mso-style-name:"EMEA Heading Boxed Empty";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.1pt;
	text-indent:-28.1pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeadingBoxed, li.EMEAHeadingBoxed, div.EMEAHeadingBoxed
	{mso-style-name:"EMEA Heading Boxed";
	margin-top:10.0pt;
	margin-right:0in;
	margin-bottom:5.0pt;
	margin-left:28.1pt;
	text-indent:-28.1pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAHeadingBoxedTitle, li.EMEAHeadingBoxedTitle, div.EMEAHeadingBoxedTitle
	{mso-style-name:"EMEA Heading Boxed Title";
	margin-top:24.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.EMEAFooter, li.EMEAFooter, div.EMEAFooter
	{mso-style-name:"EMEA Footer";
	margin:0in;
	text-align:center;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.EMEAHint, li.EMEAHint, div.EMEAHint
	{mso-style-name:"EMEA Hint";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.EMEAFigureTitle, li.EMEAFigureTitle, div.EMEAFigureTitle
	{mso-style-name:"EMEA Figure Title";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Corpsdetex, li.Corpsdetex, div.Corpsdetex
	{mso-style-name:"Corps de tex";
	margin:0in;
	font-size:11.0pt;
	font-family:"Book Antiqua",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.underline1
	{mso-style-name:underline1;
	text-decoration:underline;}
p.EMEABullet2, li.EMEABullet2, div.EMEABullet2
	{mso-style-name:"EMEA Bullet 2";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.Fill-In
	{mso-style-name:Fill-In;
	color:fuchsia;}
p.Institutionquisigne, li.Institutionquisigne, div.Institutionquisigne
	{mso-style-name:"Institution qui signe";
	margin-top:.5in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	text-align:justify;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.BMCENTRED, li.BMCENTRED, div.BMCENTRED
	{mso-style-name:"BM CENTRED";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.BMLeftAligned, li.BMLeftAligned, div.BMLeftAligned
	{mso-style-name:"BM Left Aligned";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HeaderText, li.HeaderText, div.HeaderText
	{mso-style-name:HeaderText;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.BodyText1, li.BodyText1, div.BodyText1
	{mso-style-name:"Body Text1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:57.55pt;
	text-align:justify;
	line-height:120%;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Reporttext, li.Reporttext, div.Reporttext
	{mso-style-name:"Report text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:.2in;
	margin-left:57.55pt;
	text-align:justify;
	line-height:120%;
	punctuation-wrap:simple;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.a, li.a, div.a
	{mso-style-name:_;
	margin:0in;
	font-size:12.0pt;
	font-family:Roman;}
p.pedtablecenter, li.pedtablecenter, div.pedtablecenter
	{mso-style-name:pedtablecenter;
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.pedtable, li.pedtable, div.pedtable
	{mso-style-name:pedtable;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Style6, li.Style6, div.Style6
	{mso-style-name:Style6;
	margin:0in;
	text-autospace:none;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.times, li.times, div.times
	{mso-style-name:times;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.tableentry, li.tableentry, div.tableentry
	{mso-style-name:"table entry";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman Bold",serif;
	font-weight:bold;}
span.bold1
	{mso-style-name:bold1;
	font-weight:bold;}
span.sub1
	{mso-style-name:sub1;}
span.sup1
	{mso-style-name:sup1;}
span.italics1
	{mso-style-name:italics1;
	font-style:italic;}
p.EMEABodyText, li.EMEABodyText, div.EMEABodyText
	{mso-style-name:"EMEA Body Text";
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"EFPPNA+TimesNewRoman",serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:70.8pt;
	margin-bottom:0in;
	margin-left:85.0pt;
	text-indent:-28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.msoins0
	{mso-style-name:msoins;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
p.EMEANormal1, li.EMEANormal1, div.EMEANormal1
	{mso-style-name:"EMEA Normal1";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TableParagraph, li.TableParagraph, div.TableParagraph
	{mso-style-name:"Table Paragraph";
	margin:0in;
	font-size:11.0pt;
	font-family:"Calibri",sans-serif;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
p.EMEANormal7, li.EMEANormal7, div.EMEANormal7
	{mso-style-name:"EMEA Normal7";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:595.3pt 841.9pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX
I</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=BMCENTRED><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span>

<p class=EMEAHeading1Para1 style='margin-bottom:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. Name of the medicinal
product </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra
(80&nbsp;mg&nbsp;+&nbsp;20&nbsp;mg)&nbsp;/&nbsp;ml oral solution</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>2. Qualitative and quantitative composition </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each 1&nbsp;ml of Kaletra oral solution
contains 80&nbsp;mg of lopinavir co-formulated with 20&nbsp;mg of ritonavir as
a pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><s><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=EMEANormal><u><span lang=EN-GB>Excipients with known effect:</span></u></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each 1&nbsp;ml contains 356.3&nbsp;mg of
alcohol (42.4% v/v), 168.6&nbsp;mg of high fructose corn syrup, 152.7&nbsp;mg
of propylene glycol (15.3% w/v) (see section 4.3), 10.2&nbsp;mg of polyoxyl 40
hydrogenated castor oil and 4.1&nbsp;mg of acesulfame potassium (see section
4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>For the full list of excipients, see
section 6.1. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>3. Pharmaceutical Form<i> </i></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral solution</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The solution is light yellow to orange.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4. Clinical Particulars</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.1 Therapeutic indications</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra is indicated in combination with
other antiretroviral medicinal products for the treatment of human
immunodeficiency virus (HIV-1) infected adults, adolescents and children aged
from 14 days and older.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The choice of Kaletra to treat protease
inhibitor experienced HIV-1 infected patients should be based on individual
viral resistance testing and treatment history of patients (see sections 4.4
and 5.1).</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.2 Posology and method of administration</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra should be prescribed by physicians
who are experienced in the treatment of HIV infection.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEANormal><i><span lang=EN-GB><br>
Adults and adolescents</span></i><span lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>The recommended dosage of Kaletra is
5&nbsp;ml of oral solution (400/100&nbsp;mg) twice daily taken with food.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Paediatric population aged from 14 days
and older</span></i><span lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>The oral solution formulation is the
recommended option for the most accurate dosing in children based on body
surface area or body weight. </span>However, if it is judged necessary to
resort to solid oral dosage form for children weighing less than 40&nbsp;kg or
with a BSA between 0.5 and 1.4&nbsp;m<sup>2 </sup>and able to swallow tablets,
Kaletra 100&nbsp;mg/25&nbsp;mg tablets may be used. The adult dose of Kaletra
tablets (400/100&nbsp;mg twice daily) may be used in children 40&nbsp;kg or
greater or with a Body Surface Area (BSA)* greater than 1.4&nbsp;m<sup>2</sup>.
Kaletra tablets are administered orally and must be swallowed whole and not
chewed, broken or crushed. Please refer to the Kaletra 100&nbsp;mg/25&nbsp;mg
film-coated tablets Summary of Product Characteristics.</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>Total amounts of alcohol and propylene glycol from all
medicines, including Kaletra oral solution, that are to be given to infants
should be taken into account in order to avoid toxicity from these excipients
(see section 4.4).</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal><i>Dosage recommendation for paediatric patients aged from
14 days to 6 months</i></p>

<p class=EMEANormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:12.5pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=508 colspan=3 valign=top style='width:381.05pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b>Paediatric
  dosing guidelines</b></p>
  <p class=EMEANormal align=center style='text-align:center'><b>2 weeks to 6
  months</b></p>
  </td>
 </tr>
 <tr>
  <td width=187 valign=top style='width:140.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b>Based on weight</b></p>
  <p class=EMEANormal align=center style='text-align:center'><b>(mg/kg)</b></p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b>Based on BSA
  (mg/m<sup>2</sup>)*</b></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b>Frequency</b></p>
  </td>
 </tr>
 <tr style='height:25.8pt'>
  <td width=187 valign=top style='width:140.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.8pt'>
  <p class=EMEANormal align=center style='text-align:center'>16/4 mg/kg</p>
  <p class=EMEANormal align=center style='text-align:center'>(corresponding to
  0.2 ml/kg)</p>
  </td>
  <td width=198 valign=top style='width:148.8pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.8pt'>
  <p class=EMEANormal align=center style='text-align:center'>300/75 mg/m<sup>2</sup></p>
  <p class=EMEANormal align=center style='text-align:center'>(corresponding to
  3.75 ml/m<sup>2</sup>)</p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.8pt'>
  <p class=EMEANormal>Given twice daily with food</p>
  </td>
 </tr>
</table>

<p class=EMEANormal style='margin-left:7.1pt'><span lang=EN-GB>*Body surface
area can be calculated with the following equation</span></p>

<p class=EMEANormal style='margin-left:7.1pt'><span lang=EN-GB>BSA (m<sup>2</sup>)
= </span><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>
(Height (cm) X Weight (kg) / 3600)</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>It is recommended that Kaletra not be administered in
combination with efavirenz or nevirapine in patients less than 6&nbsp;months of
age.</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal><i>Dosage recommendation for paediatric patients older than
6 months to less than 18 years</i></p>

<p class=EMEANormal><i>&nbsp;</i></p>

<p class=EMEANormal><u>Without Concomitant Efavirenz or Nevirapine</u></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal>The following tables contain dosing guidelines for Kaletra
oral solution based on body weight and BSA.</p>

<p class=EMEANormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=536 colspan=3 valign=top style='width:402.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB>Paediatric
  dosing guidelines based on body weight*<br>
  &gt;&nbsp;6 months to 18 years</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB>Body
  weight (kg)</span></b></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB>Twice
  daily oral solution dose <br>
  (dose in mg/kg)</span></b></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;text-align:center'><b><span
  lang=EN-GB>Volume of oral solution twice daily taken with food</span></b></p>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB>(80
  mg lopinavir/20 mg ritonavir per ml)**</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><span lang=EN-GB>7 to &lt; 15 kg</span></b></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>7
  to 10 kg</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&gt;
  10 to&nbsp;&lt; 15 kg</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>12/3
  mg/kg</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>1.25
  ml</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>1.75
  ml</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><span lang=EN-GB>&#8805;&nbsp;15 to 40 kg</span></b></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>15
  to 20 kg</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&gt;&nbsp;20
  to 25 kg</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&gt;&nbsp;25
  to 30 kg</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&gt;&nbsp;30
  to 35 kg</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&gt;&nbsp;35
  to 40 kg</span></p>
  </td>
  <td width=217 valign=top style='width:163.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>10/2.5&nbsp;mg/kg</span></p>
  </td>
  <td width=189 valign=top style='width:141.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>2.25
  ml</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>2.75
  ml</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>3.50
  ml</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>4.00
  ml</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>4.75
  ml</span></p>
  </td>
 </tr>
 <tr>
  <td width=130 valign=top style='width:97.6pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><span lang=EN-GB>&#8805;&nbsp;40 kg</span></b></p>
  </td>
  <td width=406 colspan=2 valign=top style='width:304.75pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>See
  adult dosage recommendation</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal> <span lang=EN-GB>*weight based dosing
recommendations are based on limited data </span></p>

<p class=EMEANormal><span lang=EN-GB> ** the volume (ml) of oral
solution represents the average dose for the weight range</span></p>

<p class=EMEANormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=487 colspan=2 valign=top style='width:365.4pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Paediatric dosing guidelines for the dose 230/57.5&nbsp;mg/m<sup>2<br>
  </sup>&gt;&nbsp;6 months to &lt;&nbsp;18 years</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Body Surface Area* (m<sup>2</sup>)</span></b></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Twice daily oral solution dose (dose in mg)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.25</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.7&nbsp;ml (57.5/14.4&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.40</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.2&nbsp;ml (96/24&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.50</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.4&nbsp;ml
  (115/28.8&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.75</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>2.2&nbsp;ml
  (172.5/43.1&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>0.80</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>2.3&nbsp;ml (184/46&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.00</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>2.9&nbsp;ml
  (230/57.5&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.25</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>3.6&nbsp;ml
  (287.5/71.9&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.3</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>3.7&nbsp;ml
  (299/74.8&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.4</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>4.0&nbsp;ml
  (322/80.5&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.5</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>4.3&nbsp;ml
  (345/86.3&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=191 valign=top style='width:143.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>1.7</span></p>
  </td>
  <td width=296 valign=top style='width:222.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>5&nbsp;ml (402.5/100.6&nbsp;mg)</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB> *Body surface area can be
calculated with the following equation</span></p>

<p class=EMEANormal><span lang=EN-GB> BSA (m<sup>2</sup>) = </span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> (Height (cm) X
Weight (kg) / 3600)</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Concomitant Therapy: Efavirenz or
Nevirapine</span></u></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><span lang=EN-GB>The 230/57.5&nbsp;mg/m<sup>2</sup> dosage
might be insufficient in some children when co&#8209;administered with
nevirapine or efavirenz. An increase of the dose of Kaletra to
300/75&nbsp;mg/m<sup>2</sup> is needed in these patients. The recommended dose
of 533/133&nbsp;mg or 6.5&nbsp;ml twice daily should not be exceeded.</span></p>

<p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=EMEANormal><i><span lang=EN-GB>Children less than 14 days of age and
premature neonates</span></i><span lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra oral solution should not be
administered to neonates before a postmenstrual age (first day of the mothers
last menstrual period to birth plus the time elapsed after birth) of 42 weeks
and a postnatal age of at least 14&nbsp;days has been reached (see section
4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Hepatic impairment</span></i><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>In HIV-infected patients with mild to
moderate hepatic impairment, an increase of approximately 30% in lopinavir
exposure has been observed but is not expected to be of clinical relevance (see
section 5.2). No data are available in patients with severe hepatic
impairment. Kaletra must not be given to these patients (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Renal impairment</span></i><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>Since the renal clearance of lopinavir and
ritonavir is negligible, increased plasma concentrations are not expected in
patients with renal impairment. Because lopinavir and ritonavir are highly
protein bound, it is unlikely that they will be significantly removed by
haemodialysis or peritoneal dialysis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra is administered orally and should
always be taken with food (see section 5.2). The dose should be administered
using a calibrated 2&nbsp;ml or 5&nbsp;ml oral dosing syringe best
corresponding to the volume prescribed.</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.3 Contraindications</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Hypersensitivity
to the active substances or to any of the excipients listed in section 6.1. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Severe hepatic insufficiency.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains lopinavir and ritonavir,
both of which are inhibitors of the P450 isoform CYP3A. Kaletra should not be
co-administered with medicinal products that are highly dependent on CYP3A for
clearance and for which elevated plasma concentrations are associated with
serious and/or life threatening events. These medicinal products include:</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=613
 style='width:459.6pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Medicinal
  product class</span></b></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Medicinal
  products within class</span></b></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Rationale</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=613 colspan=3 valign=top style='width:459.6pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>Concomitant
  medicinal product levels increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alpha<sub>1</sub>-adrenoreceptor
  antagonist</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alfuzosin</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of alfuzosin which may lead to severe hypotension. The
  concomitant administration with alfuzosin is contraindicated (see section
  4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antianginal</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX style='font-size:11.0pt'>Ranolazine</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of ranolazine which may increase the potential for serious
  and/or life-threatening reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antiarrhythmics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX style='font-size:11.0pt'>Amiodarone,
  dronedarone</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of amiodarone and dronedarone. Thereby, increasing the risk
  of arrhythmias or other serious adverse reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antibiotic</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fusidic Acid</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of fusidic acid. The concomitant administration with fusidic
  acid is contraindicated in dermatological infections (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 rowspan=2 valign=top style='width:111.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anticancer</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neratinib</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of neratinib which may increase the potential for serious
  and/or life&#8209;threatening reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Venetoclax</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of venetoclax. Increased risk of tumor lysis syndrome at the
  dose initiation and during the ramp-up phase (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anti-gout</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Colchicine</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of colchicine. Potential for serious and/or life-threatening
  reactions in patients with renal and/or hepatic impairment (see sections 4.4
  and 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antihistamines</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Astemizole,
  terfenadine</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of astemizole and terfenadine. Thereby, increasing the risk
  of serious arrhythmias from these agents (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 rowspan=3 valign=top style='width:111.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antipsychotics/
  Neuroleptics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lurasidone</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of lurasidone which may increase the potential for serious
  and/or life-threatening reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pimozide</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of pimozide. Thereby, increasing the risk of serious
  haematologic abnormalities, or other serious adverse effects from this agent
  (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Quetiapine</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of quetiapine which may lead to coma. The concomitant
  administration with quetiapine is contraindicated (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ergot alkaloids</span></p>
  <p class=MsoNormal align=right style='text-align:right'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dihydroergotamine,
  ergonovine, ergotamine, methylergonovine</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of ergot derivatives leading to acute ergot toxicity,
  including vasospasm and ischaemia (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>GI motility
  agent</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cisapride</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of cisapride. Thereby, increasing the risk of serious arrhythmias
  from this agent (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 rowspan=2 valign=top style='width:111.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hepatitis C
  virus direct acting antivirals</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Elbasvir/grazoprevir</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased risk
  of alanine transaminase (ALT) elevations (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ombitasvir/paritaprevir/ritonavir
  with or without dasabuvir</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of paritaprevir; thereby, increasing the risk of alanine
  transaminase (ALT) elevations (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=356 colspan=2 valign=top style='width:267.35pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lipid-modifying
  agents</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>HMG Co-A
  Reductase Inhibitors</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lovastatin,
  simvastatin</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of lovastatin and simvastatin; thereby, increasing the risk of
  myopathy including rhabdomyolysis (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Microsomal
  triglyceride transfer protein (MTTP) inhibitor</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lomitapide</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of lomitapide (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 rowspan=3 valign=top style='width:111.75pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Phosphodiesterase
  (PDE5) inhibitors</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Avanafil</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of avanafil (see sections 4.4 and 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sildenafil</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Contraindicated
  when used for the treatment of pulmonary arterial hypertension (PAH) only.
  Increased plasma concentrations of sildenafil. Thereby, increasing the
  potential for sildenafil-associated adverse events (which include hypotension
  and syncope). See section 4.4 and section 4.5 for co&#8209;administration of
  sildenafil in patients with erectile dysfunction.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vardenafil</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of vardenafil (see sections 4.4 and 4.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sedatives/hypnotics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Oral midazolam,
  triazolam</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of oral midazolam and triazolam. Thereby, increasing the risk
  of extreme sedation and respiratory depression from these agents. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For caution on
  parenterally administered midazolam, see section 4.5.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=613 colspan=3 valign=top style='width:459.6pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in;page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>Lopinavir/ritonavir medicinal product level
  decreased</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.75pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Herbal products</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
    style='font-size:11.0pt'>St. Johns</span><span lang=EN-GB
  style='font-size:11.0pt'> wort</span></p>
  </td>
  <td width=256 valign=top style='width:192.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Herbal preparations containing St Johns wort (<i>Hypericum
  perforatum)</i> due to the risk of decreased plasma concentrations and
  reduced clinical effects of lopinavir and ritonavir (see section 4.5).</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra oral solution is contraindicated
in children below the age of 14 days, pregnant women, patients with hepatic or
renal failure and patients treated with disulfiram or metronidazole due to the
potential risk of toxicity from the excipient propylene glycol (see section
4.4).</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.4 Special warnings
and precautions for use </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='text-decoration:none'>Patients with coexisting conditions</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Hepatic
impairment</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The safety
and efficacy of Kaletra has not been established in patients with significant
underlying liver disorders. Kaletra is contraindicated in patients with severe
liver impairment (see section 4.3). Patients with chronic hepatitis B or C and
treated with combination antiretroviral therapy are at an increased risk for
severe and potentially fatal hepatic adverse reactions. In case of concomitant
antiviral therapy for hepatitis B or C, please refer to the relevant product
information for these medicinal products.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Patients with pre-existing liver
dysfunction including chronic hepatitis have an increased frequency of liver
function abnormalities during combination antiretroviral therapy and should be
monitored according to standard practice. If there is evidence of worsening
liver disease in such patients, interruption or discontinuation of treatment
should be considered. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Elevated
transaminases with or without elevated bilirubin levels have been reported in
HIV-1 mono&#8209;infected and in individuals treated for post-exposure
prophylaxis as early as 7 days after the initiation of lopinavir/ritonavir in
conjunction with other antiretroviral agents. In some cases the hepatic
dysfunction was serious.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Appropriate laboratory testing should be
conducted prior to initiating therapy with lopinavir/ritonavir and close
monitoring should be performed during treatment.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Renal impairment</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Since the renal clearance of lopinavir and
ritonavir is negligible, increased plasma concentrations are not expected in
patients with renal impairment. Because lopinavir and ritonavir are highly
protein bound, it is unlikely that they will be significantly removed by
haemodialysis or peritoneal dialysis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Haemophilia</span></u></p>

<p class=EMEANormal><span lang=EN-GB>There have been reports of increased
bleeding, including spontaneous skin haematomas and haemarthrosis in patients
with haemophilia type A and B treated with protease inhibitors. In some
patients additional factor VIII was given. In more than half of the reported
cases, treatment with protease inhibitors was continued or reintroduced if
treatment had been discontinued. A causal relationship had been evoked,
although the mechanism of action had not been elucidated. Haemophiliac
patients should therefore be made aware of the possibility of increased
bleeding.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Pancreatitis</span></p>

<p class=EMEANormal><span lang=EN-GB>Cases of pancreatitis have been reported
in patients receiving Kaletra, including those who developed
hypertriglyceridaemia. In most of these cases patients have had a prior
history of pancreatitis and/or</span></p>

<p class=EMEANormal><span lang=EN-GB>concurrent therapy with other medicinal
products associated with pancreatitis. Marked triglyceride elevation is a risk
factor for development of pancreatitis. Patients with advanced HIV disease may
be at risk of elevated triglycerides and pancreatitis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Pancreatitis should be considered if
clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in
laboratory values (such as increased serum lipase or amylase values) suggestive
of pancreatitis should occur. Patients who exhibit these signs or symptoms
should be evaluated and Kaletra therapy should be suspended if a diagnosis of
pancreatitis is made (see section 4.8).</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Immune Reconstitution Inflammatory Syndrome</span></p>

<p class=EMEANormal><span lang=EN-GB>In HIV-infected patients with severe
immune deficiency at the time of institution of combination antiretroviral
therapy (CART), an inflammatory reaction to asymtomatic or residual
opportunistic pathogens may arise and cause serious clinical conditions, or
aggravation of symptoms. Typically, such reactions have been observed within
the first few weeks or months of initiation of CART. Relevant examples are
cytomegalovirus retinitis, generalised and/or focal mycobacterial infections,
and <i>Pneumocystis jiroveci pneumonia</i>. Any inflammatory symptoms should
be evaluated and treatment instituted when necessary.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Autoimmune disorders (such as Graves disease <span
lang=EN-GB>and autoimmune hepatitis</span>) have also been reported to occur in
the setting of immune reconstitution; however, the reported time to onset is
more variable and can occur many months after initiation of treatment.</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Osteonecrosis</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Although the etiology is considered to be
multifactorial (including corticosteroid use, alcohol consumption, severe
immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV&#8209;disease and/or long&#8209;term
exposure to combination antiretroviral therapy (CART). Patients should be
advised to seek medical advice if they experience joint aches and pain, joint
stiffness or difficulty in movement.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-style:normal'>PR interval prolongation </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir/ritonavir
has been shown to cause modest asymptomatic prolongation of the PR interval in
some healthy adult subjects. Rare reports of 2<sup>nd</sup> or 3<sup>rd</sup>
degree atroventricular block in patients with underlying structural heart
disease and pre-existing conduction system abnormalities or in patients
receiving drugs known to prolong the PR interval (such as verapamil or
atazanavir) have been reported in patients receiving lopinavir/ritonavir.
Kaletra should be used with caution in such patients (see section 5.1).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Weight and metabolic parameters</span></u></p>

<p class=EMEANormal><span lang=EN-GB>An increase in weight and in levels of
blood lipids and glucose may occur during antiretroviral therapy. Such changes
may in part be linked to disease control and life style. For lipids, there is
in some cases evidence for a treatment effect, while for weight gain there is
no strong evidence relating this to any particular treatment. For monitoring
of blood lipids and glucose, reference is made to established HIV treatment
guidelines. Lipid disorders should be managed as clinically appropriate.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-style:normal'>Interactions with medicinal products</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
contains lopinavir and ritonavir, both of which are inhibitors of the P450
isoform CYP3A. Kaletra is likely to increase plasma concentrations of
medicinal products that are primarily metabolised by CYP3A. These increases of
plasma concentrations of co-administered medicinal products could increase or
prolong their therapeutic effect and adverse events (see sections 4.3 and 4.5).
</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Strong CYP3A4 inhibitors such as protease
inhibitors may increase bedaquiline exposure which could potentially increase
the risk of bedaquiline&#8209;related adverse reactions. Therefore,
combination of bedaquiline with lopinavir/ritonavir should be avoided. However,
if the benefit outweighs the risk, co&#8209;administration of bedaquiline with
lopinavir/ritonavir must be done with caution. More frequent electrocardiogram
monitoring and monitoring of transaminases is recommended (see section 4.5 and
refer to the bedaquiline SmPC).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of delamanid with
a strong inhibitor of CYP3A (as lopinavir/ritonavir) may increase exposure to
delamanid metabolite, which has been associated with QTc prolongation.
Therefore, if co-administration of delamanid with lopinavir/ritonavir is
considered necessary, very frequent ECG monitoring throughout the full
delamanid treatment period is recommended (see section 4.5 and refer to the
delamanid SmPC).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Life-threatening and fatal drug
interactions have been reported in patients treated with colchicine and strong
inhibitors of CYP3A like ritonavir. Concomitant administration with colchicine
is contraindicated in patients with renal and/or hepatic impairment (see
sections 4.3 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The combination of Kaletra with: </span></p>

<p class=EMEANormal style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>- tadalafil, indicated for the treatment of pulmonary
arterial hypertension, is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>- riociguat is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>- vorapaxar is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>- fusidic acid in osteo-articular infections is not
recommended (see section 4.5);</span></p>

<p class=EMEANormal><span lang=EN-GB>- salmeterol is not recommended
(see section 4.5);</span></p>

<p class=EMEANormal><span lang=EN-GB>- rivaroxaban is not recommended
(see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The combination of Kaletra with atorvastatin
is not recommended. If the use of atorvastatin is considered strictly
necessary, the lowest possible dose of atorvastatin should be administered with
careful safety monitoring. Caution must also be exercised and reduced doses
should be considered if Kaletra is used concurrently with rosuvastatin. If
treatment with an HMG-CoA reductase inhibitor is indicated, pravastatin or
fluvastatin is recommended (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>PDE5 inhibitors</span></i><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>Particular caution should be used when
prescribing sildenafil or tadalafil for the treatment of erectile dysfunction
in patients receiving Kaletra. Co-administration of Kaletra with these
medicinal products is expected to substantially increase their concentrations
and may result in associated adverse events such as hypotension, syncope,
visual changes and prolonged erection (see section 4.5). Concomitant use of avanafil
or vardenafil and lopinavir/ritonavir is contraindicated (see section 4.3).
Concomitant use of sildenafil prescribed for the treatment of pulmonary
arterial hypertension with Kaletra is contraindicated (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Particular caution must be used when
prescribing Kaletra and medicinal products known to induce QT interval
prolongation such as: chlorpheniramine, quinidine, erythromycin, clarithromycin.
Indeed, Kaletra could increase concentrations of the co-administered medicinal
products and this may result in an increase of their associated cardiac adverse
reactions. Cardiac events have been reported with Kaletra in preclinical studies;
therefore, the potential cardiac effects of Kaletra cannot be currently ruled
out (see sections 4.8 and 5.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of Kaletra with
rifampicin is not recommended. Rifampicin in combination with Kaletra causes
large decreases in lopinavir concentrations which may in turn significantly
decrease the lopinavir therapeutic effect. Adequate exposure to
lopinavir/ritonavir may be achieved when a higher dose of Kaletra is used but
this is associated with a higher risk of liver and gastrointestinal toxicity.
Therefore, this co&#8209;administration should be avoided unless judged
strictly necessary (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Concomitant use of Kaletra and fluticasone
or other glucocorticoids that are metabolised by CYP3A4, such as budesonide and
triamcinolone, is not recommended unless the potential benefit of treatment
outweighs the risk of systemic corticosteroid effects, including Cushings
syndrome and adrenal suppression (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Other</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Patients taking the oral solution,
particularly those with renal impairment or with decreased ability to
metabolise propylene glycol (e.g. those of Asian origin), should be monitored
for adverse reactions potentially related to propylene glycol toxicity (i.e.
seizures, stupor, tachycardia, hyperosmolarity, lactic acidosis, renal
toxicity, haemolysis) (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra is not a cure for HIV infection or
AIDS. While effective viral suppression with antiretroviral therapy has been
proven to substantially reduce the risk of sexual transmission, a residual risk
cannot be excluded. Precautions to prevent transmission should be taken in
accordance with national guidelines. People taking Kaletra may still develop
infections or other illnesses associated with HIV disease and AIDS.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Besides propylene glycol as described
above, Kaletra oral solution contains alcohol (42%&nbsp;v/v) which<i> </i>is
potentially harmful for those suffering from liver disease, alcoholism,
epilepsy, brain injury or disease as well as for pregnant women and children.
It may modify or increase the effects of other medicines. Kaletra oral
solution contains up to 0.8&nbsp;g of fructose per dose when taken according to
the dosage recommendations. This may be unsuitable in hereditary fructose
intolerance. Kaletra oral solution contains up to 0.3 g of glycerol per dose.
Only at high inadvertent doses, it can cause headache and gastrointestinal
upset. Furthermore, polyoxol 40 hydrogenated castor oil and potassium present
in Kaletra oral solution may cause only at high inadvertent doses
gastrointestinal upset. Patients on a low potassium diet should be cautioned.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u>Particular risk of toxicity in relation to the amount of
alcohol and propylene glycol contained in Kaletra oral solution</u></p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>Healthcare professionals should be aware that Kaletra oral
solution is highly concentrated and contains 42.4% alcohol (v/v) and 15.3%
propylene glycol (w/v). Each 1&nbsp;ml of Kaletra oral solution contains
356.3&nbsp;mg of alcohol and 152.7&nbsp;mg of propylene glycol. </p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>Special attention should be given to accurate calculation
of the dose of Kaletra, transcription of the medication order, dispensing
information and dosing instructions to minimize the risk for medication errors
and overdose. This is especially important for infants and young children. </p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>Total amounts of alcohol and propylene glycol from all
medicines that are to be given to infants should be taken into account in order
to avoid toxicity from these excipients. Infants should be monitored closely
for toxicity related to Kaletra oral solution including: hyperosmolality, with
or without lactic acidosis, renal toxicity, central nervous system (CNS)
depression (including stupor, coma, and apnea), seizures, hypotonia, cardiac
arrhythmias and ECG changes, and hemolysis. Postmarketing life-threatening
cases of cardiac toxicity (including complete atrioventricular (AV) block,
bradycardia, and cardiomyopathy), lactic acidosis, acute renal failure, CNS
depression and respiratory complications leading to death have been reported,
predominantly in preterm neonates receiving Kaletra oral solution (see sections
4.3 and 4.9). </p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal><span lang=EN-GB>Based on the findings in a paediatric
study (observed exposures were approximately 35% AUC<sub>12</sub> and 75% lower
C<sub>min</sub> than in adults), young children from 14 days to 3 months could
have sub-optimal exposure with a potential risk of inadequate virologic
suppression and emergence of resistance (see section 5.2).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Because Kaletra oral solution contains
alcohol, it is not recommended for use with polyurethane feeding tubes due to
potential incompatibility.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.5  Interaction with other medicinal products and
other forms of interaction </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains lopinavir and ritonavir,
both of which are inhibitors of the P450 isoform CYP3A <i>in&nbsp;vitro</i>.
Co-administration of Kaletra and medicinal products primarily metabolised by
CYP3A may result in increased plasma concentrations of the other medicinal
product, which could increase or prolong its therapeutic and adverse
reactions. Kaletra does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or
CYP1A2 at clinically relevant concentrations (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra has been shown <i>in&nbsp;vivo</i>
to induce its own metabolism and to increase the biotransformation of some
medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and
CYP2C19) and by glucuronidation. This may result in lowered plasma
concentrations and potential decrease of efficacy of co-administered medicinal
products.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Medicinal products that are
contraindicated specifically due to the expected magnitude of interaction and
potential for serious adverse events are listed in section 4.3.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Known and theoretical interactions with
selected antiretrovirals and non-antiretroviral medicinal products are listed
in the table below. This list is not intended to be inclusive or
comprehensive. Individual SmPCs should be consulted.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Interaction
table</span></i></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Interactions
between Kaletra and co-administered medicinal products are listed in the table
below (increase is indicated as &#8593;, decrease as &#8595;, no change as
&#8596;,once daily as QD, twice daily as BID and three times daily as
&quot;TID&quot;).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Unless otherwise stated, studies detailed
below have been performed with the recommended dosage of lopinavir/ritonavir
(i.e. 400/100&nbsp;mg twice daily).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Co-administered
  drug by therapeutic area </span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Effects
  on drug levels</span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Geometric
  Mean Change (%) in AUC, C<sub>max</sub>, C<sub>min</sub></span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Mechanism
  of interaction</span></b></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Clinical
  recommendation concerning co-administration with Kaletra</span></b></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><b><i><span lang=EN-GB>Antiretroviral
  Agents</span></i></b></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Nucleoside/Nucleotide
  reverse transcriptase inhibitors (NRTIs) </span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Stavudine,
  Lamivudine</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:
  </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>No dose
  adjustment necessary.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Abacavir,
  Zidovudine</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Abacavir,
  Zidovudine:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be reduced due to increased glucuronidation by lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The
  clinical significance of reduced abacavir and zidovudine concentrations is
  unknown.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Tenofovir
  disoproxil fumarate (DF), 300&nbsp;mg QD</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB></span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(equivalent
  to 245&nbsp;mg tenofovir disoproxil)</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Tenofovir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 32%</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  &#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>min</sub>:
  &#8593; 51%</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:
  </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>No dose
  adjustment necessary. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Higher
  tenofovir concentrations could potentiate tenofovir associated adverse
  events, including renal disorders.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Non-nucleoside reverse transcriptase
  inhibitors (NNRTIs) </span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Efavirenz, 600&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8595;</span><span lang=EN-GB> 20%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595; 13%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595;</span><span
  lang=EN-GB> 42%</span></p>
  </td>
  <td width=219 colspan=5 rowspan=2 valign=top style='width:164.55pt;
  border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The Kaletra tablets dosage should be
  increased to 500/125&nbsp;mg twice daily when co-administered with
  efavirenz. </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Efavirenz, 600&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir 500/125&nbsp;mg
  BID)</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Relative to 400/100&nbsp;mg BID
  administered alone) </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Nevirapine, 200&nbsp;mg BID</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8595;</span><span lang=EN-GB> 27%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595; 19%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595;</span><span
  lang=EN-GB> 51%</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The Kaletra tablets dosage should be
  increased to 500/125&nbsp;mg twice daily when co-administered with
  nevirapine. </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-1.15pt;text-autospace:none'><span
  lang=FR style='font-size:11.0pt'>Etravirine</span></p>
  <p class=EMEANormal><span lang=FR>&nbsp;</span></p>
  <p class=EMEANormal><span lang=FR>(</span>Lopinavir/ri<span style='letter-spacing:
  -.05pt'>t</span>onavir tablet 400/<span style='letter-spacing:-.05pt'>1</span>00<span
  style='letter-spacing:-.35pt'>&nbsp;</span><span style='letter-spacing:-.1pt'>m</span>g<span
  style='letter-spacing:-.1pt'> </span>BID)</p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:.4pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%'>Etravirine:</span></p>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;text-align:justify;line-height:
  97%;text-autospace:none'><span lang=FR style='font-size:11.0pt;line-height:
  97%'>AUC:<span style='letter-spacing:-.05pt'> </span>&#8595;<span
  style='letter-spacing:-.05pt'> </span>35%</span></p>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;text-align:justify;line-height:
  97%;text-autospace:none'><span lang=FR style='font-size:11.0pt;line-height:
  97%;letter-spacing:.1pt'>C</span><sub><span lang=FR style='font-size:11.0pt;
  line-height:97%;position:relative;top:1.5pt;letter-spacing:-.05pt'>mi</span></sub><sub><span
  lang=FR style='font-size:11.0pt;line-height:97%;position:relative;top:1.5pt'>n</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:97%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:97%'>&#8595;<span style='letter-spacing:-.05pt'> </span>45%<span
  style='letter-spacing:.05pt'> </span></span></p>
  <p class=EMEANormal style='margin-left:2.2pt'><span lang=FR style='letter-spacing:
  .1pt'>C</span><sub><span lang=FR style='position:relative;top:1.5pt;
  letter-spacing:-.05pt'>ma</span></sub><sub><span lang=FR style='position:
  relative;top:1.5pt'>x</span></sub><span lang=FR style='position:relative;
  top:1.5pt'>:<span style='letter-spacing:.85pt'> </span></span><span lang=FR>&#8595;<span
  style='letter-spacing:-.05pt'> </span>30%</span></p>
  <p class=EMEANormal style='margin-left:2.2pt'><span lang=FR>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:11.1pt;text-autospace:
  none'><span lang=FR style='font-size:11.0pt'>Lopinavir:</span></p>
  <p class=MsoNormal style='margin-top:.4pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%'>AUC:<span
  style='letter-spacing:-.2pt'> </span>&#8596;<span style='letter-spacing:-.05pt'>
  </span></span></p>
  <p class=MsoNormal style='margin-top:.4pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%;letter-spacing:
  .1pt'>C</span><sub><span lang=FR style='font-size:11.0pt;line-height:95%;
  position:relative;top:1.5pt;letter-spacing:-.05pt'>mi</span></sub><sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>n</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:95%'>&#8595;<span style='letter-spacing:-.05pt'> </span>20%</span></p>
  <p class=MsoNormal style='margin-top:.4pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%;letter-spacing:
  .1pt'>C</span><sub><span lang=FR style='font-size:11.0pt;line-height:95%;
  position:relative;top:1.5pt;letter-spacing:-.05pt'>ma</span></sub><sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>x</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.7pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:95%'>&#8596;<span style='letter-spacing:-.05pt'> </span></span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>No dose adjustment necessary</p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:1.7pt;margin-bottom:.0001pt;text-autospace:none'><span
  lang=FR style='font-size:11.0pt'>Rilpivirine</span></p>
  <p class=EMEANormal><span lang=FR>&nbsp;</span></p>
  <p class=EMEANormal><span lang=FR>(</span>Lopinavir/ri<span style='letter-spacing:
  -.05pt'>t</span>onavir capsule 400/<span style='letter-spacing:-.05pt'>1</span>00<span
  style='letter-spacing:-.35pt'>&nbsp;</span><span style='letter-spacing:-.1pt'>m</span>g<span
  style='letter-spacing:-.1pt'> </span>BID)</p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%'>Rilpivirine:</span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%'>AUC:<span
  style='letter-spacing:-.05pt'> </span>&#8593;<span style='letter-spacing:
  -.2pt'> </span><span style='letter-spacing:.05pt'>52% </span></span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>C</span><sub><span lang=FR style='font-size:11.0pt;line-height:95%;
  position:relative;top:1.5pt;letter-spacing:-.05pt'>mi</span></sub><sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>n</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:95%'>&#8593;<span style='letter-spacing:-.2pt'> </span><span
  style='letter-spacing:.05pt'>74% </span></span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>C</span><sub><span lang=FR style='font-size:11.0pt;line-height:95%;
  position:relative;top:1.5pt;letter-spacing:-.05pt'>ma</span></sub><sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>x</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:95%'>&#8593;<span style='letter-spacing:-.2pt'> </span><span
  style='letter-spacing:.05pt'>29%</span></span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:11.1pt;text-autospace:
  none'><span lang=FI style='font-size:11.0pt'>Lopinavir:</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:11.1pt;text-autospace:
  none'><span lang=EN-GB style='font-size:11.0pt'>AUC:<span style='letter-spacing:
  -.15pt'> </span>&#8596;</span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=EN-GB style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>C</span><sub><span lang=EN-GB style='font-size:11.0pt;line-height:
  95%;position:relative;top:1.5pt'>min</span></sub><span lang=EN-GB
  style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=EN-GB
  style='font-size:11.0pt;line-height:95%'>&#8595;<span style='letter-spacing:
  -.2pt'> </span><span style='letter-spacing:.05pt'>11% </span></span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=EN-GB style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>C</span><sub><span lang=EN-GB style='font-size:11.0pt;line-height:
  95%;position:relative;top:1.5pt;letter-spacing:-.1pt'>m</span></sub><sub><span
  lang=EN-GB style='font-size:11.0pt;line-height:95%;position:relative;
  top:1.5pt;letter-spacing:.1pt'>a</span></sub><sub><span lang=EN-GB
  style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>x</span></sub><span
  lang=EN-GB style='font-size:11.0pt;line-height:95%;position:relative;
  top:1.5pt'>:<span style='letter-spacing:.7pt'> </span></span><span
  lang=EN-GB style='font-size:11.0pt;line-height:95%'>&#8596; </span></p>
  <p class=MsoNormal style='margin-top:.95pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:10.0pt;text-autospace:
  none'><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=EMEANormal style='margin-left:2.2pt'>(inhibition<span
  style='letter-spacing:-.4pt'> </span>of<span style='letter-spacing:.05pt'> </span>CYP3A<span
  style='letter-spacing:-.25pt'> </span>enzymes)</p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;line-height:11.25pt;text-autospace:
  none'><span lang=EN-GB style='font-size:11.0pt'>Concomitant<span
  style='letter-spacing:-.5pt'> </span>use<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>Kaletra</span><span
  style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>with</span></span></p>
  <p class=EMEANormal>rilpivirine<span style='letter-spacing:-.15pt'> </span>causes<span
  style='letter-spacing:-.25pt'> </span>an<span style='letter-spacing:-.1pt'> </span>increase
  in<span style='letter-spacing:-.1pt'> </span>the<span style='letter-spacing:
  -.1pt'> </span>plasma<span style='letter-spacing:-.3pt'> </span>concentrations<span
  style='letter-spacing:-.6pt'> </span><span style='letter-spacing:.2pt'>of </span>rilpivirine,<span
  style='letter-spacing:-.4pt'> </span>but<span style='letter-spacing:-.15pt'> </span>no<span
  style='letter-spacing:-.1pt'> </span>dose<span style='letter-spacing:-.2pt'>
  a</span>djustment<span style='letter-spacing:-.45pt'> </span>is required.</p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i>HIV CCR5  antagonist</i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Maraviroc</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Maraviroc:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 295% </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  &#8593; 97% </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>The dose of maraviroc should be decreased to
  150&nbsp;mg twice daily during co&#8209;administration with Kaletra 400/100&nbsp;mg
  twice daily. </span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Integrase inhibitor</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Raltegravir</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Raltegravir: </span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>12</sub>: &#8595; 30%</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: &#8596;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='margin-bottom:12.0pt'><span lang=EN-GB>No dose
  adjustment necessary</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Co-administration with other HIV
  protease inhibitors (PIs)</span></i></p>
  <p class=EMEANormal><span lang=EN-GB style='color:black'>According to current
  treatment guidelines, dual therapy with protease inhibitors is generally not
  recommended.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:89.05pt'>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:89.05pt'>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir/ ritonavir
  (700/100&nbsp;mg BID) </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(L</span><span lang=EN-GB>opinavir/ritonavir
  400/100&nbsp;mg BID)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>or </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir (1400&nbsp;mg BID)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(</span><span lang=EN-GB>Lopinavir/ritonavir
  533/133&nbsp;mg BID)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:89.05pt'>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Amprenavir concentrations are
  significantly reduced. </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal align=right style='text-align:right'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:89.05pt'>
  <p class=EMEANormal><span lang=EN-GB>Co-administration of increased doses of
  fosamprenavir (1400&nbsp;mg BID) with Kaletra (533/133&nbsp;mg BID) to
  protease inhibitor&#8209;experienced patients resulted in a higher incidence
  of gastrointestinal adverse events and elevations in triglycerides with the
  combination regimen without increases in virological efficacy, when compared
  with standard doses of fosamprenavir/ritonavir. Concomitant administration
  of these medicinal products is not recommended.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Indinavir, 600&nbsp;mg BID</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Indinavir: </span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8593; 3.5-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(relative to indinavir 800&nbsp;mg TID
  alone)</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(relative to historical comparison)</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The appropriate doses for this
  combination, with respect to efficacy and safety, have not been established.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Saquinavir </span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>1000&nbsp;mg BID</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Saquinavir: </span><span lang=EN-GB>&#8596;
  </span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>No
  dose adjustment necessary.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Tipranavir/ritonavir</span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>(500/100&nbsp;mg BID)</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8595; 55%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595; 70%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595; 47%</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Concomitant
  administration of these medicinal products is not recommended.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Acid reducing agents</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Omeprazole (40&nbsp;mg QD) </span></p>
  <p class=EMEANormal><span lang=EN-GB></span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Omeprazole: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ranitidine (150&nbsp;mg single dose)</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ranitidine: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Alpha</span></i><i><sub><span
  lang=EN-GB style='font-size:12.0pt'>1</span></sub></i><i><span lang=EN-GB>
  adrenoreceptor antagonist</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Alfuzosin
  </span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Alfuzosin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of alfuzosin are expected to increase.</p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Concomitant administration
  of Kaletra and alfuzosin is contra-indicated<b> </b>(see section 4.3) as
  alfuzosin-related toxicity, including hypotension, may be increased.</p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Analgesics</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fentanyl</span></p>
  <p class=EMEANormal><span lang=EN-GB></span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fentanyl:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Increased risk of side-effects
  (respiratory depression, sedation) due to higher plasma concentrations
  because of CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Careful monitoring of adverse effects
  (notably respiratory depression but also sedation) is recommended when
  fentanyl is concomitantly administered with Kaletra.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antianginal</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ranolazine</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of ranolazine are expected to increase.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The concomitant administration of
  Kaletra and ranolazine is contraindicated (see section 4.3).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antiarrhythmics</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Amiodarone, Dronedarone</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Amiodarone, Dronedarone: Concentrations
  may be increased due to CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and amiodarone or dronedarone is contraindicated (see section 4.3) as the
  risk of arrhythmias or other serious adverse reactions may be increased.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Digoxin</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Digoxin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Plasma concentrations may be increased
  due to P-glycoprotein inhibition by lopinavir/ritonavir. The increased
  digoxin level may lessen over time as P-gp induction develops.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution is warranted and therapeutic
  drug monitoring of digoxin concentrations, if available, is recommended in
  case of co&#8209;administration of Kaletra and digoxin. Particular caution
  should be used when prescribing Kaletra in patients taking digoxin as the
  acute inhibitory effect of ritonavir on P-gp is expected to significantly
  increase digoxin levels. Initiation of digoxin in patients already taking
  Kaletra is likely to result in lower than expected increases of digoxin
  concentrations.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bepridil, Systemic Lidocaine, and
  Quinidine </span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bepridil, Systemic Lidocaine, Quinidine:
  </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased when
  co-administered with lopinavir/ritonavir. </span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution is warranted and therapeutic
  drug concentration monitoring is recommended when available.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Antibiotics</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Clarithromycin</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Clarithromycin:</span><i><span
  lang=EN-GB> </span></i></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Moderate
  increases in clarithromycin AUC are expected due to CYP3A inhibition by lopinavir/ritonavir.
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>For
  patients with renal impairment (CrCL &lt;&nbsp;30&nbsp;ml/min) dose reduction
  of clarithromycin should be considered (see section 4.4). Caution should be
  exercised in administering clarithromycin with Kaletra to patients with
  impaired hepatic or renal function.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Anticancer agents and kinase
  inhibitors</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abemaciclib </span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Serum concentrations may be increased due to CYP3A inhibition
  by ritonavir.</p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of abemaciclib and
  Kaletra should be avoided. If this co&#8209;administration is judged
  unavoidable, refer to the abemaciclib SmPC for dosage adjustment
  recommendations. Monitor for ADRs related to abemaciclib.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Apalutamide</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Apalutamide is a moderate to strong CYP3A4 inducer and
  this may lead to a decreased exposure of lopinavir/ritonavir.</p>
  <p class=EMEANormal>&nbsp;</p>
  <p class=EMEANormal>Serum concentrations of apalutamide may be increased due
  to CYP3A inhibition by lopinavir/ritonavir.</p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Decreased exposure of Kaletra may result
  in potential loss of virological response. </span></p>
  <p class=EMEANormal><span lang=EN-GB>In addition, co-administration of
  apalutamide and Kaletra may lead to serious adverse events including seizure
  due to higher apalutamide levels. Concomitant use of Kaletra with
  apalutamide is not recommended.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Afatinib</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Ritonavir 200&nbsp;mg twice daily)</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Afatinib:</p>
  <p class=EMEANormal>AUC: <span lang=EN-GB>&#8593; </span></p>
  <p class=EMEANormal>C<sub>max</sub>: <span lang=EN-GB>&#8593;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>The extent of increase depends on the
  timing of ritonavir administration.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to BCRP (breast cancer </span>resistance
  protein/ABCG2)<span lang=EN-GB> and acute P-gp inhibition by
  lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised in
  administering afatinib with Kaletra. Refer to the afatinib SmPC for dosage
  adjustment recommendations. Monitor for ADRs related to afatinib.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ceritinib</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A and P&#8209;gp inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised in
  administering ceritinib with Kaletra. Refer to the ceritinib SmPC for dosage
  adjustment recommendations. Monitor for ADRs related to ceritinib.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:104.5pt'>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:104.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Most tyrosine kinase inhibitors such as
  dasatinib and nilotinib, vincristine, vinblastine</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:104.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Most tyrosine kinase inhibitors such as
  dasatinib and nilotinib, also vincristine and vinblastine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Risk of increased adverse events due to
  higher serum concentrations because of CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:104.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Careful monitoring of the tolerance of
  these anticancer agents.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Encorafenib</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co-administration of encorafenib with
  Kaletra may increase encorafenib exposure which may increase the risk of
  toxicity, including the risk of serious adverse events such as QT interval
  prolongation. </span>Co&#8209;administration of encorafenib and Kaletra should
  be avoided. If the benefit is considered to outweigh the risk and Kaletra
  must be used, patients should be carefully monitored for safety.</p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fostamatinib</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Increase in fostamatinib metabolite R406 exposure.</p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Co-administration of fostamatinib with Kaletra may
  increase fostamatinib metabolite R406 exposure resulting in dose-related
  adverse events such as hepatotoxicity, neutropenia, hypertension, or
  diarrhoea. Refer to the fostamatinib SmPC for dose reduction recommendations
  if such events occur.</p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ibrutinib</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co-administration of ibrutinib and
  Kaletra may increase ibrutinib exposure which may increase the risk of
  toxicity including risk of tumor lysis syndrome. Co&#8209;administration of
  ibrutinib and Kaletra should be avoided. If the benefit is considered to
  outweigh the risk and Kaletra must be used, reduce the ibrutinib dose to
  140&nbsp;mg and monitor patient closely for toxicity.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Neratinib</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Serum
  concentrations may be increased due to CYP3A inhibition by ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concomitant
  use of neratinib with Kaletra is contraindicated due to serious and/or life&#8209;threatening
  potential reactions including hepatotoxicity (see section 4.3).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Venetoclax</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir.</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir, resulting in increased risk
  of tumor lysis syndrome at the dose initiation and during the ramp-up phase
  (see section 4.3 and refer to the venetoclax SmPC).</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal>For patients who have completed the ramp-up phase and are
  on a steady daily dose of venetoclax, reduce the venetoclax dose by at least
  75% when used with strong CYP3A inhibitors (refer to the venetoclax SmPC for
  dosing instructions). Patients should be closely monitored for signs related
  to venetoclax toxicities.</p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Anticoagulants</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Warfarin</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=218 colspan=7 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Warfarin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be affected when co-administered with lopinavir/ritonavir due to CYP2C9
  induction. </span></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>It is
  recommended that INR (international normalised ratio) be monitored.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:104.5pt'>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:104.5pt'>
  <p class=EMEANormal>Rivaroxaban</p>
  <p class=EMEANormal>&nbsp;</p>
  <p class=EMEANormal>(Ritonavir 600&nbsp;mg twice daily)</p>
  </td>
  <td width=218 colspan=7 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:104.5pt'>
  <p class=EMEANormal>Rivaroxaban: </p>
  <p class=EMEANormal>AUC: <span lang=EN-GB>&#8593; </span>153% </p>
  <p class=EMEANormal>C<sub>max</sub>: <span lang=EN-GB>&#8593; 55</span>%</p>
  <p class=EMEANormal>Due to CYP3A and P-gp inhibition by lopinavir/ritonavir.</p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:104.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of rivaroxaban
  and Kaletra may increase rivaroxaban exposure which may increase the risk of
  bleeding.</span></p>
  <p class=EMEANormal><span lang=EN-GB>The use of rivaroxaban is not
  recommended in patients receiving concomitant treatment with Kaletra (see
  section 4.4).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Vorapaxar</p>
  </td>
  <td width=218 colspan=7 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Serum concentrations may be increased due to CYP3A
  inhibition by <span lang=EN-GB>lopinavir/ritonavir</span>.</p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The co&#8209;administration of vorapaxar
  with Kaletra is not recommended (see section 4.4 and refer to the vorapaxar
  SmPC).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Anticonvulsants</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Phenytoin</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Phenytoin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Steady-state
  concentrations was moderately decreased due to CYP2C9 and CYP2C19 induction
  by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  are decreased due to CYP3A induction by phenytoin. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised in administering phenytoin with Kaletra.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Phenytoin
  levels should be monitored when co&#8209;administering with Kaletra.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>When
  co-administered with phenytoin, an increase of Kaletra dosage may be
  envisaged. Dose adjustment has not been evaluated in clinical practice.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Carbamazepine and Phenobarbital </span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Carbamazepine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be decreased due to
  CYP3A induction by carbamazepine and phenobarbital. </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised in
  administering carbamazepine or phenobarbital with Kaletra.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Carbamazepine and phenobarbital levels
  should be monitored when co&#8209;administering with Kaletra.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>When co-administered with carbamazepine
  or phenobarbital, an increase of Kaletra dosage may be envisaged. Dose
  adjustment has not been evaluated in clinical practice</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lamotrigine
  and Valproate</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lamotrigine:
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'>AUC: &#8595; 50%</p>
  <p class=EMEANormal style='page-break-after:avoid'>C<sub>max</sub>: &#8595;
  46%</p>
  <p class=EMEANormal style='page-break-after:avoid'>C<sub>min</sub>: &#8595;
  56%</p>
  <p class=EMEANormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=EMEANormal style='page-break-after:avoid'>Due to induction of
  lamotrigine glucuronidation</p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Valproate:
  &#8595;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Patients
  should be monitored closely for a decreased VPA effect when Kaletra and valproic
  acid or valproate are given concomitantly.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  <p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>In
  patients starting or stopping Kaletra while currently taking maintenance dose
  of lamotrigine</span></u><span lang=EN-GB>: lamotrigine dose may need to be
  increased if Kaletra is added, or decreased if Kaletra is discontinued;
  therefore plasma lamotrigine monitoring should be conducted, particularly
  before and during 2 weeks after starting or stopping Kaletra, in order to see
  if lamotrigine dose adjustment is needed.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>In
  patients currently taking Kaletra and starting lamotrigine</span></u><span
  lang=EN-GB>: no dose adjustments to the recommended dose escalation of
  lamotrigine should be necessary.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='height:17.45pt'>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:17.45pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:11.0pt'>Antidepressants and Anxiolytics</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Trazodone
  single dose</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Ritonavir,
  200&nbsp;mg BID)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Trazodone:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC: </span><span
  lang=EN-GB>&#8593; 2.4-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
  events of nausea, dizziness, hypotension and syncope were observed following
  co-administration of trazodone and ritonavir. </span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>It is
  unknown whether the combination of Kaletra causes a similar increase in
  trazodone exposure. The combination should be used with caution and a lower
  dose of trazodone should be considered</span><span lang=EN-GB>.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antifungals</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ketoconazole and Itraconazole</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ketoconazole, Itraconazole:</span><i><span
  lang=EN-GB> </span></i><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir. </span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>High doses of ketoconazole and
  itraconazole (&gt;&nbsp;200&nbsp;mg/day) are not recommended.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Voriconazole</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Voriconazole: </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be decreased.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of voriconazole
  and low dose ritonavir (100&nbsp;mg BID) as contained in Kaletra should be
  avoided unless an assessment of the benefit/risk to patient justifies the use
  of voriconazole.</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Anti&#8209;gout
  agents</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Colchicine
  single dose</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Ritonavir
  200&nbsp;mg twice daily)</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Colchicine:</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>AUC: &#8593; 3-fold</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>C<sub>max</sub>: &#8593; 1.8-fold</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>Due to P-gp and/or CYP3A4 inhibition by</span><span
  lang=EN-GB style='font-size:11.0pt'> ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=219 colspan=5 valign=top style='width:164.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C</span>oncomitant
  administration of Kaletra with colchicine in patients with renal and/or
  hepatic impairment is contraindicated due to a potential increase of
  colchicine-related serious and/or life&#8209;threatening reactions such as
  neuromuscular toxicity (including rhabdomyolysis) (see sections 4.3 and 4.4).
  A reduction in colchicine dosage or an interruption of colchicine treatment
  is recommended in patients with normal renal or hepatic function if treatment
  with Kaletra is required. Refer to colchicine prescribing information.</p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=612 colspan=11 valign=top style='width:458.9pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antihistamines</span></i></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Astemizole</span></p>
  <p class=EMEANormal><span lang=EN-GB>Terfenadine</span></p>
  </td>
  <td width=217 colspan=6 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.05pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and astemizole and terfenadine is contraindicated as it may increase the risk
  of serious arrhythmias from these agents (see section 4.3).</span></p>
  </td>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=3
  colspan=2><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Anti-infectives</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fusidic acid</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fusidic acid:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Concomitant administration of Kaletra with fusidic acid
  is contra-indicated in dermatological indications due to the increased risk
  of adverse events related to fusidic acid, notably rhabdomyolysis (see
  section 4.3). When used for osteo-articular infections, where the
  co-administration is unavoidable, close clinical monitoring for muscular
  adverse events is strongly recommended (see section 4.4). </p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antimycobacterials</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bedaquiline</span></p>
  <p class=EMEANormal><span lang=EN-GB>(single dose)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir 400/100&nbsp;mg
  BID, multiple dose)</span></p>
  </td>
  <td width=211 colspan=4 valign=top style='width:158.25pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bedaquiline:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 22%</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>A more pronounced effect on bedaquiline
  plasma exposures may be observed during prolonged co&#8209;administration
  with lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>CYP3A4 inhibition likely due to
  lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=227 colspan=7 valign=top style='width:170.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to the risk of bedaquiline related
  adverse events, the combination of bedaquiline and Kaletra should be
  avoided. If the benefit outweighs the risk, co&#8209;administration of
  bedaquiline with Kaletra must be done with caution. More frequent
  electrocardiogram monitoring and monitoring of transaminases is recommended
  (see section 4.4 and refer to the bedaquiline SmPC).</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal1 style='page-break-after:avoid'><span lang=EN-GB>Delamanid
  (100&nbsp;mg BID)</span></p>
  <p class=EMEANormal1 style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Lopinavir/ritonavir
  400/100&nbsp;mg BID)</span></p>
  </td>
  <td width=211 colspan=4 valign=top style='width:158.25pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=DE>Delamanid:</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>AUC: &#8593;
  22%</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>DM-6705
  (delamanid active metabolite):</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>AUC: &#8593;
  30%</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>A more pronounced effect
  on DM-6705 exposure may be observed during prolonged co-administration with
  lopinavir/ritonavir.</p>
  </td>
  <td width=227 colspan=7 valign=top style='width:170.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Due to the risk of QTc
  prolongation associated with DM&#8209;6705, if co&#8209;administration of
  delamanid with Kaletra is considered necessary, very frequent ECG monitoring
  throughout the full delamanid treatment period is recommended (see section
  4.4 and refer to the delamanid SmPC).</p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rifabutin, 150&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=211 colspan=4 valign=top style='width:158.25pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rifabutin (parent drug and active </span><span
  lang=EN-GB>25-O-desacetyl metabolite):<i> </i></span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 5.7-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 3.5-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=227 colspan=7 valign=top style='width:170.1pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>When given with Kaletra the recommended
  dose of rifabutin is 150&nbsp;mg 3 times per week on set days (for example
  Monday-Wednesday-Friday). Increased monitoring for rifabutin-associated
  adverse reactions including neutropenia and uveitis is warranted due to an
  expected increase in exposure to rifabutin. Further dosage reduction of
  rifabutin to 150&nbsp;mg twice weekly on set days is recommended for patients
  in whom the 150&nbsp;mg dose 3 times per week is not tolerated. It should be
  kept in mind that the twice weekly dosage of 150&nbsp;mg may not provide an
  optimal exposure to rifabutin thus leading to a risk of rifamycin resistance
  and a treatment failure. No dose adjustment is needed for Kaletra. </span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Rifampicin</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Large
  decreases in lopinavir concentrations may be observed due to CYP3A induction
  by rifampicin.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=8 valign=top style='width:171.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Co&#8209;administration
  of Kaletra with rifampicin is not recommended as </span><span lang=EN-GB>the
  decrease in lopinavir concentrations may in turn significantly decrease the
  lopinavir therapeutic effect. A dose adjustment of Kaletra 400&nbsp;mg/400&nbsp;mg
  (i.e. Kaletra 400/100&nbsp;mg + ritonavir 300&nbsp;mg) twice daily has
  allowed compensating for the CYP&nbsp;3A4 inducer effect of rifampicin.
  However, such a dose adjustment might be associated with ALT/AST elevations
  and with increase in gastrointestinal disorders. Therefore, this co&#8209;administration
  should be avoided unless judged strictly necessary. If this co&#8209;administration
  is judged unavoidable, increased dose of Kaletra at 400&nbsp;mg/400&nbsp;mg
  twice daily may be administered with rifampicin under close safety and
  therapeutic drug monitoring. The Kaletra dose should be titrated upward only
  after rifampicin has been initiated (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antipsychotics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lurasidone</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of lurasidone are expected to increase.</span></p>
  </td>
  <td width=229 colspan=8 valign=top style='width:171.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The concomitant administration with
  lurasidone is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Pimozide</span></p>
  </td>
  <td width=208 colspan=2 valign=top style='width:155.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of pimozide are expected to increase.</span></p>
  </td>
  <td width=230 colspan=9 valign=top style='width:172.4pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and pimozide is contraindicated as it may increase the risk of serious
  haematologic abnormalities or other serious adverse effects from this agent
  (see section 4.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Quetiapine</span></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of quetiapine are expected to increase.</span></p>
  </td>
  <td width=229 colspan=8 valign=top style='width:171.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and quetiapine is contraindicated as it may increase quetiapine-related
  toxicity.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Benzodiazepines</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Midazolam</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=209 colspan=3 valign=top style='width:156.45pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Oral
  Midazolam: </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 13-fold </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Parenteral
  Midazolam:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 4-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=8 valign=top style='width:171.9pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
  must not be co&#8209;administered with oral midazolam (see section 4.3),
  whereas caution should be used with co&#8209;administration of Kaletra and parenteral
  midazolam. If Kaletra is co&#8209;administered with parenteral midazolam, it
  should be done in an intensive care unit (ICU) or similar setting which
  ensures close clinical monitoring and appropriate medical management in case
  of respiratory depression and/or prolonged sedation. Dosage adjustment for
  midazolam should be considered especially if more than a single dose of
  midazolam is administered.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i>Beta<sub>2</sub>-adrenoceptor
  agonist (long acting)</i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Salmeterol</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Salmeterol:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  are expected to increase due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>The combination may result in increased
  risk of cardiovascular adverse events associated with salmeterol, including
  QT prolongation, palpitations and sinus tachycardia.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>Therefore, concomitant
  administration of Kaletra with salmeterol is not recommended (see section
  4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Calcium channel blockers</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Felodipine, Nifedipine, and Nicardipine</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Felodipine, Nifedipine, Nicardipine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Clinical monitoring of therapeutic and
  adverse effects is recommended when these medicines are concomitantly
  administered with Kaletra.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Corticosteroids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Dexamethasone</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be decreased due to
  CYP3A induction by dexamethasone.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Clinical monitoring of antiviral
  efficacy is recommended when these medicines are concomitantly administered
  with Kaletra.</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Inhaled,
  injectable or intranasal fluticasone propionate, budesonide, triamcinolone</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Fluticasone
  propionate, 50&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
  lang=EN-GB>g intranasal 4 times daily:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Plasma
  concentrations &#8593;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Cortisol
  levels &#8595; 86% </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Greater
  effects may be expected when fluticasone propionate is inhaled. Systemic corticosteroid
  effects including Cushing's syndrome and adrenal suppression have been
  reported in patients receiving ritonavir and inhaled or intranasally
  administered fluticasone propionate; this could also occur with other
  corticosteroids metabolised via the P450 3A pathway e.g. budesonide and
  triamcinolone. Consequently, concomitant administration of Kaletra and these
  glucocorticoids is not recommended unless the potential benefit of treatment
  outweighs the risk of systemic corticosteroid effects (see section 4.4). A
  dose reduction of the glucocorticoid should be considered with close
  monitoring of local and systemic effects or a switch to a glucocorticoid,
  which is not a substrate for CYP3A4 (e.g. beclomethasone). Moreover, in case
  of withdrawal of glucocorticoids progressive dose reduction may have to be
  performed over a longer period. </span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Phosphodiesterase(PDE5) inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Avanafil</span></p>
  <p class=EMEANormal><span lang=EN-GB>(ritonavir 600&nbsp;mg BID) </span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Avanafil:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 13-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The use of avanafil with Kaletra is
  contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Tadalafil
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Tadalafil:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 2-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 rowspan=2 valign=top style='width:166.35pt;
  border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>For
  the treatment of pulmonary arterial hypertension</span></u><span lang=EN-GB>:
  Co&#8209;administration of Kaletra with sildenafil is contraindicated (see
  section 4.3). Co-administration of Kaletra with tadalafil is not
  recommended.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>For
  erectile dysfunction</span></u><span lang=EN-GB>:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Particular
  caution must be used when prescribing sildenafil or tadalafil in patients
  receiving Kaletra with increased monitoring for adverse events including
  hypotension, syncope, visual changes and prolonged erection (see section
  4.4). </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>When co&#8209;administered
  with Kaletra, sildenafil doses must not exceed 25&nbsp;mg in 48 hours and
  tadalafil doses must not exceed 10&nbsp;mg every 72 hours</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Sildenafil</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Sildenafil:<u> </u></span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 11-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vardenafil </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vardenafil:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 49-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The use of vardenafil with Kaletra is
  contraindicated (see section 4.3). </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Ergot alkaloids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=180 colspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Dihydroergotamine, ergonovine,
  ergotamine, methylergonovine</span></p>
  </td>
  <td width=217 colspan=7 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations may be
  increased due to CYP3A inhibition by </span><span lang=EN-GB>lopinavir/ritonavir</span><span
  style='color:black'>.</span></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  Kaletra and ergot alkaloids are contraindicated as it may lead to acute ergot
  toxicity, including vasospasm and ischaemia (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span style='color:black'>GI motility agent</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=180 colspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Cisapride</span></p>
  </td>
  <td width=217 colspan=7 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations may be
  increased due to CYP3A inhibition by </span><span lang=EN-GB>lopinavir/ritonavir</span><span
  style='color:black'>.</span></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  Kaletra and cisapride is contraindicated as it may increase the risk of
  serious arrhythmias from this agent (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span style='color:black'>HCV direct acting antivirals</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=180 colspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Elbasvir/grazoprevir</span></p>
  <p class=EMEANormal><span style='color:black'>(50/200 mg QD)</span></p>
  </td>
  <td width=217 colspan=7 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Elbasvir:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 2.71-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 1.87-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>24</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 3.58-fold</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Grazoprevir:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 11.86-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 6.31-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>24</sub>: </span><span
  lang=EN-GB>&#8593; 20.70-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(combinations of mechanisms including
  CYP3A inhibition)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  elbasvir/grazoprevir with Kaletra is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=180 colspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Glecaprevir/pibrentasvir</span></p>
  </td>
  <td width=217 colspan=7 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Serum
  concentrations may be increased due to P-glycoprotein, BCRP and OATP1B
  inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Concomitant
  administration of glecaprevir/pibrentasvir and Kaletra is not recommended due
  to an increased risk of ALT elevations associated with increased glecaprevir
  exposure.</span></p>
  </td>
 </tr>
 <tr>
  <td width=180 colspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Ombitasvir/paritaprevir/ritonavir
  + dasabuvir</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>(25/150/100&nbsp;mg
  QD + 400&nbsp;mg BID)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir/ritonavir
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>400/100&nbsp;mg
  BID</span></p>
  </td>
  <td width=217 colspan=7 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Ombitasvir:
  </span><span lang=EN-GB>&#8596;</span><span lang=EN-GB style='color:black'> </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Paritaprevir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>AUC:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.17-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>C<sub>max</sub>:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.04-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>C<sub>trough</sub>:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.36-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>(inhibition
  of CYP3A/efflux transporters)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Dasabuvir:
  </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir:
  </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=217 colspan=3 rowspan=2 valign=top style='width:163.0pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Co-administration
  is contraindicated.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir/ritonavir
  800/200&nbsp;mg QD was administered with ombitasvir/paritaprevir/ritonavir
  with or without dasabuvir. The effect on DAAs and lopinavir was similar to
  that observed when lopinavir/ritonavir 400/100&nbsp;mg BID was administered
  (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=180 colspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Ombitasvir/paritaprevir/
  ritonavir</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>(25/150/100&nbsp;mg QD)</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Lopinavir/ritonavir</span></p>
  <p class=EMEANormal><span style='color:black'>400/100&nbsp;mg BID</span></p>
  </td>
  <td width=217 colspan=7 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Ombitasvir:</span><span
  style='color:black'> </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Paritaprevir:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 6.10-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 4.76-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>trough</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 12.33-fold</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(inhibition of CYP3A/efflux
  transporters)</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width=180 colspan=2 valign=top style='width:134.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Sofosbuvir/velpatasvir/
  voxilaprevir</span></p>
  </td>
  <td width=217 colspan=7 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations of
  sofosbuvir, velpatasvir and voxilaprevir may be increased due to
  P-glycoprotein, BCRP and OATP1B1/3 inhibition by lopinavir/ritonavir.
  However, only the increase in voxilaprevir exposure is considered clinically
  relevant.</span></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>It is not recommended to co&#8209;administer
  Kaletra and sofosbuvir/velpatasvir/ voxilaprevir.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>HCV protease inhibitors</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Simeprevir 200&nbsp;mg
  daily (</span><span lang=EN-GB style='font-size:11.0pt'>ri<span
  style='letter-spacing:-.05pt'>t</span>onavir <span style='letter-spacing:
  -.05pt'>1</span>00<span style='letter-spacing:-.35pt'>&nbsp;</span><span
  style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>BID)</span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Simeprevir:</p>
  <p class=EMEANormal>AUC<span lang=EN-GB>:</span><span lang=EN-GB> </span><span
  lang=FR>&#8593;<span style='letter-spacing:-.2pt'> </span><span
  style='letter-spacing:.05pt'>7.2-fold</span></span></p>
  <p class=EMEANormal>C<sub>max</sub><span lang=EN-GB>:</span><span lang=EN-GB>
  </span><span lang=FR>&#8593; 4.7-fold</span></p>
  <p class=EMEANormal>C<sub>min</sub><span lang=EN-GB>:</span><span lang=EN-GB>
  </span><span lang=FR>&#8593; 14.4-fold</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>It is not recommended to co&#8209;administer Kaletra and simeprevir.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Herbal
  products</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>St Johns</span><span
  lang=EN-GB> wort</span><i><span lang=EN-GB> </span></i><span lang=EN-GB>(<i>Hypericum
  perforatum)</i></span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be reduced due to induction of CYP3A by the herbal preparation St
    Johns wort. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Herbal
  preparations containing St Johns wort must not be combined with lopinavir
  and ritonavir. If a patient is already taking St Johns wort, stop St&nbsp;Johns&nbsp;wort and if possible check viral levels. Lopinavir and ritonavir
  levels may increase on stopping St&nbsp;Johns&nbsp;wort. The dose of
  Kaletra may need adjusting. The inducing effect may persist for at least 2
  weeks after cessation of treatment with St Johns wort (see section 4.3).
  Therefore, Kaletra can be started safely 2 weeks after cessation of St
    John's wort. <i></i></span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Immunosuppressants</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Cyclosporin, Sirolimus (rapamycin), and
  Tacrolimus</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Cyclosporin, Sirolimus (rapamycin),
  Tacrolimus:</span><span lang=EN-GB> </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>More frequent therapeutic concentration
  monitoring is recommended until plasma levels of these products have been
  stabilised.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Lipid lowering agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lovastatin and Simvastatin</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lovastatin, Simvastatin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Markedly increased plasma concentrations
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Since increased concentrations of
  HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis,
  the combination of these agents with Kaletra is contraindicated (see section
  4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal1 style='page-break-after:avoid'><i><span lang=EN-GB>Lipid-modifying
  agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lomitapide</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>CYP3A4 inhibitors increase the exposure of lomitapide,
  with strong inhibitors increasing exposure approximately 27&#8209;fold. Due
  to CYP3A inhibition by lopinavir/ritonavir, concentrations of lomitapide are
  expected to increase.</p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Concomitant use of Kaletra with lomitapide is
  contraindicated (see prescribing information for lomitapide) (see section
  4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Atorvastatin</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Atorvastatin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 5.9-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 4.7-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The combination of Kaletra with
  atorvastatin is not recommended. If the use of atorvastatin is considered
  strictly necessary, the lowest possible dose of atorvastatin should be
  administered with careful safety monitoring (see section 4.4). </span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rosuvastatin, 20&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rosuvastatin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 2-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 5-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>While rosuvastatin is poorly metabolised
  by CYP3A4, an increase of its plasma concentrations was observed. The mechanism
  of this interaction may result from inhibition of transport proteins.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised and reduced
  doses should be considered when Kaletra is co&#8209;administered with
  rosuvastatin (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fluvastatin or Pravastatin</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fluvastatin, Pravastatin: </span></p>
  <p class=EMEANormal><span lang=EN-GB>No clinical relevant interaction
  expected.</span></p>
  <p class=EMEANormal><span lang=EN-GB>Pravastatin is not metabolised by
  CYP450.</span></p>
  <p class=EMEANormal><span lang=EN-GB>Fluvastatin is partially metabolised by
  CYP2C9.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>If treatment with an HMG-CoA reductase
  inhibitor is indicated, fluvastatin or pravastatin is recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Opioids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Buprenorphine,
  16&nbsp;mg QD</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Buprenorphine:</span><span
  lang=EN-GB> &#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>No dose
  adjustment necessary.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Methadone</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Methadone:</span><i><span lang=EN-GB> </span></i><span
  lang=EN-GB>&#8595;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Monitoring plasma concentrations of
  methadone is recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Oral contraceptives</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ethinyl Oestradiol</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ethinyl Oestradiol: &#8595;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>In case of co&#8209;administration of
  Kaletra with contraceptives containing ethinyl oestradiol (whatever the
  contraceptive formulation e.g. oral or patch), additional methods of
  contraception must be used.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Smoking
  cessation aids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Bupropion</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Buproprion
  and its active metabolite, hydroxybupropion:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC and C<sub>max</sub>
  &#8595; ~50% </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>This
  effect may be due to induction of bupropion metabolism.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>If the co&#8209;administration
  of Kaletra with bupropion is judged unavoidable, this should be done under
  close clinical monitoring for bupropion efficacy, without exceeding the
  recommended dosage, despite the observed induction.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Thyroid hormone replacement therapy</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Levothyroxine</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Post&#8209;marketing
  cases have been reported indicating a potential interaction between ritonavir
  containing products and levothyroxine.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Thyroid&#8209;stimulating
  hormone (TSH) should be monitored in patients treated with levothyroxine at
  least the first month after starting and/or ending lopinavir/ritonavir
  treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Vasodilating agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bosentan</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir - ritonavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir/ritonavir plasma
  concentrations may decrease due to CYP3A4 induction by bosentan.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Bosentan:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 5-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 6-fold</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:11.0pt'>Initially, bosentan C<sub>min</sub></span><span
  lang=EN-GB>: </span><span lang=EN-GB style='font-size:11.0pt'>&#8593; by
  approximately 48-fold.<u> </u></span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised in
  administering Kaletra with bosentan.</span></p>
  <p class=EMEANormal>When Kaletra is administered concomitantly with bosentan,
  the efficacy of the HIV therapy should be monitored and patients should be
  closely observed for bosentan toxicity, especially during the first week of
  co-administration. </p>
  </td>
 </tr>
 <tr>
  <td width=176 valign=top style='width:132.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Riociguat</span></p>
  </td>
  <td width=216 colspan=5 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A and P&#8209;gp inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=222 colspan=6 valign=top style='width:166.35pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The co&#8209;administration of riociguat
  with Kaletra is not recommended (see section 4.4 and refer to riociguat
  SmPC).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Other
  medicinal products</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=12 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Based on
  known metabolic profiles, clinically significant interactions are not
  expected between Kaletra and dapsone, trimethoprim/sulfamethoxazole,
  azithromycin or fluconazole.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=204 style='border:none'></td>
  <td width=4 style='border:none'></td>
  <td width=184 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=4 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=2 style='border:none'></td>
  <td width=209 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=2 style='border:none'></td>
 </tr>
</table>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.6 Fertility, pregnancy and lactation</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEANormal><span lang=EN-GB>As a general rule, when deciding to use
antiretroviral agents for the treatment of HIV infection in pregnant women and consequently
for reducing the risk of HIV vertical transmission to the newborn, the animal
data as well as the clinical experience in pregnant women should be taken into
account in order to characterise the safety for the foetus.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Lopinavir/ritonavir has been evaluated in over 3000 women
during pregnancy, including over 1000 during the first trimester.</p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>In post&#8209;marketing
surveillance through the Antiretroviral Pregnancy Registry, established since
January 1989, an increased risk of birth defects exposures with Kaletra has not
been reported among over 1000 women exposed during the first trimester. The
prevalence of birth defects after any trimester exposure to lopinavir is
comparable to the prevalence observed in the general population. No pattern of
birth defects suggestive of a common etiology was seen. Studies in animals
have shown reproductive toxicity (see section 5.3). Based on the data
mentioned, the malformative risk is unlikely in humans. </span>Lopinavir can
be used during pregnancy if clinically needed.</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Studies in rats revealed that lopinavir is
excreted in the milk. It is not known whether this medicinal product is
excreted in human milk. As a general rule, it is recommended that mothers
infected by HIV do not breastfeed their babies under any circumstances in order
to avoid transmission of HIV. </span></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Animal studies have shown no effects on
fertility. No human data on the effect of lopinavir/ritonavir on fertility are
available.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.7 Effects on ability to drive and use machines</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>No studies on the effects on the ability
to drive and use machines have been performed. Patients should be informed
that nausea has been reported during treatment with Kaletra (see section 4.8).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra oral solution contains
approximately 42% v/v alcohol. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.8 Undesirable effects </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>a. Summary of the safety profile</span></u></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The safety of Kaletra has been
investigated in over 2600 patients in Phase II&#8209;IV clinical trials</span><span
lang=EN-GB>, of which over 700 have received a dose of 800/200&nbsp;mg (6
capsules or 4 tablets) once daily</span><span lang=EN-GB>. Along with
nucleoside reverse transcriptase inhibitors (NRTIs), in some studies, Kaletra
was used in combination with efavirenz or nevirapine. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The most common adverse reactions related
to Kaletra therapy during clinical trials were diarrhoea</span><span
lang=EN-GB>, nausea, vomiting, hypertriglyceridaemia and hypercholesterolemia</span><span
lang=EN-GB>. </span><span lang=EN-GB>Diarrhoea, nausea and vomiting may occur
at the beginning of the treatment while hypertriglyceridaemia and
hypercholesterolemia may occur later. Treatment emergent adverse events led to
premature study discontinuation for 7% of subjects from Phase II&#8209;IV
studies.</span><span lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>It is important to note that cases of
pancreatitis have been reported in patients receiving Kaletra, including those
who developed hypertriglyceridaemia. Furthermore, rare increases in PR
interval have been reported during Kaletra therapy (see section 4.4). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in;page-break-after:avoid'><u><span
lang=EN-GB style='font-style:normal'>b. Tabulated list of adverse reactions</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Adverse
reactions from clinical trials and post-marketing experience in adult and
paediatric patients:</span></p>

<p class=EMEANormal><span lang=EN-GB>The following events have been identified
as adverse reactions. The frequency category includes all reported events of
moderate to severe intensity, regardless of the individual causality
assessment. The adverse reactions are displayed by system organ class. Within
each frequency grouping, undesirable effects are presented in order of
decreasing seriousness: very common (&#8805;1/10), common (&#8805;&nbsp;1/100 </span><span
lang=EN-GB>to&nbsp;&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1000
to&nbsp;&lt;&nbsp;1/100), rare (&#8805;1/10,000 to &lt;1/1000) and </span><span
style='color:black'>not known (cannot be estimated from the available data)</span><span
lang=EN-GB>.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=3 valign=top style='width:453.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Undesirable effects in clinical studies and post-marketing in
  adult patients</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>System organ class</span></b></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Frequency</span></b></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Adverse reaction</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Infections
  and infestations</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Very
  common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Upper
  respiratory tract infection</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lower respiratory
  tract infection, skin infections including</span><span lang=EN-GB>
  cellulitis, folliculitis and furuncle</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:29.65pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:29.65pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Blood and
  lymphatic system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.65pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:29.65pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Anaemia,
  leucopenia, </span><span lang=EN-GB>neutropenia,</span><span lang=EN-GB>
  lymphadenopathy</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypersensitivity </span><span
  lang=EN-GB>including urticaria and angioedema</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Immune reconstitution inflammatory syndrome</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Endocrine disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypogonadism </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Blood glucose disorders including
  diabetes mellitus, </span><span lang=EN-GB>hypertriglyceridaemia,
  hypercholesterolemia, weight decreased, decreased appetite</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Weight increased, increased appetite</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Anxiety</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abnormal dreams, libido decreased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Headache</span><span lang=EN-GB>
  (including migraine), neuropathy (including peripheral neuropathy),
  dizziness, insomnia</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Cerebrovascular accident, convulsion,
  dysgeusia, ageusia, tremor</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Visual impairment</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:16.6pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.6pt'>
  <p class=EMEANormal><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.6pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.6pt'>
  <p class=EMEANormal><span lang=EN-GB>Tinnitus, vertigo</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:35.7pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:35.7pt'>
  <p class=EMEANormal><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:35.7pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:35.7pt'>
  <p class=EMEANormal><span lang=EN-GB>Atherosclerosis such as </span><span
  lang=EN-GB>myocardial infarction<sup>1</sup>,</span><span lang=EN-GB>
  atrioventricular block, tricuspid valve incompetence</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypertension</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Deep vein thrombosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=3 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Diarrhoea, nausea</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Pancreatitis<sup>1</sup>, vomiting, </span><span
  lang=EN-GB>gastrooesophageal reflux disease, gastroenteritis and colitis, </span><span
  lang=EN-GB>abdominal pain (upper and lower), </span><span lang=EN-GB>abdominal
  distension, dyspepsia, haemorrhoids</span><span lang=EN-GB>, flatulence</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:52.6pt'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.6pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.6pt'>
  <p class=EMEANormal><span lang=EN-GB>Gastrointestinal haemorrhage including
  gastrointestinal ulcer, duodenitis, gastritis and rectal haemorrhage,
  stomatitis and oral ulcers</span><span lang=EN-GB>, faecal incontinence,
  constipation, dry mouth</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Hepatobiliary
  disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Hepatitis
  including AST, ALT and GGT increases</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.3pt'>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:44.3pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:44.3pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Jaundice,
  hepatic steatosis, hepatomegaly, </span><span lang=EN-GB>cholangitis,
  hyperbilirubinemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=3 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rash including maculopapular rash,
  dermatitis/rash including eczema and seborrheic dermatitis, night sweats,
  pruritus</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Alopecia, </span><span lang=EN-GB>capillaritis,
  vasculitis </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Steven-Johnson syndrome, erythema
  multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Myalgia, </span><span lang=EN-GB>musculoskeletal
  pain including arthralgia and back pain, muscle disorders such as weakness
  and spasms</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rhabdomyolysis, osteonecrosis</span><span
  lang=EN-GB> </span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Renal and urinary disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Not known</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Creatinine clearance decreased,
  nephritis, haematuria </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Nephrolithiasis</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Reproductive system and breast disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Erectile dysfunction, menstrual
  disorders - amenorrhoea, menorrhagia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.15pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=EMEANormal><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=EMEANormal><span lang=EN-GB>Fatigue including asthenia</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB> See
section 4.4: pancreatitis and lipids</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB style='color:black'>c. Description of
selected adverse reactions</span></u></p>

<p class=EMEANormal><b><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></b></p>

<p class=EMEANormal><span lang=EN-GB>Cushings syndrome has been reported in
patients receiving ritonavir and inhaled or intranasally administered
fluticasone propionate; this could also occur with other corticosteroids
metabolised via the P450 3A pathway e.g. budesonide (see section 4.4 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Increased creatine phosphokinase (CPK),
myalgia, myositis, and rarely, rhabdomyolysis have been reported with protease
inhibitors, particularly in combination with nucleoside reverse transcriptase
inhibitors.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Metabolic parameters</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Weight and levels of blood lipids and glucose
may increase during antiretroviral therapy (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>In HIV-infected patients with severe
immune deficiency at the time of initiation of combination antiretroviral
therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic
infections may arise. </span>Autoimmune disorders (such as Graves disease <span
lang=EN-GB>and autoimmune hepatitis</span>) have also been reported; however,
the reported time to onset is more variable and can occur many months after
initiation of treatment<span lang=EN-GB> (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Cases of osteonecrosis have been reported,
particularly in patients with generally acknowledged risk factors, advanced HIV
disease or long-term exposure to combination antiretroviral therapy (CART).
The frequency of this is unknown (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='font-size:11.0pt'>d. Paediatric populations</span></u></p>

<p class=MsoBodyText align=left style='margin:0in;text-align:left'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>In children 14 days of age and older, the
nature of the safety profile is similar to that seen in adults (see Table in
section b). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Reporting
of suspected adverse reactions</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the
medicinal product. Healthcare professionals are asked to report any suspected
adverse reactions </span>via <span style='background:lightgrey'>the national
reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a><span style='color:blue'>.</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.9 Overdose</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>To date, there is limited human experience
of acute overdose with Kaletra.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Overdoses with Kaletra oral solution have been reported (including
fatal outcome). The following events have been reported in association with
unintended overdoses in preterm neonates: complete atrioventricular block,
cardiomyopathy, lactic acidosis, and acute renal failure. </p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The adverse clinical signs observed in
dogs included salivation, emesis and diarrhoea/abnormal stool. The signs of
toxicity observed in mice, rats or dogs included decreased activity, ataxia,
emaciation, dehydration and tremors. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>There is no specific antidote for overdose
with Kaletra. Treatment of overdose with Kaletra is to consist of general
supportive measures including monitoring of vital signs and observation of the
clinical status of the patient. If indicated, elimination of unabsorbed active
substance is to be achieved by emesis or gastric lavage. Administration of
activated charcoal may also be used to aid in removal of unabsorbed active
substance. Since Kaletra is highly protein bound, dialysis is unlikely to be
beneficial in significant removal of the active substance.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>However, dialysis can remove both alcohol and propylene
glycol in the case of overdose with Kaletra oral solution.</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5. Pharmacological properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5.1 Pharmacodynamic properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Pharmaco-therapeutic group: antivirals for
systemic use, a</span>ntivirals for treatment of HIV infections, combinations<span
lang=EN-GB>, ATC code: J05AR10 </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Lopinavir
provides the antiviral activity of Kaletra. </span><span lang=EN-GB>Lopinavir
is an inhibitor of the HIV-1 and HIV-2 proteases. Inhibition of HIV protease
prevents cleavage of the <i>gag-pol</i> polyprotein resulting in the production
of immature, non-infectious virus. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Effects on the electrocardiogram</span></u></p>

<p class=EMEANormal><span lang=EN-GB>QTcF interval was evaluated in a
randomised, placebo and active (moxifloxacin 400&nbsp;mg once daily) controlled
crossover study in 39 healthy adults, with 10 measurements over 12 hours on Day
3. The maximum mean (95% upper confidence bound) differences in QTcF from
placebo were 3.6 (6.3) and 13.1(15.8) for 400/100&nbsp;mg twice daily and
supratherapeutic 800/200&nbsp;mg twice daily LPV/r, respectively. </span><span
lang=EN-GB>The induced QRS interval prolongation from 6 ms to 9.5 ms with high
dose lopinavir/ritonavir (800/200&nbsp;mg twice daily) contributes to QT
prolongation. </span><span lang=EN-GB>The two regimens resulted in exposures
on Day 3 which were approximately 1.5 and 3&#8209;fold higher than those
observed with recommended once daily or twice daily LPV/r doses at steady
state. No subject experienced an increase in QTcF of </span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;60 ms from baseline
or a QTcF interval exceeding the potentially clinically relevant threshold of
500 ms.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Modest prolongation of the PR interval was
also noted in subjects receiving lopinavir/ritonavir in the same study on Day
3. </span><span lang=EN-GB>The mean changes from baseline in PR interval
ranged from 11.6&nbsp;ms to 24.4&nbsp;ms in the 12 hour interval post dose.<b><i>
</i></b></span><span lang=EN-GB>Maximum PR interval was 286&nbsp;ms and no
second or third degree heart block was observed (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Antiviral activity <i>in&nbsp;vitro</i></span></u></p>

<p class=EMEANormal><span lang=EN-GB>The <i>in&nbsp;vitro </i>antiviral
activity of lopinavir against laboratory and clinical HIV strains was evaluated
in acutely infected lymphoblastic cell lines and peripheral blood lymphocytes,
respectively. In the absence of human serum, the mean IC<sub>50</sub> of
lopinavir against five different HIV-1 laboratory strains was 19 nM. In the
absence and presence of 50% human serum, the mean IC<sub>50</sub> of lopinavir
against HIV-1<sub>IIIB</sub> in MT4 cells was 17 nM and 102 nM, respectively.
In the absence of human serum, the mean IC<sub>50</sub> of lopinavir was 6.5 nM
against several HIV-1 clinical isolates.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Resistance</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>In vitro selection of resistance</span></i><span
lang=EN-GB>HIV-1 isolates with reduced susceptibility to lopinavir have been
selected <i>in&nbsp;vitro</i>. HIV-1 has been passaged <i>in&nbsp;vitro</i>
with lopinavir alone and with lopinavir plus ritonavir at concentration ratios
representing the range of plasma concentration ratios observed during Kaletra
therapy. Genotypic and phenotypic analysis of viruses selected in these
passages suggest that the presence of ritonavir, at these concentration ratios,
does not measurably influence the selection of lopinavir-resistant viruses.
Overall, the <i>in&nbsp;vitro</i> characterisation of phenotypic
cross-resistance between lopinavir and other protease inhibitors suggest that
decreased susceptibility to lopinavir correlated closely with decreased
susceptibility to ritonavir and indinavir, but did not correlate closely with
decreased susceptibility to amprenavir, saquinavir, and nelfinavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB
style='font-size:11.0pt'>Analysis of resistance in ARV-nave patients </span></i></p>

<p class=EMEANormal><span lang=EN-GB>In clinical studies with a limited number
of isolates analysed, the selection of resistance to lopinavir has not been
observed in nave patients without significant protease inhibitor resistance at
baseline. See further the detailed description of the clinical studies.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Analysis of resistance in
PI-experienced patients</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The selection of resistance to lopinavir
in patients having failed prior protease inhibitor therapy was characterised by
analysing the longitudinal isolates from 19 protease inhibitor-experienced
subjects in 2 Phase II and one Phase III studies who either experienced
incomplete virologic suppression or viral rebound subsequent to initial
response to Kaletra and who demonstrated incremental <i>in vitro</i> resistance
between baseline and rebound (defined as emergence of new mutations or 2-fold
change in phenotypic susceptibility to lopinavir). Incremental resistance was
most common in subjects whose baseline isolates had several protease
inhibitor-associated mutations, but &lt;&nbsp;40-fold reduced susceptibility to
lopinavir at baseline. Mutations V82A, I54V and M46I emerged most frequently.
Mutations L33F, I50V and V32I combined with I47V/A were also observed. The 19
isolates demonstrated a 4.3-fold increase in IC<sub>50</sub> compared to
baseline isolates (from 6.2- to 43-fold, compared to wild-type virus).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Genotypic correlates of reduced phenotypic
susceptibility to lopinavir in viruses selected by other protease inhibitors.
The <i>in&nbsp;vitro</i> antiviral activity of lopinavir against 112 clinical
isolates taken from patients failing therapy with one or more protease
inhibitors was assessed. Within this panel, the following mutations in HIV
protease were associated with reduced <i>in&nbsp;vitro</i> susceptibility to
lopinavir: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V,
V82A/F/T, I84V and L90M. The median EC<sub>50</sub> of lopinavir against
isolates with 0&nbsp;&#8722;&nbsp;3, 4&nbsp;&#8722;&nbsp;5,
6&nbsp;&#8722;&nbsp;7 and 8&nbsp;&#8722;&nbsp;10 mutations at the above amino
acid positions was 0.8, 2.7 13.5 and 44.0-fold higher than the EC<sub>50</sub>
against wild type HIV, respectively. The 16 viruses that displayed
&gt;&nbsp;20-fold change in susceptibility all contained mutations at positions
10, 54, 63 plus 82 and/or 84. In addition, they contained a median of
3&nbsp;mutations at amino acid positions 20, 24, 46, 53, 71 and 90. </span><span
lang=EN-GB>In addition to the mutations described above, mutations V32I and
I47A have been observed in rebound isolates with reduced lopinavir
susceptibility from protease inhibitor experienced patients receiving Kaletra
therapy</span><span lang=EN-GB>, and mutations I47A and L76V have been observed
in rebound isolates with reduced lopinavir susceptibility from patients
receiving Kaletra therapy.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Conclusions regarding the relevance of
particular mutations or mutational patterns are subject to change with
additional data, and it is recommended to always consult current interpretation
systems for analysing resistance test results.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Antiviral activity of Kaletra in
patients failing protease inhibitor therapy</span></i><span lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>The clinical relevance of reduced <i>in
vitro</i> susceptibility to lopinavir has been examined by assessing the
virologic response to Kaletra therapy, with respect to baseline viral genotype
and phenotype, in 56 patients previous failing therapy with multiple protease
inhibitors. The EC<sub>50</sub> of lopinavir against the 56 baseline viral
isolates ranged from 0.6 to 96-fold higher than the EC<sub>50</sub> against
wild type HIV. After 48 weeks of treatment with Kaletra, efavirenz and
nucleoside reverse transcriptase inhibitors, plasma HIV RNA </span><span
lang=EN-GB style='font-family:Symbol;layout-grid-mode:line'></span><span
lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span><span lang=EN-GB>400&nbsp;copies/ml
was observed in 93% (25/27), 73% (11/15), and 25% (2/8) of patients with
&lt;&nbsp;10&#8209;fold, 10 to 40-fold, and &gt;&nbsp;40&#8209;fold reduced
susceptibility to lopinavir at baseline, respectively. In addition, virologic
response was observed in 91% (21/23), 71% (15/21) and 33% (2/6) patients with
0&nbsp;&#8722;&nbsp;5, 6&nbsp;&#8722;&nbsp;7, and 8&nbsp;&#8722;&nbsp;10
mutations of the above mutations in HIV protease associated with reduced <i>in&nbsp;vitro</i>
susceptibility to lopinavir. Since these patients had not previously been
exposed to either Kaletra or efavirenz, part of the response may be attributed
to the antiviral activity of efavirenz, particularly in patients harbouring
highly lopinavir resistant virus. The study did not contain a control arm of
patients not receiving Kaletra.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Cross&#8209;resistance</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Activity of other protease inhibitors
against isolates that developed incremental resistance to lopinavir after
Kaletra therapy in protease inhibitor experienced patients: The presence of
cross resistance to other protease inhibitors was analysed in 18 rebound i</span><span
lang=EN-GB>solates that had demonstrated evolution of resistance to lopinavir
during 3 </span><span lang=EN-GB>Phase </span><span lang=EN-GB>II and one </span><span
lang=EN-GB>Phase </span><span lang=EN-GB>III studies of Kaletra in protease
inhibitor-experienced patients. The median fold IC<sub>50</sub> of lopinavir
for these 18 isolates at baseline and rebound was 6.9- and 63-fold,
respectively, compared to wild type virus. In general, rebound isolates either
retained (if cross-resistant at baseline) or developed significant
cross-resistance to indinavir, saquinavir and atazanavir. Modest decreases in
amprenavir activity were noted with a median increase of IC<sub>50 </sub>from
3.7- to 8-fold in the baseline and rebound isolates, respectively. Isolates
retained susceptibility to tipranavir with a median increase of IC<sub>50</sub>
in baseline and rebound isolates of 1.9- and 1.8fold, respectively, compared
to wild type virus. </span><span lang=EN-GB>Please refer to the Aptivus
Summary of Product Characteristics for additional information on the use of
tipranavir, including genotypic predictors of response, in treatment of
lopinavir-resistant HIV-1 infection. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Clinical results</span></p>

<p class=EMEANormal><span lang=EN-GB>The effects of Kaletra (in combination
with other antiretroviral agents) on biological markers (plasma HIV RNA levels
and CD4+ T-cell counts) have been investigated in controlled studies of Kaletra
of 48 to 360&nbsp;weeks duration. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Adult Use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUnderline style='margin:0in'><span lang=EN-GB
style='text-decoration:none'>Patients without prior antiretroviral therapy</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Study M98-863 was a randomised,
double-blind trial of 653 antiretroviral treatment nave patients investigating
Kaletra (400/100&nbsp;mg twice daily) compared to nelfinavir (750&nbsp;mg three
times daily) plus stavudine and lamivudine. Mean baseline CD4+ T-cell count
was 259&nbsp;cells/mm<sup>3</sup> (range: 2 to 949&nbsp;cells/ mm<sup>3</sup>)
and mean baseline plasma HIV-1 RNA was 4.9&nbsp;log<sub>10&nbsp;</sub>copies/ml
(range: 2.6 to 6.8&nbsp;log<sub>10&nbsp;</sub>copies/ml). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 1</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=515
 style='width:386.5pt;margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=515 colspan=3 valign=top style='width:386.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 48: Study M98-863</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Kaletra (N=326)</span></b></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Nelfinavir (N=327)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>HIV RNA &lt; 400 copies/ml*</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>75%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>63%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>HIV RNA &lt; 50 copies/ml*</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>67%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>52%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Mean increase from baseline in CD4+<sub>
  </sub>T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>207</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>195</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal style='margin-left:30.0pt'><span lang=EN-GB>* intent to
treat analysis where patients with missing values are considered virologic
failures </span></p>

<p class=EMEANormal style='margin-left:30.0pt'><span lang=EN-GB>
p&nbsp;&lt;&nbsp;0.001</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>One-hundred thirteen nelfinavir-treated
patients and 74 lopinavir/ritonavir-treated patients had an HIV RNA above
400&nbsp;copies/ml while on treatment from Week 24 through Week 96. Of these,
isolates from 96 nelfinavir-treated patients and 51 lopinavir/ritonavir-treated
patients could be amplified for resistance testing. Resistance to nelfinavir,
defined as the presence of the D30N or L90M mutation in protease, was observed
in 41/96 (43%) patients. Resistance to lopinavir, defined as the presence of
any primary or active site mutations in protease (see above), was observed in
0/51 (0%) patients. Lack of resistance to lopinavir was confirmed by
phenotypic analysis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Sustained virological response to Kaletra
(in combination with nucleoside/nucleotide reverse transcriptase inhibitors)
has been also observed in a small Phase II study (M97-720) through 360 weeks of
treatment. One hundred patients were originally treated with Kaletra in the
study (including 51 patients receiving 400/100&nbsp;mg twice daily and 49
patients at either 200/100&nbsp;mg twice daily or 400/200&nbsp;mg twice
daily). All patients converted to open-label Kaletra at the 400/100&nbsp;mg
twice daily dose between week 48 and week 72. <span style='color:black'>Thirty&#8209;nine
patients (39%) discontinued the study, including 16 (16%) discontinuations due
to adverse events, one of which was associated with a death. </span>Sixty&#8209;one
patients completed the study (35 patients received the recommended
400/100&nbsp;mg twice daily dose throughout the study). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 2</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=536
 style='width:402.0pt;margin-left:29.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=536 colspan=2 valign=top style='width:402.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 360: Study M97-720</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Kaletra (N=100)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 400 copies/ml</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>61%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 50 copies/ml</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>59%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Mean
  increase from baseline in CD4+ T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>501</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Through 360 weeks of treatment, genotypic
analysis of viral isolates was successfully conducted in 19 of 28 patients with
confirmed HIV RNA above 400&nbsp;copies/ml revealed no primary or active site
mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82,
84 and 90) or protease inhibitor phenotypic resistance.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUnderline style='margin:0in'><span lang=EN-GB
style='text-decoration:none'>Patients with prior antiretroviral therapy</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>M97-765 is a randomised, double-blind
trial evaluating Kaletra at two dose levels (400/100&nbsp;mg and 400/200&nbsp;mg,
both twice daily) plus nevirapine (200&nbsp;mg twice daily) and two nucleoside
reverse transcriptase inhibitors in 70 single protease inhibitor experienced,
non-nucleoside reverse transcriptase inhibitor nave patients. Median baseline
CD<sub>4</sub> cell count was 349&nbsp;cells/mm<sup>3</sup> (range
72&nbsp;to&nbsp;807&nbsp;cells/mm<sup>3</sup>) and median baseline plasma HIV-1
RNA was 4.0&nbsp;log<sub>10&nbsp;</sub>copies/ml (range
2.9&nbsp;to&nbsp;5.8&nbsp;log<sub>10</sub> copies/ml). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 3</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=536
 style='width:402.0pt;margin-left:29.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=536 colspan=2 valign=top style='width:402.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 24: Study M97-765</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Kaletra 400/100 mg (N=36)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=FR>HIV RNA &lt; 400 copies/ml (ITT)*</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>75%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=FR>HIV RNA &lt; 50 copies/ml (ITT)*</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>58%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Mean increase from baseline in CD4+
  T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>174</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB> * intent to treat analysis where
patients with missing values are considered virologic failures</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>M98-957 is
a randomised, open-label study evaluating Kaletra treatment at two dose levels
(400/100&nbsp;mg and 533/133&nbsp;mg, both twice daily) plus efavirenz
(600&nbsp;mg once daily) and nucleoside reverse transcriptase inhibitors in
57&nbsp;multiple protease inhibitor experienced, non-nucleoside reverse transcriptase
inhibitor nave patients. Between week 24 and 48, patients randomised to a
dose of 400/100&nbsp;mg were converted to a dose of 533/133&nbsp;mg. Median
baseline CD<sub>4</sub> cell count was 220&nbsp;cells/mm<sup>3</sup> (range13
to 1030 cells/mm<sup>3</sup>). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Table 4</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=536
 style='width:402.0pt;margin-left:29.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=536 colspan=2 valign=top style='width:402.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB>Outcomes
  at Week 48: Study M98-957</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Kaletra 400/100 mg (N=57)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>HIV RNA &lt; 400 copies/ml*</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>65%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Mean increase from baseline in CD4+
  T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>94</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB> * intent to treat analysis where
patients with missing values are considered virologic failures</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Paediatric Use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>M98-940 was an open-label study of a
liquid formulation of Kaletra in 100 antiretroviral nave (44%) and experienced
(56%) paediatric patients. All patients were non-nucleoside reverse
transcriptase inhibitor nave. Patients were randomised to either 230&nbsp;mg
lopinavir/57.5&nbsp;mg ritonavir per m<sup>2</sup> or 300&nbsp;mg
lopinavir/75&nbsp;mg ritonavir per m<sup>2</sup>. Nave patients also received
nucleoside reverse transcriptase inhibitors. Experienced patients received
nevirapine plus up to two nucleoside reverse transcriptase inhibitors. <span
style='layout-grid-mode:line'>Safety, efficacy and pharmacokinetic profiles of
the two dose regimens were assessed after 3 weeks of therapy in each patient.
Subsequently, all patients were continued on the 300/75&nbsp;mg per m<sup>2</sup>
dose.</span> Patients had a mean age of 5 years (range 6 months to 12 years)
with 14&nbsp;patients less than 2 years old and 6&nbsp;patients one year or
less. Mean baseline CD4+ T&#8209;cell count was 838&nbsp;cells/mm<sup>3</sup>
and mean baseline plasma HIV-1 RNA was 4.7&nbsp;log<sub>10&nbsp;</sub>copies/ml.</span></p>

<p class=EMEANormal><b><i><span lang=EN-GB>&nbsp;</span></i></b></p>

<p class=EMEANormal><span lang=EN-GB>Table 5</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=515
 style='width:386.5pt;margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=515 colspan=3 valign=top style='width:386.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB>Outcomes
  at Week 48: Study M98-940*</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Antiretroviral Nave (N=44)</span></b></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Antiretroviral Experienced (N=56)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>HIV RNA &lt; 400 copies/ml</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>84%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>75%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Mean increase from baseline in CD4+
  T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>404</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>284</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif;font-weight:normal'> * intent to treat analysis
where patients with missing values are considered virologic failures</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Study P1030 was an open&#8209;label, dose-finding trial
evaluating the pharmacokinetic profile, tolerability, safety and efficacy of Kaletra
oral solution at a dose of 300&nbsp;mg lopinavir/75&nbsp;mg ritonavir per m<sup>2
</sup>twice daily plus 2 NRTIs in HIV&#8209;1 infected infants &#8805;&nbsp;14
days and &lt;&nbsp;6 months of age. At entry, median (range) HIV&#8209;1 RNA
was 6.0&nbsp;(4.7-7.2)&nbsp;log<sub>10</sub> copies/ml and median (range)
CD4+T-cell percentage was 41&nbsp;(16&#8209;59). </p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 6</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=515
 style='width:386.5pt;margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=515 colspan=3 valign=top style='width:386.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 24: Study P1030</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Age: </span>&#8805;&nbsp;14 days and</b></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b>&lt;&nbsp;6 weeks </b></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(N=10)</span></b></p>
  </td>
  <td width=159 valign=top style='width:119.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Age: </span>&#8805;&nbsp;6 weeks and </b></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b>&lt;&nbsp;6 months</b><b> </b></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>(N=21)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 400 copies/ml*</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>70%</span></p>
  </td>
  <td width=159 valign=top style='width:119.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>48%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Median change
  from baseline in CD4+ T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=156 valign=top style='width:117.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>- 1% (95% CI: -10, 18) (n=6)</span></p>
  </td>
  <td width=159 valign=top style='width:119.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>+ 4% (95% CI: -1, 9) (n=19)</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB> *Proportion of subjects who had
HIV-1 &lt;&nbsp;400 copies/ml and had remained on study treatment</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Study P1060 was a randomised controlled trial of nevirapine
versus lopinavir/ritonavir-based therapy in subjects 2&nbsp;to&nbsp;36 months
of age infected with HIV&#8209;1 who had (Cohort I) and had not (Cohort II)
been exposed to nevirapine during pregnancy for prevention of mother&#8209;to&#8209;child
transmission. Lopinavir/ritonavir was administered twice daily at 16/4&nbsp;mg/kg<span
style='font-size:10.0pt;font-family:TimesNewRoman'> </span>for subjects 2&nbsp;months
to &lt;&nbsp;6 months, 12/3&nbsp;mg/kg for subjects &#8805;&nbsp;6 months and
&lt;&nbsp;15&nbsp;kg, 10/2.5&nbsp;mg/kg for subjects &#8805; 6 months and
&#8805;&nbsp;15&nbsp;kg to &lt;&nbsp;40&nbsp;kg, or 400/100&nbsp;mg for
subjects &#8805;&nbsp;40&nbsp;kg. The nevirapine-based regimen was 160&#8209;200&nbsp;mg/m<sup>2</sup>
once daily for 14&nbsp;days, then 160&#8209;200&nbsp;mg/m<sup>2</sup> every
12&nbsp;hours. Both treatment arms included zidovudine 180&nbsp;mg/m<sup>2</sup>
every 12&nbsp;hours and lamivudine 4&nbsp;mg/kg every 12&nbsp;hours. The median
follow&#8209;up was 48&nbsp;weeks in Cohort I and 72&nbsp;weeks in Cohort II. At
entry, median age was 0.7&nbsp;years, median CD4 T&#8209;cell count was 1147&nbsp;cells/mm<sup>3</sup>,
median CD4 T&#8209;cell was 19%, and median HIV&#8209;1 RNA was
&gt;&nbsp;750,000&nbsp;copies/ml. Among 13 subjects with viral failure in the lopinavir/ritonavir
group with resistance data available no resistance to lopinavir/ritonavir was
found.</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal style='page-break-after:avoid'>Table 7</p>

<p class=EMEANormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=554
 style='margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=554 colspan=5 valign=top style='width:415.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 24: Study P1060</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 colspan=2 valign=top style='width:166.55pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Cohort I</span></b></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:161.95pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Cohort II </span></b></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=132 valign=top style='width:99.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>lopinavir/ritonavir <b>(N=82)</b></span></p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>nevirapine <b>(N=82)</b></span></p>
  </td>
  <td width=126 valign=top style='width:94.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>lopinavir/ritonavir <b>(N=140)</b></span></p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>nevirapine <b>(N=147)</b></span></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Virologic
  failure*</span></p>
  </td>
  <td width=132 valign=top style='width:99.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'>21.7%</p>
  </td>
  <td width=90 valign=top style='width:67.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>39.6%</span></p>
  </td>
  <td width=126 valign=top style='width:94.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'>19.3%</p>
  </td>
  <td width=90 valign=top style='width:67.5pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'>40.8%</p>
  </td>
 </tr>
</table>

<p class=EMEANormal style='margin-left:30.0pt'><span lang=EN-GB>*Defined as
confirmed plasma HIV-1 RNA level &gt;&nbsp;400 copies/ml at 24 weeks or viral
rebound &gt;&nbsp;4000 copies/ml after Week 24. Overall failure rate combining
the treatment differences across age strata, weighted by the precision of the
estimate within each age stratum</span></p>

<p class=EMEANormal style='margin-left:30.0pt'><span lang=EN-GB>p=0.015 (Cohort
I); p&lt;&nbsp;0.001 (Cohort II)</span></p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>The CHER study was a randomized, open-label study comparing
3&nbsp;treatment strategies (deferred treatment, early treatment for 40&nbsp;weeks,
or early treatment for 96&nbsp;weeks) in children with perinatally acquired HIV&#8209;1
infection. The treatment regimen was zidovudine plus lamivudine plus 300&nbsp;mg
lopinavir/75&nbsp;mg ritonavir per m<sup>2</sup> twice daily until 6 months of
age, then 230&nbsp;mg lopinavir/57.5&nbsp;mg ritonavir per m<sup>2</sup> twice
daily. There were no reported events of failure attributed to therapy limiting
toxicity.</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal style='page-break-after:avoid'>Table 8</p>

<p class=EMEANormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=554
 style='margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=554 colspan=3 valign=top style='width:415.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Hazard Ratio for Death or Failure of First-line Therapy Relative<br>
  to ART Deferred Treatment: CHER Study</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=222 valign=top style='width:166.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>40 week arm (N=13)</span></b></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>96 week arm (N=13)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Hazard
  ratio for death or failure of therapy* </span></p>
  </td>
  <td width=222 valign=top style='width:166.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'>0.319</p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'>0.332</p>
  </td>
 </tr>
</table>

<p class=EMEANormal style='margin-left:30.0pt'><span lang=EN-GB>* Failure
defined as clinical, immunological disease progression, virological failure or regimen
limiting ART toxicity</span></p>

<p class=EMEANormal style='margin-left:30.0pt'><span lang=EN-GB>p=0.0005 (40
week arm); p&lt;&nbsp;0.0008 (96 week arm)</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5.2 Pharmacokinetic properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The pharmacokinetic properties of
lopinavir co-administered with ritonavir have been evaluated in healthy adult
volunteers and in HIV-infected patients; no substantial differences were
observed between the two groups. Lopinavir is essentially completely metabolised
by CYP3A. Ritonavir inhibits the metabolism of lopinavir, thereby increasing
the plasma levels of lopinavir. Across studies, administration of Kaletra
400/100&nbsp;mg twice daily yields mean steady-state lopinavir plasma
concentrations 15 to 20-fold higher than those of ritonavir in HIV-infected
patients. The plasma levels of ritonavir are less than 7% of those obtained
after the ritonavir dose of 600&nbsp;mg twice daily. The <i>in&nbsp;vitro</i>
antiviral EC<sub>50</sub> of lopinavir is approximately 10-fold lower than that
of ritonavir. Therefore, the antiviral activity of Kaletra is due to
lopinavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Multiple
dosing with 400/100&nbsp;mg Kaletra twice daily for 2 weeks and without meal
restriction produced a mean </span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB> SD lopinavir peak plasma concentration (C<sub>max</sub>) of 12.3&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;5.4&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/ml, occurring
approximately 4 hours after administration. The mean steady-state trough
concentration prior to the morning dose was 8.1&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;5.7&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/ml. Lopinavir
AUC over a 12 hour dosing interval averaged 113.2&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;60.5&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>h/ml. The
absolute bioavailability of lopinavir co-formulated with ritonavir in humans
has not been established.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Effects of food on oral absorption</span></u><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra soft capsules and liquid have been
shown to be bioequivalent under nonfasting conditions (moderate fat meal).
Administration of a single 400/100&nbsp;mg dose of Kaletra soft capsules with a
moderate fat meal (500&nbsp;&nbsp;682&nbsp;kcal, 22.7&nbsp;25.1% from fat)
was associated with a mean increase of 48% and 23% in lopinavir AUC and C<sub>max</sub>,
respectively, relative to fasting. For Kaletra oral solution, the
corresponding increases in lopinavir AUC and C<sub>max</sub> were 80% and 54%,
respectively. Administration of Kaletra with a high fat meal (872&nbsp;kcal,
55.8% from fat) increased lopinavir AUC and C<sub>max</sub> by 96% and 43%,
respectively, for soft capsules, and 130% and 56%, respectively, for oral
solution. To enhance bioavailability and minimise variability Kaletra is to be
taken with food. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Distribution</span></u><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>At steady state, lopinavir is
approximately 98&nbsp;&nbsp;&#8722;&nbsp;&nbsp;99% bound to serum proteins.
Lopinavir binds to both alpha-1-acid glycoprotein (AAG) and albumin however, it
has a higher affinity for AAG. At steady state, lopinavir protein binding
remains constant over the range of observed concentrations after
400/100&nbsp;mg Kaletra twice daily, and is similar between healthy volunteers
and HIV-positive patients.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Biotransformation</span></u><i><span
lang=EN-GB> </span></i></p>

<p class=EMEANormal><i><span lang=EN-GB>In&nbsp;vitro</span></i><span
lang=EN-GB> experiments with human hepatic microsomes indicate that lopinavir
primarily undergoes oxidative metabolism. Lopinavir is extensively metabolised
by the hepatic cytochrome P450 system, almost exclusively by isozyme CYP3A.
Ritonavir is a potent CYP3A inhibitor which inhibits the metabolism of
lopinavir and therefore, increases plasma levels of lopinavir. A <sup>14</sup>C&#8209;lopinavir
study in humans showed that 89% of the plasma radioactivity after a single
400/100&nbsp;mg Kaletra dose was due to parent active substance. At least 13
lopinavir oxidative metabolites have been identified in man. The 4-oxo and
4-hydroxymetabolite epimeric pair are the major metabolites with antiviral
activity, but comprise only minute amounts of total plasma radioactivity.
Ritonavir has been shown to induce metabolic enzymes, resulting in the
induction of its own metabolism, and likely the induction of lopinavir
metabolism. Pre-dose lopinavir concentrations decline with time during
multiple dosing, stabilising after approximately 10&nbsp;days to 2 weeks.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEANormal><span lang=EN-GB>After a 400/100&nbsp;mg <sup>14</sup>C-lopinavir/ritonavir
dose, approximately 10.4&nbsp;</span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>&nbsp;2.3% and 82.6&nbsp;</span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>&nbsp;2.5% of an administered dose of <sup>14</sup>C-lopinavir
can be accounted for in urine and faeces, respectively. Unchanged lopinavir
accounted for approximately 2.2% and 19.8% of the administered dose in urine
and faeces, respectively. After multiple dosing, less than 3% of the lopinavir
dose is excreted unchanged in the urine. The effective (peak to trough)
half-life of lopinavir over a 12&nbsp;hour dosing interval averaged
5&nbsp;&#8722;&nbsp;6 hours, and the apparent oral clearance (CL/F) of
lopinavir is 6&nbsp;to&nbsp;7&nbsp;l/h.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Special Populations</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Paediatrics </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Data from clinical
trials in children below 2 years of age include the pharmacokinetics of Kaletra
300/75&nbsp;mg/m<sup>2</sup> twice daily studied in a total of 31&nbsp;paediatric
patients, ranging in age from 14&nbsp;days to 6&nbsp;months. The
pharmacokinetics of Kaletra 300/75&nbsp;mg/m<sup>2</sup> twice daily with
nevirapine and 230/57.5&nbsp;mg/ m<sup>2</sup> twice daily alone have been
studied in 53&nbsp;paediatric patients ranging in age from 6&nbsp;months to
12&nbsp;years. The mean (SD) for the studies are reported in the table below.</span><span
lang=EN-GB style='font-size:11.0pt'> The 230/57.5&nbsp;mg/m<sup>2</sup> twice
daily regimen without nevirapine and the 300/75&nbsp;mg/m<sup>2</sup> twice
daily regimen with nevirapine provided lopinavir plasma concentrations similar
to those obtained in</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>adult patients receiving the
400/100&nbsp;mg twice daily regimen without nevirapine. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=554
 style='margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><span lang=EN-GB>C<sub>max</sub> (</span></b><b><span
  style='font-family:Symbol'>m</span>g/ml)</b></p>
  </td>
  <td width=222 valign=top style='width:166.55pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>C<sub>min</sub> (</span></b><b><span style='font-family:Symbol'>m</span>g/ml)</b></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>AUC<sub>12</sub> (</span></b><b><span style='font-family:Symbol'>m</span>g</b><b><span
  style='font-family:Symbol'></span>h/ml)</b></p>
  </td>
 </tr>
 <tr>
  <td width=554 colspan=3 valign=top style='width:415.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Age </span></b><b><span style='color:#2D2926'>&#8805; 14 days to
  &lt; 6 weeks cohort (N = 9):</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>5.17 (1.84)</span></p>
  </td>
  <td width=222 valign=top style='width:166.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>1.40
  (0.48)</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>43.39
  (14.80)</span></p>
  </td>
 </tr>
 <tr>
  <td width=554 colspan=3 valign=top style='width:415.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Age </span></b><b><span style='color:#2D2926'>&#8805; 6 weeks to
  &lt; 6 months cohort (N = 18):</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>9.39 (4.91)</span></p>
  </td>
  <td width=222 valign=top style='width:166.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>1.95
  (1.80)</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>74.50
  (37.87)</span></p>
  </td>
 </tr>
 <tr>
  <td width=554 colspan=3 valign=top style='width:415.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Age </span></b><b><span style='color:#2D2926'>&#8805; 6 months to
  &lt; 12 years cohort (N = 53):</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>8.2 (2.9)<sup>a</sup></span></p>
  </td>
  <td width=222 valign=top style='width:166.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>3.4
  (2.1)<sup>a</sup></span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>72.6
  (31.1)<sup>a</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>10.0 (3.3)<sup>b</sup></span></p>
  </td>
  <td width=222 valign=top style='width:166.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>3.6
  (3.5)<sup>b</sup></span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>85.8
  (36.9)<sup>b</sup></span></p>
  </td>
 </tr>
 <tr>
  <td width=554 colspan=3 valign=top style='width:415.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Adult</span></b><sup><span lang=EN-GB>c</span></sup></p>
  </td>
 </tr>
 <tr>
  <td width=116 valign=top style='width:87.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>12.3 (5.4)</span></p>
  </td>
  <td width=222 valign=top style='width:166.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>8.1
  (5.7)</span></p>
  </td>
  <td width=216 valign=top style='width:161.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>113.2
  (60.5)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>a.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Kaletra oral solution
230/57.5&nbsp;mg/m<sup>2</sup> twice daily regimen without nevirapine</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>b.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Kaletra oral solution 300/75&nbsp;mg/m<sup>2</sup>
twice daily regimen with nevirapine</span></p>

<p class=MsoNormal style='margin-left:46.35pt;text-indent:-.25in'><span
lang=EN-GB style='font-size:11.0pt'>c.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Kaletra film-coated
tablets 400/100&nbsp;mg twice daily at steady state</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Gender, Race and
Age </span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra pharmacokinetics have not been
studied in older people. No age or gender related pharmacokinetic differences
have been observed in adult patients. Pharmacokinetic differences due to race
have not been identified.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Renal Insufficiency </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
pharmacokinetics have not been studied in patients with renal insufficiency;
however, since the renal clearance of lopinavir is negligible, a decrease in
total body clearance is not expected in patients with renal insufficiency.</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Hepatic
Insufficiency </span></p>

<p class=EMEANormal><span lang=EN-GB>The steady state pharmacokinetic
parameters of lopinavir in HIV-infected patients with mild to moderate hepatic
impairment were compared with those of HIV-infected patients with normal
hepatic function in a multiple dose study with lopinavir/ritonavir
400/100&nbsp;mg twice daily. A limited increase in total lopinavir
concentrations of approximately 30% has been observed which is not expected to
be of clinical relevance (see section 4.2).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>5.3 Preclinical
safety data</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Repeat-dose toxicity studies in rodents and dogs
identified major target organs as the liver, kidney, thyroid, spleen and
circulating red blood cells. Hepatic changes indicated cellular swelling with
focal degeneration. While exposure eliciting these changes were comparable to
or below human clinical exposure, dosages in animals were over 6-fold the
recommended clinical dose. Mild renal tubular degeneration was confined to
mice exposed with at least twice the recommended human exposure; the kidney was
unaffected in rats and dogs. Reduced serum thyroxin led to an increased
release of TSH with resultant follicular cell hypertrophy in the thyroid glands
of rats. These changes were reversible with withdrawal of the active substance
and were absent in mice and dogs. Coombs-negative anisocytosis and
poikilocytosis were observed in rats, but not in mice or dogs. Enlarged
spleens with histiocytosis were seen in rats but not other species. Serum
cholesterol was elevated in rodents but not dogs, while triglycerides were
elevated only in mice.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>During <i>in&nbsp;vitro</i> studies,
cloned human cardiac potassium channels (HERG) were inhibited by 30% at the
highest concentrations of lopinavir/ritonavir tested, corresponding to a
lopinavir exposure 7-fold total and 15-fold free peak plasma levels achieved in
humans at the maximum recommended therapeutic dose. In contrast, similar
concentrations of lopinavir/ritonavir demonstrated no repolarisation delay in
the canine cardiac Purkinje fibres. Lower concentrations of lopinavir/ritonavir
did not produce significant potassium (HERG) current blockade. Tissue
distribution studies conducted in the rat did not suggest significant cardiac
retention of the active substance; 72-hour AUC in heart was approximately 50%
of measured plasma AUC. Therefore, it is reasonable to expect that cardiac
lopinavir levels would not be significantly higher than plasma levels.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>In dogs,
prominent U waves on the electrocardiogram have been observed associated with
prolonged PR interval and bradycardia. These effects have been assumed to be
caused by electrolyte disturbance. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>The clinical
relevance of these preclinical data is unknown, however, the potential cardiac
effects of this product in humans cannot be ruled out (see also sections 4.4
and 4.8). </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>In rats,
embryofoetotoxicity (pregnancy loss, decreased foetal viability, decreased
foetal body weights, increased frequency of skeletal variations) and postnatal
developmental toxicity (decreased survival of pups) was observed at maternally
toxic dosages. The systemic exposure to lopinavir/ritonavir at the maternal
and developmental toxic dosages was lower than the intended therapeutic
exposure in humans.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Long-term carcinogenicity studies of
lopinavir/ritonavir in mice revealed a nongenotoxic, mitogenic induction of
liver tumours, generally considered to have little relevance to human risk.
Carcinogenicity studies in rats revealed no tumourigenic findings.
Lopinavir/ritonavir was not found to be mutagenic or clastogenic in a battery
of <i>in&nbsp;vitro</i> and <i>in&nbsp;vivo</i> assays including the Ames
bacterial reverse mutation assay, the mouse lymphoma assay, the mouse
micronucleus test and chromosomal aberration assays in human lymphocytes.</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6. Pharmaceutical particulars</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.1 List of excipients</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Oral solution contains</span></u><span
lang=EN-GB>: </span></p>

<p class=EMEANormal><span lang=EN-GB>alcohol (42.4% v/v), </span></p>

<p class=EMEANormal><span lang=EN-GB>high fructose corn syrup, </span></p>

<p class=EMEANormal><span lang=EN-GB>propylene glycol (15.3% w/v), </span></p>

<p class=EMEANormal><span lang=EN-GB>purified water, </span></p>

<p class=EMEANormal><span lang=EN-GB>glycerol, </span></p>

<p class=EMEANormal><span lang=EN-GB>povidone, </span></p>

<p class=EMEANormal><span lang=EN-GB>magnasweet-110 flavour (mixture of
monoammonium glycyrrhizinate and glycerol), </span></p>

<p class=EMEANormal><span lang=EN-GB>vanilla flavour (containing
p-hydroxybenzoic acid, p-hydroxybenzaldehyde, vanillic acid, vanillin,
heliotropin, ethyl vanillin), </span></p>

<p class=EMEANormal><span lang=EN-GB>polyoxyl 40 hydrogenated castor oil, </span></p>

<p class=EMEANormal><span lang=EN-GB>cotton candy flavour (containing ethyl
maltol, ethyl vanillin, acetoin, dihydrocoumarin, propylene glycol), </span></p>

<p class=EMEANormal><span lang=EN-GB>acesulfame potassium, </span></p>

<p class=EMEANormal><span lang=EN-GB>saccharin sodium, </span></p>

<p class=EMEANormal><span lang=EN-GB>sodium chloride, </span></p>

<p class=EMEANormal><span lang=EN-GB>peppermint oil, </span></p>

<p class=EMEANormal><span lang=EN-GB>sodium citrate, </span></p>

<p class=EMEANormal><span lang=EN-GB>citric acid, </span></p>

<p class=EMEANormal><span lang=EN-GB>levomenthol.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.2 Incompatibilities</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Not applicable.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.3 Shelf life</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>2 years</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.4 Special precautions for storage</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Store in a refrigerator
(2C&nbsp;-&nbsp;8C). </span></p>

<p class=EMEANormal><span lang=EN-GB>In use storage: If kept outside of the
refrigerator, do not store above 25</span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>C and discard any unused contents after 42
days (6 weeks). It is advised to write the date of removal from the
refrigerator on the package. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.5 Nature and contents of container</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra oral solution is supplied in amber
coloured multiple-dose polyethylene terephthalate (PET) bottles in a 60&nbsp;ml
size.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Two pack sizes are available for Kaletra
oral solution:</span></p>

<p class=EMEANormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB>- 120&nbsp;ml (2&nbsp;bottles x 60&nbsp;ml) with 2 x 2&nbsp;ml
syringes with 0.1&nbsp;ml graduations<br>
<u>For volumes up to 2 ml. For larger volumes an alternative pack is
available.</u> </span></p>

<p class=EMEANormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB>- 300&nbsp;ml (5 bottles x&nbsp;60 ml) with
5&nbsp;x&nbsp;5&nbsp;ml syringes with 0.1&nbsp;ml graduations <br>
<u>For volumes greater than 2 ml. For smaller volumes an alternative pack is
available.</u></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.6 Special
precautions for disposal</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>No special
requirements.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>8. MARKETING AUTHORISATION NUMBER</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/003</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/009</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>9. Date of first authorisation/renewal of THE
authorisation</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Date of first authorisation: 20 March 2001</span></p>

<p class=EMEANormal><span lang=EN-GB>Date of latest renewal: 20 March 2011</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>10. Date of revision of the text</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Detailed information on this product </span><span
lang=EN-GB>is available on the website of the European Medicines Agency </span><a
href="http://www.ema.europa.eu"><span lang=EN-GB>http://www.ema.europa.eu</span></a></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span>

<p class=EMEAHeading1Para1 style='margin-bottom:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. Name of the medicinal
product </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>2. Qualitative and quantitative composition </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
200&nbsp;mg of lopinavir co-formulated with 50&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>For the full list of excipients, see
section 6.1. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>3. Pharmaceutical Form<i> </i></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Film-coated tablet</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Red debossed with [Abbott logo] and AL.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4. Clinical Particulars</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPCEmpty style='margin-bottom:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4.1 Therapeutic indications</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra is indicated in combination with
other antiretroviral medicinal products for the treatment of human
immunodeficiency virus (HIV-1) infected adults, adolescents and children above
the age of 2&nbsp;years. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The choice of Kaletra to treat protease
inhibitor experienced HIV-1 infected patients should be based on individual
viral resistance testing and treatment history of patients (see sections 4.4
and 5.1).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.2 Posology and method of administration</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra should be prescribed by physicians
who are experienced in the treatment of HIV infection.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra tablets must be swallowed whole
and not chewed, broken or crushed.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Adults and adolescents</span></i><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>The standard recommended dosage of Kaletra
tablets is 400/100&nbsp;mg (two 200/50&nbsp;mg) tablets twice daily taken with
or without food. In adult patients, in cases where once&#8209;daily dosing is
considered necessary for the management of the patient, Kaletra tablets may be
administered as 800/200&nbsp;mg (four 200/50&nbsp;mg tablets) once daily with
or without food. The use of a once&#8209;daily dosing should be limited to
those adult patients having only very few protease inhibitor (PI) associated
mutations (i.e. less than 3 PI mutations in line with clinical trial results,
see section 5.1 for the full description of the population) and should take
into account the risk of a lesser sustainability of the virologic suppression
(see section 5.1) and higher risk of diarrhoea (see section 4.8) compared to
the recommended standard twice&#8209;daily dosing. An oral solution is
available to patients who have difficulty swallowing. Refer to the Summary of
Product Characteristics for Kaletra oral solution for dosing instructions.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Paediatric
population (2 years of age and above)</span></i><span lang=EN-GB> </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The adult
dose of Kaletra tablets (400/100&nbsp;mg twice daily) may be used in children
40&nbsp;kg or greater or with a Body Surface Area (BSA)* greater than
1.4&nbsp;m<sup>2</sup>. For children weighing less than 40&nbsp;kg or with a
BSA between 0.5 and 1.4 m<sup>2</sup> and able to swallow tablets, please refer
to the Kaletra 100&nbsp;mg/25&nbsp;mg tablets Summary of Product
Characteristics. For children unable to swallow tablets, please refer to the
Kaletra oral solution Summary of Product Characteristics. Based on the current
data available, Kaletra should not be administered once daily in paediatric
patients (see section 5.1).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>* Body surface area can be calculated
with the following equation:</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>BSA&nbsp;(m<sup>2</sup>)
= </span><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>
(Height (cm) X Weight (kg) / 3600)</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Children less than 2 years of age</span></i><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>The safety and efficacy of Kaletra in
children aged less than 2 years have not yet been established. Currently
available data are described in section 5.2 but no recommendation on a posology
can be made. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Concomitant Therapy: Efavirenz or
nevirapine</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The following table contains dosing
guidelines for Kaletra tablets based on BSA when used in combination with
efavirenz or nevirapine in children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=462
 style='width:346.75pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=462 colspan=2 valign=top style='width:346.75pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h1 align=center style='margin-top:6.0pt;text-align:center'><span lang=EN-GB>Paediatric
  dosing guidelines with </span></h1>
  <h1 align=center style='margin-bottom:6.0pt;text-align:center'><span
  lang=EN-GB>concomitant efavirenz or nevirapine</span></h1>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  line-height:12.0pt;text-autospace:none'><span lang=EN-GB style='font-size:
  11.0pt'>Body Surface Area (m<sup>2</sup>)</span></p>
  </td>
  <td width=279 valign=top style='width:209.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoBodyText><span lang=EN-GB>Recommended lopinavir/ritonavir dosing
  (mg) twice daily. </span></p>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  line-height:12.0pt;text-autospace:none'><span lang=EN-GB style='font-size:
  11.0pt'>The adequate dosing may be achieved with the two available strengths
  of Kaletra tablets: 100/25&nbsp;mg and 200/50&nbsp;mg.*</span></p>
  </td>
 </tr>
 <tr>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-family:Symbol'></span><span
  lang=EN-GB>&nbsp;0.5 to &lt;&nbsp;0.8</span></p>
  </td>
  <td width=279 valign=top style='width:209.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>200/50&nbsp;mg</span></p>
  </td>
 </tr>
 <tr>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;0.8 to
  &lt;&nbsp;1.2</span></p>
  </td>
  <td width=279 valign=top style='width:209.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>300/75&nbsp;mg</span></p>
  </td>
 </tr>
 <tr>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;1.2 to
  &lt;&nbsp;1.4</span></p>
  </td>
  <td width=279 valign=top style='width:209.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>400/100&nbsp;mg</span></p>
  </td>
 </tr>
 <tr>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;1.4</span></p>
  </td>
  <td width=279 valign=top style='width:209.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>500/125&nbsp;mg</span></p>
  </td>
 </tr>
</table>

</div>

<p class=EMEANormal style='margin-left:.75in'><span lang=EN-GB>* Kaletra
tablets must not be chewed, broken or crushed.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=EMEANormal><span lang=EN-GB>In HIV-infected patients with mild to
moderate hepatic impairment, an increase of approximately 30% in lopinavir
exposure has been observed but is not expected to be of clinical relevance (see
section 5.2). No data are available in patients with severe hepatic
impairment. Kaletra must not be given to these patients (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Renal impairment</span></i></p>

<p class=EMEANormal><span lang=EN-GB>Since the renal clearance of lopinavir and
ritonavir is negligible, increased plasma concentrations are not expected in
patients with renal impairment. Because lopinavir and ritonavir are highly
protein bound, it is unlikely that they will be significantly removed by
haemodialysis or peritoneal dialysis. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i>Pregnancy and postpartum</i></p>

<p class=EMEANormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>No dose adjustment is required for lopinavir/ritonavir during
pregnancy and postpartum.</p>

<p class=EMEANormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Once&#8209;daily administration of lopinavir/ritonavir is not
recommended for pregnant women due to the lack of pharmacokinetic and clinical
data.</p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra tablets are administered orally
and must be swallowed whole and not chewed, broken or crushed. Kaletra tablets
can be taken with or without food.</span></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.3 Contraindications</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Hypersensitivity to the active substances
or to any of the excipients listed in section 6.1.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Severe hepatic insufficiency. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains lopinavir and ritonavir,
both of which are inhibitors of the P450 isoform CYP3A. Kaletra should not be
co-administered with medicinal products that are highly dependent on CYP3A for
clearance and for which elevated plasma concentrations are associated with
serious and/or life threatening events. These medicinal products include: </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Medicinal
  product class</span></b></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Medicinal
  products within class</span></b></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Rationale</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=4 valign=top style='width:464.3pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>Concomitant
  medicinal product levels increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alpha<sub>1</sub>-adrenoreceptor
  antagonist</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alfuzosin</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of alfuzosin which may lead to severe hypotension. The
  concomitant administration with alfuzosin is contraindicated (see section
  4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antianginal</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX style='font-size:11.0pt'>Ranolazine</span></p>
  </td>
  <td width=257 valign=top style='width:193.05pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of ranolazine which may increase the potential for serious
  and/or life-threatening reactions (see section 4.5).</span></p>
  </td>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=5><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antiarrhythmics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX style='font-size:11.0pt'>Amiodarone,
  dronedarone</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of amiodarone and dronedarone. Thereby, increasing the risk
  of arrhythmias or other serious adverse reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antibiotic</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fusidic Acid</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of fusidic acid. The concomitant administration with fusidic
  acid is contraindicated in dermatological infections (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 rowspan=2 valign=top style='width:111.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anticancer</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neratinib</span></p>
  </td>
  <td width=257 valign=top style='width:193.05pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of neratinib which may increase the potential for serious
  and/or life&#8209;threatening reactions (see section 4.5).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=5><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Venetoclax</span></p>
  </td>
  <td width=257 valign=top style='width:193.05pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of venetoclax. Increased risk of tumor lysis syndrome at the
  dose initiation and during the ramp-up phase (see section 4.5).</span></p>
  </td>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=5><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anti-gout</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Colchicine</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of colchicine. Potential for serious and/or life-threatening
  reactions in patients with renal and/or hepatic impairment (see sections 4.4
  and 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antihistamines</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Astemizole,
  terfenadine</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of astemizole and terfenadine. Thereby, increasing the risk
  of serious arrhythmias from these agents (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 rowspan=3 valign=top style='width:111.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antipsychotics/
  Neuroleptics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lurasidone</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of lurasidone which may increase the potential for serious
  and/or life-threatening reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Pimozide</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of pimozide. Thereby, increasing the risk of serious
  haematologic abnormalities, or other serious adverse effects from this agent
  (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Quetiapine</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of quetiapine which may lead to coma. The concomitant
  administration with quetiapine is contraindicated (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ergot alkaloids</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dihydroergotamine,
  ergonovine, ergotamine, methylergonovine</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of ergot derivatives leading to acute ergot toxicity,
  including vasospasm and ischaemia (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>GI motility
  agent</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cisapride</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of cisapride. Thereby, increasing the risk of serious
  arrhythmias from this agent (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 rowspan=2 valign=top style='width:111.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hepatitis C
  virus direct acting antivirals</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Elbasvir/grazoprevir</span></p>
  </td>
  <td width=257 valign=top style='width:193.05pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased risk
  of alanine transaminase (ALT) elevations (see section 4.5).</span></p>
  </td>
  <td style='border:none;padding:0in 0in 0in 0in' width=5><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ombitasvir/paritaprevir/ritonavir
  with or without dasabuvir</span></p>
  </td>
  <td width=257 valign=top style='width:193.05pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of paritaprevir; thereby, increasing the risk of alanine
  transaminase (ALT) elevations (see section 4.5).</span></p>
  </td>
  <td style='border:none;border-bottom:solid windowtext 1.0pt' width=5><p class='MsoNormal'>&nbsp;</td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=357 colspan=2 valign=top style='width:267.45pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lipid-modifying
  agents</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>HMG Co-A
  Reductase Inhibitors</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lovastatin,
  simvastatin</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of lovastatin and simvastatin; thereby, increasing the risk of
  myopathy including rhabdomyolysis (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Microsomal
  triglyceride transfer protein (MTTP) inhibitor</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lomitapide</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of lomitapide (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 rowspan=3 valign=top style='width:111.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Phosphodiesterase
  (PDE5) inhibitors</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Avanafil</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of avanafil (see sections 4.4 and 4.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sildenafil</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Contraindicated
  when used for the treatment of pulmonary arterial hypertension (PAH) only.
  Increased plasma concentrations of sildenafil. Thereby, increasing the
  potential for sildenafil-associated adverse events (which include hypotension
  and syncope). See section 4.4 and section 4.5 for co&#8209;administration of
  sildenafil in patients with erectile dysfunction.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vardenafil</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of vardenafil (see sections 4.4 and 4.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sedatives/hypnotics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Oral midazolam,
  triazolam</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of oral midazolam and triazolam. Thereby, increasing the risk
  of extreme sedation and respiratory depression from these agents. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For caution on
  parenterally administered midazolam, see section 4.5.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=4 valign=top style='width:464.3pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Lopinavir/ritonavir
  medicinal product level decreased</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=149 valign=top style='width:111.85pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Herbal products</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>St. Johns</span><span
  lang=EN-GB style='font-size:11.0pt'> wort</span></p>
  </td>
  <td width=262 colspan=2 valign=top style='width:196.85pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Herbal
  preparations containing St Johns wort (<i>Hypericum perforatum)</i> due to
  the risk of decreased plasma concentrations and reduced clinical effects of
  lopinavir and ritonavir (see section 4.5).</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.4 Special warnings and precautions for use </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='text-decoration:
none'>Patients with coexisting conditions</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Hepatic impairment</span></u><u><span
lang=EN-GB>:</span></u><span lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>The safety and efficacy of Kaletra has not
been established in patients with significant underlying liver disorders.
Kaletra is contraindicated in patients with severe liver impairment (see
section 4.3). Patients with chronic hepatitis B or C and treated with
combination antiretroviral therapy are at an increased risk for severe and
potentially fatal hepatic adverse reactions. In case of concomitant antiviral
therapy for hepatitis B or C, please refer to the relevant product information
for these medicinal products.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Patients with pre-existing liver
dysfunction including chronic hepatitis have an increased frequency of liver
function abnormalities during combination antiretroviral therapy and should be
monitored according to standard practice. If there is evidence of worsening
liver disease in such patients, interruption or discontinuation of treatment
should be considered. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Elevated transaminases with or without
elevated bilirubin levels have been reported in HIV-1 mono&#8209;infected and
in individuals treated for post-exposure prophylaxis as early as 7 days after
the initiation of lopinavir/ritonavir in conjunction with other antiretroviral
agents. In some cases the hepatic dysfunction was serious.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Appropriate laboratory testing should be
conducted prior to initiating therapy with lopinavir/ritonavir and close
monitoring should be performed during treatment.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Renal
impairment</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Since the
renal clearance of lopinavir and ritonavir is negligible, increased plasma
concentrations are not expected in patients with renal impairment. Because
lopinavir and ritonavir are highly protein bound, it is unlikely that they will
be significantly removed by haemodialysis or peritoneal dialysis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Haemophilia</span></u></p>

<p class=EMEANormal><span lang=EN-GB>There have been reports of increased
bleeding, including spontaneous skin haematomas and haemarthrosis in patients
with haemophilia type A and B treated with protease inhibitors. In some
patients additional factor VIII was given. In more than half of the reported
cases, treatment with protease inhibitors was continued or reintroduced if
treatment had been discontinued. A causal relationship had been evoked,
although the mechanism of action had not been elucidated. Haemophiliac
patients should therefore be made aware of the possibility of increased
bleeding.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-style:normal'>Pancreatitis</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Cases of
pancreatitis have been reported in patients receiving Kaletra, including those
who developed hypertriglyceridaemia. In most of these cases patients have had
a prior history of pancreatitis and/or concurrent therapy with other medicinal
products associated with pancreatitis. Marked triglyceride elevation is a risk
factor for development of pancreatitis. Patients with advanced HIV disease may
be at risk of elevated triglycerides and pancreatitis</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Pancreatitis should be considered if
clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in
laboratory values (such as increased serum lipase or amylase values) suggestive
of pancreatitis should occur. Patients who exhibit these signs or symptoms
should be evaluated and Kaletra therapy should be suspended if a diagnosis of
pancreatitis is made (see section 4.8). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Immune Reconstitution Inflammatory Syndrome</span></p>

<p class=EMEANormal><span lang=EN-GB>In HIV-infected patients with severe
immune deficiency at the time of institution of combination antiretroviral
therapy (CART), an inflammatory reaction to asymtomatic or residual
opportunistic pathogens may arise and cause serious clinical conditions, or
aggravation of symptoms. Typically, such reactions have been observed within
the first few weeks or months of initiation of CART. Relevant examples are
cytomegalovirus retinitis, generalised and/or focal mycobacterial infections,
and <i>Pneumocystis jiroveci pneumonia</i>. Any inflammatory symptoms should
be evaluated and treatment instituted when necessary.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Autoimmune disorders (such as Graves disease <span
lang=EN-GB>and autoimmune hepatitis</span>) have also been reported to occur in
the setting of immune reconstitution; however, the reported time to onset is
more variable and can occur many months after initiation of treatment.</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Osteonecrosis</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Although the etiology is considered to be
multifactorial (including corticosteroid use, alcohol consumption, severe
immunosuppression, higher body mass index), cases of osteonecrosis have been
reported particularly in patients with advanced HIV&#8209;disease and/or long&#8209;term
exposure to combination antiretroviral therapy (CART). Patients should be
advised to seek medical advice if they experience joint aches and pain, joint
stiffness or difficulty in movement.</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>PR interval prolongation </span></p>

<p class=EMEANormal><span lang=EN-GB>Lopinavir/ritonavir has been shown to
cause modest asymptomatic prolongation of the PR interval in some healthy adult
subjects. Rare reports of 2<sup>nd</sup> or 3<sup>rd</sup> degree
atroventricular block in patients with underlying structural heart disease and
pre-existing conduction system abnormalities or in patients receiving drugs
known to prolong the PR interval (such as verapamil or atazanavir) have been
reported in patients receiving lopinavir/ritonavir. Kaletra should be used
with caution in such patients (see section 5.1).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Weight
and metabolic parameters</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>An increase
in weight and in levels of blood lipids and glucose may occur during antiretroviral
therapy. Such changes may in part be linked to disease control and life
style. For lipids, there is in some cases evidence for a treatment effect,
while for weight gain there is no strong evidence relating this to any
particular treatment. For monitoring of blood lipids and glucose, reference is
made to established HIV treatment guidelines. Lipid disorders should be
managed as clinically appropriate.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-style:normal'>Interactions with medicinal products</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
contains lopinavir and ritonavir, both of which are inhibitors of the P450
isoform CYP3A. Kaletra is likely to increase plasma concentrations of
medicinal products that are primarily metabolised by CYP3A. These increases of
plasma concentrations of co-administered medicinal products could increase or
prolong their therapeutic effect and adverse events (see sections 4.3 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Strong CYP3A4 inhibitors such as protease
inhibitors may increase bedaquiline exposure which could potentially increase
the risk of bedaquiline&#8209;related adverse reactions. Therefore,
combination of bedaquiline with lopinavir/ritonavir should be avoided.
However, if the benefit outweighs the risk, co&#8209;administration of
bedaquiline with lopinavir/ritonavir must be done with caution. More frequent
electrocardiogram monitoring and monitoring of transaminases is recommended
(see section 4.5 and refer to the bedaquiline SmPC).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of delamanid with
a strong inhibitor of CYP3A (as lopinavir/ritonavir) may increase exposure to
delamanid metabolite, which has been associated with QTc prolongation.
Therefore, if co-administration of delamanid with lopinavir/ritonavir is
considered necessary, very frequent ECG monitoring throughout the full
delamanid treatment period is recommended (see section 4.5 and refer to the delamanid
SmPC).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Life-threatening and fatal drug
interactions have been reported in patients treated with colchicine and strong
inhibitors of CYP3A like ritonavir. Concomitant administration with colchicine
is contraindicated in patients with renal and/or hepatic impairment (see
sections 4.3 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The combination of Kaletra with: </span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- tadalafil, indicated for the treatment of pulmonary
arterial hypertension, is not recommended (see section 4.5); </span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- riociguat is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- vorapaxar is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- fusidic acid in osteo-articular infections is not
recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- salmeterol is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-  rivaroxaban is not recommended (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The combination of Kaletra with
atorvastatin is not recommended. If the use of atorvastatin is considered
strictly necessary, the lowest possible dose of atorvastatin should be
administered with careful safety monitoring. Caution must also be exercised
and reduced doses should be considered if Kaletra is used concurrently with
rosuvastatin. If treatment with a HMG-CoA reductase inhibitor is indicated,
pravastatin or fluvastatin is recommended (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>PDE5 inhibitors</span></i></p>

<p class=EMEANormal><span lang=EN-GB>Particular caution should be used when
prescribing sildenafil or tadalafil for the treatment of erectile dysfunction
in patients receiving Kaletra. Co-administration of Kaletra with these
medicinal products is expected to substantially increase their concentrations
and may result in associated adverse events such as hypotension, syncope,
visual changes and prolonged erection (see section 4.5). Concomitant use of avanafil
or vardenafil and lopinavir/ritonavir is contraindicated (see section 4.3).
Concomitant use of sildenafil prescribed for the treatment of pulmonary
arterial hypertension with Kaletra is contraindicated (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Particular caution must be used when
prescribing Kaletra and medicinal products known to induce QT interval
prolongation such as: chlorpheniramine, quinidine, erythromycin,
clarithromycin. Indeed, Kaletra could increase concentrations of the
co-administered medicinal products and this may result in an increase of their
associated cardiac adverse reactions. Cardiac events have been reported with
Kaletra in preclinical studies; therefore, the potential cardiac effects of
Kaletra cannot be currently ruled out (see sections 4.8 and 5.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of Kaletra with
rifampicin is not recommended. Rifampicin in combination with Kaletra causes
large decreases in lopinavir concentrations which may in turn significantly
decrease the lopinavir therapeutic effect. Adequate exposure to
lopinavir/ritonavir may be achieved when a higher dose of Kaletra is used but
this is associated with a higher risk of liver and gastrointestinal toxicity.
Therefore, this co&#8209;administration should be avoided unless judged
strictly necessary (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Concomitant use of Kaletra and fluticasone
or other glucocorticoids that are metabolised by CYP3A4, such as budesonide and
triamcinolone, is not recommended unless the potential benefit of treatment
outweighs the risk of systemic corticosteroid effects, including Cushings
syndrome and adrenal suppression (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Other</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra is not a cure for HIV infection or
AIDS. While effective viral suppression with antiretroviral therapy has been
proven to substantially reduce the risk of sexual transmission, a residual risk
cannot be excluded. Precautions to prevent transmission should be taken in
accordance with national guidelines. People taking Kaletra may still develop
infections or other illnesses associated with HIV disease and AIDS.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.5 Interaction with other medicinal products and
other forms of interaction </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains lopinavir and ritonavir,
both of which are inhibitors of the P450 isoform CYP3A <i>in&nbsp;vitro</i>.
Co-administration of Kaletra and medicinal products primarily metabolised by
CYP3A may result in increased plasma concentrations of the other medicinal product,
which could increase or prolong its therapeutic and adverse reactions. Kaletra
does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or CYP1A2 at
clinically relevant concentrations (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra has been shown <i>in&nbsp;vivo</i>
to induce its own metabolism and to increase the biotransformation of some
medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and
CYP2C19) and by glucuronidation. This may result in lowered plasma
concentrations and potential decrease of efficacy of co-administered medicinal
products.</span></p>

<p class=EMEANormal><span lang=EN-GB></span></p>

<p class=EMEANormal><span lang=EN-GB>Medicinal products that are
contraindicated specifically due to the expected magnitude of interaction and
potential for serious adverse events are listed in section 4.3.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>All interaction studies, when otherwise
not stated, were performed using Kaletra capsules, which gives an approximately
20% lower exposure of lopinavir than the 200/50&nbsp;mg tablets.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Known and theoretical interactions with
selected antiretrovirals and non-antiretroviral medicinal products are listed
in the table below. This list is not intended to be inclusive or
comprehensive. Individual SmPCs should be consulted.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Interaction table</span></i></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Interactions between Kaletra and
co-administered medicinal products are listed in the table below (increase is
indicated as &#8593;, decrease as &#8595;, no change as &#8596;,once
daily as QD, twice daily as BID and three times daily as &quot;TID&quot;).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Unless otherwise stated, studies detailed
below have been performed with the recommended dosage of lopinavir/ritonavir
(i.e. 400/100&nbsp;mg twice daily).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=614
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr style='height:82.85pt'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:82.85pt'>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Co-administered
  drug by therapeutic area </span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:82.85pt'>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Effects
  on drug levels</span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Geometric
  Mean Change (%) in AUC, C<sub>max</sub>, C<sub>min</sub></span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Mechanism
  of interaction</span></b></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:82.85pt'>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Clinical
  recommendation concerning co-administration with Kaletra</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><i><span lang=EN-GB>Antiretroviral Agents</span></i></b></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Nucleoside/Nucleotide reverse
  transcriptase inhibitors (NRTIs) </span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Stavudine, Lamivudine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abacavir, Zidovudine</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abacavir, Zidovudine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be reduced due to
  increased glucuronidation by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The clinical significance of reduced
  abacavir and zidovudine concentrations is unknown.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Tenofovir disoproxil fumarate (DF),
  300&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(equivalent to 245&nbsp;mg tenofovir disoproxil)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Tenofovir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 32%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8593; 51%</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary.</span></p>
  <p class=EMEANormal><span lang=EN-GB>Higher tenofovir concentrations could
  potentiate tenofovir associated adverse events, including renal disorders.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Non-nucleoside
  reverse transcriptase inhibitors (NNRTIs) </span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Efavirenz, 600&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8595;</span><span lang=EN-GB> 20%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595; 13%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595;</span><span
  lang=EN-GB> 42%</span></p>
  </td>
  <td width=238 colspan=2 rowspan=2 valign=top style='width:178.7pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The
  Kaletra tablets dosage should be increased to 500/125&nbsp;mg twice daily
  when co-administered with efavirenz. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
  must not be administered once daily in combination with efavirenz.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Efavirenz, 600&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir 500/125&nbsp;mg
  BID)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Relative to 400/100&nbsp;mg BID
  administered alone) </span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Nevirapine, 200&nbsp;mg BID</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8595;</span><span lang=EN-GB> 27%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595; 19%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595;</span><span
  lang=EN-GB> 51%</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The Kaletra tablets dosage should be
  increased to 500/125&nbsp;mg twice daily when co-administered with
  nevirapine. </span></p>
  <p class=EMEANormal><span lang=EN-GB>Kaletra must not be administered once
  daily in combination with nevirapine.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Etravirine</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir tablet 400/100 mg
  BID)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=FI>Etravirine:</span></p>
  <p class=EMEANormal><span lang=FI>AUC: &#8595; 35%</span></p>
  <p class=EMEANormal><span lang=FI>C<sub>min</sub>: &#8595; 45% </span></p>
  <p class=EMEANormal><span lang=FI>C<sub>max</sub>: &#8595; 30%</span></p>
  <p class=EMEANormal><span lang=FI>&nbsp;</span></p>
  <p class=EMEANormal><span lang=FI>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8596; </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595; 20%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8596; </span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rilpivirine</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir capsule 400/100 mg
  BID)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=FI>Rilpivirine:</span></p>
  <p class=EMEANormal><span lang=FI>AUC: &#8593; 52% </span></p>
  <p class=EMEANormal><span lang=FI>C<sub>min</sub>: &#8593; 74% </span></p>
  <p class=EMEANormal><span lang=FI>C<sub>max</sub>: &#8593; 29%</span></p>
  <p class=EMEANormal><span lang=FI>&nbsp;</span></p>
  <p class=EMEANormal><span lang=FI>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595; 11% </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8596; </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(inhibition of CYP3A enzymes)</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant use of Kaletra with</span></p>
  <p class=EMEANormal><span lang=EN-GB>rilpivirine causes an increase in the
  plasma concentrations of rilpivirine, but no dose adjustment is required.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i>HIV CCR5  antagonist</i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Maraviroc</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Maraviroc:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 295% </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  &#8593; 97% </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>The dose of maraviroc should be decreased to
  150&nbsp;mg twice daily during co&#8209;administration with Kaletra 400/100
  mg twice daily. </span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Integrase
  inhibitor</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Raltegravir</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Raltegravir:
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  &#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>12</sub>:
  &#8595; 30%</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:
  &#8596;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='margin-bottom:12.0pt;page-break-after:avoid'><span
  lang=EN-GB>No dose adjustment necessary</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Co-administration with other HIV
  protease inhibitors (PIs)</span></i></p>
  <p class=EMEANormal><span lang=EN-GB style='color:black'>According to current
  treatment guidelines, dual therapy with protease inhibitors is generally not recommended.</span></p>
  </td>
 </tr>
 <tr style='height:26.35pt'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.35pt'>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir/ ritonavir
  (700/100&nbsp;mg BID) </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(L</span><span lang=EN-GB>opinavir/ritonavir
  400/100&nbsp;mg BID)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>or </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir (1400&nbsp;mg BID)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(</span><span lang=EN-GB>Lopinavir/ritonavir
  533/133&nbsp;mg BID)</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.35pt'>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Amprenavir concentrations are
  significantly reduced. </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal align=right style='text-align:right'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.35pt'>
  <p class=EMEANormal><span lang=EN-GB>Co-administration of increased doses of
  fosamprenavir (1400&nbsp;mg BID) with Kaletra (533/133&nbsp;mg BID) to
  protease inhibitor&#8209;experienced patients resulted in a higher incidence
  of gastrointestinal adverse events and elevations in triglycerides with the
  combination regimen without increases in virological efficacy, when compared
  with standard doses of fosamprenavir/ritonavir. Concomitant administration
  of these medicinal products is not recommended. </span></p>
  <p class=EMEANormal><span lang=EN-GB>Kaletra must not be administered once
  daily in combination with amprenavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Indinavir, 600&nbsp;mg BID</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Indinavir: </span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8593; 3.5-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(relative to indinavir 800&nbsp;mg TID
  alone)</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(relative to historical comparison)</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The appropriate doses for this
  combination, with respect to efficacy and safety, have not been established.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Saquinavir </span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>1000&nbsp;mg BID</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Saquinavir: </span><span lang=EN-GB>&#8596;
  </span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>No
  dose adjustment necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Tipranavir/ritonavir</span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>(500/100&nbsp;mg BID)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8595; 55%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595; 70%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595; 47%</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Concomitant
  administration of these medicinal products is not recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Acid reducing agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Omeprazole (40&nbsp;mg QD) </span></p>
  <p class=EMEANormal><span lang=EN-GB></span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Omeprazole: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ranitidine (150&nbsp;mg single dose)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ranitidine: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Alpha</span></i><i><sub><span
  lang=EN-GB style='font-size:12.0pt'>1</span></sub></i><i><span lang=EN-GB>
  adrenoreceptor antagonist</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Alfuzosin
  </span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Alfuzosin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of alfuzosin are expected to increase.</p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Concomitant administration
  of Kaletra and alfuzosin is contra-indicated<b> </b>(see section 4.3) as
  alfuzosin-related toxicity, including hypotension, may be increased.</p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Analgesics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fentanyl</span></p>
  <p class=EMEANormal><span lang=EN-GB></span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fentanyl:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Increased risk of side-effects
  (respiratory depression, sedation) due to higher plasma concentrations
  because of CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Careful monitoring of adverse effects
  (notably respiratory depression but also sedation) is recommended when
  fentanyl is concomitantly administered with Kaletra.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antianginal</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ranolazine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of ranolazine are expected to increase.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The concomitant administration of
  Kaletra and ranolazine is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Antiarrhythmics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Amiodarone,
  Dronedarone</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Amiodarone,
  Dronedarone: Concentrations may be increased due to CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concomitant
  administration of Kaletra and amiodarone or dronedarone is contraindicated
  (see section 4.3) as the risk of arrhythmias or other serious adverse
  reactions may be increased.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Digoxin</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Digoxin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Plasma
  concentrations may be increased due to P-glycoprotein inhibition by lopinavir/ritonavir.
  The increased digoxin level may lessen over time as P&#8209;gp induction
  develops.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  is warranted and therapeutic drug monitoring of digoxin concentrations, if
  available, is recommended in case of co&#8209;administration of Kaletra and
  digoxin. Particular caution should be used when prescribing Kaletra in
  patients taking digoxin as the acute inhibitory effect of ritonavir on P&#8209;gp
  is expected to significantly increase digoxin levels. Initiation of digoxin
  in patients already taking Kaletra is likely to result in lower than expected
  increases of digoxin concentrations.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bepridil, Systemic Lidocaine, and
  Quinidine </span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bepridil, Systemic Lidocaine, Quinidine:
  </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased when
  co-administered with lopinavir/ritonavir. </span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution is warranted and therapeutic
  drug concentration monitoring is recommended when available.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Antibiotics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Clarithromycin</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Clarithromycin:</span><i><span
  lang=EN-GB> </span></i></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Moderate
  increases in clarithromycin AUC are expected due to CYP3A inhibition by lopinavir/ritonavir.
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>For
  patients with renal impairment (CrCL &lt;&nbsp;30&nbsp;ml/min) dose reduction
  of clarithromycin should be considered (see section 4.4). Caution should be
  exercised in administering clarithromycin with Kaletra to patients with
  impaired hepatic or renal function.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Anticancer agents and kinase
  inhibitors</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abemaciclib</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Serum concentrations may be increased due to CYP3A inhibition
  by ritonavir.</p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of abemaciclib and
  Kaletra should be avoided. If this co&#8209;administration is judged
  unavoidable, refer to the abemaciclib SmPC for dosage adjustment
  recommendations. Monitor for ADRs related to abemaciclib.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Apalutamide</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Apalutamide is a moderate to strong CYP3A4 inducer and
  this may lead to a decreased exposure of lopinavir/ritonavir.</p>
  <p class=EMEANormal>&nbsp;</p>
  <p class=EMEANormal>Serum concentrations of apalutamide may be increased due
  to CYP3A inhibition by lopinavir/ritonavir.</p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Decreased exposure of Kaletra may result
  in potential loss of virological response. </span></p>
  <p class=EMEANormal><span lang=EN-GB>In addition, co-administration of
  apalutamide and Kaletra may lead to serious adverse events including seizure
  due to higher apalutamide levels. Concomitant use of Kaletra with apalutamide
  is not recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Afatinib</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Ritonavir 200 mg twice daily)</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Afatinib:</p>
  <p class=EMEANormal>AUC: <span lang=EN-GB>&#8593; </span></p>
  <p class=EMEANormal>C<sub>max</sub>: <span lang=EN-GB>&#8593;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>The extent of increase depends on the
  timing of ritonavir administration.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to BCRP (breast cancer </span>resistance
  protein/ABCG2)<span lang=EN-GB> and acute P-gp inhibition by
  lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised in
  administering afatinib with Kaletra. Refer to the afatinib SmPC for dosage
  adjustment recommendations. Monitor for ADRs related to afatinib.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Ceritinib</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Serum
  concentrations may be increased due to CYP3A and P&#8209;gp inhibition by
  lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised in administering ceritinib with Kaletra. Refer to the
  ceritinib SmPC for dosage adjustment recommendations. Monitor for ADRs
  related to ceritinib.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Most tyrosine kinase inhibitors such as
  dasatinib and nilotinib, vincristine, vinblastine</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Most tyrosine kinase inhibitors such as
  dasatinib and nilotinib, also vincristine and vinblastine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Risk of increased adverse events due to
  higher serum concentrations because of CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Careful monitoring of the tolerance of
  these anticancer agents.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Encorafenib</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co-administration of encorafenib with
  Kaletra may increase encorafenib exposure which may increase the risk of
  toxicity, including the risk of serious adverse events such as QT interval
  prolongation. </span>Co&#8209;administration of encorafenib and Kaletra should
  be avoided. If the benefit is considered to outweigh the risk and Kaletra
  must be used, patients should be carefully monitored for safety.</p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fostamatinib</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Increase in fostamatinib metabolite R406 exposure.</p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Co-administration of fostamatinib with Kaletra may
  increase fostamatinib metabolite R406 exposure resulting in dose-related
  adverse events such as hepatotoxicity, neutropenia, hypertension, or
  diarrhoea. Refer to the fostamatinib SmPC for dose reduction recommendations
  if such events occur.</p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ibrutinib</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co-administration of ibrutinib and
  Kaletra may increase ibrutinib exposure which may increase the risk of
  toxicity including risk of tumor lysis syndrome. Co&#8209;administration of
  ibrutinib and Kaletra should be avoided. If the benefit is considered to
  outweigh the risk and Kaletra must be used, reduce the ibrutinib dose to
  140&nbsp;mg and monitor patient closely for toxicity.</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Neratinib</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant use of neratinib with
  Kaletra is contraindicated due to serious and/or life&#8209;threatening
  potential reactions including hepatotoxicity (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Venetoclax</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Serum
  concentrations may be increased due to CYP3A inhibition by
  lopinavir/ritonavir, resulting in increased risk of tumor lysis syndrome at
  the dose initiation and during the ramp-up phase (see section 4.3 and refer
  to the venetoclax SmPC).</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>For patients who have
  completed the ramp-up phase and are on a steady daily dose of venetoclax,
  reduce the venetoclax dose by at least 75% when used with strong CYP3A
  inhibitors (refer to the venetoclax SmPC for dosing instructions). Patients
  should be closely monitored for signs related to venetoclax toxicities.</p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Anticoagulants</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Warfarin</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Warfarin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be affected when
  co-administered with lopinavir/ritonavir due to CYP2C9 induction. </span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>It is recommended that INR
  (international normalised ratio) be monitored.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Rivaroxaban</p>
  <p class=EMEANormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=EMEANormal style='page-break-after:avoid'>(Ritonavir 600&nbsp;mg
  twice daily)</p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Rivaroxaban: </p>
  <p class=EMEANormal style='page-break-after:avoid'>AUC: <span lang=EN-GB>&#8593;
  </span>153% </p>
  <p class=EMEANormal style='page-break-after:avoid'>C<sub>max</sub>: <span
  lang=EN-GB>&#8593; 55</span>%</p>
  <p class=EMEANormal style='page-break-after:avoid'>Due to CYP3A and P&#8209;gp
  inhibition by lopinavir/ritonavir.</p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Co&#8209;administration
  of rivaroxaban and Kaletra may increase rivaroxaban exposure which may
  increase the risk of bleeding.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The use
  of rivaroxaban is not recommended in patients receiving concomitant treatment
  with Kaletra (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Vorapaxar</p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Serum concentrations may be increased due to CYP3A
  inhibition by <span lang=EN-GB>lopinavir/ritonavir</span>.</p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The co&#8209;administration of vorapaxar
  with Kaletra is not recommended (see section 4.4 and refer to the vorapaxar
  SmPC).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Anticonvulsants</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Phenytoin</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Phenytoin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Steady-state concentrations was
  moderately decreased due to CYP2C9 and CYP2C19 induction by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations are decreased due to
  CYP3A induction by phenytoin. </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised in
  administering phenytoin with Kaletra.</span></p>
  <p class=EMEANormal><span lang=EN-GB>Phenytoin levels should be monitored
  when co&#8209;administering with Kaletra.</span></p>
  <p class=EMEANormal><span lang=EN-GB>When co-administered with phenytoin, an
  increase of Kaletra dosage may be envisaged. Dose adjustment has not been
  evaluated in clinical practice.</span></p>
  <p class=EMEANormal><span lang=EN-GB>Kaletra must not be administered once
  daily in combination with phenytoin.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Carbamazepine
  and Phenobarbital </span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Carbamazepine:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Serum
  concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be decreased due to CYP3A induction by carbamazepine and phenobarbital. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised in administering carbamazepine or phenobarbital with Kaletra.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Carbamazepine
  and phenobarbital levels should be monitored when co&#8209;administering with
  Kaletra.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>When
  co-administered with carbamazepine or phenobarbital, an increase of Kaletra
  dosage may be envisaged. Dose adjustment has not been evaluated in clinical
  practice.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
  must not be administered once daily in combination with carbamazepine and
  phenobarbital.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lamotrigine and Valproate</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lamotrigine: </span></p>
  <p class=EMEANormal>AUC: &#8595; 50%</p>
  <p class=EMEANormal>C<sub>max</sub>: &#8595; 46%</p>
  <p class=EMEANormal>C<sub>min</sub>: &#8595; 56%</p>
  <p class=EMEANormal>&nbsp;</p>
  <p class=EMEANormal>Due to induction of lamotrigine glucuronidation</p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Valproate: &#8595;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Patients should be monitored closely for
  a decreased VPA effect when Kaletra and valproic acid or valproate are given
  concomitantly.</span></p>
  <p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  <p class=EMEANormal><u><span lang=EN-GB>In patients starting or stopping
  Kaletra while currently taking maintenance dose of lamotrigine</span></u><span
  lang=EN-GB>: </span></p>
  <p class=EMEANormal><span lang=EN-GB>lamotrigine dose may need to be
  increased if Kaletra is added, or decreased if Kaletra is discontinued;
  therefore plasma lamotrigine monitoring should be conducted, particularly
  before and during 2 weeks after starting or stopping Kaletra, in order to see
  if lamotrigine dose adjustment is needed.</span></p>
  <p class=EMEANormal><u><span lang=EN-GB>In patients currently taking Kaletra
  and starting lamotrigine</span></u><span lang=EN-GB>: no dose adjustments to
  the recommended dose escalation of lamotrigine should be necessary. </span></p>
  </td>
 </tr>
 <tr style='height:11.65pt'>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:11.0pt'>Antidepressants and Anxiolytics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Trazodone
  single dose</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Ritonavir,
  200&nbsp;mg BID)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Trazodone:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC: </span><span
  lang=EN-GB>&#8593; 2.4-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
  events of nausea, dizziness, hypotension and syncope were observed following
  co-administration of trazodone and ritonavir. </span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>It is
  unknown whether the combination of Kaletra causes a similar increase in
  trazodone exposure. The combination should be used with caution and a lower
  dose of trazodone should be considered</span><span lang=EN-GB>.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antifungals</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ketoconazole and Itraconazole</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ketoconazole, Itraconazole:</span><i><span
  lang=EN-GB> </span></i><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir. </span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>High doses of ketoconazole and
  itraconazole (&gt;&nbsp;200&nbsp;mg/day) are not recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Voriconazole</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Voriconazole: </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be decreased.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of voriconazole
  and low dose ritonavir (100&nbsp;mg BID) as contained in Kaletra should be
  avoided unless an assessment of the benefit/risk to patient justifies the use
  of voriconazole.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Anti&#8209;gout
  agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Colchicine
  single dose</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Ritonavir
  200&nbsp;mg twice&#8209;daily)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Colchicine:</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>AUC: &#8593; 3-fold</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>C<sub>max</sub>: &#8593; 1.8-fold</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>Due to P-gp and/or CYP3A4 inhibition by</span><span
  lang=EN-GB style='font-size:11.0pt'> ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C</span>oncomitant
  administration of Kaletra with colchicine in patients with renal and/or
  hepatic impairment is contraindicated due to a potential increase of
  colchicine-related serious and/or life&#8209;threatening reactions such as
  neuromuscular toxicity (including rhabdomyolysis) (see sections 4.3 and 4.4).
  A reduction in colchicine dosage or an interruption of colchicine treatment
  is recommended in patients with normal renal or hepatic function if treatment
  with Kaletra is required. Refer to colchicine prescribing information.</p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antihistamines</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Astemizole</span></p>
  <p class=EMEANormal><span lang=EN-GB>Terfenadine</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and astemizole and terfenadine is contraindicated as it may increase the risk
  of serious arrhythmias from these agents (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Anti-infectives</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fusidic acid</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fusidic acid:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Concomitant administration of Kaletra with fusidic acid
  is contra-indicated in dermatological indications due to the increased risk
  of adverse events related to fusidic acid, notably rhabdomyolysis (see
  section 4.3). When used for osteo-articular infections, where the
  co-administration is unavoidable, close clinical monitoring for muscular
  adverse events is strongly recommended (see section 4.4). </p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Antimycobacterials</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bedaquiline</span></p>
  <p class=EMEANormal><span lang=EN-GB>(single dose)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir 400/100&nbsp;mg
  BID, multiple dose)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bedaquiline:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 22%</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>A more pronounced effect on bedaquiline
  plasma exposures may be observed during prolonged co&#8209;administration
  with lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>CYP3A4 inhibition likely due to
  lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to the risk of bedaquiline related
  adverse events, the combination of bedaquiline and Kaletra should be
  avoided. If the benefit outweighs the risk, co&#8209;administration of
  bedaquiline with Kaletra must be done with caution. More frequent
  electrocardiogram monitoring and monitoring of transaminases is recommended
  (see section 4.4 and refer to the bedaquiline SmPC).</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal1 style='page-break-after:avoid'><span lang=EN-GB>Delamanid
  (100 mg BID)</span></p>
  <p class=EMEANormal1 style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Lopinavir/ritonavir
  400/100&nbsp;mg BID)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=DE>Delamanid:</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>AUC: &#8593;
  22%</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:2.2pt;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>DM-6705
  (delamanid active metabolite):</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;page-break-after:
  avoid'><span lang=DE style='font-family:"Times New Roman",serif'>AUC: &#8593;
  30%</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>&nbsp;</p>
  <p class=EMEANormal style='page-break-after:avoid'>A more pronounced effect
  on DM-6705 exposure may be observed during prolonged co-administration with
  lopinavir/ritonavir.</p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Due to the risk of QTc
  prolongation associated with DM&#8209;6705, if co&#8209;administration of
  delamanid with Kaletra is considered necessary, very frequent ECG monitoring
  throughout the full delamanid treatment period is recommended (see section
  4.4 and refer to the delamanid SmPC).</p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rifabutin, 150&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rifabutin (parent drug and active </span><span
  lang=EN-GB>25-O-desacetyl metabolite):<i> </i></span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 5.7-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 3.5-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>When given with Kaletra the recommended
  dose of rifabutin is 150&nbsp;mg 3 times per week on set days (for example
  Monday-Wednesday-Friday). Increased monitoring for rifabutin-associated
  adverse reactions including neutropenia and uveitis is warranted due to an
  expected increase in exposure to rifabutin. Further dosage reduction of
  rifabutin to 150&nbsp;mg twice weekly on set days is recommended for patients
  in whom the 150&nbsp;mg dose 3 times per week is not tolerated. It should be
  kept in mind that the twice weekly dosage of 150&nbsp;mg may not provide an
  optimal exposure to rifabutin thus leading to a risk of rifamycin resistance
  and a treatment failure. No dose adjustment is needed for Kaletra. </span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Rifampicin</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Large
  decreases in lopinavir concentrations may be observed due to CYP3A induction
  by rifampicin.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Co&#8209;administration
  of Kaletra with rifampicin is not recommended as </span><span lang=EN-GB>the
  decrease in lopinavir concentrations may in turn significantly decrease the
  lopinavir therapeutic effect. A dose adjustment of Kaletra
  400&nbsp;mg/400&nbsp;mg (i.e. Kaletra 400/100&nbsp;mg + ritonavir
  300&nbsp;mg) twice daily has allowed compensating for the CYP&nbsp;3A4
  inducer effect of rifampicin. However, such a dose adjustment might be
  associated with ALT/AST elevations and with increase in gastrointestinal
  disorders. Therefore, this co&#8209;administration should be avoided unless
  judged strictly necessary. If this co&#8209;administration is judged
  unavoidable, increased dose of Kaletra at 400&nbsp;mg/400&nbsp;mg twice daily
  may be administered with rifampicin under close safety and therapeutic drug
  monitoring. The Kaletra dose should be titrated upward only after rifampicin
  has been initiated (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antipsychotics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lurasidone</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of lurasidone are expected to increase.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The concomitant administration with
  lurasidone is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Pimozide</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of pimozide are expected to increase.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and pimozide is contraindicated as it may increase the risk of serious
  haematologic abnormalities or other serious adverse effects from this agent
  (see section 4.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Quetiapine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of quetiapine are expected to increase.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and quetiapine is contraindicated as it may increase quetiapine-related
  toxicity.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Benzodiazepines</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Midazolam</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Oral
  Midazolam: </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 13-fold </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Parenteral
  Midazolam:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 4-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
  must not be co&#8209;administered with oral midazolam (see section 4.3),
  whereas caution should be used with co&#8209;administration of Kaletra and
  parenteral midazolam. If Kaletra is co&#8209;administered with parenteral
  midazolam, it should be done in an intensive care unit (ICU) or similar
  setting which ensures close clinical monitoring and appropriate medical
  management in case of respiratory depression and/or prolonged sedation.
  Dosage adjustment for midazolam should be considered especially if more than
  a single dose of midazolam is administered.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i>Beta<sub>2</sub>-adrenoceptor
  agonist (long acting)</i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Salmeterol</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Salmeterol:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  are expected to increase due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>The combination may result in increased
  risk of cardiovascular adverse events associated with salmeterol, including
  QT prolongation, palpitations and sinus tachycardia.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>Therefore, concomitant
  administration of Kaletra with salmeterol is not recommended (see section
  4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Calcium channel blockers</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Felodipine, Nifedipine, and Nicardipine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Felodipine, Nifedipine, Nicardipine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Clinical monitoring of therapeutic and
  adverse effects is recommended when these medicines are concomitantly
  administered with Kaletra.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Corticosteroids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Dexamethasone</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be decreased due to
  CYP3A induction by dexamethasone.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Clinical monitoring of antiviral
  efficacy is recommended when these medicines are concomitantly administered
  with Kaletra.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Inhaled,
  injectable or intranasal fluticasone propionate, budesonide, triamcinolone</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Fluticasone
  propionate, 50&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
  lang=EN-GB>g intranasal 4 times daily:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Plasma
  concentrations &#8593;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Cortisol
  levels &#8595; 86% </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Greater
  effects may be expected when fluticasone propionate is inhaled. Systemic
  corticosteroid effects including Cushing's syndrome and adrenal suppression
  have been reported in patients receiving ritonavir and inhaled or
  intranasally administered fluticasone propionate; this could also occur with
  other corticosteroids metabolised via the P450 3A pathway e.g. budesonide and
  triamcinolone. Consequently, concomitant administration of Kaletra and these
  glucocorticoids is not recommended unless the potential benefit of treatment
  outweighs the risk of systemic corticosteroid effects (see section 4.4). A
  dose reduction of the glucocorticoid should be considered with close
  monitoring of local and systemic effects or a switch to a glucocorticoid,
  which is not a substrate for CYP3A4 (e.g. beclomethasone). Moreover, in case
  of withdrawal of glucocorticoids progressive dose reduction may have to be
  performed over a longer period. </span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Phosphodiesterase(PDE5)
  inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Avanafil </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(ritonavir
  600&nbsp;mg BID) </span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Avanafil:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 13-fold </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The use
  of avanafil with Kaletra is contraindicated (see section 4.3). </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Tadalafil </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Tadalafil:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 2-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 rowspan=2 valign=top style='width:178.7pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><u><span lang=EN-GB>For the treatment of pulmonary
  arterial hypertension</span></u><span lang=EN-GB>: Co&#8209;administration of
  Kaletra with sildenafil is contraindicated (see section 4.3). Co-administration
  of Kaletra with tadalafil is not recommended.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><u><span lang=EN-GB>For erectile dysfunction</span></u><span
  lang=EN-GB>:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Particular caution must be used when
  prescribing sildenafil or tadalafil in patients receiving Kaletra with
  increased monitoring for adverse events including hypotension, syncope,
  visual changes and prolonged erection (see section 4.4). </span></p>
  <p class=EMEANormal><span lang=EN-GB>When co&#8209;administered with Kaletra,
  sildenafil doses must not exceed 25&nbsp;mg in 48 hours and tadalafil doses
  must not exceed 10&nbsp;mg every 72 hours. </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Sildenafil</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Sildenafil:<u> </u></span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 11-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vardenafil </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vardenafil:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 49-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The use of vardenafil with Kaletra is
  contraindicated (see section 4.3). </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Ergot alkaloids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Dihydroergotamine, ergonovine,
  ergotamine, methylergonovine</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations may be
  increased due to CYP3A inhibition by </span><span lang=EN-GB>lopinavir/ritonavir</span><span
  style='color:black'>.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  Kaletra and ergot alkaloids are contraindicated as it may lead to acute ergot
  toxicity, including vasospasm and ischaemia (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span style='color:black'>GI motility agent</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Cisapride</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations may be
  increased due to CYP3A inhibition by </span><span lang=EN-GB>lopinavir/ritonavir</span><span
  style='color:black'>.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  Kaletra and cisapride is contraindicated as it may increase the risk of
  serious arrhythmias from this agent (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span style='color:black'>HCV direct acting antivirals</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Elbasvir/grazoprevir</span></p>
  <p class=EMEANormal><span style='color:black'>(50/200 mg QD)</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Elbasvir:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 2.71-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 1.87-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>24</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 3.58-fold</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Grazoprevir:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 11.86-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 6.31-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>24</sub>: </span><span
  lang=EN-GB>&#8593; 20.70-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(combinations of mechanisms including
  CYP3A inhibition)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  elbasvir/grazoprevir with Kaletra is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Glecaprevir/pibrentasvir</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations may be
  increased due to P-glycoprotein, BCRP and OATP1B inhibition by
  lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  glecaprevir/pibrentasvir and Kaletra is not recommended due to an increased
  risk of ALT elevations associated with increased glecaprevir exposure.</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Ombitasvir/paritaprevir/ritonavir
  + dasabuvir</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>(25/150/100&nbsp;mg
  QD + 400&nbsp;mg BID)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir/ritonavir
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>400/100&nbsp;mg
  BID</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Ombitasvir:
  </span><span lang=EN-GB>&#8596;</span><span lang=EN-GB style='color:black'> </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Paritaprevir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>AUC:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.17-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>C<sub>max</sub>:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.04-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>C<sub>trough</sub>:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.36-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>(inhibition
  of CYP3A/efflux transporters)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Dasabuvir:
  </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir:
  </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=236 rowspan=2 valign=top style='width:177.2pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Co-administration
  is contraindicated.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir/ritonavir
  800/200&nbsp;mg QD was administered with ombitasvir/paritaprevir/ritonavir
  with or without dasabuvir. The effect on DAAs and lopinavir was similar to
  that observed when lopinavir/ritonavir 400/100&nbsp;mg BID was administered
  (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Ombitasvir/paritaprevir/
  ritonavir</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>(25/150/100&nbsp;mg
  QD)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir/ritonavir</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>400/100&nbsp;mg
  BID</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Ombitasvir:</span><span
  style='color:black'> </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Paritaprevir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>AUC:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>6.10-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>C<sub>max</sub>:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>4.76-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>C<sub>trough</sub>:
  </span><span lang=EN-GB>&#8593;</span><span style='color:black'> 12.33-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(inhibition
  of CYP3A/efflux transporters)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:
  </span><span lang=EN-GB>&#8596;</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Sofosbuvir/velpatasvir/
  voxilaprevir</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations of
  sofosbuvir, velpatasvir and voxilaprevir may be increased due to
  P-glycoprotein, BCRP and OATP1B1/3 inhibition by lopinavir/ritonavir.
  However, only the increase in voxilaprevir exposure is considered clinically
  relevant.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>It is not recommended to co&#8209;administer
  Kaletra and sofosbuvir/velpatasvir/ voxilaprevir.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>HCV
  protease inhibitors</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Simeprevir 200 mg
  daily (</span><span lang=EN-GB style='font-size:11.0pt'>ri<span
  style='letter-spacing:-.05pt'>t</span>onavir <span style='letter-spacing:
  -.05pt'>1</span>00<span style='letter-spacing:-.35pt'> </span><span
  style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>BID)</span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Simeprevir:</p>
  <p class=EMEANormal>AUC<span lang=EN-GB>:</span><span lang=EN-GB> </span><span
  lang=FR>&#8593;<span style='letter-spacing:-.2pt'> </span><span
  style='letter-spacing:.05pt'>7.2-fold</span></span></p>
  <p class=EMEANormal>C<sub>max</sub><span lang=EN-GB>:</span><span lang=EN-GB>
  </span><span lang=FR>&#8593; 4.7-fold</span></p>
  <p class=EMEANormal>C<sub>min</sub><span lang=EN-GB>:</span><span lang=EN-GB>
  </span><span lang=FR>&#8593; 14.4-fold</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>It is not recommended to co&#8209;administer Kaletra and simeprevir.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Herbal
  products</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>St Johns</span><span
  lang=EN-GB> wort</span><i><span lang=EN-GB> </span></i><span lang=EN-GB>(<i>Hypericum
  perforatum)</i></span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be reduced due to induction of CYP3A by the herbal preparation St
    Johns wort. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Herbal
  preparations containing St Johns wort must not be combined with lopinavir
  and ritonavir. If a patient is already taking St Johns wort, stop St&nbsp;Johns&nbsp;wort and if possible check viral levels. Lopinavir and ritonavir
  levels may increase on stopping St&nbsp;Johns&nbsp;wort. The dose of
  Kaletra may need adjusting. The inducing effect may persist for at least 2
  weeks after cessation of treatment with St Johns wort (see section 4.3).
  Therefore, Kaletra can be started safely 2 weeks after cessation of St
    John's wort. <i></i></span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Immunosuppressants</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Cyclosporin,
  Sirolimus (rapamycin), and Tacrolimus</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Cyclosporin,
  Sirolimus (rapamycin), Tacrolimus:</span><span lang=EN-GB> </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be increased due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>More
  frequent therapeutic concentration monitoring is recommended until plasma
  levels of these products have been stabilised.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Lipid lowering agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lovastatin and Simvastatin</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lovastatin, Simvastatin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Markedly increased plasma concentrations
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Since increased concentrations of
  HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis,
  the combination of these agents with Kaletra is contraindicated (see section
  4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal1 style='page-break-after:avoid'><i><span lang=EN-GB>Lipid-modifying
  agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lomitapide</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>CYP3A4 inhibitors increase
  the exposure of lomitapide, with strong inhibitors increasing exposure
  approximately 27&#8209;fold. Due to CYP3A inhibition by lopinavir/ritonavir,
  concentrations of lomitapide are expected to increase.</p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Concomitant use of Kaletra
  with lomitapide is contraindicated (see prescribing information for
  lomitapide) (see section 4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Atorvastatin</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Atorvastatin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 5.9-fold </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  &#8593; 4.7-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The
  combination of Kaletra with atorvastatin is not recommended. If the use of
  atorvastatin is considered strictly necessary, the lowest possible dose of
  atorvastatin should be administered with careful safety monitoring (see
  section 4.4). </span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Rosuvastatin,
  20&nbsp;mg QD</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Rosuvastatin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 2-fold </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  <sub></sub>&#8593; 5-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>While
  rosuvastatin is poorly metabolised by CYP3A4, an increase of its plasma
  concentrations was observed. The mechanism of this interaction may result
  from inhibition of transport proteins.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised and reduced doses should be considered when Kaletra is co&#8209;administered
  with rosuvastatin (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fluvastatin or Pravastatin</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fluvastatin, Pravastatin: </span></p>
  <p class=EMEANormal><span lang=EN-GB>No clinical relevant interaction
  expected.</span></p>
  <p class=EMEANormal><span lang=EN-GB>Pravastatin is not metabolised by
  CYP450.</span></p>
  <p class=EMEANormal><span lang=EN-GB>Fluvastatin is partially metabolised by
  CYP2C9.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>If treatment with an HMG-CoA reductase
  inhibitor is indicated, fluvastatin or pravastatin is recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Opioids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Buprenorphine,
  16&nbsp;mg QD</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Buprenorphine:</span><span
  lang=EN-GB> &#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>No dose
  adjustment necessary.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Methadone</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Methadone:</span><i><span
  lang=EN-GB> </span></i><span lang=EN-GB>&#8595;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Monitoring
  plasma concentrations of methadone is recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Oral contraceptives</span></i></p>
  </td>
 </tr>
 <tr style='height:96.25pt'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:96.25pt'>
  <p class=EMEANormal><span lang=EN-GB>Ethinyl Oestradiol</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:96.25pt'>
  <p class=EMEANormal><span lang=EN-GB>Ethinyl Oestradiol: &#8595;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=238 colspan=2 valign=top style='width:178.7pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:96.25pt'>
  <p class=EMEANormal><span lang=EN-GB>In case of co&#8209;administration of
  Kaletra with contraceptives containing ethinyl oestradiol (whatever the
  contraceptive formulation e.g. oral or patch), additional methods of
  contraception must be used.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Smoking cessation aids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bupropion</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Buproprion and its active metabolite,
  hydroxybupropion:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC and C<sub>max</sub> &#8595; ~50% </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>This effect may be due to induction of
  bupropion metabolism.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>If the co&#8209;administration of Kaletra
  with bupropion is judged unavoidable, this should be done under close
  clinical monitoring for bupropion efficacy, without exceeding the recommended
  dosage, despite the observed induction.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Thyroid
  hormone replacement therapy</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Levothyroxine</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Post&#8209;marketing
  cases have been reported indicating a potential interaction between ritonavir
  containing products and levothyroxine.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Thyroid&#8209;stimulating
  hormone (TSH) should be monitored in patients treated with levothyroxine at
  least the first month after starting and/or ending lopinavir/ritonavir
  treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Vasodilating
  agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Bosentan</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir
  - ritonavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir/ritonavir
  plasma concentrations may decrease due to CYP3A4 induction by bosentan.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Bosentan:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 5-fold </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  <sub></sub>&#8593; 6-fold</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>Initially, bosentan C<sub>min</sub>: </span><span
  lang=EN-GB style='font-size:11.0pt'>&#8593; by approximately 48-fold.<u> </u></span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised in administering Kaletra with bosentan.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>When Kaletra is administered
  concomitantly with bosentan, the efficacy of the HIV therapy should be
  monitored and patients should be closely observed for bosentan toxicity,
  especially during the first week of co-administration. </p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Riociguat</span></p>
  </td>
  <td width=218 colspan=3 valign=top style='width:163.5pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A and P&#8209;gp inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=236 valign=top style='width:177.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The co&#8209;administration of riociguat
  with Kaletra is not recommended (see section 4.4 and refer to riociguat
  SmPC).</span></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Other medicinal products</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=614 colspan=5 valign=top style='width:460.7pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Based on known metabolic profiles,
  clinically significant interactions are not expected between Kaletra and
  dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=207 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=181 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=224 style='border:none'></td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.6 Fertility, pregnancy and lactation</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEANormal><span lang=EN-GB>As a general rule, when deciding to use
antiretroviral agents for the treatment of HIV infection in pregnant women and
consequently for reducing the risk of HIV vertical transmission to the newborn,
the animal data as well as the clinical experience in pregnant women should be
taken into account in order to characterise the safety for the foetus.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Lopinavir/ritonavir has been evaluated in over 3000 women
during pregnancy, including over 1000 during the first trimester.</p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>In post&#8209;marketing
surveillance through the Antiretroviral Pregnancy Registry, established since
January 1989, an increased risk of birth defects exposures with Kaletra has not
been reported among over 1000 women exposed during the first trimester. The
prevalence of birth defects after any trimester exposure to lopinavir is
comparable to the prevalence observed in the general population. No pattern of
birth defects suggestive of a common etiology was seen. Studies in animals
have shown reproductive toxicity (see section 5.3). Based on the data
mentioned, the malformative risk is unlikely in humans. </span>Lopinavir can
be used during pregnancy if clinically needed.</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Studies in
rats revealed that lopinavir is excreted in the milk. It is not known whether
this medicinal product is excreted in human milk. As a general rule, it is
recommended that mothers infected by HIV do not breastfeed their babies under
any circumstances in order to avoid transmission of HIV. </span></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Animal studies have shown no effects on
fertility. No human data on the effect of lopinavir/ritonavir on fertility are
available.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.7 Effects on ability to drive and use machines</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>No studies on the effects on the ability
to drive and use machines have been performed. Patients should be informed
that nausea has been reported during treatment with Kaletra (see section 4.8).</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.8 Undesirable effects </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>a. Summary of the safety profile</span></u></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The safety of Kaletra has been
investigated in over 2600 patients in Phase II&#8209;IV clinical trials, of
which over 700 have received a dose of 800/200&nbsp;mg (6 capsules or 4
tablets) once daily. Along with nucleoside reverse transcriptase inhibitors (NRTIs),
in some studies, Kaletra was used in combination with efavirenz or nevirapine.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The most common adverse reactions related
to Kaletra therapy during clinical trials were diarrhoea</span><span
lang=EN-GB>, nausea, vomiting, hypertriglyceridaemia and hypercholesterolemia</span><span
lang=EN-GB>. The risk of diarrhoea may be greater with once&#8209;daily dosing
of Kaletra. </span><span lang=EN-GB>Diarrhoea, nausea and vomiting may occur
at the beginning of the treatment while hypertriglyceridaemia and
hypercholesterolemia may occur later. Treatment emergent adverse events led to
premature study discontinuation for 7% of subjects from Phase II&#8209;IV
studies.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>It is important to note that cases of
pancreatitis have been reported in patients receiving Kaletra, including those
who developed hypertriglyceridaemia. Furthermore, rare increases in PR
interval have been reported during Kaletra therapy (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><u><span lang=EN-GB
style='font-style:normal'>b. Tabulated list of adverse reactions</span></u></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Adverse
reactions</span><span lang=EN-GB> from clinical trials and post-marketing
experience in adult and paediatric patients:</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The following
events have been identified as adverse reactions. The frequency category
includes all reported events of moderate to severe intensity, regardless of the
individual causality assessment.</span><span lang=EN-GB style='font-size:11.0pt'>
The adverse reactions are displayed by system organ class. Within each
frequency grouping, undesirable effects are presented in order of decreasing
seriousness: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 </span><span
lang=EN-GB style='font-size:11.0pt'>to&nbsp;&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1000
to&nbsp;&lt;&nbsp;1/100), rare (&#8805;1/10,000 to &lt;1/1000) and </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>not known (cannot be estimated
from the available data)</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=3 valign=top style='width:453.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Undesirable effects in clinical studies and post-marketing in
  adult patients</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>System organ class</span></b></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Frequency</span></b></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Adverse reaction</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Upper respiratory tract infection</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lower respiratory tract infection, skin
  infections including cellulitis, folliculitis and furuncle</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.5pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=EMEANormal style='text-align:justify'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Anaemia, leucopenia, neutropenia,
  lymphadenopathy</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypersensitivity including urticaria and
  angioedema</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Immune </span><span lang=EN-GB>reconstitution
  inflammatory<i> </i></span><span lang=EN-GB>syndrome</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.65pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=EMEANormal><span lang=EN-GB>Endocrine disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:11.65pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypogonadism </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Blood glucose disorders including
  diabetes mellitus, hypertriglyceridaemia, hypercholesterolemia, weight
  decreased, decreased appetite </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Weight increased, increased appetite</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Anxiety</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abnormal dreams, libido decreased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Headache (including migraine),
  neuropathy (including peripheral neuropathy), dizziness, insomnia</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:28.35pt'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.35pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:28.35pt'>
  <p class=EMEANormal><span lang=EN-GB>Cerebrovascular accident, convulsion,
  dysgeusia, ageusia, tremor </span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Visual impairment</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:9.0pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:9.0pt'>
  <p class=EMEANormal><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.0pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:9.0pt'>
  <p class=EMEANormal><span lang=EN-GB>Tinnitus, vertigo</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.5pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:38.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Atherosclerosis such as myocardial
  infarction, atrioventricular block, tricuspid valve incompetence</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypertension </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Deep vein thrombosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=3 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Gastrointestinal disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Very common</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Diarrhoea, nausea</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Pancreatitis<sup>1</sup>, vomiting,
  gastrooesophageal reflux disease, gastroenteritis and colitis, abdominal pain
  (upper and lower), abdominal distension, dyspepsia, haemorrhoids, flatulence</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:50.55pt'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.55pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.55pt'>
  <p class=EMEANormal><span lang=EN-GB>Gastrointestinal haemorrhage including
  gastrointestinal ulcer, duodenitis, gastritis and rectal haemorrhage,
  stomatitis and oral ulcers, faecal incontinence, constipation, dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hepatobiliary disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hepatitis including AST, ALT and GGT
  increases</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:44.65pt'>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:44.65pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:44.65pt'>
  <p class=EMEANormal><span lang=EN-GB>Jaundice, hepatic steatosis,
  hepatomegaly, cholangitis, hyperbilirubinemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=3 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rash including maculopapular rash,
  dermatitis/rash including eczema and seborrheic dermatitis, night sweats,
  pruritus</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Alopecia, capillaritis, vasculitis </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:26.05pt'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.05pt'>
  <p class=EMEANormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.05pt'>
  <p class=EMEANormal><span lang=FR>Stevens-Johnson syndrome, erythema
  multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Myalgia, </span><span lang=EN-GB>musculoskeletal
  pain including arthralgia and back pain, muscle disorders such as weakness
  and spasms</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rhabdomyolysis, osteonecrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Renal and urinary disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Not known</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Creatinine clearance decreased,
  nephritis, haematuria</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Nephrolithiasis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:23.25pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:23.25pt'>
  <p class=EMEANormal><span lang=EN-GB>Reproductive system and breast disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.25pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:23.25pt'>
  <p class=EMEANormal><span lang=EN-GB>Erectile dysfunction, menstrual
  disorders - amenorrhoea, menorrhagia </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.45pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.45pt'>
  <p class=EMEANormal><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.45pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.45pt'>
  <p class=EMEANormal><span lang=EN-GB>Fatigue including asthenia</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB> See
section 4.4: pancreatitis and lipids</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB style='color:black'>c. Description of
selected adverse reactions</span></u></p>

<p class=EMEANormal><b><i><span lang=EN-GB style='color:black'>&nbsp;</span></i></b></p>

<p class=EMEANormal><span lang=EN-GB>Cushings syndrome has been reported in
patients receiving ritonavir and inhaled or intranasally administered
fluticasone propionate; this could also occur with other corticosteroids
metabolised via the P450 3A pathway e.g. budesonide (see section 4.4 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Increased creatine phosphokinase (CPK),
myalgia, myositis, and rarely, rhabdomyolysis have been reported with protease
inhibitors, particularly in combination with nucleoside reverse transcriptase
inhibitors.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Metabolic parameters</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>In HIV-infected patients with severe
immune deficiency at the time of initiation of combination antiretroviral
therapy (CART), an inflammatory reaction to asymptomatic or residual
opportunistic infections may arise. </span>Autoimmune disorders (such as
Graves disease <span lang=EN-GB>and autoimmune hepatitis</span>) have also
been reported; however, the reported time to onset is more variable and can
occur many months after initiation of treatment<span lang=EN-GB> (see section
4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Cases of osteonecrosis have been reported,
particularly in patients with generally acknowledged risk factors, advanced HIV
disease or long-term exposure to combination antiretroviral therapy (CART).
The frequency of this is unknown (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='font-size:11.0pt'>d. Paediatric populations</span></u></p>

<p class=MsoBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>In children 2 years of age and older, the
nature of the safety profile is similar to that seen in adults (see Table in
section b). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Reporting of suspected adverse
reactions</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions </span>via <span
style='background:lightgrey'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a><span style='color:blue'>.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.9 Overdose</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>To date,
there is limited human experience of acute overdose with Kaletra.</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The adverse clinical signs observed in
dogs included salivation, emesis and diarrhoea/abnormal stool. The signs of
toxicity observed in mice, rats or dogs included decreased activity, ataxia,
emaciation, dehydration and tremors. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>There is no specific antidote for overdose
with Kaletra. Treatment of overdose with Kaletra is to consist of general
supportive measures including monitoring of vital signs and observation of the
clinical status of the patient. If indicated, elimination of unabsorbed active
substance is to be achieved by emesis or gastric lavage. Administration of
activated charcoal may also be used to aid in removal of unabsorbed active
substance. Since Kaletra is highly protein bound, dialysis is unlikely to be
beneficial in significant removal of the active substance.</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5.  Pharmacological properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5.1  Pharmacodynamic properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Pharmaco-therapeutic group: antivirals for
systemic use, a</span>ntivirals for treatment of HIV infections, combinations<span
lang=EN-GB>, ATC code: J05AR10 </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Lopinavir
provides the antiviral activity of Kaletra. </span><span lang=EN-GB>Lopinavir
is an inhibitor of the HIV-1 and HIV-2 proteases. Inhibition of HIV protease
prevents cleavage of the <i>gag-pol</i> polyprotein resulting in the production
of immature, non-infectious virus. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Effects on the electrocardiogram</span></u></p>

<p class=EMEANormal><span lang=EN-GB>QTcF interval was evaluated in a
randomised, placebo and active (moxifloxacin 400&nbsp;mg once daily) controlled
crossover study in 39 healthy adults, with 10 measurements over 12 hours on Day
3. The maximum mean (95% upper confidence bound) differences in QTcF from
placebo were 3.6 (6.3) and 13.1(15.8) for 400/100&nbsp;mg twice daily and
supratherapeutic 800/200&nbsp;mg twice daily LPV/r, respectively. </span><span
lang=EN-GB>The induced QRS interval prolongation from 6 ms to 9.5 ms with high
dose lopinavir/ritonavir (800/200&nbsp;mg twice daily) contributes to QT
prolongation. </span><span lang=EN-GB>The two regimens resulted in exposures
on Day 3 which were approximately 1.5 and 3&#8209;fold higher than those
observed with recommended once&#8209;daily or twice&#8209;daily LPV/r doses at
steady state. No subject experienced an increase in QTcF of </span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;60 ms from
baseline or a QTcF interval exceeding the potentially clinically relevant
threshold of 500 ms.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Modest prolongation of the PR interval was
also noted in subjects receiving lopinavir/ritonavir in the same study on Day
3. </span><span lang=EN-GB>The mean changes from baseline in PR interval
ranged from 11.6 ms to 24.4 ms in the 12 hour interval post dose.<b><i> </i></b></span><span
lang=EN-GB>Maximum PR interval was 286 ms and no second or third degree heart
block was observed (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Antiviral activity <i>in&nbsp;vitro</i></span></u></p>

<p class=EMEANormal><span lang=EN-GB>The <i>in&nbsp;vitro </i>antiviral
activity of lopinavir against laboratory and clinical HIV strains was evaluated
in acutely infected lymphoblastic cell lines and peripheral blood lymphocytes,
respectively. In the absence of human serum, the mean IC<sub>50</sub> of
lopinavir against five different HIV-1 laboratory strains was 19&nbsp;nM. In
the absence and presence of 50% human serum, the mean IC<sub>50</sub> of
lopinavir against HIV-1<sub>IIIB</sub> in MT4 cells was 17&nbsp;nM and
102&nbsp;nM, respectively. In the absence of human serum, the mean IC<sub>50</sub>
of lopinavir was 6.5&nbsp;nM against several HIV-1 clinical isolates.</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></p>

<p class=EMEAHeadingUI style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-style:normal'>Resistance</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>In vitro
selection of resistance</span></i></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV-1
isolates with reduced susceptibility to lopinavir have been selected <i>in&nbsp;vitro</i>.
HIV-1 has been passaged <i>in&nbsp;vitro</i> with lopinavir alone and with
lopinavir plus ritonavir at concentration ratios representing the range of
plasma concentration ratios observed during Kaletra therapy. Genotypic and
phenotypic analysis of viruses selected in these passages suggest that the
presence of ritonavir, at these concentration ratios, does not measurably
influence the selection of lopinavir-resistant viruses. Overall, the <i>in&nbsp;vitro</i>
characterisation of phenotypic cross-resistance between lopinavir and other
protease inhibitors suggest that decreased susceptibility to lopinavir
correlated closely with decreased susceptibility to ritonavir and indinavir,
but did not correlate closely with decreased susceptibility to amprenavir,
saquinavir, and nelfinavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><i><span lang=EN-GB
style='font-size:11.0pt'>Analysis of resistance in ARV-nave patients </span></i></p>

<p class=EMEANormal><span lang=EN-GB>In clinical studies with a limited number
of isolates analysed, the selection of resistance to lopinavir has not been
observed in nave patients without significant protease inhibitor resistance at
baseline. See further the detailed description of the clinical studies.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Analysis of resistance in
PI-experienced patients</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The selection of resistance to lopinavir
in patients having failed prior protease inhibitor therapy was characterised by
analysing the longitudinal isolates from 19 protease inhibitor-experienced
subjects in 2 Phase II and one Phase III studies who either experienced
incomplete virologic suppression or viral rebound subsequent to initial
response to Kaletra and who demonstrated incremental <i>in vitro</i> resistance
between baseline and rebound (defined as emergence of new mutations or 2-fold
change in phenotypic susceptibility to lopinavir). Incremental resistance was
most common in subjects whose baseline isolates had several protease
inhibitor-associated mutations, but &lt;&nbsp;40-fold reduced susceptibility to
lopinavir at baseline. Mutations V82A, I54V and M46I emerged most frequently.
Mutations L33F, I50V and V32I combined with I47V/A were also observed. The 19
isolates demonstrated a 4.3-fold increase in IC<sub>50</sub> compared to
baseline isolates (from 6.2- to 43-fold, compared to wild-type virus).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Genotypic correlates of reduced phenotypic
susceptibility to lopinavir in viruses selected by other protease inhibitors.
The <i>in&nbsp;vitro</i> antiviral activity of lopinavir against 112 clinical
isolates taken from patients failing therapy with one or more protease
inhibitors was assessed. Within this panel, the following mutations in HIV
protease were associated with reduced <i>in&nbsp;vitro</i> susceptibility to
lopinavir: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V,
V82A/F/T, I84V and L90M. The median EC<sub>50</sub> of lopinavir against
isolates with 0&nbsp;&#8722;&nbsp;3, 4&nbsp;&#8722;&nbsp;5,
6&nbsp;&#8722;&nbsp;7 and 8&nbsp;&#8722;&nbsp;10 mutations at the above amino
acid positions was 0.8, 2.7 13.5 and 44.0-fold higher than the EC<sub>50</sub>
against wild type HIV, respectively. The 16 viruses that displayed
&gt;&nbsp;20-fold change in susceptibility all contained mutations at positions
10, 54, 63 plus 82 and/or 84. In addition, they contained a median of 3
mutations at amino acid positions 20, 24, 46, 53, 71 and 90. </span><span
lang=EN-GB>In addition to the mutations described above, mutations V32I and
I47A have been observed in rebound isolates with reduced lopinavir
susceptibility from protease inhibitor experienced patients receiving Kaletra
therapy</span><span lang=EN-GB>, and mutations I47A and L76V have been observed
in rebound isolates with reduced lopinavir susceptibility from patients
receiving Kaletra therapy.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Conclusions regarding the relevance of
particular mutations or mutational patterns are subject to change with
additional data, and it is recommended to always consult current interpretation
systems for analysing resistance test results.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Antiviral activity of Kaletra in
patients failing protease inhibitor therapy</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The clinical relevance of reduced <i>in&nbsp;vitro</i>
susceptibility to lopinavir has been examined by assessing the virologic
response to Kaletra therapy, with respect to baseline viral genotype and
phenotype, in 56 patients previous failing therapy with multiple protease
inhibitors. The EC<sub>50</sub> of lopinavir against the 56 baseline viral
isolates ranged from 0.6 to 96-fold higher than the EC<sub>50</sub> against
wild type HIV. After 48 weeks of treatment with Kaletra, efavirenz and
nucleoside reverse transcriptase inhibitors, plasma HIV RNA </span><span
lang=EN-GB style='font-family:Symbol;layout-grid-mode:line'></span><span
lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span><span lang=EN-GB>400&nbsp;copies/ml
was observed in 93% (25/27), 73% (11/15), and 25% (2/8) of patients with
&lt;&nbsp;10&#8209;fold, 10 to 40-fold, and &gt;&nbsp;40&#8209;fold reduced
susceptibility to lopinavir at baseline, respectively. In addition, virologic
response was observed in 91% (21/23), 71% (15/21) and 33% (2/6) patients with
0&nbsp;&#8722;&nbsp;5, 6&nbsp;&#8722;&nbsp;7, and 8&nbsp;&#8722;&nbsp;10
mutations of the above mutations in HIV protease associated with reduced <i>in&nbsp;vitro</i>
susceptibility to lopinavir. Since these patients had not previously been
exposed to either Kaletra or efavirenz, part of the response may be attributed
to the antiviral activity of efavirenz, particularly in patients harbouring
highly lopinavir resistant virus. The study did not contain a control arm of
patients not receiving Kaletra.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Cross&#8209;resistance</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Activity of other protease inhibitors
against isolates that developed incremental resistance to lopinavir after
Kaletra therapy in protease inhibitor experienced patients: The presence of
cross resistance to other protease inhibitors was analysed in 18 rebound i</span><span
lang=EN-GB>solates that had demonstrated evolution of resistance to lopinavir
during 3 </span><span lang=EN-GB>Phase </span><span lang=EN-GB>II and one </span><span
lang=EN-GB>Phase </span><span lang=EN-GB>III studies of Kaletra in protease
inhibitor-experienced patients. The median fold IC<sub>50</sub> of lopinavir
for these 18 isolates at baseline and rebound was 6.9- and 63-fold,
respectively, compared to wild type virus. In general, rebound isolates either
retained (if cross-resistant at baseline) or developed significant
cross-resistance to indinavir, saquinavir and atazanavir. Modest decreases in
amprenavir activity were noted with a median increase of IC<sub>50 </sub>from
3.7- to 8-fold in the baseline and rebound isolates, respectively. Isolates
retained susceptibility to tipranavir with a median increase of IC<sub>50</sub>
in baseline and rebound isolates of 1.9- and 1.8fold, respectively, compared
to wild type virus. </span><span lang=EN-GB>Please refer to the Aptivus
Summary of Product Characteristics for additional information on the use of
tipranavir, including genotypic predictors of response, in treatment of
lopinavir-resistant HIV-1 infection.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Clinical results</span></p>

<p class=EMEANormal><span lang=EN-GB>The effects of Kaletra (in combination
with other antiretroviral agents) on biological markers (plasma HIV RNA levels
and CD4+<sub> </sub>T-cell counts) have been investigated in controlled studies
of Kaletra of 48&nbsp;to 360 weeks duration. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Adult Use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUnderline style='margin:0in'><span lang=EN-GB
style='text-decoration:none'>Patients without prior antiretroviral therapy</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Study M98-863 was a randomised,
double-blind trial of 653 antiretroviral treatment nave patients investigating
Kaletra (400/100&nbsp;mg twice daily) compared to nelfinavir (750&nbsp;mg three
times daily) plus stavudine and lamivudine. Mean baseline CD4+ T-cell count
was 259&nbsp;cells/mm<sup>3</sup> (range: 2 to 949&nbsp;cells/ mm<sup>3</sup>)
and mean baseline plasma HIV-1 RNA was 4.9&nbsp;log<sub>10&nbsp;</sub>copies/ml
(range: 2.6 to 6.8&nbsp;log<sub>10&nbsp;</sub>copies/ml). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 1</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=515
 style='width:386.5pt;margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=515 colspan=3 valign=top style='width:386.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 48: Study M98-863</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Kaletra (N=326)</span></b></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Nelfinavir (N=327)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 400 copies/ml*</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>75%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>63%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 50 copies/ml*</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>67%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>52%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Mean
  increase from baseline in CD4+<sub> </sub>T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>207</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>195</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal style='margin-left:30.0pt'><span lang=EN-GB>* intent to
treat analysis where patients with missing values are considered virologic
failures </span></p>

<p class=EMEANormal style='margin-left:30.0pt'><span lang=EN-GB>
p&nbsp;&lt;&nbsp;0.001</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>One-hundred thirteen nelfinavir-treated
patients and 74 lopinavir/ritonavir-treated patients had an HIV RNA above
400&nbsp;copies/ml while on treatment from Week 24 through Week 96. Of these,
isolates from 96 nelfinavir-treated patients and 51 lopinavir/ritonavir-treated
patients could be amplified for resistance testing. Resistance to nelfinavir,
defined as the presence of the D30N or L90M mutation in protease, was observed
in 41/96 (43%) patients. Resistance to lopinavir, defined as the presence of
any primary or active site mutations in protease (see above), was observed in
0/51 (0%) patients. Lack of resistance to lopinavir was confirmed by
phenotypic analysis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Study M05-730 was a randomised,
open-label, multicentre trial comparing treatment with Kaletra 800/200&nbsp;mg
once daily plus tenofovir DF and emtricitabine versus Kaletra 400/100&nbsp;mg
twice daily plus tenofovir DF and emtricitabine in 664 antiretroviral
treatment-nave patients. </span><span lang=EN-GB>Given the pharmacokinetic
interaction between Kaletra and tenofovir (see section 4.5), the results of
this study might not be strictly extrapolable when other backbone regimens are
used with Kaletra</span><span lang=EN-GB>. Patients were randomised in a 1:1
ratio to receive either Kaletra 800/200&nbsp;mg once daily (n&nbsp;=&nbsp;333)
or Kaletra 400/100&nbsp;mg twice daily (n&nbsp;=&nbsp;331). Further
stratification within each group was 1:1 (tablet versus soft capsule).
Patients were administered either the tablet or the soft capsule formulation
for 8 weeks, after which all patients were administered the tablet formulation
once daily or twice daily for the remainder of the study. Patients were
administered emtricitabine 200&nbsp;mg once daily and tenofovir DF 300&nbsp;mg once
daily (equivalent to 245 mg tenofovir disoproxil). Protocol defined
non-inferiority of once&#8209;daily dosing compared with twice&#8209;daily
dosing was demonstrated if the lower bound of the 95% confidence interval for
the difference in proportion of subjects responding (once daily minus twice
daily) excluded -12% at Week 48. Mean age of patients enrolled was 39 years
(range: 19 to 71); 75% were Caucasian, and 78% were male. Mean baseline CD4+
T-cell count was 216 cells/mm3 (range: 20 to 775 cells/mm<sup>3</sup>) and mean
baseline plasma HIV-1 RNA was 5.0&nbsp;log<sub>10</sub>&nbsp;copies/ml (range:
1.7 to 7.0&nbsp;log<sub>10</sub>&nbsp;copies/ml). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Table 2</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=592 colspan=7 valign=top style='width:444.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>Virologic Response of Study Subjects at
  Week 48 and Week 96</span></u></b></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><u><span lang=EN-GB style='font-size:11.0pt'><span
   style='text-decoration:none'>&nbsp;</span></span></u></b></p>
  </td>
  <td width=216 colspan=3 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-indent:-5.4pt'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>Week 48</span></u></b></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:162.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>Week 96</span></u></b></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><u><span lang=EN-GB style='font-size:11.0pt'><span
   style='text-decoration:none'>&nbsp;</span></span></u></b></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>QD</span></u></b></p>
  </td>
  <td width=66 valign=top style='width:49.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>BID </span></u></b></p>
  </td>
  <td width=86 valign=top style='width:64.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>Difference</span></u></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>[95% CI]</span></u></b></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>QD</span></u></b></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>BID </span></u></b></p>
  </td>
  <td width=89 valign=top style='width:66.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>Difference</span></u></b></p>
  <p class=MsoNormal align=center style='text-align:center'><b><u><span
  lang=EN-GB style='font-size:11.0pt'>[95% CI]</span></u></b></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>NC= Failure</span></u></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>257/333</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(77.2%)</span></p>
  </td>
  <td width=66 valign=top style='width:49.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>251/331</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(75.8%)</span></p>
  </td>
  <td width=86 valign=top style='width:64.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>1.3 %</span></p>
  <p class=MsoNormal align=center style='text-align:center'><u><span
  lang=EN-GB style='font-size:11.0pt'>[-5.1, 7.8]</span></u></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>216/333</span></p>
  <p class=MsoNormal align=center style='text-align:center'><u><span
  lang=EN-GB style='font-size:11.0pt'>(64.9%)</span></u></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>229/331</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(69.2%)</span></p>
  </td>
  <td width=89 valign=top style='width:66.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>-4.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><u><span
  lang=EN-GB style='font-size:11.0pt'>[-11.5, 2.8]</span></u></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Observed data</span></u></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>257/295</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(87.1%)</span></p>
  </td>
  <td width=66 valign=top style='width:49.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>250/280</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(89.3%)</span></p>
  </td>
  <td width=86 valign=top style='width:64.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>-2.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><u><span
  lang=EN-GB style='font-size:11.0pt'>[-7.4, 3.1]</span></u></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>216/247</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(87.4%)</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>229/248</span></p>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>(92.3%)</span></p>
  </td>
  <td width=89 valign=top style='width:66.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>-4.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center'><u><span
  lang=EN-GB style='font-size:11.0pt'>[-10.2, 0.4]</span></u></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Mean increase
  from baseline in CD4+ T-cell count (cells/mm3)</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>186</span></p>
  </td>
  <td width=66 valign=top style='width:49.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>198</span></p>
  </td>
  <td width=86 valign=top style='width:64.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>238</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>254</span></p>
  </td>
  <td width=89 valign=top style='width:66.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Through Week 96, genotypic resistance
testing results were available from 25 patients in the QD group and 26 patients
in the BID group who had incomplete virologic response. In the QD group, no
patient demonstrated lopinavir resistance, and in the BID group, 1 patient who
had significant protease inhibitor resistance at baseline demonstrated
additional lopinavir resistance on study.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Sustained virological response to Kaletra
(in combination with nucleoside/nucleotide reverse transcriptase inhibitors)
has been also observed in a small Phase II study (M97-720) through 360 weeks of
treatment. One hundred patients were originally treated with Kaletra in the
study (including 51 patients receiving 400/100&nbsp;mg twice daily and 49
patients at either 200/100&nbsp;mg twice daily or 400/200&nbsp;mg twice
daily). All patients converted to open-label Kaletra at the 400/100&nbsp;mg
twice&#8209;daily dose between week 48 and week 72. <span style='color:black'>Thirty&#8209;nine
patients (39%) discontinued the study, including 16 (16%) discontinuations due
to adverse events, one of which was associated with a death. </span>Sixty&#8209;one
patients completed the study (35 patients received the recommended
400/100&nbsp;mg twice&#8209;daily dose throughout the study). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 3</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=536
 style='width:402.0pt;margin-left:29.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=536 colspan=2 valign=top style='width:402.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB>Outcomes
  at Week 360: Study M97-720</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Kaletra (N=100)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>HIV RNA &lt; 400 copies/ml</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>61%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>HIV RNA &lt; 50 copies/ml</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>59%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Mean increase from baseline in CD4+
  T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>501</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Through 360 weeks of treatment, genotypic
analysis of viral isolates was successfully conducted in 19 of 28 patients with
confirmed HIV RNA above 400&nbsp;copies/ml revealed no primary or active site
mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82,
84 and 90) or protease inhibitor phenotypic resistance.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUnderline style='margin:0in'><span lang=EN-GB
style='text-decoration:none'>Patients with prior antiretroviral therapy</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>M06-802 was a randomised open-label study
comparing the safety, tolerability and antiviral activity of once&#8209;daily
and twice&#8209;daily dosing of lopinavir/ritonavir tablets in 599 subjects
with detectable viral loads while receiving their current antiviral therapy.
Patients had not been on prior lopinavir/ritonavir therapy. They were
randomised in a 1:1 ratio to receive either lopinavir/ritonavir 800/200&nbsp;mg
once daily (n = 300) or lopinavir/ritonavir 400/100&nbsp;mg twice daily (n =
299). Patients were administered at least two nucleoside/nucleotide reverse
transcriptase inhibitors selected by the investigator. The enrolled population
was moderately PI-experienced with more than half of patients having never received
prior PI and around 80% of patients presenting a viral strain with less than 3
PI mutations. Mean age of patients enrolled was 41&nbsp;years (range: 21 to
73); 51% were Caucasian and 66% were male. Mean baseline CD4+ T-cell count was
254 cells/mm<sup>3</sup> (range: 4 to 952&nbsp;cells/mm<sup>3</sup>) and mean
baseline plasma HIV-1 RNA was 4.3&nbsp;log<sub>10</sub>&nbsp;copies/ml (range:
1.7 to 6.6&nbsp;log<sub>10</sub>&nbsp;copies/ml). Around 85% of patients had a
viral load of &lt;&nbsp;100,000&nbsp;copies/ml.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 4</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=459 colspan=4 valign=top style='width:344.2pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB style='color:black'>Virologic Response of Study Subjects at Week
  48 Study 802</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=199 valign=top style='width:149.35pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>QD</span></b></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>BID</span></b></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>Difference</span></b></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='color:black'>[95% CI]</span></b></p>
  </td>
 </tr>
 <tr style='height:28.35pt'>
  <td width=199 valign=top style='width:149.35pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:28.35pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>NC= Failure</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.35pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>171/300 (57%)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.35pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>161/299 (53.8%)</span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.35pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>3.2%</span></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>[-4.8%, 11.1%]</span></p>
  </td>
 </tr>
 <tr style='height:25.95pt'>
  <td width=199 valign=top style='width:149.35pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:25.95pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>Observed data</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>171/225 (76.0%)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>161/223 (72.2%)</span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>3.8%</span></p>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>[-4.3%, 11.9%]</span></p>
  </td>
 </tr>
 <tr style='height:25.95pt'>
  <td width=199 valign=top style='width:149.35pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:25.95pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Mean
  increase from baseline in CD4+<sub> </sub>T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>135</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>122</span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Through Week 48, genotypic resistance
testing results were available from 75 patients in the QD group and 75 patients
in the BID group who had incomplete virologic response. In the QD group, 6/75
(8%) patients demonstrated new primary protease inhibitor mutations (codons 30,
32, 48, 50, 82, 84, 90), as did 12/77 (16%) patients in the BID group.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Paediatric Use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>M98-940 was an open-label study of a
liquid formulation of Kaletra in 100 antiretroviral nave (44%) and experienced
(56%) paediatric patients. All patients were non-nucleoside reverse
transcriptase inhibitor nave. Patients were randomised to either 230&nbsp;mg
lopinavir/57.5&nbsp;mg ritonavir per m<sup>2</sup> or 300&nbsp;mg
lopinavir/75&nbsp;mg ritonavir per m<sup>2</sup>. Nave patients also received
nucleoside reverse transcriptase inhibitors. Experienced patients received
nevirapine plus up to two nucleoside reverse transcriptase inhibitors. <span
style='layout-grid-mode:line'>Safety, efficacy and pharmacokinetic profiles of
the two dose regimens were assessed after 3 weeks of therapy in each patient.
Subsequently, all patients were continued on the 300/75&nbsp;mg per m<sup>2</sup>
dose.</span> Patients had a mean age of 5&nbsp;years (range 6 months to 12
years) with 14 patients less than 2 years old and 6 patients one year or less.
Mean baseline CD4+ T-cell count was 838&nbsp;cells/mm<sup>3</sup> and mean
baseline plasma HIV-1 RNA was 4.7&nbsp;log<sub>10&nbsp;</sub>copies/ml. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 5 </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=515
 style='width:386.5pt;margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=515 colspan=3 valign=top style='width:386.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 48: Study M98-940</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Antiretroviral Nave (N=44)</span></b></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Antiretroviral Experienced (N=56)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>HIV RNA &lt; 400 copies/ml</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>84%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>75%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Mean increase from baseline in CD4+
  T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>404</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>284</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif;font-weight:normal'>KONCERT/PENTA 18 is a prospective
multicentre, randomised, open-label study that evaluated the pharmacokinetic
profile, efficacy and safety of twice-daily versus once-daily dosing of
lopinavir/ritonavir 100&nbsp;mg/25&nbsp;mg tablets dosed by weight as part of
combination antiretroviral therapy (cART) in virologically suppressed HIV-1
infected children (n=173). Children were eligible when they were aged &lt;18
years, &#8805;15 kg in weight, receiving cART that included
lopinavir/ritonavir, HIV-1 ribonucleic acid (RNA) &lt;50 copies/ml for at least
24 weeks and able to swallow tablets. At week 48, the efficacy and safety with
twice-daily dosing (n=87) in the paediatric population given
lopinavir/ritonavir 100&nbsp;mg/25&nbsp;mg tablets was consistent with the
efficacy and safety findings in previous adult and paediatric studies using
lopinavir/ritonavir twice daily. The percentage of patients with confirmed
viral rebound &gt;50 copies/ml during 48 weeks of follow&#8209;up was higher in
the paediatric patients receiving lopinavir/ritonavir tablets once daily (12%)
than in patients receiving the twice-daily dosing (8%, p = 0.19), mainly due to
lower adherence in the once-daily group. The efficacy data favouring the
twice-daily regimen are reinforced by a differential in pharmacokinetic
parameters significantly favouring the twice-daily regimen (see section 5.2).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5.2 Pharmacokinetic properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The
pharmacokinetic properties of lopinavir co-administered with ritonavir have
been evaluated in healthy adult volunteers and in HIV-infected patients; no
substantial differences were observed between the two groups. Lopinavir is
essentially completely metabolised by CYP3A. Ritonavir inhibits the metabolism
of lopinavir, thereby increasing the plasma levels of lopinavir. Across
studies, administration of Kaletra 400/100&nbsp;mg twice daily yields mean
steady-state lopinavir plasma concentrations 15 to 20-fold higher than those of
ritonavir in HIV-infected patients. The plasma levels of ritonavir are less
than 7% of those obtained after the ritonavir dose of 600&nbsp;mg twice daily.
The <i>in&nbsp;vitro</i> antiviral EC<sub>50</sub> of lopinavir is
approximately 10-fold lower than that of ritonavir. Therefore, the antiviral
activity of Kaletra is due to lopinavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Multiple dosing with 400/100&nbsp;mg
Kaletra twice daily for 2 weeks and without meal restriction produced a mean </span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> SD lopinavir
peak plasma concentration (C<sub>max</sub>) of 12.3&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;5.4&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/ml, occurring
approximately 4 hours after administration. The mean steady-state trough
concentration prior to the morning dose was 8.1&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;5.7&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/ml. Lopinavir
AUC over a 12 hour dosing interval averaged 113.2&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;60.5&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>h/ml. The
absolute bioavailability of lopinavir co-formulated with ritonavir in humans
has not been established.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Effects of food on oral absorption</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Administration of a single 400/100&nbsp;mg
dose of Kaletra tablets under fed conditions (high fat, 872 kcal, 56% from fat)
compared to fasted state was associated with no significant changes in C<sub>max</sub>
and AUC<sub>inf</sub>. Therefore, Kaletra tablets may be taken with or without
food. Kaletra tablets have also shown less pharmacokinetic variability under
all meal conditions compared to Kaletra soft capsules.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>At steady
state, lopinavir is approximately 98&nbsp;&#8722;&nbsp;99% bound to serum
proteins. Lopinavir binds to both alpha-1-acid glycoprotein (AAG) and albumin
however, it has a higher affinity for AAG. At steady state, lopinavir protein
binding remains constant over the range of observed concentrations after
400/100&nbsp;mg Kaletra twice daily, and is similar between healthy volunteers
and HIV-positive patients.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=EMEANormal><i><span lang=EN-GB>In&nbsp;vitro</span></i><span
lang=EN-GB> experiments with human hepatic microsomes indicate that lopinavir
primarily undergoes oxidative metabolism. Lopinavir is extensively metabolised
by the hepatic cytochrome P450 system, almost exclusively by isozyme CYP3A.
Ritonavir is a potent CYP3A inhibitor which inhibits the metabolism of
lopinavir and therefore, increases plasma levels of lopinavir. A <sup>14</sup>C&#8209;lopinavir
study in humans showed that 89% of the plasma radioactivity after a single
400/100&nbsp;mg Kaletra dose was due to parent active substance. At least 13
lopinavir oxidative metabolites have been identified in man. The 4-oxo and
4-hydroxymetabolite epimeric pair are the major metabolites with antiviral
activity, but comprise only minute amounts of total plasma radioactivity.
Ritonavir has been shown to induce metabolic enzymes, resulting in the induction
of its own metabolism, and likely the induction of lopinavir metabolism.
Pre-dose lopinavir concentrations decline with time during multiple dosing,
stabilising after approximately 10 days to 2 weeks.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEANormal><span lang=EN-GB>After a 400/100&nbsp;mg <sup>14</sup>C-lopinavir/ritonavir
dose, approximately 10.4&nbsp;</span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>&nbsp;2.3% and 82.6&nbsp;</span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>&nbsp;2.5% of an administered dose of <sup>14</sup>C-lopinavir
can be accounted for in urine and faeces, respectively. Unchanged lopinavir
accounted for approximately 2.2% and 19.8% of the administered dose in urine
and faeces, respectively. After multiple dosing, less than 3% of the lopinavir
dose is excreted unchanged in the urine. The effective (peak to trough)
half-life of lopinavir over a 12&nbsp;hour dosing interval averaged
5&nbsp;&#8722;&nbsp;6 hours, and the apparent oral clearance (CL/F) of
lopinavir is 6 to 7&nbsp;l/h.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Once&#8209;daily dosing: the
pharmacokinetics of once daily Kaletra have been evaluated in HIV-infected
subjects nave to antiretroviral treatment. Kaletra 800/200&nbsp;mg was
administered in combination with emtricitabine 200&nbsp;mg and tenofovir DF
300&nbsp;mg as part of a once&#8209;daily regimen. Multiple dosing of
800/200&nbsp;mg Kaletra once daily for 2 weeks without meal restriction (n=16)
produced a mean  SD lopinavir peak plasma concentration (C<sub>max</sub>) of
14.8  3.5&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g/ml, occurring approximately 6 hours after administration. The
mean steady-state trough concentration prior to the morning dose was
5.5&nbsp;&nbsp;5.4&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g/ml. Lopinavir AUC over a 24 hour dosing interval averaged 206.5 
89.7&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g</span><span style='font-family:Symbol'></span><span lang=EN-GB>h/ml.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>As compared to the BID regimen, the once&#8209;daily
dosing is associated with a reduction in the C<sub>min</sub>/C<sub>trough</sub>
values of approximately 50%. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Special Populations</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Paediatrics</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There are limited
pharmacokinetic data in children below 2 years of age. The pharmacokinetics of
Kaletra oral solution 300/75&nbsp;mg/m<sup>2</sup> twice daily and
230/57.5&nbsp;mg/m<sup>2</sup> twice daily have been studied in a total of 53
paediatric patients, ranging in age from 6 months to 12 years. The lopinavir
mean steady-state AUC, C<sub>max</sub>, and C<sub>min</sub> were 72.6&nbsp;</span><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;31.1&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>m</span><span lang=EN-GB
style='font-size:11.0pt'>g</span><span lang=EN-GB style='font-size:11.0pt;
font-family:Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>h/ml,
8.2&nbsp;</span><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;2.9&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>m</span><span lang=EN-GB
style='font-size:11.0pt'>g/ml and 3.4&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'></span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;2.1&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>m</span><span lang=EN-GB
style='font-size:11.0pt'>g/ml, respectively after Kaletra oral solution
230/57.5&nbsp;mg/m<sup>2</sup> twice daily without nevirapine (n=12), and were
85.8&nbsp;</span><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;36.9&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>m</span><span lang=EN-GB
style='font-size:11.0pt'>g</span><span lang=EN-GB style='font-size:11.0pt;
font-family:Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>h/ml,
10.0&nbsp;</span><span lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;3.3&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>m</span><span lang=EN-GB
style='font-size:11.0pt'>g/ml and 3.6&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'></span><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;3.5&nbsp;</span><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol'>m</span><span lang=EN-GB
style='font-size:11.0pt'>g/ml, respectively after 300/75&nbsp;mg/m<sup>2</sup>
twice daily with nevirapine (n=12). The 230/57.5&nbsp;mg/m<sup>2</sup> twice&#8209;daily
regimen without nevirapine and the 300/75&nbsp;mg/m<sup>2</sup> twice&#8209;daily
regimen with nevirapine provided lopinavir plasma concentrations similar to
those obtained in</span><span lang=EN-GB style='font-size:11.0pt'> </span><span
lang=EN-GB style='font-size:11.0pt'>adult patients receiving the 400/100&nbsp;mg
twice&#8209;daily regimen without nevirapine. </span></p>

<p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Gender, Race and
Age </span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra pharmacokinetics have not been
studied in older people. No age or gender related pharmacokinetic differences
have been observed in adult patients. Pharmacokinetic differences due to race
have not been identified.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Pregnancy and postpartum</span></p>

<p class=EMEANormal style='page-break-after:avoid'>In an open-label
pharmacokinetic study, 12 HIV-infected pregnant women who were less than 20
weeks of gestation and on combination antiretroviral therapy initially received
lopinavir/ritonavir 400 mg/100 mg (two 200/50 mg tablets) twice daily up to a
gestational age of 30 weeks. At 30 weeks age of gestation, the dose was
increased to 500/125 mg (two 200/50 mg tablets plus one 100/25 mg tablet) twice
daily until subjects were 2 weeks postpartum. Plasma concentrations of
lopinavir were measured over four 12-hour periods during second trimester
(20-24 weeks gestation), third trimester before dose increase (30 weeks
gestation), third trimester after dose increase (32 weeks gestation), and at 8
weeks post-partum. The dose increase did not result in a significant increase
in the plasma lopinavir concentration. </p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>In another open-label pharmacokinetic study, 19
HIV-infected pregnant women received lopinavir/ritonavir 400/100 mg twice daily
as part of combination antiretroviral therapy during pregnancy from before
conception. A series of blood samples were collected pre-dose and at intervals
over the course of 12 hours in trimester 2 and trimester 3, at birth, and 46
weeks postpartum (in women who continued treatment post-delivery) for
pharmacokinetic analysis of total and unbound levels of plasma lopinavir
concentrations.</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>The pharmacokinetic data from HIV-1 infected pregnant women
receiving lopinavir/ritonavir tablets 400/100 mg twice daily are presented in
Table 6 (see section 4.2).</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal style='page-break-after:avoid'>Table 6</p>

<p class=EMEANormal style='page-break-after:avoid'>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='margin-left:4.65pt;border-collapse:collapse;border:none'>
 <tr style='height:25.15pt'>
  <td width=638 colspan=4 style='width:6.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Mean (%CV) Steady-State
  Pharmacokinetic Parameters of </span></b><b><span lang=EN-GB
  style='font-size:11.0pt'>Lopinavir <br>
  in HIV-Infected Pregnant Women</span></b></p>
  </td>
 </tr>
 <tr style='height:26.5pt'>
  <td width=191 style='width:143.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:26.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Pharmacokinetic<br>
  Parameter</span></b></p>
  </td>
  <td width=158 style='width:118.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>2nd Trimester<br>
  n = 17*</span></b></p>
  </td>
  <td width=154 style='width:115.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>3rd Trimester<br>
  n = 23</span></b></p>
  </td>
  <td width=135 style='width:101.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.5pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Postpartum<br>
  n = 17**</span></b></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=191 nowrap style='width:143.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid;text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>AUC<sub>0-12</sub>
  &#956;g</span><span lang=EN-GB style='font-family:Symbol'></span><span
  lang=EN-GB style='font-size:11.0pt'>hr/mL</span></p>
  </td>
  <td width=158 nowrap style='width:118.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>68.7 (20.6)</span></p>
  </td>
  <td width=154 nowrap style='width:115.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>61.3 (22.7)</span></p>
  </td>
  <td width=135 nowrap style='width:101.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>94.3 (30.3)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=191 nowrap style='width:143.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>C<sub>max</sub></span></p>
  </td>
  <td width=158 nowrap style='width:118.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>7.9 (21.1)</span></p>
  </td>
  <td width=154 nowrap style='width:115.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>7.5 (18.7)</span></p>
  </td>
  <td width=135 nowrap style='width:101.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>9.8 (24.3)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=191 nowrap style='width:143.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>C<sub>predose</sub> &#956;g
  /mL</span></p>
  </td>
  <td width=158 nowrap style='width:118.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>4.7 (25.2)</span></p>
  </td>
  <td width=154 nowrap style='width:115.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>4.3 (39.0)</span></p>
  </td>
  <td width=135 nowrap style='width:101.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>6.5 (40.4)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=638 nowrap colspan=4 style='width:6.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>* n = 18 for C<sub>max</sub></span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>** n = 16 for C<sub>predose</sub></span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Renal Insufficiency </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
pharmacokinetics have not been studied in patients with renal insufficiency;
however, since the renal clearance of lopinavir is negligible, a decrease in
total body clearance is not expected in patients with renal insufficiency.</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Hepatic
Insufficiency</span></p>

<p class=EMEANormal><span lang=EN-GB>The steady state pharmacokinetic
parameters of lopinavir in HIV-infected patients with mild to moderate hepatic
impairment were compared with those of HIV-infected patients with normal
hepatic function in a multiple dose study with lopinavir/ritonavir
400/100&nbsp;mg twice daily. A limited increase in total lopinavir
concentrations of approximately 30% has been observed which is not expected to
be of clinical relevance (see section 4.2).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>5.3 Preclinical
safety data</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Repeat-dose toxicity studies in rodents and dogs
identified major target organs as the liver, kidney, thyroid, spleen and
circulating red blood cells. Hepatic changes indicated cellular swelling with
focal degeneration. While exposure eliciting these changes were comparable to
or below human clinical exposure, dosages in animals were over 6-fold the
recommended clinical dose. Mild renal tubular degeneration was confined to
mice exposed with at least twice the recommended human exposure; the kidney was
unaffected in rats and dogs. Reduced serum thyroxin led to an increased
release of TSH with resultant follicular cell hypertrophy in the thyroid glands
of rats. These changes were reversible with withdrawal of the active substance
and were absent in mice and dogs. Coombs-negative anisocytosis and
poikilocytosis were observed in rats, but not in mice or dogs. Enlarged
spleens with histiocytosis were seen in rats but not other species. Serum
cholesterol was elevated in rodents but not dogs, while triglycerides were
elevated only in mice. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>During <i>in&nbsp;vitro</i> studies,
cloned human cardiac potassium channels (HERG) were inhibited by 30% at the
highest concentrations of lopinavir/ritonavir tested, corresponding to a
lopinavir exposure 7-fold total and 15-fold free peak plasma levels achieved in
humans at the maximum recommended therapeutic dose. In contrast, similar
concentrations of lopinavir/ritonavir demonstrated no repolarisation delay in
the canine cardiac Purkinje fibres. Lower concentrations of
lopinavir/ritonavir did not produce significant potassium (HERG) current
blockade. Tissue distribution studies conducted in the rat did not suggest
significant cardiac retention of the active substance; 72-hour AUC in heart was
approximately 50% of measured plasma AUC. Therefore, it is reasonable to
expect that cardiac lopinavir levels would not be significantly higher than
plasma levels.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>In dogs,
prominent U waves on the electrocardiogram have been observed associated with
prolonged PR interval and bradycardia. These effects have been assumed to be
caused by electrolyte disturbance. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>The clinical
relevance of these preclinical data is unknown, however, the potential cardiac
effects of this product in humans cannot be ruled out (see also sections 4.4
and 4.8). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>In rats,
embryofoetotoxicity (pregnancy loss, decreased foetal viability, decreased
foetal body weights, increased frequency of skeletal variations) and postnatal
developmental toxicity (decreased survival of pups) was observed at maternally
toxic dosages. The systemic exposure to lopinavir/ritonavir at the maternal
and developmental toxic dosages was lower than the intended therapeutic
exposure in humans. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Long-term
carcinogenicity studies of lopinavir/ritonavir in mice revealed a nongenotoxic,
mitogenic induction of liver tumours, generally considered to have little
relevance to human risk. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Carcinogenicity
studies in rats revealed no tumourigenic findings. Lopinavir/ritonavir was not
found to be mutagenic or clastogenic in a battery of <i>in&nbsp;vitro</i> and <i>in&nbsp;vivo</i>
assays including the Ames bacterial reverse mutation assay, the mouse lymphoma
assay, the mouse micronucleus test and chromosomal aberration assays in human
lymphocytes.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6. Pharmaceutical particulars</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.1 List of excipients</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Tablet contents</span></u><span
lang=EN-GB>: </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Copovidone</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Sorbitan
laurate</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Colloidal anhydrous
silica</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Sodium
stearyl fumarate</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB
style='layout-grid-mode:line'>Film-coating</span></u><span lang=EN-GB
style='layout-grid-mode:line'>: </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Hypromellose</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Titanium dioxide</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Macrogols type 400 (Polyethylene glycol 400)</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Hydroxypropyl cellulose</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Talc </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Colloidal anhydrous silica</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Macrogols type 3350 (Polyethylene glycol 3350)</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Red ferric oxide E172</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Polysorbate 80</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.2 Incompatibilities</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Not
applicable.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.3 Shelf life</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Bottle packs: 4 years.</span></p>

<p class=EMEANormal><span lang=EN-GB>Blister packs: 3 years.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.4 Special
precautions for storage</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>This
medicinal product does not require any special storage conditions.</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.5 Nature and contents of container</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>High density polyethylene (HDPE) bottles
closed with propylene caps. Each bottle contains 120 tablets. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Two pack sizes are
available:</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>- 1
bottle of 120 tablets</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>- multipack
containing 360 (3 bottles of 120) film-coated tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Blisters packs - polyvinyl chloride (PVC)
blisters with fluoropolymer foil backing </span></p>

<p class=EMEANormal><span lang=EN-GB>Two pack sizes are available:</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>-  carton containing 120 film-coated tablets</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- multipack containing 120 (3 cartons of 40) film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Not all pack sizes
may be marketed.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.6 Special precautions for disposal</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>No special requirements.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>8. MARKETING
AUTHORISATION NUMBERS</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>EU/1/01/172/004</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>EU/1/01/172/005</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>EU/1/01/172/007</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>EU/1/01/172/008</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>9. Date of first authorisation/renewal of THE
authorisation</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Date of first authorisation: 20 March 2001</span></p>

<p class=EMEANormal><span lang=EN-GB>Date of latest renewal: 20 March 2011</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>10. Date of revision
of the text</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Detailed information on this product </span><span
lang=EN-GB>is available on the website of the European Medicines Agency </span><a
href="http://www.ema.europa.eu"><span lang=EN-GB>http://www.ema.europa.eu</span></a></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeading1Para1 style='margin-bottom:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. Name of the medicinal
product </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 100&nbsp;mg/25&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>2. Qualitative and quantitative composition </span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
100&nbsp;mg of lopinavir co-formulated with 25&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>For the full list of excipients, see
section 6.1. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>3. Pharmaceutical Form<i> </i></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Film-coated tablet</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Pale pink debossed with [Abbott logo] and
AC.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4. Clinical Particulars</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPCEmpty style='margin-bottom:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4.1 Therapeutic indications</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra is indicated in combination with
other antiretroviral medicinal products for the treatment of human
immunodeficiency virus (HIV-1) infected children above the age of 2&nbsp;years,
adolescents and adults. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The choice of Kaletra to treat protease
inhibitor experienced HIV-1 infected patients should be based on individual
viral resistance testing and treatment history of patients (see sections 4.4
and 5.1).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.2 Posology and method of administration</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra should be prescribed by physicians
who are experienced in the treatment of HIV infection.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra tablets must be swallowed whole
and not chewed, broken or crushed. </span></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><u><span lang=EN-GB>Posology</span></u></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Adults and adolescents</span></i><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>The standard recommended dosage of Kaletra
tablets is 400/100&nbsp;mg (two 200/50&nbsp;mg) tablets twice daily taken with
or without food. In adult patients, in cases where once&#8209;daily dosing is
considered necessary for the management of the patient, Kaletra tablets may be
administered as 800/200&nbsp;mg (four 200/50&nbsp;mg tablets) once daily with
or without food. The use of a once&#8209;daily dosing should be limited to
those adult patients having only very few protease inhibitor (PI) associated
mutations (i.e. less than 3 PI mutations in line with clinical trial results,
see section 5.1 for the full description of the population) and should take
into account the risk of a lesser sustainability of the virologic suppression
(see section 5.1) and higher risk of diarrhoea (see section 4.8) compared to
the recommended standard twice&#8209;daily dosing. An oral solution is
available to patients who have difficulty swallowing. Refer to the Summary of
Product Characteristics for Kaletra oral solution for dosing instructions.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Paediatric population (2 years of age
and above)</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The adult dose of Kaletra tablets
(400/100&nbsp;mg twice daily) may be used in children 40&nbsp;kg or greater or
with a Body Surface Area (BSA)* greater than 1.4&nbsp;m<sup>2</sup>. For
children weighing less than 40&nbsp;kg or with a BSA between 0.5 and 1.4&nbsp;m<sup>2
</sup>and able to swallow tablets, refer to the dosing guideline tables below.
For children unable to swallow tablets, please refer to the Kaletra oral
solution Summary of Product Characteristics. Based on the current data
available, Kaletra should not be administered once daily in paediatric patients
(see section 5.1).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Before prescribing Kaletra 100/25&nbsp;mg
tablets, infants and young children should be assessed for the ability to
swallow intact tablets. If a child is unable to reliably swallow a Kaletra
tablet, Kaletra oral solution formulation should be prescribed.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The following table contains dosing
guidelines for Kaletra 100/25&nbsp;mg tablets based on body weight and BSA. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=530
 style='width:397.7pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=530 colspan=3 valign=top style='width:397.7pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h1 align=center style='margin-top:6.0pt;margin-right:0in;margin-bottom:6.0pt;
  margin-left:0in;text-align:center'><span lang=EN-GB>Paediatric dosing
  guidelines<br>
  without concomitant efavirenz or nevirapine* </span></h1>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=125 valign=top style='width:93.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  line-height:12.0pt;text-autospace:none'><span lang=EN-GB style='font-size:
  11.0pt'>Weight (kg)</span></p>
  </td>
  <td width=169 valign=top style='width:126.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  line-height:12.0pt;text-autospace:none'><span lang=EN-GB style='font-size:
  11.0pt'>Body Surface Area (m<sup>2</sup>)</span></p>
  </td>
  <td width=237 valign=top style='width:177.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h3><span lang=EN-GB>Recommended number of </span></h3>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  line-height:12.0pt;text-autospace:none'><span lang=EN-GB style='font-size:
  11.0pt'>100/25&nbsp;mg tablets twice-daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>15 to 25</span></p>
  </td>
  <td width=169 valign=top style='width:126.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;0.5 to
  &lt;&nbsp;0.9</span></p>
  </td>
  <td width=237 valign=top style='width:177.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoCommentText align=center style='text-align:center;line-height:
  12.0pt;text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>2
  tablets (200/50&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>&gt;&nbsp;25
  to 35</span></p>
  </td>
  <td width=169 valign=top style='width:126.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;0.9 to
  &lt;&nbsp;1.4</span></p>
  </td>
  <td width=237 valign=top style='width:177.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>3 tablets
  (300/75&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=125 valign=top style='width:93.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>&gt;&nbsp;35</span></p>
  </td>
  <td width=169 valign=top style='width:126.75pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;1.4</span></p>
  </td>
  <td width=237 valign=top style='width:177.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>4 tablets
  (400/100&nbsp;mg)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=EMEANormal><span lang=EN-GB> *weight based dosing
recommendations are based on limited data </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>If more convenient for patients, the
Kaletra 200/50&nbsp;mg tablets may also be considered alone or in combination
with the Kaletra 100/25&nbsp;mg tablet to achieve the recommended dose.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>* Body surface area can be calculated
with the following equation:</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>BSA&nbsp;(m<sup>2</sup>)
= </span><span lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>
(Height (cm) X Weight (kg) / 3600)</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Children less than 2 years of age</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The safety and efficacy of Kaletra in
children aged less than 2 years have not been established. Currently available
data are described in section 5.2 but no recommendation on the posology can be
made.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Concomitant Therapy: Efavirenz or
nevirapine</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The following table contains dosing
guidelines for Kaletra 100/25&nbsp;mg tablets based on BSA when used in
combination with efavirenz or nevirapine in children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=425
 style='width:319.0pt;border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=425 colspan=2 valign=top style='width:319.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h1 align=center style='margin-top:6.0pt;text-align:center'><span lang=EN-GB>Paediatric
  dosing guidelines with concomitant </span></h1>
  <h1 align=center style='margin-bottom:6.0pt;text-align:center'><span
  lang=EN-GB>efavirenz or nevirapine </span></h1>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;text-align:center;
  line-height:12.0pt;text-autospace:none'><span lang=EN-GB style='font-size:
  11.0pt'>Body Surface Area (m<sup>2</sup>)</span></p>
  </td>
  <td width=242 valign=top style='width:181.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <h3><span lang=EN-GB>Recommended number of </span></h3>
  <p class=MsoNormal align=center style='margin-bottom:6.0pt;text-align:center;
  line-height:12.0pt;text-autospace:none'><span lang=EN-GB style='font-size:
  11.0pt'>100/25&nbsp;mg tablets twice-daily</span></p>
  </td>
 </tr>
 <tr>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeader align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-family:Symbol'></span><span
  lang=EN-GB>&nbsp;0.5 to &lt;&nbsp;0.8</span></p>
  </td>
  <td width=242 valign=top style='width:181.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>2 tablets
  (200/50&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;0.8 to
  &lt;&nbsp;1.2</span></p>
  </td>
  <td width=242 valign=top style='width:181.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>3 tablets
  (300/75&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;1.2 to
  &lt;&nbsp;1.4</span></p>
  </td>
  <td width=242 valign=top style='width:181.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>4 tablets
  (400/100&nbsp;mg)</span></p>
  </td>
 </tr>
 <tr>
  <td width=183 valign=top style='width:137.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt;font-family:
  Symbol'></span><span lang=EN-GB style='font-size:11.0pt'>&nbsp;1.4</span></p>
  </td>
  <td width=242 valign=top style='width:181.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:12.0pt;
  text-autospace:none'><span lang=EN-GB style='font-size:11.0pt'>5 tablets
  (500/125 mg)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>If more convenient for patients, the
Kaletra 200/50&nbsp;mg tablets may also be considered alone or in combination
with the Kaletra 100/25&nbsp;mg tablet to achieve the recommended dose.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Hepatic impairment</span></i></p>

<p class=EMEANormal><span lang=EN-GB>In HIV-infected patients with mild to
moderate hepatic impairment, an increase of approximately 30% in lopinavir
exposure has been observed but is not expected to be of clinical relevance (see
section 5.2). No data are available in patients with severe hepatic
impairment. Kaletra must not be given to these patients (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Renal
impairment</span></i></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Since the
renal clearance of lopinavir and ritonavir is negligible, increased plasma
concentrations are not expected in patients with renal impairment. Because
lopinavir and ritonavir are highly protein bound, it is unlikely that they will
be significantly removed by haemodialysis or peritoneal dialysis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i>Pregnancy and postpartum</i></p>

<p class=EMEANormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>No dose adjustment is required for lopinavir/ritonavir during
pregnancy and postpartum.</p>

<p class=EMEANormal style='margin-left:14.2pt;text-indent:-14.2pt'><span
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Once&#8209;daily administration of lopinavir/ritonavir is not
recommended for pregnant women due to the lack of pharmacokinetic and clinical
data.</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Method of administration</span></u></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra tablets are administered orally
and must be swallowed whole and not chewed, broken or crushed. Kaletra tablets
can be taken with or without food.</span></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.3 Contraindications</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Hypersensitivity to the active substances
or to any of the excipients listed in section 6.1.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Severe hepatic insufficiency. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains lopinavir and ritonavir,
both of which are inhibitors of the P450 isoform CYP3A. Kaletra should not be
co-administered with medicinal products that are highly dependent on CYP3A for
clearance and for which elevated plasma concentrations are associated with
serious and/or life threatening events. These medicinal products include: </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=635
 style='width:476.1pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Medicinal
  product class</span></b></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Medicinal
  products within class</span></b></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Rationale</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=635 colspan=3 valign=top style='width:476.1pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoHeading7 style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><span lang=EN-GB style='font-size:11.0pt'>Concomitant
  medicinal product levels increased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alpha<sub>1</sub>-adrenoreceptor
  antagonist</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Alfuzosin</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of alfuzosin which may lead to severe hypotension. The
  concomitant administration with alfuzosin is contraindicated (see section
  4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antianginal</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX style='font-size:11.0pt'>Ranolazine</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of ranolazine which may increase the potential for serious
  and/or life-threatening reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antiarrhythmics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=ES-MX style='font-size:11.0pt'>Amiodarone,
  dronedarone</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of amiodarone and dronedarone. Thereby, increasing the risk
  of arrhythmias or other serious adverse reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antibiotic</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Fusidic Acid</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of fusidic acid. The concomitant administration with fusidic
  acid is contraindicated in dermatological infections (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 rowspan=2 valign=top style='width:121.25pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anticancer</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Neratinib</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of neratinib which may increase the potential for serious
  and/or life&#8209;threatening reactions (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Venetoclax</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-top:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of venetoclax. Increased risk of tumor lysis syndrome at the
  dose initiation and during the ramp-up phase (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Anti-gout</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Colchicine</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of colchicine. Potential for serious and/or life-threatening
  reactions in patients with renal and/or hepatic impairment (see sections 4.4
  and 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Antihistamines</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Astemizole,
  terfenadine</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of astemizole and terfenadine. Thereby, increasing the risk
  of serious arrhythmias from these agents (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 rowspan=3 valign=top style='width:121.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Antipsychotics/ Neuroleptics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Lurasidone</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Increased plasma concentrations of lurasidone which
  may increase the potential for serious and/or life-threatening reactions (see
  section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Pimozide</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Increased plasma concentrations of pimozide.
  Thereby, increasing the risk of serious haematologic abnormalities, or other
  serious adverse effects from this agent (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Quetiapine</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of quetiapine which may lead to coma. The concomitant
  administration with quetiapine is contraindicated (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ergot alkaloids</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Dihydroergotamine,
  ergonovine, ergotamine, methylergonovine</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of ergot derivatives leading to acute ergot toxicity,
  including vasospasm and ischaemia (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>GI motility
  agent</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Cisapride</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of cisapride. Thereby, increasing the risk of serious
  arrhythmias from this agent (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 rowspan=2 valign=top style='width:121.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Hepatitis C
  virus direct acting antivirals</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Elbasvir/grazoprevir</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased risk
  of alanine transaminase (ALT) elevations (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Ombitasvir/paritaprevir/ritonavir
  with or without dasabuvir</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of paritaprevir; thereby, increasing the risk of alanine transaminase
  (ALT) elevations (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=369 colspan=2 valign=top style='width:276.85pt;border:none;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lipid-modifying
  agents</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>HMG Co-A
  Reductase Inhibitors</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lovastatin,
  simvastatin</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of lovastatin and simvastatin; thereby, increasing the risk of
  myopathy including rhabdomyolysis (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Microsomal
  triglyceride transfer protein (MTTP) inhibitor</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Lomitapide</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of lomitapide (see section 4.5).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 rowspan=3 valign=top style='width:121.25pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Phosphodiesterase (PDE5) inhibitors</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Avanafil</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Increased plasma concentrations of avanafil (see
  sections 4.4 and 4.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Sildenafil</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Contraindicated when used for the treatment of
  pulmonary arterial hypertension (PAH) only. Increased plasma concentrations
  of sildenafil. Thereby, increasing the potential for sildenafil-associated
  adverse events (which include hypotension and syncope). See section 4.4 and
  section 4.5 for co&#8209;administration of sildenafil in patients with
  erectile dysfunction.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vardenafil</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of vardenafil (see sections 4.4 and 4.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Sedatives/hypnotics</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Oral midazolam,
  triazolam</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Increased plasma
  concentrations of oral midazolam and triazolam. Thereby, increasing the risk
  of extreme sedation and respiratory depression from these agents. </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>For caution on
  parenterally administered midazolam, see section 4.5.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=635 colspan=3 valign=top style='width:476.1pt;border:none;
  border-bottom:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
  6.0pt;margin-left:0in'><b><span lang=EN-GB style='font-size:11.0pt'>Lopinavir/ritonavir
  medicinal product level decreased</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=162 valign=top style='width:121.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Herbal products</span></p>
  </td>
  <td width=207 valign=top style='width:155.6pt;border:none;border-bottom:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>St. Johns</span><span
  lang=EN-GB style='font-size:11.0pt'> wort</span></p>
  </td>
  <td width=266 valign=top style='width:199.25pt;border:none;border-bottom:
  solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Herbal
  preparations containing St Johns wort (<i>Hypericum perforatum)</i> due to
  the risk of decreased plasma concentrations and reduced clinical effects of
  lopinavir and ritonavir (see section 4.5).</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.4 Special warnings and precautions for use </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='text-decoration:
none'>Patients with coexisting conditions</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Hepatic impairment</span></u></p>

<p class=EMEANormal><span lang=EN-GB>The safety and efficacy of Kaletra has not
been established in patients with significant underlying liver disorders.
Kaletra is contraindicated in patients with severe liver impairment (see
section 4.3). Patients with chronic hepatitis B or C and treated with
combination antiretroviral therapy are at an increased risk for severe and
potentially fatal hepatic adverse reactions. In case of concomitant antiviral
therapy for hepatitis B or C, please refer to the relevant product information
for these medicinal products.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Patients with pre-existing liver
dysfunction including chronic hepatitis have an increased frequency of liver
function abnormalities during combination antiretroviral therapy and should be
monitored according to standard practice. If there is evidence of worsening
liver disease in such patients, interruption or discontinuation of treatment
should be considered. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Elevated transaminases with or without
elevated bilirubin levels have been reported in HIV-1 mono&#8209;infected and
in individuals treated for post-exposure prophylaxis as early as 7 days after
the initiation of lopinavir/ritonavir in conjunction with other antiretroviral
agents. In some cases the hepatic dysfunction was serious.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Appropriate laboratory testing should be
conducted prior to initiating therapy with lopinavir/ritonavir and close
monitoring should be performed during treatment.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Renal
impairment</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Since the
renal clearance of lopinavir and ritonavir is negligible, increased plasma
concentrations are not expected in patients with renal impairment. Because
lopinavir and ritonavir are highly protein bound, it is unlikely that they will
be significantly removed by haemodialysis or peritoneal dialysis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Haemophilia</span></u></p>

<p class=EMEANormal><span lang=EN-GB>There have been reports of increased
bleeding, including spontaneous skin haematomas and haemarthrosis in patients
with haemophilia type A and B treated with protease inhibitors. In some
patients additional factor VIII was given. In more than half of the reported
cases, treatment with protease inhibitors was continued or reintroduced if
treatment had been discontinued. A causal relationship had been evoked,
although the mechanism of action had not been elucidated. Haemophiliac
patients should therefore be made aware of the possibility of increased
bleeding.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Pancreatitis</span></p>

<p class=EMEANormal><span lang=EN-GB>Cases of pancreatitis have been reported
in patients receiving Kaletra, including those who developed
hypertriglyceridaemia. In most of these cases patients have had a prior
history of pancreatitis and/or concurrent therapy with other medicinal products
associated with pancreatitis. Marked triglyceride elevation is a risk factor
for development of pancreatitis. Patients with advanced HIV disease may be at
risk of elevated triglycerides and pancreatitis</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Pancreatitis should be considered if
clinical symptoms (nausea, vomiting, abdominal pain) or abnormalities in
laboratory values (such as increased serum lipase or amylase values) suggestive
of pancreatitis should occur. Patients who exhibit these signs or symptoms
should be evaluated and Kaletra therapy should be suspended if a diagnosis of
pancreatitis is made (see section 4.8). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-style:normal'>Immune Reconstitution Inflammatory Syndrome</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>In
HIV-infected patients with severe immune deficiency at the time of institution
of combination antiretroviral therapy (CART), an inflammatory reaction to
asymtomatic or residual opportunistic pathogens may arise and cause serious
clinical conditions, or aggravation of symptoms. Typically, such reactions
have been observed within the first few weeks or months of initiation of CART.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal
mycobacterial infections, and <i>Pneumocystis jiroveci pneumonia</i>. Any
inflammatory symptoms should be evaluated and treatment instituted when
necessary.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Autoimmune disorders (such as Graves disease <span
lang=EN-GB>and autoimmune hepatitis</span>) have also been reported to occur in
the setting of immune reconstitution; however, the reported time to onset is
more variable and can occur many months after initiation of treatment.</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Osteonecrosis</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Although
the etiology is considered to be multifactorial (including corticosteroid use,
alcohol consumption, severe immunosuppression, higher body mass index), cases
of osteonecrosis have been reported particularly in patients with advanced HIV&#8209;disease
and/or long&#8209;term exposure to combination antiretroviral therapy (CART).
Patients should be advised to seek medical advice if they experience joint
aches and pain, joint stiffness or difficulty in movement.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>PR interval prolongation </span></p>

<p class=EMEANormal><span lang=EN-GB>Lopinavir/ritonavir has been shown to
cause modest asymptomatic prolongation of the PR interval in some healthy adult
subjects. Rare reports of 2<sup>nd</sup> or 3<sup>rd</sup> degree
atroventricular block in patients with underlying structural heart disease and
pre-existing conduction system abnormalities or in patients receiving drugs
known to prolong the PR interval (such as verapamil or atazanavir) have been
reported in patients receiving lopinavir/ritonavir. Kaletra should be used
with caution in such patients (see section 5.1).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Weight and metabolic parameters</span></u></p>

<p class=EMEANormal><span lang=EN-GB>An increase in weight and in levels of
blood lipids and glucose may occur during antiretroviral therapy. Such changes
may in part be linked to disease control and life style. For lipids, there is
in some cases evidence for a treatment effect, while for weight gain there is
no strong evidence relating this to any particular treatment. For monitoring
of blood lipids and glucose, reference is made to established HIV treatment
guidelines. Lipid disorders should be managed as clinically appropriate.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Interactions with medicinal products</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains lopinavir and ritonavir,
both of which are inhibitors of the P450 isoform CYP3A. Kaletra is likely to
increase plasma concentrations of medicinal products that are primarily
metabolised by CYP3A. These increases of plasma concentrations of
co-administered medicinal products could increase or prolong their therapeutic
effect and adverse events (see sections 4.3 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Strong CYP3A4 inhibitors such as protease
inhibitors may increase bedaquiline exposure which could potentially increase
the risk of bedaquiline&#8209;related adverse reactions. Therefore,
combination of bedaquiline with lopinavir/ritonavir should be avoided.
However, if the benefit outweighs the risk, co&#8209;administration of bedaquiline
with lopinavir/ritonavir must be done with caution. More frequent
electrocardiogram monitoring and monitoring of transaminases is recommended
(see section 4.5 and refer to the bedaquiline SmPC).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of delamanid with
a strong inhibitor of CYP3A (as lopinavir/ritonavir) may increase exposure to
delamanid metabolite, which has been associated with QTc prolongation.
Therefore, if co-administration of delamanid with lopinavir/ritonavir is
considered necessary, very frequent ECG monitoring throughout the full
delamanid treatment period is recommended (see section 4.5 and refer to the
delamanid SmPC).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Life-threatening and fatal drug
interactions have been reported in patients treated with colchicine and strong
inhibitors of CYP3A like ritonavir. Concomitant administration with colchicine
is contraindicated in patients with renal and/or hepatic impairment (see
sections 4.3 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The combination of Kaletra with: </span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- tadalafil, indicated for the treatment of pulmonary
arterial hypertension, is not recommended (see section 4.5); </span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- riociguat is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- vorapaxar is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- fusidic acid in osteo-articular infections is not
recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- salmeterol is not recommended (see section 4.5);</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB>- rivaroxaban is not recommended (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The
combination of Kaletra with atorvastatin is not recommended. If the use of
atorvastatin is considered strictly necessary, the lowest possible dose of
atorvastatin should be administered with careful safety monitoring. Caution
must also be exercised and reduced doses should be considered if Kaletra is
used concurrently with rosuvastatin. If treatment with a HMG-CoA reductase
inhibitor is indicated, pravastatin or fluvastatin is recommended (see section
4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>PDE5 inhibitors</span></i></p>

<p class=EMEANormal><span lang=EN-GB>Particular caution should be used when
prescribing sildenafil or tadalafil for the treatment of erectile dysfunction
in patients receiving Kaletra. Co-administration of Kaletra with these
medicinal products is expected to substantially increase their concentrations
and may result in associated adverse events such as hypotension, syncope,
visual changes and prolonged erection (see section 4.5). Concomitant use of avanafil
or vardenafil and lopinavir/ritonavir is contraindicated (see section 4.3).
Concomitant use of sildenafil prescribed for the treatment of pulmonary
arterial hypertension with Kaletra is contraindicated (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Particular caution must be used when
prescribing Kaletra and medicinal products known to induce QT interval
prolongation such as: chlorpheniramine, quinidine, erythromycin,
clarithromycin. Indeed, Kaletra could increase concentrations of the
co-administered medicinal products and this may result in an increase of their
associated cardiac adverse reactions. Cardiac events have been reported with
Kaletra in preclinical studies; therefore, the potential cardiac effects of
Kaletra cannot be currently ruled out (see sections 4.8 and 5.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of Kaletra with
rifampicin is not recommended. Rifampicin in combination with Kaletra causes
large decreases in lopinavir concentrations which may in turn significantly
decrease the lopinavir therapeutic effect. Adequate exposure to
lopinavir/ritonavir may be achieved when a higher dose of Kaletra is used but
this is associated with a higher risk of liver and gastrointestinal toxicity.
Therefore, this co&#8209;administration should be avoided unless judged
strictly necessary (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Concomitant use of Kaletra and fluticasone
or other glucocorticoids that are metabolised by CYP3A4, such as budesonide and
triamcinolone, is not recommended unless the potential benefit of treatment
outweighs the risk of systemic corticosteroid effects, including Cushings
syndrome and adrenal suppression (see section 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Other</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra is not a cure for HIV infection or
AIDS. While effective viral suppression with antiretroviral therapy has been
proven to substantially reduce the risk of sexual transmission, a residual risk
cannot be excluded. Precautions to prevent transmission should be taken in
accordance with national guidelines. People taking Kaletra may still develop
infections or other illnesses associated with HIV disease and AIDS.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.5 Interaction with other medicinal products and
other forms of interaction </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains lopinavir and ritonavir,
both of which are inhibitors of the P450 isoform CYP3A <i>in&nbsp;vitro</i>.
Co-administration of Kaletra and medicinal products primarily metabolised by
CYP3A may result in increased plasma concentrations of the other medicinal
product, which could increase or prolong its therapeutic and adverse
reactions. Kaletra does not inhibit CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP2B6 or
CYP1A2 at clinically relevant concentrations (see section 4.3).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra has been shown <i>in&nbsp;vivo</i>
to induce its own metabolism and to increase the biotransformation of some
medicinal products metabolised by cytochrome P450 enzymes (including CYP2C9 and
CYP2C19) and by glucuronidation. This may result in lowered plasma
concentrations and potential decrease of efficacy of co-administered medicinal
products.</span></p>

<p class=EMEANormal><span lang=EN-GB></span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Medicinal
products that are contraindicated specifically due to the expected magnitude of
interaction and potential for serious adverse events are listed in section 4.3.</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>All
interaction studies, when otherwise not stated, were performed using Kaletra
capsules, which gives an approximately 20% lower exposure of lopinavir than the
200/50&nbsp;mg tablets.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Known and theoretical interactions with
selected antiretrovirals and non-antiretroviral medicinal products are listed
in the table below. This list is not intended to be inclusive or
comprehensive. Individual SmPCs should be consulted.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Interaction table</span></i></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Interactions between Kaletra and
co-administered medicinal products are listed in the table below (increase is
indicated as &#8593;, decrease as &#8595;, no change as &#8596;,once
daily as QD, twice daily as BID and three times daily as &quot;TID&quot;).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Unless otherwise stated, studies detailed
below have been performed with the recommended dosage of lopinavir/ritonavir
(i.e. 400/100&nbsp;mg twice daily).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=605
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><span lang=EN-GB>Co-administered drug by therapeutic
  area </span></b></p>
  <p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><span lang=EN-GB>Effects on drug levels</span></b></p>
  <p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal><b><span lang=EN-GB>Geometric Mean Change (%) in AUC, C<sub>max</sub>,
  C<sub>min</sub></span></b></p>
  <p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>
  <p class=EMEANormal><b><span lang=EN-GB>Mechanism of interaction</span></b></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><span lang=EN-GB>Clinical recommendation concerning
  co-administration with Kaletra</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><b><i><span lang=EN-GB>Antiretroviral Agents</span></i></b></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Nucleoside/Nucleotide reverse
  transcriptase inhibitors (NRTIs) </span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Stavudine, Lamivudine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abacavir, Zidovudine</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abacavir, Zidovudine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be reduced due to
  increased glucuronidation by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The clinical significance of reduced
  abacavir and zidovudine concentrations is unknown.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Tenofovir disoproxil fumarate (DF),
  300&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(equivalent to 245&nbsp;mg tenofovir
  disoproxil)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Tenofovir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 32%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8593; 51%</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary.</span></p>
  <p class=EMEANormal><span lang=EN-GB>Higher tenofovir concentrations could
  potentiate tenofovir associated adverse events, including renal disorders.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Non-nucleoside
  reverse transcriptase inhibitors (NNRTIs) </span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Efavirenz, 600&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8595;</span><span lang=EN-GB> 20%</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  &#8595; 13%</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>min</sub>:
  &#8595;</span><span lang=EN-GB> 42%</span></p>
  </td>
  <td width=229 colspan=2 rowspan=2 valign=top style='width:171.6pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The
  Kaletra tablets dosage should be increased to 500/125&nbsp;mg twice daily
  when co-administered with efavirenz. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
  must not be administered once daily in combination with efavirenz.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Efavirenz, 600&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir 500/125&nbsp;mg
  BID)</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Relative to 400/100&nbsp;mg BID
  administered alone) </span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Nevirapine, 200&nbsp;mg BID</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8595;</span><span lang=EN-GB> 27%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595; 19%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595;</span><span
  lang=EN-GB> 51%</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The Kaletra tablets dosage should be
  increased to 500/125&nbsp;mg twice daily when co-administered with
  nevirapine. </span></p>
  <p class=EMEANormal><span lang=EN-GB>Kaletra must not be administered once
  daily in combination with nevirapine.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;page-break-after:avoid;
  text-autospace:none'><span lang=FR style='font-size:11.0pt'>Etravirine</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=FR>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=FR>(</span>Lopinavir/ri<span
  style='letter-spacing:-.05pt'>t</span>onavir tablet 400/<span
  style='letter-spacing:-.05pt'>1</span>00<span style='letter-spacing:-.35pt'> </span><span
  style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>BID)</p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:.4pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;page-break-after:
  avoid;text-autospace:none'><span lang=FR style='font-size:11.0pt;line-height:
  95%'>Etravirine:</span></p>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;text-align:justify;line-height:
  97%;page-break-after:avoid;text-autospace:none'><span lang=FR
  style='font-size:11.0pt;line-height:97%'>AUC:<span style='letter-spacing:
  -.05pt'> </span>&#8595;<span style='letter-spacing:-.05pt'> </span>35%</span></p>
  <p class=MsoNormal style='margin-top:.25pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;text-align:justify;line-height:
  97%;page-break-after:avoid;text-autospace:none'><span lang=FR
  style='font-size:11.0pt;line-height:97%;letter-spacing:.1pt'>C</span><sub><span
  lang=FR style='font-size:11.0pt;line-height:97%;position:relative;top:1.5pt;
  letter-spacing:-.05pt'>mi</span></sub><sub><span lang=FR style='font-size:
  11.0pt;line-height:97%;position:relative;top:1.5pt'>n</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:97%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:97%'>&#8595;<span style='letter-spacing:-.05pt'> </span>45%<span
  style='letter-spacing:.05pt'> </span></span></p>
  <p class=EMEANormal style='margin-left:2.2pt;page-break-after:avoid'><span
  lang=FR style='letter-spacing:.1pt'>C</span><sub><span lang=FR
  style='position:relative;top:1.5pt;letter-spacing:-.05pt'>ma</span></sub><sub><span
  lang=FR style='position:relative;top:1.5pt'>x</span></sub><span lang=FR
  style='position:relative;top:1.5pt'>:<span style='letter-spacing:.85pt'> </span></span><span
  lang=FR>&#8595;<span style='letter-spacing:-.05pt'> </span>30%</span></p>
  <p class=EMEANormal style='margin-left:2.2pt;page-break-after:avoid'><span
  lang=FR>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:11.1pt;page-break-after:
  avoid;text-autospace:none'><span lang=FR style='font-size:11.0pt'>Lopinavir:</span></p>
  <p class=MsoNormal style='margin-top:.4pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;page-break-after:
  avoid;text-autospace:none'><span lang=FR style='font-size:11.0pt;line-height:
  95%'>AUC:<span style='letter-spacing:-.2pt'> </span>&#8596;<span
  style='letter-spacing:-.05pt'> </span></span></p>
  <p class=MsoNormal style='margin-top:.4pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;page-break-after:
  avoid;text-autospace:none'><span lang=FR style='font-size:11.0pt;line-height:
  95%;letter-spacing:.1pt'>C</span><sub><span lang=FR style='font-size:11.0pt;
  line-height:95%;position:relative;top:1.5pt;letter-spacing:-.05pt'>mi</span></sub><sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>n</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:95%'>&#8595;<span style='letter-spacing:-.05pt'> </span>20%</span></p>
  <p class=EMEANormal style='margin-left:2.2pt;page-break-after:avoid'><span
  lang=FR style='letter-spacing:.1pt'>C</span><sub><span lang=FR
  style='position:relative;top:1.5pt;letter-spacing:-.05pt'>ma</span></sub><sub><span
  lang=FR style='position:relative;top:1.5pt'>x</span></sub><span lang=FR
  style='position:relative;top:1.5pt'>:<span style='letter-spacing:.7pt'> </span></span><span
  lang=FR>&#8596;<span style='letter-spacing:-.05pt'> </span></span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>No dose adjustment
  necessary</p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;text-autospace:none'><span
  lang=FR style='font-size:11.0pt'>Rilpivirine</span></p>
  <p class=EMEANormal><span lang=FR>&nbsp;</span></p>
  <p class=EMEANormal><span lang=FR>(</span>Lopinavir/ri<span style='letter-spacing:
  -.05pt'>t</span>onavir capsule 400/<span style='letter-spacing:-.05pt'>1</span>00<span
  style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.1pt'>m</span>g<span
  style='letter-spacing:-.1pt'> </span>BID)</p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%'>Rilpivirine:</span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%'>AUC:<span
  style='letter-spacing:-.05pt'> </span>&#8593;<span style='letter-spacing:
  -.2pt'> </span><span style='letter-spacing:.05pt'>52% </span></span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>C</span><sub><span lang=FR style='font-size:11.0pt;line-height:95%;
  position:relative;top:1.5pt;letter-spacing:-.05pt'>mi</span></sub><sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>n</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:95%'>&#8593;<span style='letter-spacing:-.2pt'> </span><span
  style='letter-spacing:.05pt'>74% </span></span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>C</span><sub><span lang=FR style='font-size:11.0pt;line-height:95%;
  position:relative;top:1.5pt;letter-spacing:-.05pt'>ma</span></sub><sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>x</span></sub><span
  lang=FR style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=FR style='font-size:
  11.0pt;line-height:95%'>&#8593;<span style='letter-spacing:-.2pt'> </span><span
  style='letter-spacing:.05pt'>29%</span></span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=FR style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>&nbsp;</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:11.1pt;text-autospace:
  none'><span lang=FI style='font-size:11.0pt'>Lopinavir:</span></p>
  <p class=MsoNormal style='margin-top:0in;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:11.1pt;text-autospace:
  none'><span lang=EN-GB style='font-size:11.0pt'>AUC:<span style='letter-spacing:
  -.15pt'> </span>&#8596;</span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=EN-GB style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>C</span><sub><span lang=EN-GB style='font-size:11.0pt;line-height:
  95%;position:relative;top:1.5pt'>min</span></sub><span lang=EN-GB
  style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>:<span
  style='letter-spacing:.85pt'> </span></span><span lang=EN-GB
  style='font-size:11.0pt;line-height:95%'>&#8595;<span style='letter-spacing:
  -.2pt'> </span><span style='letter-spacing:.05pt'>11% </span></span></p>
  <p class=MsoNormal style='margin-top:.45pt;margin-right:60.3pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:95%;text-autospace:
  none'><span lang=EN-GB style='font-size:11.0pt;line-height:95%;letter-spacing:
  .05pt'>C</span><sub><span lang=EN-GB style='font-size:11.0pt;line-height:
  95%;position:relative;top:1.5pt;letter-spacing:-.1pt'>m</span></sub><sub><span
  lang=EN-GB style='font-size:11.0pt;line-height:95%;position:relative;
  top:1.5pt;letter-spacing:.1pt'>a</span></sub><sub><span lang=EN-GB
  style='font-size:11.0pt;line-height:95%;position:relative;top:1.5pt'>x</span></sub><span
  lang=EN-GB style='font-size:11.0pt;line-height:95%;position:relative;
  top:1.5pt'>:<span style='letter-spacing:.7pt'> </span></span><span
  lang=EN-GB style='font-size:11.0pt;line-height:95%'>&#8596; </span></p>
  <p class=MsoNormal style='margin-top:.95pt;margin-right:-1.0pt;margin-bottom:
  0in;margin-left:2.2pt;margin-bottom:.0001pt;line-height:10.0pt;text-autospace:
  none'><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  <p class=EMEANormal>(inhibition<span style='letter-spacing:-.4pt'> </span>of<span
  style='letter-spacing:.05pt'> </span>CYP3A<span style='letter-spacing:-.25pt'>
  </span>enzymes)</p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-right:-1.0pt;line-height:11.25pt;text-autospace:
  none'><span lang=EN-GB style='font-size:11.0pt'>Concomitant<span
  style='letter-spacing:-.5pt'> </span>use<span style='letter-spacing:-.15pt'> </span>of<span
  style='letter-spacing:-.05pt'> </span><span style='letter-spacing:.05pt'>Kaletra</span><span
  style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>with</span></span></p>
  <p class=EMEANormal>rilpivirine<span style='letter-spacing:-.15pt'> </span>causes<span
  style='letter-spacing:-.25pt'> </span>an<span style='letter-spacing:-.1pt'> </span>increase
  in<span style='letter-spacing:-.1pt'> </span>the<span style='letter-spacing:
  -.1pt'> </span>plasma<span style='letter-spacing:-.3pt'> </span>concentrations<span
  style='letter-spacing:-.6pt'> </span><span style='letter-spacing:.2pt'>of </span>rilpivirine,<span
  style='letter-spacing:-.4pt'> </span>but<span style='letter-spacing:-.15pt'> </span>no<span
  style='letter-spacing:-.1pt'> </span>dose<span style='letter-spacing:-.2pt'>
  a</span>djustment<span style='letter-spacing:-.45pt'> </span>is required.</p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i>HIV CCR5  antagonist</i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Maraviroc</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Maraviroc:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 295% </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 97% </span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The dose of
  maraviroc should be decreased to 150&nbsp;mg twice daily during co&#8209;administration
  with Kaletra 400/100 mg twice daily. </span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Integrase inhibitor</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Raltegravir</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Raltegravir: </span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>12</sub>: &#8595; 30%</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: &#8596;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='margin-bottom:12.0pt'><span lang=EN-GB>No dose
  adjustment necessary</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Co-administration
  with other HIV protease inhibitors (PIs)</span></i></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
  style='color:black'>According to current treatment guidelines, dual therapy
  with protease inhibitors is generally not recommended.</span></p>
  </td>
 </tr>
 <tr style='height:89.05pt'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:89.05pt'>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir/ ritonavir
  (700/100&nbsp;mg BID) </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(L</span><span lang=EN-GB>opinavir/ritonavir
  400/100&nbsp;mg BID)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>or </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir (1400&nbsp;mg BID)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(</span><span lang=EN-GB>Lopinavir/ritonavir
  533/133&nbsp;mg BID)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:89.05pt'>
  <p class=EMEANormal><span lang=EN-GB>Fosamprenavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Amprenavir concentrations are
  significantly reduced. </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal align=right style='text-align:right'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:89.05pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Co-administration
  of increased doses of fosamprenavir (1400&nbsp;mg BID) with Kaletra
  (533/133&nbsp;mg BID) to protease inhibitor&#8209;experienced patients
  resulted in a higher incidence of gastrointestinal adverse events and
  elevations in triglycerides with the combination regimen without increases in
  virological efficacy, when compared with standard doses of
  fosamprenavir/ritonavir. Concomitant administration of these medicinal
  products is not recommended.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
  must not be administered once daily in combination with amprenavir.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Indinavir,
  600&nbsp;mg BID</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Indinavir:
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>min</sub>:
  <a name="OLE_LINK2"></a><a name="OLE_LINK3">&#8593; </a>3.5-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  &#8595;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(relative
  to indinavir 800&nbsp;mg TID alone)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:
  </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(relative
  to historical comparison)</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The
  appropriate doses for this combination, with respect to efficacy and safety,
  have not been established.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Saquinavir </span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>1000&nbsp;mg BID</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Saquinavir: </span><span lang=EN-GB>&#8596;
  </span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>No
  dose adjustment necessary.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>Tipranavir/ritonavir</span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>(500/100&nbsp;mg BID)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8595; 55%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>min</sub>: &#8595; 70%</span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8595; 47%</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'>Concomitant
  administration of these medicinal products is not recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Acid reducing agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Omeprazole (40&nbsp;mg QD) </span></p>
  <p class=EMEANormal><span lang=EN-GB></span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Omeprazole: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ranitidine (150&nbsp;mg single dose)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ranitidine: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>No dose adjustment necessary</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Alpha</span></i><i><sub><span
  lang=EN-GB style='font-size:12.0pt'>1</span></sub></i><i><span lang=EN-GB>
  adrenoreceptor antagonist</span></i></p>
  </td>
 </tr>
 <tr style='height:75.85pt'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:75.85pt'>
  <p class=EMEANormal><span lang=EN-GB>Alfuzosin </span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:75.85pt'>
  <p class=EMEANormal><span lang=EN-GB>Alfuzosin:</span></p>
  <p class=EMEANormal>Due to CYP3A inhibition by lopinavir/ritonavir,
  concentrations of alfuzosin are expected to increase.</p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:75.85pt'>
  <p class=EMEANormal>Concomitant administration of Kaletra and alfuzosin is
  contra-indicated<b> </b>(see section 4.3) as alfuzosin-related toxicity,
  including hypotension, may be increased.</p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Analgesics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fentanyl</span></p>
  <p class=EMEANormal><span lang=EN-GB></span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fentanyl:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Increased risk of side-effects
  (respiratory depression, sedation) due to higher plasma concentrations
  because of CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Careful monitoring of adverse effects
  (notably respiratory depression but also sedation) is recommended when
  fentanyl is concomitantly administered with Kaletra.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Antianginal</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Ranolazine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir, concentrations of ranolazine are
  expected to increase.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The concomitant administration of
  Kaletra and ranolazine is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antiarrhythmics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Amiodarone, Dronedarone</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Amiodarone, Dronedarone: Concentrations
  may be increased due to CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and amiodarone or dronedarone is contraindicated (see section 4.3) as the
  risk of arrhythmias or other serious adverse reactions may be increased.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Digoxin</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Digoxin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Plasma
  concentrations may be increased due to P-glycoprotein inhibition by lopinavir/ritonavir.
  The increased digoxin level may lessen over time as P-gp induction develops.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  is warranted and therapeutic drug monitoring of digoxin concentrations, if
  available, is recommended in case of co&#8209;administration of Kaletra and
  digoxin. Particular caution should be used when prescribing Kaletra in
  patients taking digoxin as the acute inhibitory effect of ritonavir on P&#8209;gp
  is expected to significantly increase digoxin levels. Initiation of digoxin
  in patients already taking Kaletra is likely to result in lower than expected
  increases of digoxin concentrations.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bepridil, Systemic Lidocaine, and
  Quinidine </span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bepridil, Systemic Lidocaine, Quinidine:
  </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased when
  co-administered with lopinavir/ritonavir. </span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution is warranted and therapeutic
  drug concentration monitoring is recommended when available.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antibiotics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Clarithromycin</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Clarithromycin:</span><i><span
  lang=EN-GB> </span></i></p>
  <p class=EMEANormal><span lang=EN-GB>Moderate increases in clarithromycin AUC
  are expected due to CYP3A inhibition by lopinavir/ritonavir. </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>For patients with renal impairment (CrCL
  &lt;&nbsp;30&nbsp;ml/min) dose reduction of clarithromycin should be
  considered (see section 4.4). Caution should be exercised in administering
  clarithromycin with Kaletra to patients with impaired hepatic or renal
  function.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Anticancer agents and kinase
  inhibitors</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abemaciclib</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Serum concentrations may be increased due to CYP3A inhibition
  by ritonavir.</p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of abemaciclib and
  Kaletra should be avoided. If this co&#8209;administration is judged
  unavoidable, refer to the abemaciclib SmPC for dosage adjustment
  recommendations. Monitor for ADRs related to abemaciclib.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Apalutamide</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Apalutamide is a moderate to strong CYP3A4 inducer and
  this may lead to a decreased exposure of lopinavir/ritonavir.</p>
  <p class=EMEANormal>&nbsp;</p>
  <p class=EMEANormal style='page-break-after:avoid'>Serum concentrations of
  apalutamide may be increased due to CYP3A inhibition by lopinavir/ritonavir.</p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Decreased exposure of Kaletra may result
  in potential loss of virological response. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>In
  addition, co-administration of apalutamide and Kaletra may lead to serious
  adverse events including seizure due to higher apalutamide levels.
  Concomitant use of Kaletra with apalutamide is not recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Afatinib</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Ritonavir
  200 mg twice daily)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Afatinib:</p>
  <p class=EMEANormal style='page-break-after:avoid'>AUC: <span lang=EN-GB>&#8593;
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'>C<sub>max</sub>: <span
  lang=EN-GB>&#8593;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The
  extent of increase depends on the timing of ritonavir administration.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  BCRP (breast cancer </span>resistance protein/ABCG2)<span lang=EN-GB> and
  acute P-gp inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised in administering afatinib with Kaletra. Refer to the
  afatinib SmPC for dosage adjustment recommendations. Monitor for ADRs
  related to afatinib.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Ceritinib</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Serum
  concentrations may be increased due to CYP3A and P&#8209;gp inhibition by
  lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised in administering ceritinib with Kaletra. Refer to the
  ceritinib SmPC for dosage adjustment recommendations. Monitor for ADRs
  related to ceritinib.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Most tyrosine kinase inhibitors such as
  dasatinib and nilotinib, vincristine, vinblastine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Most tyrosine kinase inhibitors such as
  dasatinib and nilotinib, also vincristine and vinblastine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Risk of increased adverse events due to
  higher serum concentrations because of CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Careful monitoring of the tolerance of
  these anticancer agents.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Encorafenib</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co-administration of encorafenib with
  Kaletra may increase encorafenib exposure which may increase the risk of
  toxicity, including the risk of serious adverse events such as QT interval
  prolongation. </span>Co&#8209;administration of encorafenib and Kaletra should
  be avoided. If the benefit is considered to outweigh the risk and Kaletra
  must be used, patients should be carefully monitored for safety.</p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Fostamatinib</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Increase in fostamatinib metabolite R406 exposure.</p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Co-administration of fostamatinib with Kaletra may
  increase fostamatinib metabolite R406 exposure resulting in dose-related
  adverse events such as hepatotoxicity, neutropenia, hypertension, or
  diarrhoea. Refer to the fostamatinib SmPC for dose reduction recommendations
  if such events occur.</p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ibrutinib</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co-administration of ibrutinib and
  Kaletra may increase ibrutinib exposure which may increase the risk of
  toxicity including risk of tumor lysis syndrome. Co&#8209;administration of
  ibrutinib and Kaletra should be avoided. If the benefit is considered to
  outweigh the risk and Kaletra must be used, reduce the ibrutinib dose to
  140&nbsp;mg and monitor patient closely for toxicity.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Neratinib</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant use of neratinib with
  Kaletra is contraindicated due to serious and/or life&#8209;threatening
  potential reactions including hepatotoxicity (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Venetoclax</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Serum
  concentrations may be increased due to CYP3A inhibition by
  lopinavir/ritonavir, resulting in increased risk of tumor lysis syndrome at
  the dose initiation and during the ramp-up phase (see section 4.3 and refer
  to the venetoclax SmPC).</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>For patients who have
  completed the ramp-up phase and are on a steady daily dose of venetoclax,
  reduce the venetoclax dose by at least 75% when used with strong CYP3A
  inhibitors (refer to the venetoclax SmPC for dosing instructions). Patients
  should be closely monitored for signs related to venetoclax toxicities.</p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Anticoagulants</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Warfarin</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Warfarin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be affected when co-administered with lopinavir/ritonavir due to CYP2C9
  induction. </span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>It is
  recommended that INR (international normalised ratio) be monitored.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Rivaroxaban</p>
  <p class=EMEANormal>&nbsp;</p>
  <p class=EMEANormal>(Ritonavir 600&nbsp;mg twice daily)</p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Rivaroxaban: </p>
  <p class=EMEANormal>AUC: <span lang=EN-GB>&#8593; </span>153% </p>
  <p class=EMEANormal>C<sub>max</sub>: <span lang=EN-GB>&#8593; 55</span>%</p>
  <p class=EMEANormal>Due to CYP3A and P&#8209;gp inhibition by
  lopinavir/ritonavir.</p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of rivaroxaban
  and Kaletra may increase rivaroxaban exposure which may increase the risk of
  bleeding.</span></p>
  <p class=EMEANormal><span lang=EN-GB>The use of rivaroxaban is not
  recommended in patients receiving concomitant treatment with Kaletra (see
  section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Vorapaxar</p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Serum concentrations may be increased due to CYP3A
  inhibition by <span lang=EN-GB>lopinavir/ritonavir</span>.</p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The co&#8209;administration of vorapaxar
  with Kaletra is not recommended (see section 4.4 and refer to the vorapaxar
  SmPC).</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Anticonvulsants</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Phenytoin</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Phenytoin:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Steady-state
  concentrations was moderately decreased due to CYP2C9 and CYP2C19 induction
  by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  are decreased due to CYP3A induction by phenytoin. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised in administering phenytoin with Kaletra.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Phenytoin
  levels should be monitored when co&#8209;administering with Kaletra.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>When
  co-administered with phenytoin, an increase of Kaletra dosage may be
  envisaged. Dose adjustment has not been evaluated in clinical practice.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
  must not be administered once daily in combination with phenytoin.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Carbamazepine
  and Phenobarbital </span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Carbamazepine:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Serum
  concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be decreased due to CYP3A induction by carbamazepine and phenobarbital. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Caution
  should be exercised in administering carbamazepine or phenobarbital with
  Kaletra.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Carbamazepine
  and phenobarbital levels should be monitored when co&#8209;administering with
  Kaletra.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>When
  co-administered with carbamazepine or phenobarbital, an increase of Kaletra
  dosage may be envisaged. Dose adjustment has not been evaluated in clinical
  practice.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
  must not be administered once daily in combination with carbamazepine and
  phenobarbital.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lamotrigine and Valproate</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lamotrigine: </span></p>
  <p class=EMEANormal>AUC: &#8595; 50%</p>
  <p class=EMEANormal>C<sub>max</sub>: &#8595; 46%</p>
  <p class=EMEANormal>C<sub>min</sub>: &#8595; 56%</p>
  <p class=EMEANormal>&nbsp;</p>
  <p class=EMEANormal>Due to induction of lamotrigine glucuronidation</p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Valproate: &#8595;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Patients should be monitored closely for
  a decreased VPA effect when Kaletra and valproic acid or valproate are given
  concomitantly.</span></p>
  <p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>
  <p class=EMEANormal><u><span lang=EN-GB>In patients starting or stopping
  Kaletra while currently taking maintenance dose of lamotrigine</span></u><span
  lang=EN-GB>: </span></p>
  <p class=EMEANormal><span lang=EN-GB>lamotrigine dose may need to be
  increased if Kaletra is added, or decreased if Kaletra is discontinued;
  therefore plasma lamotrigine monitoring should be conducted, particularly
  before and during 2 weeks after starting or stopping Kaletra, in order to see
  if lamotrigine dose adjustment is needed.</span></p>
  <p class=EMEANormal><u><span lang=EN-GB>In patients currently taking Kaletra
  and starting lamotrigine</span></u><span lang=EN-GB>: no dose adjustments to
  the recommended dose escalation of lamotrigine should be necessary.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:8.6pt'>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:8.6pt'>
  <p class=MsoNormal style='page-break-after:avoid'><i><span lang=EN-GB
  style='font-size:11.0pt'>Antidepressants and Anxiolytics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Trazodone
  single dose</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Ritonavir,
  200&nbsp;mg BID)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Trazodone:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC: </span><span
  lang=EN-GB>&#8593; 2.4-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Adverse
  events of nausea, dizziness, hypotension and syncope were observed following
  co-administration of trazodone and ritonavir. </span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>It is
  unknown whether the combination of Kaletra causes a similar increase in
  trazodone exposure. The combination should be used with caution and a lower
  dose of trazodone should be considered</span><span lang=EN-GB>.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antifungals</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ketoconazole and Itraconazole</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ketoconazole, Itraconazole:</span><i><span
  lang=EN-GB> </span></i><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A inhibition by lopinavir/ritonavir. </span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>High doses of ketoconazole and
  itraconazole (&gt;&nbsp;200&nbsp;mg/day) are not recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Voriconazole</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Voriconazole: </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be decreased.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Co&#8209;administration of voriconazole
  and low dose ritonavir (100&nbsp;mg BID) as contained in Kaletra should be
  avoided unless an assessment of the benefit/risk to patient justifies the use
  of voriconazole.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Anti&#8209;gout
  agents:</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Colchicine
  single dose</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>(Ritonavir
  200&nbsp;mg twice daily)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Colchicine:</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>AUC: &#8593; 3-fold</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>C<sub>max</sub>: &#8593; 1.8-fold</span></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>Due to P-gp and/or CYP3A4 inhibition by</span><span
  lang=EN-GB style='font-size:11.0pt'> ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C</span>oncomitant
  administration of Kaletra with colchicine in patients with renal and/or
  hepatic impairment is contraindicated due to a potential increase of
  colchicine-related serious and/or life&#8209;threatening reactions such as
  neuromuscular toxicity (including rhabdomyolysis) (see sections 4.3 and 4.4).
  A reduction in colchicine dosage or an interruption of colchicine treatment
  is recommended in patients with normal renal or hepatic function if treatment
  with Kaletra is required. Refer to colchicine prescribing information.</p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Antihistamines</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Astemizole</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Terfenadine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Serum
  concentrations may be increased due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concomitant
  administration of Kaletra and astemizole and terfenadine is contraindicated
  as it may increase the risk of serious arrhythmias from these agents (see
  section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Anti-infectives</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Fusidic
  acid</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Fusidic
  acid:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be increased due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'>Concomitant administration
  of Kaletra with fusidic acid is contra-indicated in dermatological
  indications due to the increased risk of adverse events related to fusidic
  acid, notably rhabdomyolysis (see section 4.3). When used for
  osteo-articular infections, where the co-administration is unavoidable, close
  clinical monitoring for muscular adverse events is strongly recommended (see
  section 4.4). </p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antimycobacterials</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bedaquiline</span></p>
  <p class=EMEANormal><span lang=EN-GB>(single dose)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir 400/100&nbsp;mg
  BID, multiple dose)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bedaquiline:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 22%</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>A more pronounced effect on bedaquiline
  plasma exposures may be observed during prolonged co&#8209;administration
  with lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>CYP3A4 inhibition likely due to
  lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to the risk of bedaquiline related
  adverse events, the combination of bedaquiline and Kaletra should be
  avoided. If the benefit outweighs the risk, co&#8209;administration of
  bedaquiline with Kaletra must be done with caution. More frequent
  electrocardiogram monitoring and monitoring of transaminases is recommended
  (see section 4.4 and refer to the bedaquiline SmPC).</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal1><span lang=EN-GB>Delamanid (100 mg BID)</span></p>
  <p class=EMEANormal1><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(Lopinavir/ritonavir 400/100&nbsp;mg
  BID)</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=DE>Delamanid:</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt'><span lang=DE
  style='font-family:"Times New Roman",serif'>AUC: &#8593; 22%</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:2.2pt;margin-bottom:.0001pt'><span lang=DE
  style='font-family:"Times New Roman",serif'>&nbsp;</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt'><span lang=DE
  style='font-family:"Times New Roman",serif'>DM-6705 (delamanid active
  metabolite):</span></p>
  <p class=TableParagraph style='margin-top:.05pt;margin-right:8.6pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt'><span lang=DE
  style='font-family:"Times New Roman",serif'>AUC: &#8593; 30%</span></p>
  <p class=EMEANormal>&nbsp;</p>
  <p class=EMEANormal>A more pronounced effect on DM-6705 exposure may be
  observed during prolonged co-administration with lopinavir/ritonavir.</p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Due to the risk of QTc prolongation associated with DM&#8209;6705,
  if co&#8209;administration of delamanid with Kaletra is considered necessary,
  very frequent ECG monitoring throughout the full delamanid treatment period
  is recommended (see section 4.4 and refer to the delamanid SmPC).</p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Rifabutin,
  150&nbsp;mg QD</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Rifabutin
  (parent drug and active </span><span lang=EN-GB>25-O-desacetyl metabolite):<i>
  </i></span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 5.7-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>C<sub>max</sub>:
  &#8593; 3.5-fold </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>When
  given with Kaletra the recommended dose of rifabutin is 150&nbsp;mg 3 times
  per week on set days (for example Monday-Wednesday-Friday). Increased
  monitoring for rifabutin-associated adverse reactions including neutropenia
  and uveitis is warranted due to an expected increase in exposure to
  rifabutin. Further dosage reduction of rifabutin to 150&nbsp;mg twice weekly
  on set days is recommended for patients in whom the 150&nbsp;mg dose 3 times
  per week is not tolerated. It should be kept in mind that the twice weekly
  dosage of 150&nbsp;mg may not provide an optimal exposure to rifabutin thus
  leading to a risk of rifamycin resistance and a treatment failure. No dose
  adjustment is needed for Kaletra. </span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Rifampicin</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Large
  decreases in lopinavir concentrations may be observed due to CYP3A induction
  by rifampicin.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Co&#8209;administration
  of Kaletra with rifampicin is not recommended as </span><span lang=EN-GB>the
  decrease in lopinavir concentrations may in turn significantly decrease the
  lopinavir therapeutic effect. A dose adjustment of Kaletra
  400&nbsp;mg/400&nbsp;mg (i.e. Kaletra 400/100&nbsp;mg + ritonavir
  300&nbsp;mg) twice daily has allowed compensating for the CYP&nbsp;3A4
  inducer effect of rifampicin. However, such a dose adjustment might be
  associated with ALT/AST elevations and with increase in gastrointestinal
  disorders. Therefore, this co&#8209;administration should be avoided unless
  judged strictly necessary. If this co&#8209;administration is judged
  unavoidable, increased dose of Kaletra at 400&nbsp;mg/400&nbsp;mg twice daily
  may be administered with rifampicin under close safety and therapeutic drug
  monitoring. The Kaletra dose should be titrated upward only after rifampicin
  has been initiated (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Antipsychotics</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lurasidone</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of lurasidone are expected to increase.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The concomitant administration with
  lurasidone is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Pimozide</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A inhibition by lopinavir/ritonavir, concentrations of pimozide are
  expected to increase.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concomitant
  administration of Kaletra and pimozide is contraindicated as it may increase
  the risk of serious haematologic abnormalities or other serious adverse
  effects from this agent (see section 4.3)</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Quetiapine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by
  lopinavir/ritonavir, concentrations of quetiapine are expected to increase.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Concomitant administration of Kaletra
  and quetiapine is contraindicated as it may increase quetiapine-related
  toxicity.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Benzodiazepines</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Midazolam</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Oral Midazolam: </span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 13-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>Parenteral Midazolam:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 4-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Kaletra must not be co&#8209;administered
  with oral midazolam (see section 4.3), whereas caution should be used with co&#8209;administration
  of Kaletra and parenteral midazolam. If Kaletra is co&#8209;administered
  with parenteral midazolam, it should be done in an intensive care unit (ICU)
  or similar setting which ensures close clinical monitoring and appropriate
  medical management in case of respiratory depression and/or prolonged
  sedation. Dosage adjustment for midazolam should be considered especially if
  more than a single dose of midazolam is administered.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i>Beta<sub>2</sub>-adrenoceptor
  agonist (long acting)</i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Salmeterol</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Salmeterol:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  are expected to increase due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>The combination may result in increased
  risk of cardiovascular adverse events associated with salmeterol, including
  QT prolongation, palpitations and sinus tachycardia.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'>Therefore, concomitant
  administration of Kaletra with salmeterol is not recommended (see section
  4.4).</p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Calcium channel blockers</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Felodipine, Nifedipine, and Nicardipine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Felodipine, Nifedipine, Nicardipine:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Clinical monitoring of therapeutic and
  adverse effects is recommended when these medicines are concomitantly
  administered with Kaletra.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Corticosteroids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Dexamethasone</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be decreased due to
  CYP3A induction by dexamethasone.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Clinical monitoring of antiviral
  efficacy is recommended when these medicines are concomitantly administered
  with Kaletra.</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Inhaled,
  injectable or intranasal fluticasone propionate, budesonide, triamcinolone</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Fluticasone
  propionate, 50&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
  lang=EN-GB>g intranasal 4 times daily:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Plasma
  concentrations &#8593;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Cortisol
  levels &#8595; 86% </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Greater
  effects may be expected when fluticasone propionate is inhaled. Systemic corticosteroid
  effects including Cushing's syndrome and adrenal suppression have been
  reported in patients receiving ritonavir and inhaled or intranasally
  administered fluticasone propionate; this could also occur with other
  corticosteroids metabolised via the P450 3A pathway e.g. budesonide and
  triamcinolone. Consequently, concomitant administration of Kaletra and these
  glucocorticoids is not recommended unless the potential benefit of treatment
  outweighs the risk of systemic corticosteroid effects (see section 4.4). A
  dose reduction of the glucocorticoid should be considered with close
  monitoring of local and systemic effects or a switch to a glucocorticoid,
  which is not a substrate for CYP3A4 (e.g. beclomethasone). Moreover, in case
  of withdrawal of glucocorticoids progressive dose reduction may have to be
  performed over a longer period. </span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Phosphodiesterase(PDE5)
  inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:51.7pt'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:51.7pt'>
  <p class=EMEANormal><span lang=EN-GB>Avanafil </span></p>
  <p class=EMEANormal><span lang=EN-GB>(ritonavir 600&nbsp;mg BID) </span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:51.7pt'>
  <p class=EMEANormal><span lang=EN-GB>Avanafil:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 13-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:51.7pt'>
  <p class=EMEANormal><span lang=EN-GB>The use of avanafil with Kaletra is
  contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:77.55pt'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:77.55pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Tadalafil
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:77.55pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Tadalafil:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>AUC:
  &#8593; 2-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Due to
  CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 rowspan=2 valign=top style='width:171.6pt;border-top:
  none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:77.55pt'>
  <p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>For
  the treatment of pulmonary arterial hypertension</span></u><span lang=EN-GB>:
  Co&#8209;administration of Kaletra with sildenafil is contraindicated (see
  section 4.3). Co-administration of Kaletra with tadalafil is not
  recommended.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>For
  erectile dysfunction</span></u><span lang=EN-GB>:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Particular
  caution must be used when prescribing sildenafil or tadalafil in patients
  receiving Kaletra with increased monitoring for adverse events including
  hypotension, syncope, visual changes and prolonged erection (see section
  4.4). </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>When co&#8209;administered
  with Kaletra, sildenafil doses must not exceed 25&nbsp;mg in 48 hours and
  tadalafil doses must not exceed 10&nbsp;mg every 72 hours. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Sildenafil</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><i><span lang=EN-GB>&nbsp;</span></i></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Sildenafil:<u> </u></span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 11-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vardenafil </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vardenafil:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 49-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The use of vardenafil with Kaletra is
  contraindicated (see section 4.3). </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Ergot alkaloids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Dihydroergotamine, ergonovine,
  ergotamine, methylergonovine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations may be
  increased due to CYP3A inhibition by </span><span lang=EN-GB>lopinavir/ritonavir</span><span
  style='color:black'>.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  Kaletra and ergot alkaloids are contraindicated as it may lead to acute ergot
  toxicity, including vasospasm and ischaemia (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span style='color:black'>GI motility agent</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Cisapride</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations may be
  increased due to CYP3A inhibition by </span><span lang=EN-GB>lopinavir/ritonavir</span><span
  style='color:black'>.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  Kaletra and cisapride is contraindicated as it may increase the risk of
  serious arrhythmias from this agent (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span style='color:black'>HCV direct acting antivirals</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Elbasvir/grazoprevir</span></p>
  <p class=EMEANormal><span style='color:black'>(50/200 mg QD)</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Elbasvir:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 2.71-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 1.87-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>24</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 3.58-fold</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Grazoprevir:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  style='color:black'> 11.86-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 6.31-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>24</sub>: </span><span
  lang=EN-GB>&#8593; 20.70-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(combinations of mechanisms including
  CYP3A inhibition)</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Concomitant administration of
  elbasvir/grazoprevir with Kaletra is contraindicated (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Glecaprevir/pibrentasvir</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Serum
  concentrations may be increased due to P-glycoprotein, BCRP and OATP1B
  inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Concomitant
  administration of glecaprevir/pibrentasvir and Kaletra is not recommended due
  to an increased risk of ALT elevations associated with increased glecaprevir
  exposure.</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Ombitasvir/paritaprevir/ritonavir
  + dasabuvir</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>(25/150/100&nbsp;mg
  QD + 400&nbsp;mg BID)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir/ritonavir
  </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>400/100&nbsp;mg
  BID</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Ombitasvir:
  </span><span lang=EN-GB>&#8596;</span><span lang=EN-GB style='color:black'> </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Paritaprevir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>AUC:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.17-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>C<sub>max</sub>:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.04-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>C<sub>trough</sub>:
  </span><span lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>2.36-fold</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>(inhibition
  of CYP3A/efflux transporters)</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Dasabuvir:
  </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir:
  </span><span lang=EN-GB>&#8596;</span></p>
  </td>
  <td width=227 rowspan=2 valign=top style='width:170.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Co-administration
  is contraindicated.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span style='color:black'>Lopinavir/ritonavir
  800/200&nbsp;mg QD was administered with ombitasvir/paritaprevir/ritonavir
  with or without dasabuvir. The effect on DAAs and lopinavir was similar to
  that observed when lopinavir/ritonavir 400/100&nbsp;mg BID was administered
  (see section 4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Ombitasvir/paritaprevir/
  ritonavir</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>(25/150/100&nbsp;mg QD)</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Lopinavir/ritonavir</span></p>
  <p class=EMEANormal><span style='color:black'>400/100&nbsp;mg BID</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Ombitasvir:</span><span
  style='color:black'> </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Paritaprevir:</span></p>
  <p class=EMEANormal><span style='color:black'>AUC: </span><span lang=EN-GB>&#8593;</span><span
  lang=EN-GB style='color:black'> </span><span style='color:black'>6.10-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>max</sub>: </span><span
  lang=EN-GB>&#8593;</span><span lang=EN-GB style='color:black'> </span><span
  style='color:black'>4.76-fold</span></p>
  <p class=EMEANormal><span style='color:black'>C<sub>trough</sub>: </span><span
  lang=EN-GB>&#8593;</span><span style='color:black'> 12.33-fold</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>(inhibition of CYP3A/efflux
  transporters)</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir: </span><span lang=EN-GB>&#8596;</span></p>
  <p class=EMEANormal><span style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Sofosbuvir/velpatasvir/
  voxilaprevir</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>Serum concentrations of
  sofosbuvir, velpatasvir and voxilaprevir may be increased due to
  P-glycoprotein, BCRP and OATP1B1/3 inhibition by lopinavir/ritonavir.
  However, only the increase in voxilaprevir exposure is considered clinically
  relevant.</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span style='color:black'>It is not recommended to co&#8209;administer
  Kaletra and sofosbuvir/velpatasvir/ voxilaprevir.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>HCV protease inhibitors</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Simeprevir 200 mg
  daily (</span><span lang=EN-GB style='font-size:11.0pt'>ri<span
  style='letter-spacing:-.05pt'>t</span>onavir <span style='letter-spacing:
  -.05pt'>1</span>00<span style='letter-spacing:-.35pt'> </span><span
  style='letter-spacing:-.1pt'>m</span>g<span style='letter-spacing:-.1pt'> </span>BID)</span></p>
  <p style='margin:0in'><span lang=EN-GB style='font-size:11.0pt;font-family:
  "Times New Roman",serif'>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Simeprevir:</p>
  <p class=EMEANormal>AUC<span lang=EN-GB>:</span><span lang=EN-GB> </span><span
  lang=FR>&#8593;<span style='letter-spacing:-.2pt'> </span><span
  style='letter-spacing:.05pt'>7.2-fold</span></span></p>
  <p class=EMEANormal>C<sub>max</sub><span lang=EN-GB>:</span><span lang=EN-GB>
  </span><span lang=FR>&#8593; 4.7-fold</span></p>
  <p class=EMEANormal>C<sub>min</sub><span lang=EN-GB>:</span><span lang=EN-GB>
  </span><span lang=FR>&#8593; 14.4-fold</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
  color:black'>It is not recommended to co&#8209;administer Kaletra and simeprevir.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Herbal
  products</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>St Johns</span><span
  lang=EN-GB> wort</span><i><span lang=EN-GB> </span></i><span lang=EN-GB>(<i>Hypericum
  perforatum)</i></span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Lopinavir:</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Concentrations
  may be reduced due to induction of CYP3A by the herbal preparation St
    Johns wort. </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Herbal
  preparations containing St Johns wort must not be combined with lopinavir
  and ritonavir. If a patient is already taking St Johns wort, stop St&nbsp;Johns&nbsp;wort and if possible check viral levels. Lopinavir and ritonavir
  levels may increase on stopping St&nbsp;Johns&nbsp;wort. The dose of
  Kaletra may need adjusting. The inducing effect may persist for at least 2
  weeks after cessation of treatment with St Johns wort (see section 4.3).
  Therefore, Kaletra can be started safely 2 weeks after cessation of St
    John's wort. <i></i></span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Immunosuppressants</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Cyclosporin, Sirolimus (rapamycin), and
  Tacrolimus</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Cyclosporin, Sirolimus (rapamycin),
  Tacrolimus:</span><span lang=EN-GB> </span></p>
  <p class=EMEANormal><span lang=EN-GB>Concentrations may be increased due to
  CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>More frequent therapeutic concentration
  monitoring is recommended until plasma levels of these products have been
  stabilised.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Lipid lowering agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lovastatin and Simvastatin</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lovastatin, Simvastatin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Markedly increased plasma concentrations
  due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Since increased concentrations of
  HMG-CoA reductase inhibitors may cause myopathy, including rhabdomyolysis,
  the combination of these agents with Kaletra is contraindicated (see section
  4.3).</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal1 style='page-break-after:avoid'><i><span lang=EN-GB>Lipid-modifying
  agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lomitapide</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>CYP3A4 inhibitors increase the exposure of lomitapide,
  with strong inhibitors increasing exposure approximately 27&#8209;fold. Due
  to CYP3A inhibition by lopinavir/ritonavir, concentrations of lomitapide are
  expected to increase.</p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal>Concomitant use of Kaletra with lomitapide is
  contraindicated (see prescribing information for lomitapide) (see section
  4.3).</p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Atorvastatin</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Atorvastatin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 5.9-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 4.7-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The combination of Kaletra with
  atorvastatin is not recommended. If the use of atorvastatin is considered
  strictly necessary, the lowest possible dose of atorvastatin should be
  administered with careful safety monitoring (see section 4.4). </span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rosuvastatin, 20&nbsp;mg QD</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rosuvastatin:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 2-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 5-fold</span></p>
  <p class=EMEANormal><span lang=EN-GB>While rosuvastatin is poorly metabolised
  by CYP3A4, an increase of its plasma concentrations was observed. The mechanism
  of this interaction may result from inhibition of transport proteins.</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised and reduced
  doses should be considered when Kaletra is co&#8209;administered with
  rosuvastatin (see section 4.4).</span></p>
  </td>
 </tr>
 <tr>
  <td width=161 colspan=2 valign=top style='width:120.5pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Fluvastatin
  or Pravastatin</span></p>
  </td>
  <td width=217 colspan=2 valign=top style='width:163.0pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Fluvastatin,
  Pravastatin: </span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>No
  clinical relevant interaction expected.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Pravastatin
  is not metabolised by CYP450.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Fluvastatin
  is partially metabolised by CYP2C9.</span></p>
  </td>
  <td width=227 valign=top style='width:170.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>If
  treatment with an HMG-CoA reductase inhibitor is indicated, fluvastatin or
  pravastatin is recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Opioids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Buprenorphine,
  16&nbsp;mg QD</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Buprenorphine:</span><span
  lang=EN-GB> &#8596;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>No dose
  adjustment necessary.</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Methadone</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Methadone:</span><i><span
  lang=EN-GB> </span></i><span lang=EN-GB>&#8595;</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Monitoring
  plasma concentrations of methadone is recommended.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Oral contraceptives</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ethinyl Oestradiol</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Ethinyl Oestradiol: &#8595;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>In case of co&#8209;administration of
  Kaletra with contraceptives containing ethinyl oestradiol (whatever the
  contraceptive formulation e.g. oral or patch), additional methods of
  contraception must be used.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Smoking cessation aids</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bupropion</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Buproprion and its active metabolite,
  hydroxybupropion:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC and C<sub>max</sub> &#8595; ~50% </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>This effect may be due to induction of
  bupropion metabolism.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>If the co&#8209;administration of Kaletra
  with bupropion is judged unavoidable, this should be done under close
  clinical monitoring for bupropion efficacy, without exceeding the recommended
  dosage, despite the observed induction.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Thyroid hormone replacement therapy</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Levothyroxine</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Post&#8209;marketing cases have been
  reported indicating a potential interaction between ritonavir containing
  products and levothyroxine.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Thyroid&#8209;stimulating hormone (TSH)
  should be monitored in patients treated with levothyroxine at least the first
  month after starting and/or ending lopinavir/ritonavir treatment.</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><i><span lang=EN-GB>Vasodilating agents</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Bosentan</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir - ritonavir:</span></p>
  <p class=EMEANormal><span lang=EN-GB>Lopinavir/ritonavir plasma
  concentrations may decrease due to CYP3A4 induction by bosentan.</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Bosentan:</span></p>
  <p class=EMEANormal><span lang=EN-GB>AUC: &#8593; 5-fold </span></p>
  <p class=EMEANormal><span lang=EN-GB>C<sub>max</sub>: &#8593; 6-fold</span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:11.0pt'>Initially, bosentan C<sub>min</sub>: </span><span
  lang=EN-GB style='font-size:11.0pt'>&#8593; by approximately 48-fold.<u> </u></span></p>
  <p class=EMEANormal><span lang=EN-GB>Due to CYP3A4 inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Caution should be exercised in
  administering Kaletra with bosentan.</span></p>
  <p class=EMEANormal>When Kaletra is administered concomitantly with bosentan,
  the efficacy of the HIV therapy should be monitored and patients should be
  closely observed for bosentan toxicity, especially during the first week of
  co&#8209;administration. </p>
  </td>
 </tr>
 <tr>
  <td width=160 valign=top style='width:120.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Riociguat</span></p>
  </td>
  <td width=216 colspan=2 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Serum concentrations may be increased
  due to CYP3A and P&#8209;gp inhibition by lopinavir/ritonavir.</span></p>
  </td>
  <td width=229 colspan=2 valign=top style='width:171.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>The co&#8209;administration of riociguat
  with Kaletra is not recommended (see section 4.4 and refer to riociguat
  SmPC).</span></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>Other
  medicinal products</span></i></p>
  </td>
 </tr>
 <tr>
  <td width=605 colspan=5 valign=top style='width:6.3in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Based on
  known metabolic profiles, clinically significant interactions are not
  expected between Kaletra and dapsone, trimethoprim/sulfamethoxazole,
  azithromycin or fluconazole.</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=207 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=184 style='border:none'></td>
  <td width=1 style='border:none'></td>
  <td width=213 style='border:none'></td>
 </tr>
</table>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.6 Fertility, pregnancy and lactation</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Pregnancy</span></u></p>

<p class=EMEANormal><span lang=EN-GB>As a general rule, when deciding to use
antiretroviral agents for the treatment of HIV infection in pregnant women and
consequently for reducing the risk of HIV vertical transmission to the newborn,
the animal data as well as the clinical experience in pregnant women should be
taken into account in order to characterise the safety for the foetus.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal>Lopinavir/ritonavir has been evaluated in over 3000 women
during pregnancy, including over 1000 during the first trimester.</p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>In post&#8209;marketing
surveillance through the Antiretroviral Pregnancy Registry, established since
January 1989, an increased risk of birth defects exposures with Kaletra has not
been reported among over 1000 women exposed during the first trimester. The
prevalence of birth defects after any trimester exposure to lopinavir is
comparable to the prevalence observed in the general population. No pattern of
birth defects suggestive of a common etiology was seen. Studies in animals
have shown reproductive toxicity (see section 5.3). Based on the data
mentioned, the malformative risk is unlikely in humans. </span>Lopinavir can
be used during pregnancy if clinically needed.</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Breastfeeding</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Studies in rats revealed that lopinavir is
excreted in the milk. It is not known whether this medicinal product is
excreted in human milk. As a general rule, it is recommended that mothers
infected by HIV do not breastfeed their babies under any circumstances in order
to avoid transmission of HIV. </span></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><u><span lang=EN-GB>Fertility</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Animal studies have shown no effects on
fertility. No human data on the effect of lopinavir/ritonavir on fertility are
available.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.7 Effects on ability to drive and use machines</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>No studies on the effects on the ability
to drive and use machines have been performed. Patients should be informed
that nausea has been reported during treatment with Kaletra (see section 4.8).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>4.8 Undesirable effects </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>a. Summary of the safety profile</span></u></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The safety of Kaletra has been
investigated in over 2600 patients in Phase II&#8209;IV clinical trials, of
which over 700 have received a dose of 800/200&nbsp;mg (6 capsules or 4
tablets) once daily. Along with nucleoside reverse transcriptase inhibitors
(NRTIs), in some studies, Kaletra was used in combination with efavirenz or
nevirapine.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The most common adverse reactions related
to Kaletra therapy during clinical trials were diarrhoea</span><span
lang=EN-GB>, nausea, vomiting, hypertriglyceridaemia and hypercholesterolemia</span><span
lang=EN-GB>. The risk of diarrhoea may be greater with once&#8209;daily dosing
of Kaletra. </span><span lang=EN-GB>Diarrhoea, nausea and vomiting may occur
at the beginning of the treatment while hypertriglyceridaemia and
hypercholesterolemia may occur later. Treatment emergent adverse events led to
premature study discontinuation for 7% of subjects from Phase II&#8209;IV
studies.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>It is important to note that cases of
pancreatitis have been reported in patients receiving Kaletra, including those
who developed hypertriglyceridaemia. Furthermore, rare increases in PR
interval have been reported during Kaletra therapy (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><u><span lang=EN-GB
style='font-style:normal'>b. Tabulated list of adverse reactions</span></u></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Adverse
reactions</span><span lang=EN-GB> from clinical trials and post-marketing
experience in adult and paediatric patients:</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The following
events have been identified as adverse reactions. The frequency category
includes all reported events of moderate to severe intensity, regardless of the
individual causality assessment.</span><span lang=EN-GB style='font-size:11.0pt'>
The adverse reactions are displayed by system organ class. Within each
frequency grouping, undesirable effects are presented in order of decreasing
seriousness: very common (&#8805;&nbsp;1/10), common (&#8805;&nbsp;1/100 </span><span
lang=EN-GB style='font-size:11.0pt'>to&nbsp;&lt;&nbsp;1/10), uncommon (&#8805;&nbsp;1/1000
to&nbsp;&lt;&nbsp;1/100), rare (&#8805;1/10,000 to &lt;1/1000) and </span><span
lang=EN-GB style='font-size:11.0pt;color:black'>not known (cannot be estimated
from the available data)</span><span lang=EN-GB style='font-size:11.0pt'>.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='page-break-inside:avoid'>
  <td width=604 colspan=3 valign=top style='width:453.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Undesirable effects in clinical studies and post-marketing in
  adult patients</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>System organ class</span></b></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Frequency</span></b></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Adverse reaction</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Infections and infestations</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Very common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Upper respiratory tract infection</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Lower respiratory tract infection, skin
  infections including cellulitis, folliculitis and furuncle</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.5pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Blood and lymphatic system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=EMEANormal style='text-align:justify'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Anaemia, leucopenia, neutropenia,
  lymphadenopathy</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Immune system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypersensitivity including urticaria and
  angioedema</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Immune </span><span lang=EN-GB>reconstitution
  inflammatory<i> </i></span><span lang=EN-GB>syndrome</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:13.9pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=EMEANormal><span lang=EN-GB>Endocrine disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:13.9pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypogonadism </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Metabolism and nutrition disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Blood glucose disorders including
  diabetes mellitus, hypertriglyceridaemia, hypercholesterolemia, weight
  decreased, decreased appetite </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Weight increased, increased appetite</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Psychiatric disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Anxiety</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Abnormal dreams, libido decreased</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Nervous system disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Headache (including migraine),
  neuropathy (including peripheral neuropathy), dizziness, insomnia</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.15pt'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=EMEANormal><span lang=EN-GB>Cerebrovascular accident, convulsion,
  dysgeusia, ageusia, tremor </span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Eye disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Visual impairment</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.1pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:14.1pt'>
  <p class=EMEANormal><span lang=EN-GB>Ear and labyrinth disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.1pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:14.1pt'>
  <p class=EMEANormal><span lang=EN-GB>Tinnitus, vertigo</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.5pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:38.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Cardiac disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:38.5pt'>
  <p class=EMEANormal><span lang=EN-GB>Atherosclerosis such as myocardial
  infarction, atrioventricular block, tricuspid valve incompetence</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Vascular disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hypertension </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Deep vein thrombosis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=3 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Gastrointestinal
  disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Very
  common</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Diarrhoea,
  nausea</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Pancreatitis<sup>1</sup>,
  vomiting, gastrooesophageal reflux disease, gastroenteritis and colitis,
  abdominal pain (upper and lower), abdominal distension, dyspepsia,
  haemorrhoids, flatulence</span></p>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:52.6pt'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.6pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:52.6pt'>
  <p class=EMEANormal><span lang=EN-GB>Gastrointestinal haemorrhage including
  gastrointestinal ulcer, duodenitis, gastritis and rectal haemorrhage,
  stomatitis and oral ulcers, faecal incontinence, constipation, dry mouth</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hepatobiliary disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Hepatitis including AST, ALT and GGT
  increases</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:40.4pt'>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:40.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:40.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Jaundice, hepatic steatosis,
  hepatomegaly, cholangitis, hyperbilirubinemia</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=3 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Skin and subcutaneous tissue disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:solid windowtext 1.0pt;
  border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rash including maculopapular rash,
  dermatitis/rash including eczema and seborrheic dermatitis, night sweats,
  pruritus</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Alopecia, capillaritis, vasculitis </span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:26.55pt'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=EMEANormal><span lang=EN-GB>Rare</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.55pt'>
  <p class=EMEANormal><span lang=FR>Stevens&#8209;Johnson syndrome, erythema
  multiforme</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=202 rowspan=2 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Musculoskeletal and connective tissue
  disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Myalgia, </span><span lang=EN-GB>musculoskeletal
  pain including arthralgia and back pain, muscle disorders such as weakness
  and spasms</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Rhabdomyolysis, osteonecrosis</span></p>
  </td>
 </tr>
 <tr>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Renal and urinary disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Uncommon</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span lang=EN-GB>Not known</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Creatinine clearance decreased,
  nephritis, haematuria</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  <p class=EMEANormal><span style='color:black'>Nephrolithiasis</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.95pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:25.95pt'>
  <p class=EMEANormal><span lang=EN-GB>Reproductive system and breast disorders</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.95pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.95pt'>
  <p class=EMEANormal><span lang=EN-GB>Erectile dysfunction, menstrual
  disorders - amenorrhoea, menorrhagia </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:26.35pt'>
  <td width=202 valign=top style='width:151.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:26.35pt'>
  <p class=EMEANormal><span lang=EN-GB>General disorders and administration
  site conditions</span></p>
  </td>
  <td width=110 valign=top style='width:82.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.35pt'>
  <p class=EMEANormal><span lang=EN-GB>Common</span></p>
  </td>
  <td width=292 valign=top style='width:218.7pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.35pt'>
  <p class=EMEANormal><span lang=EN-GB>Fatigue including asthenia</span></p>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><sup><span lang=EN-GB>1</span></sup><span lang=EN-GB> See
section 4.4: pancreatitis and lipids</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB
style='color:black'>c. Description of selected adverse reactions</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><b><i><span lang=EN-GB
style='color:black'>&nbsp;</span></i></b></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Cushings
syndrome has been reported in patients receiving ritonavir and inhaled or
intranasally administered fluticasone propionate; this could also occur with
other corticosteroids metabolised via the P450 3A pathway e.g. budesonide (see
section 4.4 and 4.5).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Increased creatine phosphokinase (CPK),
myalgia, myositis, and rarely, rhabdomyolysis have been reported with protease
inhibitors, particularly in combination with nucleoside reverse transcriptase
inhibitors.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Metabolic parameters</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Weight and levels of blood lipids and
glucose may increase during antiretroviral therapy (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>In HIV-infected patients with severe
immune deficiency at the time of initiation of combination antiretroviral
therapy (CART), an inflammatory reaction to asymptomatic or residual
opportunistic infections may arise. </span>Autoimmune disorders (such as
Graves disease <span lang=EN-GB>and autoimmune hepatitis</span>) have also
been reported; however, the reported time to onset is more variable and can
occur many months after initiation of treatment<span lang=EN-GB> (see section
4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Cases of osteonecrosis have been reported,
particularly in patients with generally acknowledged risk factors, advanced HIV
disease or long-term exposure to combination antiretroviral therapy (CART).
The frequency of this is unknown (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><u><span lang=EN-GB
style='font-size:11.0pt'>d. Paediatric populations</span></u></p>

<p class=MsoBodyText align=left style='margin:0in;text-align:left;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>In children 2 years of age and older, the
nature of the safety profile is similar to that seen in adults (see Table in
section b). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Reporting of suspected adverse
reactions</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Reporting suspected adverse reactions
after authorisation of the medicinal product is important. It allows continued
monitoring of the benefit/risk balance of the medicinal product. Healthcare
professionals are asked to report any suspected adverse reactions </span>via <span
style='background:lightgrey'>the national reporting system listed in </span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='background:lightgrey'>Appendix V</span></a><span style='color:blue'>.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4.9 Overdose</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>To date, there is limited human experience
of acute overdose with Kaletra.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The adverse clinical signs observed in
dogs included salivation, emesis and diarrhoea/abnormal stool. The signs of
toxicity observed in mice, rats or dogs included decreased activity, ataxia,
emaciation, dehydration and tremors. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>There is no specific antidote for overdose
with Kaletra. Treatment of overdose with Kaletra is to consist of general
supportive measures including monitoring of vital signs and observation of the
clinical status of the patient. If indicated, elimination of unabsorbed active
substance is to be achieved by emesis or gastric lavage. Administration of
activated charcoal may also be used to aid in removal of unabsorbed active
substance. Since Kaletra is highly protein bound, dialysis is unlikely to be
beneficial in significant removal of the active substance.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5. Pharmacological properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5.1 Pharmacodynamic properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Pharmaco-therapeutic group: antivirals for
systemic use, a</span>ntivirals for treatment of HIV infections, combinations<span
lang=EN-GB>, ATC code: J05AR10 </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Mechanism of action</span></u></p>

<p class=EMEANormal><span lang=EN-GB>L<span style='layout-grid-mode:line'>opinavir
provides the antiviral activity of Kaletra. </span>Lopinavir is an inhibitor
of the HIV-1 and HIV-2 proteases. Inhibition of HIV protease prevents cleavage
of the <i>gag-pol</i> polyprotein resulting in the production of immature,
non-infectious virus. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Effects on the electrocardiogram</span></u></p>

<p class=EMEANormal><span lang=EN-GB>QTcF interval was evaluated in a
randomised, placebo and active (moxifloxacin 400&nbsp;mg once daily) controlled
crossover study in 39 healthy adults, with 10 measurements over 12 hours on Day
3. The maximum mean (95% upper confidence bound) differences in QTcF from
placebo were 3.6 (6.3) and 13.1(15.8) for 400/100&nbsp;mg twice daily and
supratherapeutic 800/200&nbsp;mg twice daily LPV/r, respectively. </span><span
lang=EN-GB>The induced QRS interval prolongation from 6 ms to 9.5 ms with high
dose lopinavir/ritonavir (800/200 mg twice daily) contributes to QT
prolongation. </span><span lang=EN-GB>The two regimens resulted in exposures
on Day 3 which were approximately 1.5 and 3&#8209;fold higher than those
observed with recommended once&#8209;daily or twice&#8209;daily LPV/r doses at
steady state. No subject experienced an increase in QTcF of </span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;60 ms from
baseline or a QTcF interval exceeding the potentially clinically relevant
threshold of 500 ms.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Modest prolongation of the PR interval was
also noted in subjects receiving lopinavir/ritonavir in the same study on Day
3. </span><span lang=EN-GB>The mean changes from baseline in PR interval
ranged from 11.6 ms to 24.4 ms in the 12 hour interval post dose.<b><i> </i></b></span><span
lang=EN-GB>Maximum PR interval was 286 ms and no second or third degree heart
block was observed (see section 4.4).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Antiviral activity <i>in&nbsp;vitro</i></span></u></p>

<p class=EMEANormal><span lang=EN-GB>The <i>in&nbsp;vitro </i>antiviral
activity of lopinavir against laboratory and clinical HIV strains was evaluated
in acutely infected lymphoblastic cell lines and peripheral blood lymphocytes,
respectively. In the absence of human serum, the mean IC<sub>50</sub> of
lopinavir against five different HIV-1 laboratory strains was 19&nbsp;nM. In
the absence and presence of 50% human serum, the mean IC<sub>50</sub> of
lopinavir against HIV-1<sub>IIIB</sub> in MT4 cells was 17&nbsp;nM and
102&nbsp;nM, respectively. In the absence of human serum, the mean IC<sub>50</sub>
of lopinavir was 6.5&nbsp;nM against several HIV-1 clinical isolates.</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></p>

<p class=EMEAHeadingUI style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Resistance</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><i><span lang=EN-GB>In vitro
selection of resistance</span></i></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV-1
isolates with reduced susceptibility to lopinavir have been selected <i>in&nbsp;vitro</i>.
HIV-1 has been passaged <i>in&nbsp;vitro</i> with lopinavir alone and with
lopinavir plus ritonavir at concentration ratios representing the range of
plasma concentration ratios observed during Kaletra therapy. Genotypic and
phenotypic analysis of viruses selected in these passages suggest that the
presence of ritonavir, at these concentration ratios, does not measurably
influence the selection of lopinavir-resistant viruses. Overall, the <i>in&nbsp;vitro</i>
characterisation of phenotypic cross-resistance between lopinavir and other
protease inhibitors suggest that decreased susceptibility to lopinavir
correlated closely with decreased susceptibility to ritonavir and indinavir,
but did not correlate closely with decreased susceptibility to amprenavir,
saquinavir, and nelfinavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i>Analysis of resistance in ARV-nave patients</i><span
lang=EN-GB>In clinical studies with a limited number of isolates analysed, the
selection of resistance to lopinavir has not been observed in nave patients
without significant protease inhibitor resistance at baseline. See further the
detailed description of the clinical studies.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Analysis of resistance in
PI-experienced patients</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The selection of resistance to lopinavir
in patients having failed prior protease inhibitor therapy was characterised by
analysing the longitudinal isolates from 19 protease inhibitor-experienced
subjects in 2 Phase II and one Phase III studies who either experienced
incomplete virologic suppression or viral rebound subsequent to initial
response to Kaletra and who demonstrated incremental <i>in vitro</i> resistance
between baseline and rebound (defined as emergence of new mutations or 2-fold
change in phenotypic susceptibility to lopinavir). Incremental resistance was
most common in subjects whose baseline isolates had several protease
inhibitor-associated mutations, but &lt;&nbsp;40-fold reduced susceptibility to
lopinavir at baseline. Mutations V82A, I54V and M46I emerged most frequently.
Mutations L33F, I50V and V32I combined with I47V/A were also observed. The 19
isolates demonstrated a 4.3-fold increase in IC<sub>50</sub> compared to
baseline isolates (from 6.2- to 43-fold, compared to wild-type virus).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Genotypic correlates of reduced phenotypic
susceptibility to lopinavir in viruses selected by other protease inhibitors.
The <i>in&nbsp;vitro</i> antiviral activity of lopinavir against 112 clinical
isolates taken from patients failing therapy with one or more protease
inhibitors was assessed. Within this panel, the following mutations in HIV
protease were associated with reduced <i>in&nbsp;vitro</i> susceptibility to
lopinavir: L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V,
V82A/F/T, I84V and L90M. The median EC<sub>50</sub> of lopinavir against
isolates with 0&nbsp;&#8722;&nbsp;3, 4&nbsp;&#8722;&nbsp;5,
6&nbsp;&#8722;&nbsp;7 and 8&nbsp;&#8722;&nbsp;10 mutations at the above amino
acid positions was 0.8, 2.7 13.5 and 44.0-fold higher than the EC<sub>50</sub>
against wild type HIV, respectively. The 16 viruses that displayed
&gt;&nbsp;20-fold change in susceptibility all contained mutations at positions
10, 54, 63 plus 82 and/or 84. In addition, they contained a median of 3
mutations at amino acid positions 20, 24, 46, 53, 71 and 90. </span><span
lang=EN-GB>In addition to the mutations described above, mutations V32I and
I47A have been observed in rebound isolates with reduced lopinavir
susceptibility from protease inhibitor experienced patients receiving Kaletra
therapy</span><span lang=EN-GB>, and mutations I47A and L76V have been observed
in rebound isolates with reduced lopinavir susceptibility from patients receiving
Kaletra therapy.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Conclusions regarding the relevance of
particular mutations or mutational patterns are subject to change with
additional data, and it is recommended to always consult current interpretation
systems for analysing resistance test results.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><i><span lang=EN-GB>Antiviral activity of Kaletra in
patients failing protease inhibitor therapy</span></i></p>

<p class=EMEANormal><span lang=EN-GB>The clinical relevance of reduced <i>in&nbsp;vitro</i>
susceptibility to lopinavir has been examined by assessing the virologic
response to Kaletra therapy, with respect to baseline viral genotype and
phenotype, in 56 patients previous failing therapy with multiple protease
inhibitors. The EC<sub>50</sub> of lopinavir against the 56 baseline viral
isolates ranged from 0.6 to 96-fold higher than the EC<sub>50</sub> against
wild type HIV. After 48 weeks of treatment with Kaletra, efavirenz and
nucleoside reverse transcriptase inhibitors, plasma HIV RNA </span><span
lang=EN-GB style='font-family:Symbol;layout-grid-mode:line'></span><span
lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span><span lang=EN-GB>400&nbsp;copies/ml
was observed in 93% (25/27), 73% (11/15), and 25% (2/8) of patients with
&lt;&nbsp;10&#8209;fold, 10 to 40-fold, and &gt;&nbsp;40&#8209;fold reduced
susceptibility to lopinavir at baseline, respectively. In addition, virologic
response was observed in 91% (21/23), 71% (15/21) and 33% (2/6) patients with
0&nbsp;&#8722;&nbsp;5, 6&nbsp;&#8722;&nbsp;7, and 8&nbsp;&#8722;&nbsp;10
mutations of the above mutations in HIV protease associated with reduced <i>in&nbsp;vitro</i>
susceptibility to lopinavir. Since these patients had not previously been
exposed to either Kaletra or efavirenz, part of the response may be attributed
to the antiviral activity of efavirenz, particularly in patients harbouring
highly lopinavir resistant virus. The study did not contain a control arm of
patients not receiving Kaletra.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Cross&#8209;resistance</span></u><span
lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>Activity of other protease inhibitors
against isolates that developed incremental resistance to lopinavir after
Kaletra therapy in protease inhibitor experienced patients: The presence of
cross resistance to other protease inhibitors was analysed in 18 rebound i</span><span
lang=EN-GB>solates that had demonstrated evolution of resistance to lopinavir
during 3 </span><span lang=EN-GB>Phase </span><span lang=EN-GB>II and one </span><span
lang=EN-GB>Phase </span><span lang=EN-GB>III studies of Kaletra in protease
inhibitor-experienced patients. The median fold IC<sub>50</sub> of lopinavir
for these 18 isolates at baseline and rebound was 6.9- and 63-fold,
respectively, compared to wild type virus. In general, rebound isolates either
retained (if cross-resistant at baseline) or developed significant
cross-resistance to indinavir, saquinavir and atazanavir. Modest decreases in
amprenavir activity were noted with a median increase of IC<sub>50 </sub>from
3.7- to 8-fold in the baseline and rebound isolates, respectively. Isolates
retained susceptibility to tipranavir with a median increase of IC<sub>50</sub>
in baseline and rebound isolates of 1.9- and 1.8fold, respectively, compared
to wild type virus. </span><span lang=EN-GB>Please refer to the Aptivus
Summary of Product Characteristics for additional information on the use of
tipranavir, including genotypic predictors of response, in treatment of
lopinavir-resistant HIV-1 infection.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='font-style:
normal'>Clinical results</span></p>

<p class=EMEANormal><span lang=EN-GB>The effects of Kaletra (in combination
with other antiretroviral agents) on biological markers (plasma HIV RNA levels
and CD4+ T-cell counts) have been investigated in controlled studies of Kaletra
of 48&nbsp;to 360 weeks duration. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Adult Use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUnderline style='margin:0in'><span lang=EN-GB
style='text-decoration:none'>Patients without prior antiretroviral therapy</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Study M98-863 was a randomised,
double-blind trial of 653 antiretroviral treatment nave patients investigating
Kaletra (400/100&nbsp;mg twice daily) compared to nelfinavir (750&nbsp;mg three
times daily) plus stavudine and lamivudine. Mean baseline CD4+ T-cell count
was 259&nbsp;cells/mm<sup>3</sup> (range: 2 to 949&nbsp;cells/ mm<sup>3</sup>)
and mean baseline plasma HIV-1 RNA was 4.9&nbsp;log<sub>10&nbsp;</sub>copies/ml
(range: 2.6 to 6.8&nbsp;log<sub>10&nbsp;</sub>copies/ml). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 1</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=515
 style='width:386.5pt;margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=515 colspan=3 valign=top style='width:386.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 48: Study M98-863</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Kaletra (N=326)</span></b></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Nelfinavir (N=327)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 400 copies/ml*</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>75%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>63%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 50 copies/ml*</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>67%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>52%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Mean
  increase from baseline in CD4+<sub> </sub>T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>207</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>195</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal style='margin-left:30.0pt;page-break-after:avoid'><span
lang=EN-GB>* intent to treat analysis where patients with missing values are
considered virologic failures </span></p>

<p class=EMEANormal style='margin-left:30.0pt;page-break-after:avoid'><span
lang=EN-GB> p&nbsp;&lt;&nbsp;0.001</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>One-hundred thirteen nelfinavir-treated
patients and 74 lopinavir/ritonavir-treated patients had an HIV RNA above
400&nbsp;copies/ml while on treatment from Week 24 through Week 96. Of these,
isolates from 96 nelfinavir-treated patients and 51 lopinavir/ritonavir-treated
patients could be amplified for resistance testing. Resistance to nelfinavir,
defined as the presence of the D30N or L90M mutation in protease, was observed
in 41/96 (43%) patients. Resistance to lopinavir, defined as the presence of
any primary or active site mutations in protease (see above), was observed in
0/51 (0%) patients. Lack of resistance to lopinavir was confirmed by
phenotypic analysis.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Study M05-730 was a randomised,
open-label, multicentre trial comparing treatment with Kaletra 800/200&nbsp;mg
once daily plus tenofovir DF and emtricitabine versus Kaletra 400/100&nbsp;mg
twice daily plus tenofovir DF and emtricitabine in 664 antiretroviral
treatment-nave patients. </span><span lang=EN-GB>Given the pharmacokinetic
interaction between Kaletra and tenofovir (see section 4.5), the results of
this study might not be strictly extrapolable when other backbone regimens are
used with Kaletra. </span><span lang=EN-GB>Patients were randomised in a 1:1
ratio to receive either Kaletra 800/200&nbsp;mg once daily (n&nbsp;=&nbsp;333)
or Kaletra 400/100&nbsp;mg twice daily (n&nbsp;=&nbsp;331). Further
stratification within each group was 1:1 (tablet versus soft capsule).
Patients were administered either the tablet or the soft capsule formulation
for 8 weeks, after which all patients were administered the tablet formulation
once daily or twice daily for the remainder of the study. Patients were
administered emtricitabine 200&nbsp;mg once daily and tenofovir DF 300&nbsp;mg once
daily (equivalent to 245 mg tenofovir disoproxil). Protocol defined
non-inferiority of once&#8209;daily dosing compared with twice&#8209;daily
dosing was demonstrated if the lower bound of the 95% confidence interval for
the difference in proportion of subjects responding (once daily minus twice
daily) excluded -12% at Week 48. Mean age of patients enrolled was 39 years
(range: 19 to 71); 75% were Caucasian, and 78% were male. Mean baseline CD4+
T-cell count was 216 cells/mm3 (range: 20 to 775 cells/mm<sup>3</sup>) and mean
baseline plasma HIV-1 RNA was 5.0&nbsp;log<sub>10</sub>&nbsp;copies/ml (range:
1.7 to 7.0&nbsp;log<sub>10</sub>&nbsp;copies/ml). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 2</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='margin-left:5.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=592 colspan=7 valign=top style='width:444.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:11.0pt'>Virologic Response of Study Subjects at
  Week 48 and Week 96</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=216 colspan=3 valign=top style='width:2.25in;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;text-indent:-5.4pt;
  page-break-after:avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Week 48</span></b></p>
  </td>
  <td width=217 colspan=3 valign=top style='width:162.6pt;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Week 96</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>QD</span></b></p>
  </td>
  <td width=66 valign=top style='width:49.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>BID </span></b></p>
  </td>
  <td width=86 valign=top style='width:64.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Difference</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>[95% CI]</span></b></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>QD</span></b></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>BID </span></b></p>
  </td>
  <td width=89 valign=top style='width:66.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>Difference</span></b></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB style='font-size:11.0pt'>[95% CI]</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>NC= Failure</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>257/333</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(77.2%)</span></p>
  </td>
  <td width=66 valign=top style='width:49.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>251/331</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(75.8%)</span></p>
  </td>
  <td width=86 valign=top style='width:64.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>1.3 %</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[-5.1, 7.8]</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>216/333</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(64.9%)</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>229/331</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(69.2%)</span></p>
  </td>
  <td width=89 valign=top style='width:66.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>-4.3%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[-11.5, 2.8]</span></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Observed data</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>257/295</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(87.1%)</span></p>
  </td>
  <td width=66 valign=top style='width:49.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>250/280</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(89.3%)</span></p>
  </td>
  <td width=86 valign=top style='width:64.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>-2.2%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[-7.4, 3.1]</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>216/247</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(87.4%)</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>229/248</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>(92.3%)</span></p>
  </td>
  <td width=89 valign=top style='width:66.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>-4.9%</span></p>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>[-10.2, 0.4]</span></p>
  </td>
 </tr>
 <tr>
  <td width=159 valign=top style='width:119.4pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Mean increase from baseline in CD4+ T-cell count
  (cells/mm3)</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>186</span></p>
  </td>
  <td width=66 valign=top style='width:49.7pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>198</span></p>
  </td>
  <td width=86 valign=top style='width:64.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>238</span></p>
  </td>
  <td width=64 valign=top style='width:48.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>254</span></p>
  </td>
  <td width=89 valign=top style='width:66.6pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Through Week 96, genotypic resistance
testing results were available from 25 patients in the QD group and 26 patients
in the BID group who had incomplete virologic response. In the QD group, no
patient demonstrated lopinavir resistance, and in the BID group, 1 patient who
had significant protease inhibitor resistance at baseline demonstrated
additional lopinavir resistance on study.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Sustained virological response to Kaletra
(in combination with nucleoside/nucleotide reverse transcriptase inhibitors)
has been also observed in a small Phase II study (M97-720) through 360 weeks of
treatment. One hundred patients were originally treated with Kaletra in the
study (including 51 patients receiving 400/100&nbsp;mg twice daily and 49
patients at either 200/100&nbsp;mg twice daily or 400/200&nbsp;mg twice
daily). All patients converted to open-label Kaletra at the 400/100&nbsp;mg
twice daily dose between week 48 and week 72. <span style='color:black'>Thirty&#8209;nine
patients (39%) discontinued the study, including 16 (16%) discontinuations due
to adverse events, one of which was associated with a death. </span>Sixty&#8209;one
patients completed the study (35 patients received the recommended
400/100&nbsp;mg twice&#8209;daily dose throughout the study). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Table 3</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=536
 style='width:402.0pt;margin-left:29.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=536 colspan=2 valign=top style='width:402.0pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center;page-break-after:avoid'><b><span
  lang=EN-GB>Outcomes at Week 360: Study M97-720</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><b><span lang=EN-GB>Kaletra (N=100)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 400 copies/ml</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>61%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>HIV RNA
  &lt; 50 copies/ml</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>59%</span></p>
  </td>
 </tr>
 <tr>
  <td width=392 valign=top style='width:294.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Mean
  increase from baseline in CD4+ T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=144 valign=top style='width:1.5in;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center;page-break-after:
  avoid'><span lang=EN-GB>501</span></p>
  </td>
 </tr>
</table>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Through 360 weeks of treatment, genotypic
analysis of viral isolates was successfully conducted in 19 of 28 patients with
confirmed HIV RNA above 400&nbsp;copies/ml revealed no primary or active site
mutations in protease (amino acids at positions 8, 30, 32, 46, 47, 48, 50, 82,
84 and 90) or protease inhibitor phenotypic resistance</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUnderline style='margin:0in'><span lang=EN-GB
style='text-decoration:none'>Patients with prior antiretroviral therapy</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>M06-802 was a randomised open-label study
comparing the safety, tolerability and antiviral activity of once&#8209;daily
and twice&#8209;daily dosing of lopinavir/ritonavir tablets in 599 subjects
with detectable viral loads while receiving their current antiviral therapy.
Patients had not been on prior lopinavir/ritonavir therapy. They were
randomised in a 1:1 ratio to receive either lopinavir/ritonavir 800/200&nbsp;mg
once daily (n = 300) or lopinavir/ritonavir 400/100&nbsp;mg twice daily (n =
299). Patients were administered at least two nucleoside/nucleotide reverse
transcriptase inhibitors selected by the investigator. The enrolled population
was moderately PI-experienced with more than half of patients having never
received prior PI and around 80% of patients presenting a viral strain with
less than 3 PI mutations. Mean age of patients enrolled was 41&nbsp;years
(range: 21 to 73); 51% were Caucasian and 66% were male. Mean baseline CD4+
T-cell count was 254 cells/mm<sup>3</sup> (range: 4 to 952 cells/mm<sup>3</sup>)
and mean baseline plasma HIV-1 RNA was 4.3&nbsp;log<sub>10</sub>&nbsp;copies/ml
(range: 1.7 to 6.6&nbsp;log<sub>10</sub>&nbsp;copies/ml). Around 85% of
patients had a viral load of &lt;&nbsp;100,000&nbsp;copies/ml.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Table 4</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div align=center>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0
 style='border-collapse:collapse'>
 <tr>
  <td width=459 colspan=4 valign=top style='width:344.2pt;border:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB
  style='color:black'>Virologic Response of Study Subjects at Week 48 Study 802</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=199 valign=top style='width:149.35pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in'>
  <p class=EMEANormal><b><span lang=EN-GB style='color:black'>&nbsp;</span></b></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>QD</span></b></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>BID</span></b></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>Difference</span></b></p>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB style='color:black'>[95% CI]</span></b></p>
  </td>
 </tr>
 <tr style='height:28.35pt'>
  <td width=199 valign=top style='width:149.35pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:28.35pt'>
  <p class=EMEANormal><span lang=EN-GB style='color:black'>NC= Failure</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.35pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>171/300 (57%)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:28.35pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>161/299 (53.8%)</span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:28.35pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>3.2%</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>[-4.8%, 11.1%]</span></p>
  </td>
 </tr>
 <tr style='height:25.95pt'>
  <td width=199 valign=top style='width:149.35pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:25.95pt'>
  <p class=EMEANormal><span lang=EN-GB style='color:black'>Observed data</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>171/225 (76.0%)</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>161/223 (72.2%)</span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>3.8%</span></p>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>[-4.3%, 11.9%]</span></p>
  </td>
 </tr>
 <tr style='height:25.95pt'>
  <td width=199 valign=top style='width:149.35pt;border:solid black 1.0pt;
  border-top:none;padding:0in 0in 0in 0in;height:25.95pt'>
  <p class=EMEANormal><span lang=EN-GB>Mean increase from baseline in CD4+<sub>
  </sub>T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=80 valign=top style='width:60.0pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>135</span></p>
  </td>
  <td width=72 valign=top style='width:.75in;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 0in 0in 0in;
  height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>122</span></p>
  </td>
  <td width=108 valign=top style='width:80.85pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 0in 0in 0in;height:25.95pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB
  style='color:black'>&nbsp;</span></p>
  </td>
 </tr>
</table>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Through Week 48, genotypic resistance
testing results were available from 75 patients in the QD group and 75 patients
in the BID group who had incomplete virologic response. In the QD group, 6/75
(8%) patients demonstrated new primary protease inhibitor mutations (codons 30,
32, 48, 50, 82, 84, 90), as did 12/77 (16%) patients in the BID group.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Paediatric Use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>M98-940 was an open-label study of a
liquid formulation of Kaletra in 100 antiretroviral nave (44%) and experienced
(56%) paediatric patients. All patients were non-nucleoside reverse
transcriptase inhibitor nave. Patients were randomised to either 230&nbsp;mg
lopinavir/57.5&nbsp;mg ritonavir per m<sup>2</sup> or 300&nbsp;mg
lopinavir/75&nbsp;mg ritonavir per m<sup>2</sup>. Nave patients also received
nucleoside reverse transcriptase inhibitors. Experienced patients received
nevirapine plus up to two nucleoside reverse transcriptase inhibitors. <span
style='layout-grid-mode:line'>Safety, efficacy and pharmacokinetic profiles of
the two dose regimens were assessed after 3 weeks of therapy in each patient.
Subsequently, all patients were continued on the 300/75&nbsp;mg per m<sup>2</sup>
dose.</span> Patients had a mean age of 5&nbsp;years (range 6 months to 12
years) with 14 patients less than 2 years old and 6 patients one year or less.
Mean baseline CD4+ T-cell count was 838&nbsp;cells/mm<sup>3</sup> and mean
baseline plasma HIV-1 RNA was 4.7&nbsp;log<sub>10&nbsp;</sub>copies/ml. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Table 5</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=515
 style='width:386.5pt;margin-left:35.4pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=515 colspan=3 valign=top style='width:386.5pt;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='margin-top:6.0pt;margin-right:0in;
  margin-bottom:6.0pt;margin-left:0in;text-align:center'><b><span lang=EN-GB>Outcomes
  at Week 48: Study M98-940</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Antiretroviral Nave (N=44)</span></b></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><b><span
  lang=EN-GB>Antiretroviral Experienced (N=56)</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>HIV RNA &lt; 400 copies/ml</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>84%</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>75%</span></p>
  </td>
 </tr>
 <tr>
  <td width=200 valign=top style='width:150.0pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal><span lang=EN-GB>Mean increase from baseline in CD4+
  T-cell count (cells/mm<sup>3</sup>)</span></p>
  </td>
  <td width=168 valign=top style='width:1.75in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>404</span></p>
  </td>
  <td width=147 valign=top style='width:110.5pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>284</span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif;font-weight:normal'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif;font-weight:normal'>KONCERT/PENTA 18 is a prospective
multicentre, randomised, open-label study that evaluated the pharmacokinetic
profile, efficacy and safety of twice-daily versus once-daily dosing of
lopinavir/ritonavir 100&nbsp;mg/25&nbsp;mg tablets dosed by weight as part of
combination antiretroviral therapy (cART) in virologically suppressed HIV-1
infected children (n=173). Children were eligible when they were aged &lt;18
years, &#8805;15 kg in weight, receiving cART that included
lopinavir/ritonavir, HIV-1 ribonucleic acid (RNA) &lt;50 copies/ml for at least
24 weeks and able to swallow tablets. At week 48, the efficacy and safety with
twice-daily dosing (n=87) in the paediatric population given lopinavir/ritonavir
100&nbsp;mg/25&nbsp;mg tablets was consistent with the efficacy and safety
findings in previous adult and paediatric studies using lopinavir/ritonavir
twice daily. The percentage of patients with confirmed viral rebound &gt;50
copies/ml during 48 weeks of follow-up was higher in the paediatric patients
receiving lopinavir/ritonavir tablets once daily (12%) than in patients
receiving the twice-daily dosing (8%, p = 0.19), mainly due to lower adherence
in the once-daily group. The efficacy data favouring the twice-daily regimen
are reinforced by a differential in pharmacokinetic parameters significantly
favouring the twice-daily regimen (see section 5.2). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>5.2 Pharmacokinetic properties</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The
pharmacokinetic properties of lopinavir co-administered with ritonavir have
been evaluated in healthy adult volunteers and in HIV-infected patients; no
substantial differences were observed between the two groups. Lopinavir is
essentially completely metabolised by CYP3A. Ritonavir inhibits the metabolism
of lopinavir, thereby increasing the plasma levels of lopinavir. Across
studies, administration of Kaletra 400/100&nbsp;mg twice daily yields mean
steady-state lopinavir plasma concentrations 15 to 20-fold higher than those of
ritonavir in HIV-infected patients. The plasma levels of ritonavir are less
than 7% of those obtained after the ritonavir dose of 600&nbsp;mg twice daily.
The <i>in&nbsp;vitro</i> antiviral EC<sub>50</sub> of lopinavir is
approximately 10-fold lower than that of ritonavir. Therefore, the antiviral
activity of Kaletra is due to lopinavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Absorption</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Multiple dosing with 400/100&nbsp;mg
Kaletra twice daily for 2 weeks and without meal restriction produced a mean </span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB> SD lopinavir
peak plasma concentration (C<sub>max</sub>) of 12.3&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;5.4&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/ml, occurring
approximately 4 hours after administration. The mean steady-state trough
concentration prior to the morning dose was 8.1&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;5.7&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g/ml. Lopinavir
AUC over a 12 hour dosing interval averaged 113.2&nbsp;</span><span lang=EN-GB
style='font-family:Symbol'></span><span lang=EN-GB>&nbsp;60.5&nbsp;</span><span
lang=EN-GB style='font-family:Symbol'>m</span><span lang=EN-GB>g</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>h/ml. The
absolute bioavailability of lopinavir co-formulated with ritonavir in humans
has not been established.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Effects of food on oral absorption</span></u></p>

<p class=EMEANormal><span lang=EN-GB>Administration of a single 400/100&nbsp;mg
dose of Kaletra tablets under fed conditions (high fat, 872 kcal, 56% from fat)
compared to fasted state was associated with no significant changes in C<sub>max</sub>
and AUC<sub>inf</sub>. Therefore, Kaletra tablets may be taken with or without
food. Kaletra tablets have also shown less pharmacokinetic variability under
all meal conditions compared to Kaletra soft capsules.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><u><span lang=EN-GB>Distribution</span></u></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>At steady
state, lopinavir is approximately 98&nbsp;&#8722;&nbsp;99% bound to serum proteins.
Lopinavir binds to both alpha-1-acid glycoprotein (AAG) and albumin however, it
has a higher affinity for AAG. At steady state, lopinavir protein binding
remains constant over the range of observed concentrations after
400/100&nbsp;mg Kaletra twice daily, and is similar between healthy volunteers
and HIV-positive patients.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Biotransformation</span></u></p>

<p class=EMEANormal><i><span lang=EN-GB>In&nbsp;vitro</span></i><span
lang=EN-GB> experiments with human hepatic microsomes indicate that lopinavir
primarily undergoes oxidative metabolism. Lopinavir is extensively metabolised
by the hepatic cytochrome P450 system, almost exclusively by isozyme CYP3A.
Ritonavir is a potent CYP3A inhibitor which inhibits the metabolism of
lopinavir and therefore, increases plasma levels of lopinavir. A <sup>14</sup>C&#8209;lopinavir
study in humans showed that 89% of the plasma radioactivity after a single
400/100&nbsp;mg Kaletra dose was due to parent active substance. At least 13
lopinavir oxidative metabolites have been identified in man. The 4-oxo and
4-hydroxymetabolite epimeric pair are the major metabolites with antiviral
activity, but comprise only minute amounts of total plasma radioactivity.
Ritonavir has been shown to induce metabolic enzymes, resulting in the
induction of its own metabolism, and likely the induction of lopinavir
metabolism. Pre-dose lopinavir concentrations decline with time during
multiple dosing, stabilising after approximately 10 days to 2 weeks.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Elimination</span></u></p>

<p class=EMEANormal><span lang=EN-GB>After a 400/100&nbsp;mg <sup>14</sup>C-lopinavir/ritonavir
dose, approximately 10.4&nbsp;</span><span lang=EN-GB style='font-family:Symbol'></span><span
lang=EN-GB>&nbsp;2.3% and 82.6&nbsp;</span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>&nbsp;2.5% of an administered dose of <sup>14</sup>C-lopinavir
can be accounted for in urine and faeces, respectively. Unchanged lopinavir
accounted for approximately 2.2% and 19.8% of the administered dose in urine
and faeces, respectively. After multiple dosing, less than 3% of the lopinavir
dose is excreted unchanged in the urine. The effective (peak to trough)
half-life of lopinavir over a 12&nbsp;hour dosing interval averaged
5&nbsp;&#8722;&nbsp;6 hours, and the apparent oral clearance (CL/F) of
lopinavir is 6 to 7&nbsp;l/h.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Once&#8209;daily dosing: the
pharmacokinetics of once daily Kaletra have been evaluated in HIV-infected
subjects nave to antiretroviral treatment. Kaletra 800/200&nbsp;mg was
administered in combination with emtricitabine 200&nbsp;mg and tenofovir DF
300&nbsp;mg as part of a once&#8209;daily regimen. Multiple dosing of
800/200&nbsp;mg Kaletra once daily for 2 weeks without meal restriction (n=16)
produced a mean  SD lopinavir peak plasma concentration (C<sub>max</sub>) of
14.8  3.5&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g/ml, occurring approximately 6 hours after administration. The
mean steady-state trough concentration prior to the morning dose was
5.5&nbsp;&nbsp;5.4&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g/ml. Lopinavir AUC over a 24 hour dosing interval averaged
206.5&nbsp;&nbsp;89.7&nbsp;</span><span lang=EN-GB style='font-family:Symbol'>m</span><span
lang=EN-GB>g</span><span style='font-family:Symbol'></span><span lang=EN-GB>h/ml.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>As compared to the BID regimen, the once&#8209;daily
dosing is associated with a reduction in the C<sub>min</sub>/C<sub>trough</sub>
values of approximately 50%. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingUI style='margin:0in'><span lang=EN-GB style='text-decoration:
none'>Special Populations</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Paediatrics</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>There are limited
pharmacokinetic data in children below 2 years of age. </span><span
lang=EN-GB style='font-size:11.0pt'>The pharmacokinetics of Kaletra 100/25&nbsp;mg
tablet twice-daily weight-band dosing without nevirapine have been studied in a
total of 53 paediatric patients. The lopinavir mean &nbsp;standard deviation
steady-state AUC, C<sub>max</sub> and C<sub>12</sub> were 112.5&nbsp;&nbsp;37.1&nbsp;&#956;g</span><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'></span><span
lang=EN-GB style='font-size:11.0pt'>h/ml, 12.4&nbsp;&nbsp;3.5&nbsp;&#956;g/ml
and 5.71&nbsp;&nbsp;2.99&nbsp;&#956;g/ml, respectively. The twice-daily
weight-band dosing </span><span lang=EN-GB style='font-size:11.0pt'>without
nevirapine provided lopinavir plasma concentrations similar to those obtained
in</span><span lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB
style='font-size:11.0pt'>adult patients receiving the 400/100&nbsp;mg twice&#8209;daily
regimen without nevirapine. </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Gender, Race and
Age </span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra pharmacokinetics have not been
studied in older people. No age or gender related pharmacokinetic differences
have been observed in adult patients. Pharmacokinetic differences due to race
have not been identified.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Pregnancy and postpartum</span></p>

<p class=EMEANormal style='page-break-after:avoid'>In an open-label
pharmacokinetic study, 12 HIV-infected pregnant women who were less than 20
weeks of gestation and on combination antiretroviral therapy initially received
lopinavir/ritonavir 400 mg/100 mg (two 200/50 mg tablets) twice daily up to a
gestational age of 30 weeks. At 30 weeks age of gestation, the dose was
increased to 500/125 mg (two 200/50 mg tablets plus one 100/25 mg tablet) twice
daily until subjects were 2 weeks postpartum. Plasma concentrations of
lopinavir were measured over four 12-hour periods during second trimester
(20-24 weeks gestation), third trimester before dose increase (30 weeks
gestation), third trimester after dose increase (32 weeks gestation), and at 8
weeks post-partum. The dose increase did not result in a significant increase
in the plasma lopinavir concentration. </p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>In another open-label pharmacokinetic study, 19
HIV-infected pregnant women received lopinavir/ritonavir 400/100 mg twice daily
as part of combination antiretroviral therapy during pregnancy from before
conception. A series of blood samples were collected pre-dose and at intervals
over the course of 12 hours in trimester 2 and trimester 3, at birth, and 46
weeks postpartum (in women who continued treatment post-delivery) for
pharmacokinetic analysis of total and unbound levels of plasma lopinavir
concentrations.</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>The pharmacokinetic data from HIV-1 infected pregnant women
receiving lopinavir/ritonavir tablets 400/100 mg twice daily are presented in
Table 6 (see section 4.2).</p>

<p class=EMEANormal>&nbsp;</p>

<p class=EMEANormal>Table 6</p>

<p class=EMEANormal>&nbsp;</p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='margin-left:4.65pt;border-collapse:collapse;border:none'>
 <tr style='height:25.15pt'>
  <td width=638 colspan=4 style='width:6.65in;border:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.15pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Mean (%CV) Steady-State Pharmacokinetic
  Parameters of </span></b><b><span lang=EN-GB style='font-size:11.0pt'>Lopinavir
  <br>
  in HIV-Infected Pregnant Women</span></b></p>
  </td>
 </tr>
 <tr style='height:26.5pt'>
  <td width=191 style='width:143.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:26.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Pharmacokinetic<br>
  Parameter</span></b></p>
  </td>
  <td width=158 style='width:118.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>2nd Trimester<br>
  n = 17*</span></b></p>
  </td>
  <td width=154 style='width:115.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>3rd Trimester<br>
  n = 23</span></b></p>
  </td>
  <td width=135 style='width:101.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:26.5pt'>
  <p class=MsoNormal align=center style='text-align:center'><b><span
  lang=EN-GB style='font-size:11.0pt'>Postpartum<br>
  n = 17**</span></b></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=191 nowrap style='width:143.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center;text-autospace:none'><span
  lang=EN-GB style='font-size:11.0pt'>AUC<sub>0-12</sub> &#956;g</span><span
  lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB
  style='font-size:11.0pt'>hr/mL</span></p>
  </td>
  <td width=158 nowrap style='width:118.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>68.7 (20.6)</span></p>
  </td>
  <td width=154 nowrap style='width:115.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>61.3 (22.7)</span></p>
  </td>
  <td width=135 nowrap style='width:101.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>94.3 (30.3)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=191 nowrap style='width:143.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>C<sub>max</sub></span></p>
  </td>
  <td width=158 nowrap style='width:118.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>7.9 (21.1)</span></p>
  </td>
  <td width=154 nowrap style='width:115.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>7.5 (18.7)</span></p>
  </td>
  <td width=135 nowrap style='width:101.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>9.8 (24.3)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=191 nowrap style='width:143.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>C<sub>predose</sub> &#956;g /mL</span></p>
  </td>
  <td width=158 nowrap style='width:118.75pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>4.7 (25.2)</span></p>
  </td>
  <td width=154 nowrap style='width:115.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>4.3 (39.0)</span></p>
  </td>
  <td width=135 nowrap style='width:101.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
  style='font-size:11.0pt'>6.5 (40.4)</span></p>
  </td>
 </tr>
 <tr style='height:12.75pt'>
  <td width=638 nowrap colspan=4 style='width:6.65in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>* n = 18 for C<sub>max
  </sub>** n = 16 for C<sub>predose</sub></span></p>
  </td>
 </tr>
</table>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Renal
Insufficiency </span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra pharmacokinetics have not been
studied in patients with renal insufficiency; however, since the renal
clearance of lopinavir is negligible, a decrease in total body clearance is not
expected in patients with renal insufficiency.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span lang=EN-GB>Hepatic
Insufficiency</span></p>

<p class=EMEANormal><span lang=EN-GB>The steady state pharmacokinetic
parameters of lopinavir in HIV-infected patients with mild to moderate hepatic
impairment were compared with those of HIV-infected patients with normal
hepatic function in a multiple dose study with lopinavir/ritonavir
400/100&nbsp;mg twice daily. A limited increase in total lopinavir
concentrations of approximately 30% has been observed which is not expected to
be of clinical relevance (see section 4.2).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>5.3 Preclinical
safety data</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB
style='layout-grid-mode:line'>Repeat-dose toxicity studies in rodents and dogs
identified major target organs as the liver, kidney, thyroid, spleen and
circulating red blood cells. Hepatic changes indicated cellular swelling with
focal degeneration. While exposure eliciting these changes were comparable to
or below human clinical exposure, dosages in animals were over 6-fold the
recommended clinical dose. Mild renal tubular degeneration was confined to
mice exposed with at least twice the recommended human exposure; the kidney was
unaffected in rats and dogs. Reduced serum thyroxin led to an increased
release of TSH with resultant follicular cell hypertrophy in the thyroid glands
of rats. These changes were reversible with withdrawal of the active substance
and were absent in mice and dogs. Coombs-negative anisocytosis and
poikilocytosis were observed in rats, but not in mice or dogs. Enlarged
spleens with histiocytosis were seen in rats but not other species. Serum
cholesterol was elevated in rodents but not dogs, while triglycerides were
elevated only in mice. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>During <i>in&nbsp;vitro</i> studies,
cloned human cardiac potassium channels (HERG) were inhibited by 30% at the
highest concentrations of lopinavir/ritonavir tested, corresponding to a
lopinavir exposure 7-fold total and 15-fold free peak plasma levels achieved in
humans at the maximum recommended therapeutic dose. In contrast, similar
concentrations of lopinavir/ritonavir demonstrated no repolarisation delay in
the canine cardiac Purkinje fibres. Lower concentrations of lopinavir/ritonavir
did not produce significant potassium (HERG) current blockade. Tissue
distribution studies conducted in the rat did not suggest significant cardiac
retention of the active substance; 72-hour AUC in heart was approximately 50%
of measured plasma AUC. Therefore, it is reasonable to expect that cardiac
lopinavir levels would not be significantly higher than plasma levels.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>In dogs,
prominent U waves on the electrocardiogram have been observed associated with
prolonged PR interval and bradycardia. These effects have been assumed to be
caused by electrolyte disturbance. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>The clinical
relevance of these preclinical data is unknown, however, the potential cardiac
effects of this product in humans cannot be ruled out (see also sections 4.4
and 4.8). </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>In rats,
embryofoetotoxicity (pregnancy loss, decreased foetal viability, decreased
foetal body weights, increased frequency of skeletal variations) and postnatal
developmental toxicity (decreased survival of pups) was observed at maternally
toxic dosages. The systemic exposure to lopinavir/ritonavir at the maternal
and developmental toxic dosages was lower than the intended therapeutic
exposure in humans. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Long-term
carcinogenicity studies of lopinavir/ritonavir in mice revealed a nongenotoxic,
mitogenic induction of liver tumours, generally considered to have little
relevance to human risk. </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Carcinogenicity
studies in rats revealed no tumourigenic findings. Lopinavir/ritonavir was not
found to be mutagenic or clastogenic in a battery of <i>in&nbsp;vitro</i> and <i>in&nbsp;vivo</i>
assays including the Ames bacterial reverse mutation assay, the mouse lymphoma
assay, the mouse micronucleus test and chromosomal aberration assays in human
lymphocytes.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6. Pharmaceutical particulars</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.1 List of excipients</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB>Tablet contents</span></u><span
lang=EN-GB>: </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Copovidone</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Sorbitan
laurate</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Colloidal
anhydrous silica</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Sodium
stearyl fumarate</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><u><span lang=EN-GB style='layout-grid-mode:line'>Film-coating</span></u><span
lang=EN-GB style='layout-grid-mode:line'>: </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Polyvinyl
alcohol</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Titanium
dioxide</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Talc </span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Macrogols
type 3350 (Polyethylene glycol 3350)</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Red ferric oxide
E172</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>6.2 Incompatibilities</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Not
applicable.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.3 Shelf life</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>3 years.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.4 Special precautions for storage</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>This medicinal product does not require
any special storage conditions.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.5 Nature and contents of container</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>High density polyethylene (HDPE) bottles
closed with propylene caps. </span></p>

<p class=EMEANormal><span lang=EN-GB>Bottle containing 60 film-coated tablets.
</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>6.6 Special precautions for disposal</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>No special requirements.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>7. MARKETING AUTHORISATION HOLDER</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>8. MARKETING AUTHORISATION NUMBERS</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/006</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>9. Date of first authorisation/renewal of THE authorisation</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Date of first authorisation: 20 March 2001</span></p>

<p class=EMEANormal><span lang=EN-GB>Date of latest renewal: 20 March 2011</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1 style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>10. Date of revision of the text</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Detailed information on this product </span><span
lang=EN-GB>is available on the website of the European Medicines Agency </span><a
href="http://www.ema.europa.eu"><span lang=EN-GB>http://www.ema.europa.eu</span></a></p>

<p class=EMEAHeadingLeaflet style='margin-top:0in;margin-right:0in;margin-bottom:
12.0pt;margin-left:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX
II</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default style='margin-left:78.0pt;text-indent:-21.3pt'><b><span
lang=EN-GB style='font-size:11.0pt'>A. MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE </span></b></p>

<p class=Default style='margin-left:78.0pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:78.0pt;text-indent:-21.3pt'><b><span
lang=EN-GB style='font-size:11.0pt'>B. CONDITIONS OR RESTRICTIONS REGARDING
SUPPLY AND </span></b></p>

<p class=Default style='margin-left:78.0pt;text-indent:-21.3pt'><b><span
lang=EN-GB style='font-size:11.0pt'> USE </span></b></p>

<p class=Default style='margin-left:78.0pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:78.0pt;text-indent:-21.3pt'><b><span
lang=EN-GB style='font-size:11.0pt'>C.  OTHER CONDITIONS AND REQUIREMENTS OF
THE </span></b></p>

<p class=Default style='margin-left:78.0pt;text-indent:-21.3pt'><b><span
lang=EN-GB style='font-size:11.0pt'> MARKETING AUTHORISATION </span></b></p>

<p class=Default style='margin-left:78.0pt;text-indent:-21.3pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:49.5pt;margin-bottom:
0in;margin-left:78.0pt;margin-bottom:.0001pt;text-indent:-21.3pt'><b><span
lang=EN-GB style='font-size:11.0pt'>D.  CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<h2 style='margin-left:1.25in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></h2>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:88.0pt;margin-bottom:.0001pt;text-indent:-31.3pt'><b><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:12.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=BMLeftAligned><span lang=EN-GB style='font-size:11.0pt'>A. MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal><u><span lang=EN-GB style='font-size:11.0pt'>Name and
address of the manufacturer(s) responsible for batch release</span></u></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB
style='font-size:11.0pt'>Kaletra oral solution:</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='font-size:11.0pt'>AbbVie Logistics B.V., Zuiderzeelaan 53, 8017 JV
Zwolle, The Netherlands</span></p>

<p class=MsoNormal style='text-align:justify'><span lang=DE style='font-size:
11.0pt'>AbbVie Deutschland GmbH &amp; Co. KG, <span style='layout-grid-mode:
line'>Knollstrasse, 67061 Ludwigshafen, Germany</span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=DE
style='font-size:11.0pt'>Kaletra 200 mg/50 mg film-coated tablets and Kaletra 100
mg/25 mg film-coated tablets:</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=DE style='font-size:
11.0pt'>AbbVie Deutschland GmbH &amp; Co. KG, <span style='layout-grid-mode:
line'>Knollstrasse, 67061 Ludwigshafen, Germany</span></span></p>

<p class=MsoNormal style='text-align:justify'><span lang=DE style='font-size:
11.0pt;layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='text-align:justify'><u><span lang=EN-GB
style='font-size:11.0pt;layout-grid-mode:line'>Kaletra 200 mg/50 mg film-coated
tablets:</span></u></p>

<p class=MsoNormal style='text-align:justify'><span lang=EN-GB
style='font-size:11.0pt'>Fournier Laboratories Ireland Limited, Carrigtwohill
Business Park, Anngrove, Carrigtwohill, Co. Cork, Ireland</span></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB>The printed package leaflet of the
medicinal product must state the name and address of the manufacturer responsible
for the release of the concerned batch.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=BMLeftAligned><span lang=EN-GB style='font-size:11.0pt'>B. CONDITIONS
</span><span lang=EN-GB style='font-size:11.0pt'>OR RESTRICTIONS REGARDING
SUPPLY AND USE</span></p>

<p class=EMEANormal style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Medicinal product subject to medical
prescription.</span></p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BMLeftAligned style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>C. OTHER CONDITIONS AND REQUIREMENTS
OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<h4 style='margin-left:28.35pt;text-indent:-28.35pt'><span lang=EN-GB
style='font-family:Symbol;font-style:normal'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-style:normal'>Periodic safety update
reports (PSURs)</span></b></h4>

<p class=MsoNormal style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>The requirements for
submission of PSURs for this medicinal product are set out in the list of Union
reference dates (EURD list) provided for under Article 107c(7) of Directive
2001/83/EC and any subsequent updates published on the European medicines web&#8209;portal.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=BMLeftAligned style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt'>D. CONDITIONS OR RESTRICTIONS WITH
REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT </span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='font-size:11.0pt'>Risk management plan
(RMP) </span></b></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEAHeadingItalic style='margin:0in'><span style='font-style:normal'>The
marketing authorisation holder (MAH) shall perform the required
pharmacovigilance activities and interventions detailed in the agreed RMP
presented in Module 1.8.2 of the marketing authorisation and any agreed
subsequent updates of the RMP.</span></p>

<p class=EMEANormal>&nbsp;</p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB>An updated RMP
should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:1.4pt;
margin-left:.5in;text-indent:-.25in;text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>At the
request of the European Medicines Agency; </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:1.4pt;
margin-left:.5in;text-indent:-.25in;text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;font-family:Symbol;color:black'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt;color:black'>Whenever
the risk management system is modified, especially as the result of new
information being received that may lead to a significant change to the
benefit/risk profile or as the result of an important (pharmacovigilance or
risk minimisation) milestone being reached. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEATitle><span lang=EN-GB style='font-family:"Times New Roman",serif'>ANNEX
III</span></p>

<p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading1Para1 align=center style='margin-bottom:12.0pt;text-align:
center'><span lang=EN-GB style='font-family:"Times New Roman",serif'>LABELLING</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> AND PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=BMCENTRED><span lang=EN-GB>A. LaBELLING</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING </span></p>

<p class=EMEAHeadingBoxedTitle style='margin-top:12.0pt;margin-right:0in;
margin-bottom:0in;margin-left:30.05pt;text-indent:-30.05pt'><span lang=EN-GB
style='text-transform:none'>Oral solution - Carton </span><span lang=EN-GB
style='text-transform:none'>containing 300 ml (5 bottles x 60 ml) oral solution
</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=FR>Kaletra (80 mg&nbsp;+&nbsp;20
mg)&nbsp;/&nbsp;ml oral solution</span></p>

<p class=EMEANormal><span lang=FR>(lopinavir&nbsp;+&nbsp;ritonavir)</span></p>

<p class=EMEANormal><span lang=FR>For adults and children weighing greater than
15 kg.</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each ml contains: lopinavir 80&nbsp;mg and
ritonavir 20&nbsp;mg.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Includes: alcohol, high fructose corn
syrup, propylene glycol, glycerol, polyoxyl 40 hydrogenated castor oil,
potassium (as acesulfame potassium).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>300&nbsp;ml (5 bottles x 60&nbsp;ml) <span
style='background:lightgrey'>oral solution</span> with five <b>5 ml</b> oral
dosing syringes.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>For volumes greater than 2&nbsp;ml.</span></p>

<p class=EMEANormal><span lang=EN-GB>Use the 5&nbsp;ml oral dosing syringe to
prepare a dose.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL WARNING(S),
IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>Store in a refrigerator</span></b></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/003</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON
USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra </span><span lang=FR>(80
mg&nbsp;+&nbsp;20 mg)&nbsp;/&nbsp;ml </span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. UNIQUE IDENTIFIER  2D
BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>2D barcode carrying the unique
identifier included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. UNIQUE IDENTIFIER  HUMAN
READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>PC</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>SN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>NN</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON
THE OUTER PACKAGING </span></p>

<p class=EMEAHeadingBoxedTitle style='margin-top:12.0pt;margin-right:0in;
margin-bottom:0in;margin-left:0in'><span lang=EN-GB style='text-transform:none'>Oral
solution - Carton </span><span lang=EN-GB style='text-transform:none'>containing
120&nbsp;ml (2 bottles x 60 ml) oral solution </span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=FR>Kaletra (80 mg&nbsp;+&nbsp;20
mg)&nbsp;/&nbsp;ml oral solution</span></p>

<p class=EMEANormal><span lang=FR>(lopinavir&nbsp;+&nbsp;ritonavir)</span></p>

<p class=EMEANormal><span lang=FR>For children 2 weeks or older and weighing up
to 15 kg</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each ml contains: lopinavir 80&nbsp;mg and
ritonavir 20&nbsp;mg.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Includes: alcohol, high fructose corn
syrup, propylene glycol, glycerol, polyoxyl 40 hydrogenated castor oil,
potassium (as acesulfame potassium).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>120&nbsp;ml (2 bottles x 60&nbsp;ml) <span
style='background:lightgrey'>oral solution</span> with two <b>2&nbsp;ml</b>
oral dosing syringes.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>For volumes up to 2 ml.</span></p>

<p class=EMEANormal><span lang=EN-GB>Use the 2&nbsp;ml oral dosing syringe to
prepare a dose.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL WARNING(S),
IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE
CONDITIONS</span></p>

</div>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Store in
a refrigerator</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/009</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON
USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra </span><span lang=FR>(80
mg&nbsp;+&nbsp;20 mg)&nbsp;/&nbsp;ml </span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. UNIQUE IDENTIFIER  2D
BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;color:black;background:#BFBFBF'>2D barcode carrying the
unique identifier included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. UNIQUE IDENTIFIER  HUMAN READABLE
DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>PC</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>SN</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;color:black;background:#BFBFBF'>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE
IMMEDIATE PACKAGING</span></p>

<p class=EMEAHeadingBoxedEmpty style='margin-top:12.0pt;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='text-transform:none'>Oral Solution  Bottle label</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=FR>Kaletra (80&nbsp;mg&nbsp;+&nbsp;20&nbsp;mg) /
ml oral solution</span></p>

<p class=EMEANormal><span lang=FR>(lopinavir&nbsp;+&nbsp;ritonavir)</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each ml contains lopinavir 80&nbsp;mg and
ritonavir 20&nbsp;mg.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>3. LIST OF EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Includes: alcohol (42&nbsp;%&nbsp;v/v see
leaflet), high fructose corn syrup, propylene glycol, glycerol, polyoxyl 40
hydrogenated castor oil, potassium (as acesulfame potassium).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>60&nbsp;ml <span style='background:lightgrey'>oral
solution</span></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>Important to open</span></p>

<p class=EMEANormal><span lang=EN-GB>Make sure you have the correct syringe for
the dose.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL WARNING(S),
IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE
CONDITIONS</span></p>

</div>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Store in
a refrigerator</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>In use
storage: If kept outside of the refrigerator, do not store above 25</span><span
lang=EN-GB style='font-family:Symbol'></span><span lang=EN-GB>C and discard
any unused contents after 42 days (6 weeks). It is advised to write the date
of removal from the refrigerator on the package. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>10. SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>AbbVie (logo)</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON
USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. </span><span
style='font-weight:normal'>UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. </span><span
style='font-weight:normal'>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='text-transform:none'>200 mg/50 mg tablets  Carton of 1 bottle</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><sub><span lang=EN-GB
style='font-family:"Times New Roman",serif'></span></sub><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
200&nbsp;mg of lopinavir co-formulated with 50&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>3. LIST OF
EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>120 film-coated tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE
CONDITIONS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;border:none;padding:0in'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/004</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. UNIQUE IDENTIFIER  2D
BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>2D barcode carrying the unique
identifier included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. UNIQUE IDENTIFIER  HUMAN
READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>PC</span></p>

<p class=EMEANormal>SN</p>

<p class=EMEANormal><span style='background:lightgrey'>NN</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in'><span lang=EN-GB
style='text-transform:none'>200 mg/50 mg Tablets  Carton of multipack containing
360 (3 bottles of 120) film-coated tablets  including blue box</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><sub><span lang=EN-GB
style='font-family:"Times New Roman",serif'></span></sub><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
200&nbsp;mg of lopinavir co-formulated with 50&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>3. LIST OF
EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Multipack: 360 (3 bottles of 120)
film-coated tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>3 month pack</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE
CONDITIONS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;border:none;padding:0in'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS
OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/007</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg tablets</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. UNIQUE IDENTIFIER  2D
BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>2D barcode carrying the unique
identifier included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. UNIQUE IDENTIFIER  HUMAN
READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>PC</span></p>

<p class=EMEANormal>SN</p>

<p class=EMEANormal><span style='background:lightgrey'>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE ON THE
IMMEDIATE PACKAGING</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='text-transform:none'>200 mg/50 mg tablets  Bottle label</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
200&nbsp;mg of lopinavir co-formulated with 50&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>3. LIST OF
EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>120 film-coated tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/004</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/007</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. </span><span
style='font-weight:normal'>UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:#CCCCCC'>Not applicable</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. </span><span
style='font-weight:normal'>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span style='color:black;background:#CCCCCC'>Not applicable</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:none'>Outer carton of
multipacks of 120 (3 cartons of 40 film-coated 200 mg/50 mg film-coated tablets)
- including the blue box </span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:none'>Carton of
blister pack containing 120 200 mg/50 mg film-coated tablets</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
200&nbsp;mg of lopinavir co-formulated with 50&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>3. LIST OF
EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Multipack: 120 (3 packs of 40) film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB style='background:lightgrey'>120 film-coated
tablets</span><span lang=EN-GB> </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL WARNING(S),
IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/005 <span style='background:
lightgrey'> multipack: 120 (3 packs of 40) film-coated tablets</span></span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/008 <span style='background:
lightgrey'> carton of 120 film-coated tablets</span></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>2D barcode carrying the unique
identifier included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. UNIQUE IDENTIFIER  HUMAN
READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>PC</span></p>

<p class=EMEANormal>SN</p>

<p class=EMEANormal><span style='background:lightgrey'>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE InTERMEDIATE
CARTON </span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='text-transform:none'>Inner carton of multipack of </span><span
lang=EN-GB style='font-family:"Times New Roman",serif'>120</span><span
lang=EN-GB style='text-transform:none'> (3 packs of 40) 200 mg/50 mg film-coated
tablets)  without blue box</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
200&nbsp;mg of lopinavir co-formulated with 50&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>3. LIST OF
EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>40 film-coated tablets. Component of a
multipack, cant be sold separately. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL WARNING(S),
IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp; Co.
KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/005</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>15</span><span lang=EN-GB
style='font-family:"Times New Roman",serif;text-transform:none'>.</span><span
lang=EN-GB style='font-family:"Times New Roman",serif'> INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg tablets</span></p>

<p class=MsoNormal><span lang=EN-GB style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. </span><span
style='font-weight:normal'>UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:#CCCCCC'>Not applicable</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. </span><span
style='font-weight:normal'>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span style='color:black;background:#CCCCCC'>Not applicable</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>MINIMUM PARTICULARS TO APPEAR ON
BLISTERS OR STRIPS</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='text-transform:none'>200 mg/50 mg tablets  Blister of 8 film-coated
tablets or Blister of 12 film-coated tablets</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 200&nbsp;mg/50&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. NAME OF THE MARKETING
AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>AbbVie </span><span lang=EN-GB
style='background:lightgrey'>(as logo)</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>3. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 0in'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;border:none;padding:0in'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>4. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin:0in;text-indent:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-family:"Times New Roman",serif'>OTHER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
text-transform:uppercase'><br clear=all style='page-break-before:always'>
</span></b>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE OUTER
PACKAGING </span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='text-transform:none'>100 mg/ 25 mg tablets  Carton of 1 bottle</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 100&nbsp;mg/25&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><sub><span lang=EN-GB
style='font-family:"Times New Roman",serif'></span></sub><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
100&nbsp;mg of lopinavir co-formulated with 25&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>3. LIST OF
EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>60 film-coated tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE
CONDITIONS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 2.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in;page-break-after:avoid;
border:none;padding:0in'><span lang=EN-GB style='font-family:"Times New Roman",serif'>11. NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp; Co.
KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/006</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 100&nbsp;mg/25&nbsp;mg tablets</span></p>

<p class=EMEANormal><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. UNIQUE IDENTIFIER  2D
BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>2D barcode carrying the unique
identifier included.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. UNIQUE IDENTIFIER  HUMAN
READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>PC</span></p>

<p class=EMEANormal>SN</p>

<p class=EMEANormal><span style='background:lightgrey'>NN</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>PARTICULARS TO APPEAR ON THE ON THE
IMMEDIATE PACKAGING</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='text-transform:none'>100 mg/25 mg tablets - bottle label</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>1. NAME OF THE MEDICINAL
PRODUCT</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra 100&nbsp;mg/25&nbsp;mg film-coated
tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>2. STATEMENT OF ACTIVE
SUBSTANCE(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Each film-coated tablet contains
100&nbsp;mg of lopinavir co-formulated with 25&nbsp;mg of ritonavir as a
pharmacokinetic enhancer.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>3. LIST OF
EXCIPIENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>4. PHARMACEUTICAL FORM AND
CONTENTS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>60 film-coated tablets</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>5. METHOD AND ROUTE(S) OF
ADMINISTRATION</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=EMEANormal><span lang=EN-GB>Oral use</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>6. SPECIAL WARNING THAT THE
MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Keep out of the sight and reach of
children.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedEmpty style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:28.05pt;margin-bottom:.0001pt;text-indent:-28.05pt'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>7. OTHER SPECIAL
WARNING(S), IF NECESSARY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxed style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.05pt;text-indent:-28.05pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>8. EXPIRY DATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EXP</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>9. SPECIAL STORAGE CONDITIONS</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:27.5pt;text-indent:-27.5pt'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>10. SPECIAL PRECAUTIONS FOR
DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH
MEDICINAL PRODUCTS, IF APPROPRIATE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>11. NAME AND ADDRESS OF THE
MARKETING AUTHORISATION HOLDER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>Knollstrasse</span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>67061 Ludwigshafen</span></p>

<p class=EMEANormal><span lang=EN-GB>Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>12. MARKETING AUTHORISATION
NUMBER(S)</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>EU/1/01/172/006</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>13. BATCH NUMBER</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Lot</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>14. GENERAL CLASSIFICATION FOR
SUPPLY</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>15. INSTRUCTIONS ON USE</span></p>

</div>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>16. Information in braille</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>17. </span><span
style='font-weight:normal'>UNIQUE IDENTIFIER  2D BARCODE</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black;
background:#CCCCCC'>Not applicable</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=EMEAHeadingBoxedTitle style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>18. </span><span
style='font-weight:normal'>UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></p>

</div>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span style='color:black;background:#CCCCCC'>Not applicable</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=BMCENTRED><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB></span></p>

<p class=EMEAHeadingLeaflet align=center style='margin:0in;text-align:center'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Package leaflet:
Information for the user</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal align=center style='text-align:center'><b><span lang=FR>Kaletra
(80&nbsp;mg&nbsp;+&nbsp;20&nbsp;mg)&nbsp;/&nbsp;ml oral solution</span></b></p>

<p class=EMEANormal align=center style='text-align:center'><span lang=FR>(lopinavir&nbsp;+&nbsp;ritonavir)</span></p>

<p class=EMEANormal align=center style='text-align:center'><span lang=FR>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you or your child.</span></b></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you or
your child only. Do not pass it on to others. It may harm them, even if their
signs of illness are the same as yours.</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=EMEANormal><span lang=EN-GB>1. What Kaletra is and what it is
used for</span></p>

<p class=EMEANormal><span lang=EN-GB>2. What you need to know before you or
your child takes Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>3. How to take Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEANormal><span lang=EN-GB>5. How to store Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>1. <b>What
Kaletra is and what it is used for</b></span></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Your doctor has prescribed Kaletra to help to control your Human
Immunodeficiency Virus (HIV) infection. Kaletra does this by slowing down the
spread of the infection in your body.</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Kaletra is not a cure for HIV infection or AIDS.</p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra is used by children 14 days of age and older,
adolescents and adults who are infected with HIV, the virus which causes AIDS.
</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Kaletra contains the active substances <span lang=EN-GB>lopinavir
and ritonavir.</span> <span lang=EN-GB>Kaletra is an antiretroviral medicine.
It belongs to a group of medicines called protease inhibitors.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra is prescribed for use in combination
with other antiviral medicines. Your doctor will discuss with you and determine
which medicines are best for you.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>2. What
you need to know before you or your child takes Kaletra</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Do not take Kaletra</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to lopinavir, ritonavir or
any of the other ingredients of Kaletra (see section 6); </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have severe liver problems.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Do not take Kaletra with any of the following medicines:</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>astemizole or terfenadine (commonly used to
treat allergy symptoms  these medicines may be available without
prescription);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>midazolam taken orally (taken by mouth),
triazolam (used to relieve anxiety and/or trouble sleeping);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pimozide (used to treat schizophrenia);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lurasidone (used to treat depression);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ranolazine (used to treat chronic chest pain
[angina]);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cisapride (used to relieve certain stomach
problems);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ergotamine, dihydroergotamine, ergonovine,
methylergonovine (used to treat headaches);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amiodarone, dronedarone (used to treat abnormal
heart beat);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lovastatin, simvastatin (used to lower blood
cholesterol);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lomitapide (used to lower blood cholesterol);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alfuzosin (used in men to treat symptoms of an
enlarged prostate (benign prostatic hyperplasia (BPH));</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fusidic acid (used to treat skin infections
caused by <i>Staphylococcus</i> bacteria such as impetigo and infected
dermatitis). Fusidic acid used to treat long-term infections of the bones and
joints may be taken under doctors supervision (see <b>Other medicines and
Kaletra</b> section);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine (used to treat gout) if you have
kidney and/or liver problems (see the section on <b>Other medicines and Kaletra</b>);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>elbasvir/grazoprevir (used to treat chronic
hepatitis C virus [HCV]);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ombitasvir/paritaprevir/ritonavir with or
without dasabuvir (used to treat chronic hepatitis C virus [HCV]);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>neratinib (used to treat breast cancer);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>avanafil or vardenafil (used to treat erectile
dysfunction);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sildenafil used to treat pulmonary arterial
hypertension (high blood pressure in the pulmonary artery). Sildenafil used to
treat erectile dysfunction may be taken under doctors supervision (see <b>Other
medicines and Kaletra</b> section);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>products that contain St Johns wort (<i>Hypericum
perforatum</i>).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Read the list of medicines below under
Other medicines and Kaletra </span></b><span lang=EN-GB>for information on
certain other medicines which require special care.</span></p>

<p class=EMEANormal style='margin-left:30.0pt;text-indent:-30.0pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB>If you are currently taking any of these
medicines, ask your doctor about making necessary changes either in the
treatment for your other condition(s) or in your antiretroviral treatment. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Warnings and precautions</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Talk to your doctor or pharmacist before
taking Kaletra.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Important information</span></b></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>People taking Kaletra may still develop
infections or other illnesses associated with HIV disease and AIDS. It is
therefore important that you remain under the supervision of your doctor while
taking Kaletra. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>You can still pass on HIV when taking this medicine</span></b><span
lang=EN-GB>, although the risk is lowered by effective antiretroviral therapy.
Discuss with your doctor the precautions needed to avoid infecting other people.</span></p>

<p class=EMEABullet style='margin-left:28.35pt;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tell your doctor if you or your
child have/had</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Haemophilia</span></b><span lang=EN-GB> type
A and B as Kaletra might increase the risk of bleeding.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diabetes</span></b><span lang=EN-GB> as
increased blood sugars has been reported in patients receiving Kaletra.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A history of <b>liver problems</b> as patients
with a history of liver disease, including chronic hepatitis B or C are at
increased risk of severe and potentially fatal liver side effects.</span></p>

<p class=EMEAHeadingLeaflet style='margin-top:0in;margin-right:0in;margin-bottom:
0in;margin-left:28.35pt;text-indent:-28.35pt'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-weight:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tell your doctor if you or your
child experience</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-weight:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, vomiting, abdominal pain, difficulty
breathing and severe weakness of the muscles in the legs and arms as these symptoms
may indicate raised lactic acid levels.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Thirst, frequent urination, blurred vision or
weight loss as this may indicate raised sugar levels in the blood.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, vomiting, abdominal pain as large
increases in the amount of triglycerides (fats in the blood) have been
considered a risk factor for pancreatitis (inflammation of the pancreas) and
these symptoms may suggest this condition.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In some patients with advanced HIV infection and
a history of opportunistic infection, signs and symptoms of inflammation from
previous infections may occur soon after anti-HIV treatment is started. It is
believed that these symptoms are due to an improvement in the bodys immune
response, enabling the body to fight infections that may have been present with
no obvious symptoms.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections,
autoimmune disorders (a condition that occurs when the immune system attacks
healthy body tissue) may also occur after you start taking medicines for the
treatment of your HIV infection. Autoimmune disorders may occur many months
after the start of treatment. If you notice any symptoms of infection or other
symptoms such as muscle weakness, weakness beginning in the hands and feet and
moving up towards the trunk of the body, palpitations, tremor or hyperactivity,
please inform your doctor immediately to seek necessary treatment.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Joint stiffness, aches and pains </span></b><span
lang=EN-GB>(especially of the hip, knee and shoulder) and difficulty in
movement<b> </b>as some patients taking these medicines may develop a bone
disease called osteonecrosis (death of bone tissue caused by loss of blood
supply to the bone). The length of combination</span><span lang=EN-GB>
antiretroviral therapy, corticosteroid use, alcohol consumption, severe
immunosuppression (reduction in the activity of the immune system), higher body
mass index, among others, may be some of the many risk factors for developing
this disease. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Muscle pain, </span></b><span lang=EN-GB>tenderness
or weakness, particularly in combination with these medicines. On rare
occasions these muscle disorders have been serious. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Symptoms of dizziness, lightheadedness, fainting
or sensation of abnormal heartbeats. Kaletra may cause changes in your heart
rhythm and the electrical activity of your heart. These changes may be seen on
an ECG (electrocardiogram).</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Other medicines and Kaletra</span></p>

<p class=EMEANormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=EMEANormal><b><span lang=EN-GB>Tell your doctor or pharmacist if you or
your child are taking, have recently taken or might take any other medicines. </span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antibiotics (e.g.&nbsp;rifabutin, rifampicin,
clarithromycin);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticancer medicines (e.g. abemaciclib, afatinib,
apalutamide, ceritinib, encorafenib, ibrutinib, venetoclax, most tyrosine
kinases inhibitors such as dasatinib and nilotinib, also vincristine and
vinblastine);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticoagulants (e.g. warfarin, rivaroxaban,
vorapaxar);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antidepressants (e.g. trazodone, bupropion);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti-epilepsy medicines (e.g. carbamazepine,
phenytoin, phenobarbital, lamotrigine and valproate);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>antifungals (e.g.&nbsp;ketoconazole, itraconazole,
voriconazole);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti-gout medicines (e.g. colchicine). You must
not take Kaletra with colchicine if you have kidney and/or liver problems (see
also <b>Do not take Kaletra</b> above);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti&#8209;tuberculosis medicine (bedaquiline,
delamanid);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antiviral medicine used to treat chronic
hepatitis C virus (HCV) infection in adults (e.g. glecaprevir/pibrentasvir, simeprevir
and sofosbuvir/velpatasvir/voxilaprevir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction medicines (e.g. sildenafil
and tadalafil);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fusidic acid used to treat long-term infections
of the bones and joints (e.g. osteomyelitis);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart medicines including:</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>digoxin;</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>calcium channel antagonists (e.g. felodipine,
nifedipine, nicardipine);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to correct heart rhythm
(e.g.&nbsp;bepridil, systemic lidocaine, quinidine);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>HIV CCR5-antagonist (e.g. maraviroc);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>HIV-1 integrase inhibitor (e.g. raltegravir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>medicines used to treat low blood platelet count
(e.g. fostamatinib);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>levothyroxine (used to treat thyroid problems);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to lower blood cholesterol (e.g.
atorvastatin, lovastatin, rosuvastatin or simvastatin);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat asthma and other
lung-related problems such as chronic obstructive pulmonary disease (COPD)
(e.g. salmeterol);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat pulmonary </span>arterial
hypertension (high blood pressure in the pulmonary artery) <span lang=EN-GB>(e.g.
bosentan, riociguat, sildenafil, tadalafil);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines affecting the immune system (e.g.
cyclosporin, sirolimus (rapamycin), tacrolimus);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used for smoking cessation (e.g.
bupropion);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain-relieving medicines (e.g. fentanyl);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>morphine-like medicines (e.g. methadone);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>oral contraceptive or using a patch
contraceptive to prevent pregnancy (see section below titled <b>Contraceptives</b>);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>protease inhibitors (e.g. fosamprenavir,
indinavir, ritonavir, saquinavir, tipranavir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sedatives (e.g. midazolam administered by injection);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>steroids (e.g.&nbsp;budesonide, dexamethasone,
fluticasone propionate, ethinyl oestradiol, triamcinolone);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines that cause a reaction with alcohol
(e.g. disulfiram).</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Read the list of medicines above Do not take Kaletra with any of
the following medicines</span></b><span lang=EN-GB> for information on
medicines that you must not take with Kaletra.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Please tell your doctor or pharmacist if
you or your child are taking, have recently taken or might take any other
medicines, including medicines obtained without prescription.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Erectile dysfunction medicines (avanafil, vardenafil, sildenafil,
tadalafil)</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not take Kaletra</span></b><span
lang=EN-GB> if you are currently taking avanafil or vardenafil.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You must not take Kaletra with sildenafil used
to treat pulmonary arterial hypertension </span>(high blood pressure in the
pulmonary artery) <span lang=EN-GB>(see also <b>Do not take Kaletra</b> section
above).</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you take sildenafil or tadalafil and Kaletra
together, you may be at risk of side effects such as low blood pressure,
passing out, visual changes and penile erection lasting more than 4 hours. If
an erection lasts longer than 4 hours, you should get medical help <b>immediately</b>
to avoid permanent damage to your penis. Your doctor can explain these
symptoms to you.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Contraceptives</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are currently using an oral contraceptive
or using a patch contraceptive to prevent pregnancy, you should use an
additional or different type of contraception (e.g. condom) as Kaletra may
reduce the effectiveness of oral and patch contraceptives.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra does not reduce the risk of passing HIV
to others. Appropriate precautions (e.g. use of a condom) should be taken to
prevent passing on the disease through sexual contact.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pregnancy and breast-feeding</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor <b>immediately</b> if you are
planning to have a baby, you are pregnant, think you may be pregnant or if you
are breast-feeding. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are pregnant or breastfeeding, talk to
your doctor or pharmacist before taking this medicine because it contains
propylene glycol and alcohol. Pregnant or breast-feeding mothers should not
take Kaletra oral solution unless specifically directed by the doctor. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is recommended that HIV-infected women do not
breast-feed their infants because there is a possibility that the baby can be
infected with HIV through your breast milk.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Driving or using machines</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
has not specifically been tested for its possible effects on the ability to
drive a car or operate machines. Do not drive a car or operate machinery if
you experience any side effects (e.g. nausea) that impact your ability to do so
safely. Instead, contact your doctor.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
contains 42%&nbsp;v/v alcohol. The amount of alcohol in this medicine may
affect your ability to drive or use machines and may affect your judgement and
reaction times.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in;page-break-after:avoid'><span
lang=EN-GB>Important information about some of the ingredients of Kaletra</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Kaletra
contains 42% v/v alcohol and </span>15% propylene glycol w/v<span lang=EN-GB>.
</span>Each 1&nbsp;ml of Kaletra oral solution contains 356.3&nbsp;mg of
alcohol and 152.7&nbsp;mg of propylene glycol. <span lang=EN-GB>Alcohol and
propylene glycol are potentially harmful for those suffering from liver
disease, kidney disease, alcoholism, epilepsy, brain injury or disease, as well
as for pregnant women and children. They may modify or increase the effect of
other medicines.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>At the recommended adult dose(s) of this
medicine, the estimated blood alcohol concentration in your body is about
0.002&nbsp;-&nbsp;0.01 g/dL. This is similar to an adult drinking 4-22&nbsp;ml
of beer or 1-4 ml of wine. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Other medicines may also contain alcohol
and alcohol may be consumed in food and drinks. The combined effects may lead
to increased blood alcohol levels and increase the side effects of alcohol.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>This medicinal product contains up to
0.8&nbsp;g of fructose per dose when taken according to the dosage recommendations.
Unsuitable in hereditary fructose intolerance. Due to the possibility of
undetected fructose intolerance, this medicinal product should only be given to
babies and infants after consultation with a doctor.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains glycerol which is harmful
in high doses. Can cause headache and stomach upset and diarrhoea.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains polyoxyl 40 hydrogenated
castor oil. This may cause nausea, vomiting, colic, severe purgation at high
doses. It should not be given when intestinal obstruction is present.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Kaletra contains potassium as acesulfame
potassium, which may be harmful to people on a low potassium diet. High
potassium in the blood can cause stomach upset and diarrhoea.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
contains sodium as saccharin sodium, sodium chloride and sodium citrate, which
may be harmful to people on a low sodium diet.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>3. How to
take Kaletra</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal style='margin-left:12.0pt;text-indent:-12.0pt;background:
#D9D9D9'><span lang=EN-GB style='color:black'> Kaletra is recommended for
use in adults and children 14 days of age and older who are infected with HIV.</span></p>

<p class=EMEANormal style='margin-left:12.0pt;text-indent:-12.0pt;background:
#D9D9D9'><span lang=EN-GB style='color:black'> Take care when dosing
children. Dosing should be less than 5&nbsp;ml twice daily for children
weighing less than 40&nbsp;kg.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>If you or your child is able to swallow
tablets, Kaletra is also supplied as film-coated tablets containing 200&nbsp;mg
of lopinavir and 50&nbsp;mg of ritonavir and film-coated tablets containing
100&nbsp;mg of lopinavir and 25&nbsp;mg of ritonavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Always
take this medicine exactly as your doctor has told you. Check with your doctor
or pharmacist if you are not sure how you should take your medicine.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>How much Kaletra should be taken
and when?</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>For children 14 days and older and weighing up to 15 kg</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will decide the right dose based on
the childs height and weight. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is important that all doses of Kaletra oral
solution are taken with food.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use the <b>2 ml </b>oral syringe provided to
measure the dose.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>For children weighing more than 15 kg</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor will decide the right dose based on
the childs height and weight. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is important that all doses of Kaletra oral
solution are taken with food.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use the <b>5 ml</b> oral syringe provided to
measure the dose.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Use in adults</span></b></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The usual adult dose is 5&nbsp;ml of the oral
solution twice a day i.e. every 12 hours, in combination with other anti-HIV
medicines. Your doctor will advise on the amount of Kaletra to be taken. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is important that all doses of Kaletra oral
solution are taken with food.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Use the <b>5 ml</b> oral syringe provided to
measure the dose. </span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB
style='background:yellow'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>How do I measure the correct dose?</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If the dose is up to 2&nbsp;ml - use the <b>2&nbsp;ml</b>
oral dosing syringe to prepare a dose. </span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If the dose is between 2&nbsp;ml and 5&nbsp;ml -
use the <b>5&nbsp;ml</b> oral dosing syringe to prepare a dose. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Check with your pharmacist that you have
the correct size of syringe. If you are not sure how to use the oral dosing
syringe ask your doctor, pharmacist or nurse. They will tell you how to use
the syringe correctly. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Do not shake the bottle  this is because
air bubbles can form which will affect how well you can measure the dose. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Open the child-proof cap by pushing down
on it with your palm and twisting it counter clockwise, or in the direction of
the arrow on the top of the cap. Talk to your pharmacist if you have
difficulty opening the bottle.</span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB><img border=0 width=611 height=167
id="Picture 1" src="Kaletra_files/image001.gif"></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b>Using the 2 ml oral dosing syringe for doses up to 2 ml </b></p>

<p class=EMEANormal><span style='position:relative;z-index:251658240'><span
style='position:absolute;left:195px;top:-95521px;width:375px;height:1px'><img
width=375 height=1 src="Kaletra_files/image002.gif"></span></span><b>&nbsp;</b></p>

<br clear=ALL>

<p class=MsoNormal style='margin-right:347.15pt'><span lang=EN-GB
style='font-size:11.0pt'>The syringe has two main parts, a plunger and a
barrel. In this picture we have pulled out the plunger so that you can see
each part clearly.</span></p>

<p class=EMEANormal style='margin-right:410.95pt'><b>&nbsp;</b></p>

<p class=EMEANormal><b>&nbsp;</b></p>

<p class=EMEANormal><b>&nbsp;</b></p>

<p class=EMEANormal><b>&nbsp;</b></p>

<p class=EMEANormal><b>&nbsp;</b></p>

<p class=EMEANormal><b>&nbsp;</b></p>

<p class=EMEANormal><img width=281 height=1 src="Kaletra_files/image003.gif"
align=left hspace=12></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:283.5pt;
margin-bottom:10.0pt;margin-left:14.2pt;text-indent:-14.2pt'><span lang=EN-GB
style='font-size:11.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Push the plunger all of
the way into the barrel. </span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:283.5pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Place the tip of the
syringe into the liquid. </span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:283.5pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Pull up the plunger
until the correct dose amount is shown on the plunger. You should see the ml
marking aligned to the top of the collar of the barrel. </span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:162.9pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Turn the syringe so
that the tip is pointing up, gently tap it and push plunger to remove any air
bubbles.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:162.9pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>After removing the air
bubbles, look at the dose mark.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:162.9pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>If the ml mark on the
collar is more than the prescribed dose, push the plunger to the prescribed
dose. </span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:162.9pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>If the ml mark on the
collar is less than the prescribed dose, draw up more solution to the
prescribed dose.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:162.9pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>6.  Place the dosing syringe in your
childs mouth towards the cheek and gently push the plunger down to release the
medicine.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:162.9pt;margin-bottom:
10.0pt;margin-left:14.2pt;text-indent:-14.2pt'><span lang=EN-GB
style='font-size:11.0pt'>Replace the bottle cap after each dose. </span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><img width=346 height=1
src="Kaletra_files/image004.gif" align=left hspace=12><b><span lang=EN-GB
style='font-size:11.0pt'>Using the 5 ml oral dosing syringe for doses more than
2 ml</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:283.4pt;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>The syringe has two main parts, a plunger
and a barrel. In this picture we have pulled out the plunger so that you can
see each part clearly.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><b><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><b><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><b><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><b><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-left:28.35pt;page-break-after:avoid'><b><u><span
lang=EN-GB style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:382.6pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt'><b><u><span lang=EN-GB
style='font-size:11.0pt'><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:85.05pt;
margin-bottom:10.0pt;margin-left:14.2pt;text-indent:-14.2pt'><span lang=EN-GB
style='font-size:11.0pt'>1.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><img width=308 height=1 src="Kaletra_files/image005.gif"
align=left hspace=12><span lang=EN-GB style='font-size:11.0pt'>Push the plunger
all of the way into the barrel. </span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:85.05pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>2.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Place the tip of the
syringe into the liquid.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:85.05pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>3.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Pull up the plunger
until the black O ring is on the correct dose ml mark on the barrel.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:85.05pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>4.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Turn the syringe so
that the tip is pointing up, gently tap it and push plunger to remove any air
bubbles. </span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:84.95pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>5.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>After removing the air
bubbles, look at the dose mark.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:63.65pt;
margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>If the ml mark on the
black O ring is more than the prescribed dose, push the plunger to the
prescribed dose. </span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:63.8pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-14.15pt'><span
lang=EN-GB style='font-size:11.0pt;font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>If the ml mark on the
black O ring is less than the prescribed dose, draw up more solution to the
prescribed dose.</span></p>

<p class=MsoListParagraph style='margin-top:0in;margin-right:162.9pt;
margin-bottom:0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:11.0pt'>6.<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB style='font-size:11.0pt'>Place the dosing syringe
in your childs mouth towards the cheek and gently push the plunger down to
release the medicine.</span></p>

<p class=MsoNormal style='margin-right:63.8pt'><span lang=EN-GB
style='font-size:11.0pt'>Replace the bottle cap after each dose. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>After each dose of Kaletra separate the
plunger and the syringe. Wash the plunger and the syringe with washing up
liquid and warm water as soon as you can; you may soak both in soapy water for
up to 15&nbsp;minutes. Rinse the syringe and plunger with clean water. Put
the syringe back together and draw up and expel tap water a few times to
rinse. Let the syringe dry completely before you use that syringe for dosing. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Do not use the dosing syringes supplied
with Kaletra oral solution to administer any other medicines you or your child
may be taking. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child take more
Kaletra than you should</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you realise you have taken more Kaletra than
you were supposed to, contact your doctor right away. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you cannot contact your doctor, go to the
hospital.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child forget to take
Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose within 6 hours of your normal
dosing time, take your missed dose as soon as possible, and then continue with
your normal dose at the regular time as prescribed by your doctor.</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose by more than 6 hours after your
normal dosing time, do not take the missed dose. Take the next dose as usual.
Do not take a double dose to make up for a forgotten dose.</p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child stop taking
Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not stop or change the daily dose of Kaletra
without first consulting with your doctor.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra should always be taken twice every day
to help control your HIV infection, no matter how much better you feel. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Taking Kaletra as recommended should give you
the best chance of delaying the development of resistance to the product.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If a side effect is preventing you from taking
Kaletra as directed tell your doctor right away. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Always keep enough Kaletra on hand so you dont
run out. When you travel or need to stay in the hospital make sure you will
have enough Kaletra to last until you can get a new supply.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Continue to take this medicine until your doctor
tells you otherwise.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>4. Possible
side effects</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB>Like all medicines, Kaletra can cause side
effects, although not everybody gets them. It may be difficult to tell which
side effects have been caused by Kaletra and which may occur due to other
medicines you take at the same time or by the complications of the HIV
infection. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>During HIV therapy there may be an
increase in weight and in levels of blood lipids and glucose. This is partly
linked to restored health and life style, and in the case of blood lipids
sometimes to the HIV medicines themselves. Your doctor will test for these
changes.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>The following side effects have been
reported by patients who took this medicine.</span></b><span lang=EN-GB> You
should tell your doctor promptly about these or any other symptoms. If the
condition persists or worsens, seek medical attention.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Very common:</span></b><span
lang=EN-GB> may affect more than 1 in 10 people</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea; </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>upper respiratory tract infection.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Common:</span></b><span lang=EN-GB> may
affect up to 1 in 10 people</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the pancreas;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>vomiting, enlarged abdomen, pain in the lower and upper stomach
area, passing wind, indigestion, decreased appetite, reflux from your stomach
to your oesophagus which may cause pain; </p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Tell your doctor</span></b><span lang=EN-GB>
if you experience nausea, vomiting or abdominal pain as these may be suggestive
of pancreatitis (inflammation of the pancreas).</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling or inflammation of the stomach,
intestines and colon;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased cholesterol levels in your blood,
increased triglycerides (a form of fat) levels in your blood, high blood
pressure;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased ability of the body to handle sugar including
diabetes mellitus, weight loss;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low number of red blood cells, low number of
white blood cells which are usually used to fight infection;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, eczema, accumulation of scales of greasy
skin;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness, anxiety, difficulty in sleeping;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling tired, lack of strength and energy,
headache including migraine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>haemorrhoids;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the liver including increased
liver enzymes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions including hives and
inflammation in the mouth;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lower respiratory tract infection;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>enlargement of the lymph nodes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impotence, abnormally heavy or extended
menstrual flow or a lack of menstruation;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle disorders such as weakness and spasms,
pain in the joints, muscles and back;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>damage to nerves of the peripheral nervous
system;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>night sweats, itching, rash including raised
bumps on the skin, infection of the skin, inflammation of skin or hair pores,
accumulation of fluid in the cells or tissues. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Uncommon:</span></b><span lang=EN-GB> may
affect up to 1 in 100 people </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal dreams;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>loss or changed sense of taste;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an abnormality in your electrocardiogram (ECG)
called atrioventricular block;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>plaque building up inside your arteries which
could lead to heart attack and stroke;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels and capillaries;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the bile duct;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>uncontrolled shaking of the body;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>deep vein inflammation related to a blood clot;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dry mouth;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inability to control your bowels;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the first section of the small
intestine just after the stomach, wound or ulcer in the digestive tract,
bleeding from the intestinal tract or rectum;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red blood cells in the urine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>yellowing of the skin or whites of eyes
(jaundice);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fatty deposits in the liver, enlarged liver;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lack of functioning of the testes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a flare-up of symptoms related to an inactive
infection in your body (immune reconstitution);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased appetite;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormally high level of bilirubin (a pigment
produced from the breakdown of red blood cells) in the blood</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased sexual desire;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the kidney;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bone death caused by poor blood supply to the
area;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores or ulcerations, inflammation of the
stomach and intestine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breakdown of muscle fibres resulting in the
release of muscle fibre contents (myoglobin) into the bloodstream;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a sound in one ear or both ears, such as
buzzing, ringing or whistling;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tremor;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal closure of one of the valves (tricuspid
valve in your heart);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vertigo (spinning feeling);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>eye disorder, abnormal vision;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight gain.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Rare: </span></b><span lang=EN-GB>may
affect up to 1 in 1,000 people</span><span lang=EN-GB> </span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe or life-threatening skin rashes and
blisters (Stevens-Johnson syndrome and erythema multiforme).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Not known: </span></b><span
lang=EN-GB style='font-size:11.0pt'>frequency<b> </b><span style='color:black'>cannot
be estimated from the available data</span></span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney stones.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>If any of the side effects gets serious,
or if you notice any side effects not listed in this leaflet, please inform
your doctor or pharmacist.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Reporting
of side effects</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><b><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>If you get
any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. You can also report side
effects directly via <span style='background:lightgrey'>the national reporting
system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a><span lang=EN-GB>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>5. How to
store Kaletra</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use Kaletra after the expiry date which
is stated on the bottle.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine if you notice the
solution is discoloured or contains particles.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>How should I store Kaletra and for
how long?</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol;layout-grid-mode:line'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Store in a refrigerator (2C&nbsp;-&nbsp;8C).</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In use storage: If kept outside of the
refrigerator, do not store above 25</span><span lang=EN-GB style='font-family:
Symbol'></span><span lang=EN-GB>C and discard any unused contents after 42
days (6 weeks). It is advised to write the date of removal from the
refrigerator on the package.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is important to keep Kaletra in the bottle it
came in and replace the bottle cap after each dose. Do not transfer it to any
other container. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>How should I dispose of any unused
Kaletra?</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Do
not throw away any medicines via wastewater. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>6. Contents of the pack and other information</span></b></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>What Kaletra contains</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>The active
substances are lopinavir and ritonavir.</span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Each ml of
Kaletra oral solution contains 80&nbsp;mg of lopinavir and 20&nbsp;mg of
ritonavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The other ingredients are: </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Alcohol, high fructose corn syrup,
propylene glycol, purified water, glycerol, povidone, magnasweet-110 flavour
(mixture of monoammonium glycyrrhizinate and glycerol), vanilla flavour
(containing p&#8209;hydroxybenzoic acid, p-hydroxybenzaldehyde, vanillic acid,
vanillin, heliotropin, ethyl vanillin), polyoxyl 40 hydrogenated castor oil,
cotton candy flavour (containing ethyl maltol, ethyl vanillin, acetoin,
dihydrocoumarin, propylene glycol), acesulfame potassium, saccharin sodium, sodium
chloride, peppermint oil, sodium citrate, citric acid, levomenthol.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB style='font-family:
"Times New Roman",serif'>What Kaletra looks like and contents of the pack</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
oral solution comes in a multiple-dose 60&nbsp;ml amber bottle. Each ml of
Kaletra contains 80&nbsp;mg of lopinavir and 20&nbsp;mg of ritonavir.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Two
pack sizes are available:</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>120 ml (2 bottles x 60 ml). The 2 bottle pack
also contains two 2&nbsp;ml syringes with 0.1&nbsp;ml graduations. <br>
<u>For volumes up to 2 ml. For larger volumes an alternative pack is
available.</u></span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>300 ml (5 bottles x 60 ml). The 5&nbsp;bottle
pack also contains five&nbsp;5&nbsp;ml syringes with 0.1&nbsp;ml graduations. <br>
<u>For volumes greater than 2 ml. For smaller volumes an alternative pack is
available.</u></span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>Marketing
Authorisation Holder</span><span lang=EN-GB style='font-weight:normal'>: </span></p>

<p class=MsoNormal style='line-height:12.0pt;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp;
Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Manufacturer</span></b><span
lang=EN-GB>:  </span></p>

<p class=EMEANormal><span lang=DE>AbbVie Deutschland GmbH &amp; Co. KG,
Knollstrasse, 67061 Ludwigshafen, Germany</span></p>

<p class=EMEANormal><span lang=EN-GB style='background:lightgrey'>AbbVie Logistics
B.V., Zuiderzeelaan 53, 8017 JV Zwolle, The Netherlands</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE style='font-size:11.0pt'>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>AbbVie SA</span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR style='font-size:
  11.0pt'>Tl/Tel: +32 10 </span><span lang=FR style='font-size:11.0pt'>477811</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>AbbVie UAB </span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=LV style='font-size:
  11.0pt'>Tel: +370 5 205 3023</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG
  style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='font-size:11.0pt'>&#1040;&#1073;&#1042;&#1080;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>&#1058;&#1077;&#1083;.</span><span
  lang=IT style='font-size:11.0pt;color:black'>: +359 2 90 30 430</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie SA</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Belgique/Belgien</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tl/Tel: +32 10
  477811</span></p>
  <p class=MsoNormal><span lang=HU style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie s.r.o. </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +420 233 098
  111</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU style='font-size:11.0pt'>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=HU style='font-size:11.0pt'>AbbVie Kft.</span></p>
  <p class=MsoNormal><span lang=HU style='font-size:11.0pt'>Tel.: +36 1 455 8600</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:50.75pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.75pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +45 72
  30-20-28</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.75pt'>
  <p class=MsoNormal><b><span lang=MT style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal><span lang=FI style='font-size:11.0pt'>V.J.Salomone Pharma
  Limited </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +356
  22983201</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE
  style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp; Co. KG</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>Tel: 00800 222843 33 (gebhrenfrei)</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>Tel: +49 (0) 611&nbsp;/&nbsp;1720-0</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ET
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=NL
  style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>AbbVie B.V.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>Tel: +31 (0)88 322 2843</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=ET
  style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ET
  style='font-size:11.0pt'>AbbVie O </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ET
  style='font-size:11.0pt'>Tel: +372 </span><span lang=EN-GB style='font-size:
  11.0pt'>623 1011</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=NO-BOK
  style='font-size:11.0pt'>Norge</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>AbbVie AS</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>Tlf: +47 67 81 80 00</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EL
  style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ET
  style='font-size:11.0pt'>AbbVie </span><span lang=EL style='font-size:11.0pt'>&#934;&#913;&#929;&#924;&#913;&#922;&#917;&#933;&#932;&#921;&#922;&#919;
  &#913;.&#917;.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL
  style='font-size:11.0pt'>&#932;&#951;&#955;: +30 </span><span lang=EN-GB
  style='font-size:11.0pt'>214 4165 555</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ES
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE
  style='font-size:11.0pt'>sterreich</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>AbbVie GmbH </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>Tel: +43 1 20589-0</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PL
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=ES
  style='font-size:11.0pt'>Espaa</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT
  style='font-size:11.0pt'>AbbVie Spain, S.L.U. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT
  style='font-size:11.0pt'>Tel: +34 9 1 384 0910</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=PL
  style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PL
  style='font-size:11.0pt'>AbbVie Polska Sp. z o.o.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=ES
  style='font-size:11.0pt'>Tel.: +48 22 </span><span lang=PL style='font-size:
  11.0pt'>372 78 00 </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PL
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:49.45pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>AbbVie</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tl: +33 (0)1 45 60
  13 00</span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span lang=PT style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>AbbVie, Lda. </span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +351 (0)21
  1908400</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:49.45pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=PT
  style='font-size:11.0pt'>Hrvatska </span></b></p>
  <p class=MsoNormal><span lang=HR style='font-size:11.0pt'>AbbVie d.o.o.</span></p>
  <p class=MsoNormal><span lang=HR style='font-size:11.0pt'>Tel: +385 (0)1 </span><span
  style='font-size:11.0pt'>5625 501</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>Romnia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>AbbVie
  S.R.L.</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>Tel: +40 21 529 30
  35</span></p>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie Limited </span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Tel: +353 (0)1
  4287900</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL style='font-size:11.0pt'>AbbVie
  Biofarmacevtska druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=SL style='font-size:11.0pt'>Tel: +386 (1)32 08
  060</span></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS style='font-size:11.0pt'>sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +354 535
  7000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK style='font-size:11.0pt'>Slovensk
  republika</span></b></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>AbbVie s.r.o.</span></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>Tel: +421 2 5050
  0777</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=PT style='font-size:
  11.0pt'>AbbVie S.r.l. </span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR style='font-size:
  11.0pt'>Tel: +39 06 928921</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie</span><span
  lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB
  style='font-size:11.0pt'>Oy</span><span lang=EN-GB style='font-size:11.0pt'> </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Puh/Tel: +358
  (0)</span><span lang=EN-GB> </span><span lang=EN-GB style='font-size:11.0pt'>10
  2411 200</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Lifepharma (Z.A.M.)
  Ltd</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&#932;&#951;&#955;:
  +357 22 34 74 40</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>AbbVie AB</span></p>
  <p class=MsoNormal><span lang=DA style='font-size:11.0pt'>Tel: +46 (0)8 684
  44 600</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.35pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:44.35pt'>
  <p class=MsoNormal><b><span lang=LV style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>AbbVie SIA </span></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>Tel: +371 67605000</span></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:44.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>United
  Kingdom (Northern Ireland)</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland
  GmbH &amp; Co. KG</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +44 (0)1628
  561090</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>This leaflet was last revised in</span></b><span
lang=EN-GB>: {MM/YYYY}</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeadingLeaflet align=center style='margin:0in;text-align:center'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Package leaflet:
Information for the user</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal align=center style='text-align:center'><b><span lang=EN-GB>Kaletra
200&nbsp;mg/50&nbsp;mg film&#8209;coated tablets</span></b></p>

<p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you or your child.</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you or
your child only. Do not pass it on to others. It may harm them, even if their
signs of illness are the same as yours.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=EMEANormal><span lang=EN-GB>1. What Kaletra is and what it is
used for</span></p>

<p class=EMEANormal><span lang=EN-GB>2. What you need to know before you or
your child takes Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>3. How to take Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEANormal><span lang=EN-GB>5. How to store Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>1. What
Kaletra is and what it is used for</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor has prescribed Kaletra to help to control
your Human Immunodeficiency Virus (HIV) infection. Kaletra does this by
slowing down the spread of the infection in your body.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra is not a cure for HIV infection or AIDS.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra is used by children 2 years of age or
older, adolescents and adults who are infected with HIV, the virus which causes
AIDS. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra contains the active substances lopinavir
and ritonavir. Kaletra is an antiretroviral medicine. It belongs to a group
of medicines called protease inhibitors.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra is prescribed for use in combination
with other antiviral medicines. Your doctor will discuss with you and determine
which medicines are best for you.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>2. What
you need to know before you or your child takes Kaletra</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Do not take Kaletra</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to lopinavir, ritonavir or
any of the other ingredients of Kaletra (see section 6); </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have severe liver problems.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Do not take Kaletra with any of the following medicines:</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>astemizole or terfenadine (commonly used to treat allergy
symptoms  these medicines may be available without prescription);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>midazolam taken orally (taken by mouth), triazolam (used to
relieve anxiety and/or trouble sleeping);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>pimozide (used to treat schizophrenia);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>quetiapine (used to treat schizophrenia, bipolar disorder and
major depressive disorder);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>lurasidone (used to treat depression);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>ranolazine (used to treat chronic chest pain [angina]);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>cisapride (used to relieve certain stomach problems);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>ergotamine, dihydroergotamine, ergonovine, methylergonovine (used
to treat headaches);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>amiodarone, dronedarone (used to treat abnormal heart beat);</p>

<p class=EMEABullet style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lovastatin, simvastatin (used to lower blood
cholesterol);</span></p>

<p class=EMEABullet style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lomitapide (used to lower blood cholesterol);</span></p>

<p class=EMEABullet style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alfuzosin (used in men to treat symptoms of an
enlarged prostate (benign prostatic hyperplasia (BPH));</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fusidic acid (used to treat skin infections
caused by <i>Staphylococcus</i> bacteria such as impetigo and infected
dermatitis). Fusidic acid used to treat long-term infections of the bones and
joints may be taken under doctors supervision (see <b>Other medicines and
Kaletra</b> section);</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine (used to treat gout) if you have
kidney and/or liver problems (see the section on <b>Other medicines and Kaletra</b>);</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>elbasvir/grazoprevir (used to treat chronic
hepatitis C virus [HCV]);</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ombitasvir/paritaprevir/ritonavir with or
without dasabuvir (used to treat chronic hepatitis C virus [HCV]);</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>neratinib (used to treat breast cancer);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>avanafil or vardenafil (used to treat erectile dysfunction);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>sildenafil used to treat pulmonary arterial hypertension (high
blood pressure in the pulmonary artery). Sildenafil used to treat erectile
dysfunction may be taken under doctors supervision (see <b>Other medicines and
Kaletra</b> section);</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>products that contain St Johns wort (<i>Hypericum perforatum</i>).</p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Read the list of medicines below under
Other medicines and Kaletra </span></b><span lang=EN-GB>for information on
certain other medicines which require special care.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>If you are currently taking any of these
medicines, ask your doctor about making necessary changes either in the
treatment for your other condition(s) or in your antiretroviral treatment. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Warnings and precautions</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Talk to your doctor or pharmacist before
taking Kaletra.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Important information</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>People taking Kaletra may still develop
infections or other illnesses associated with HIV disease and AIDS. It is
therefore important that you remain under the supervision of your doctor while
taking Kaletra. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>You can still pass on HIV when taking this medicine</span></b><span
lang=EN-GB>, although the risk is lowered by effective antiretroviral therapy.
Discuss with your doctor the precautions needed to avoid infecting other people.</span></p>

<p class=EMEABullet style='margin-left:28.35pt;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tell your doctor if you or your
child have/had</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Haemophilia</span></b><span lang=EN-GB> type
A and B as Kaletra might increase the risk of bleeding.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diabetes</span></b><span lang=EN-GB> as
increased blood sugars has been reported in patients receiving Kaletra.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A history of <b>liver problems</b> as patients
with a history of liver disease, including chronic hepatitis B or C are at
increased risk of severe and potentially fatal liver side effects.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-weight:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tell your doctor if you or your
child experience</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, vomiting, abdominal pain, difficulty
breathing and severe weakness of the muscles in the legs and arms as these
symptoms may indicate raised lactic acid levels.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Thirst, frequent urination, blurred vision or
weight loss as this may indicate raised sugar levels in the blood.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, vomiting, abdominal pain as large
increases in the amount of triglycerides (fats in the blood) have been
considered a risk factor for pancreatitis (inflammation of the pancreas) and
these symptoms may suggest this condition.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In some patients with advanced HIV infection and
a history of opportunistic infection, signs and symptoms of inflammation from
previous infections may occur soon after anti-HIV treatment is started. It is
believed that these symptoms are due to an improvement in the bodys immune
response, enabling the body to fight infections that may have been present with
no obvious symptoms.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections,
autoimmune disorders (a condition that occurs when the immune system attacks
healthy body tissue) may also occur after you start taking medicines for the
treatment of your HIV infection. Autoimmune disorders may occur many months
after the start of treatment. If you notice any symptoms of infection or other
symptoms such as muscle weakness, weakness beginning in the hands and feet and
moving up towards the trunk of the body, palpitations, tremor or hyperactivity,
please inform your doctor immediately to seek necessary treatment.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Joint stiffness, aches and pains </span></b><span
lang=EN-GB>(especially of the hip, knee and shoulder) and difficulty in
movement<b> </b>as some patients taking these medicines may develop a bone
disease called osteonecrosis (death of bone tissue caused by loss of blood
supply to the bone). The length of combination</span><span lang=EN-GB>
antiretroviral therapy, corticosteroid use, alcohol consumption, severe
immunosuppression (reduction in the activity of the immune system), higher body
mass index, among others, may be some of the many risk factors for developing
this disease. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Muscle pain, </span></b><span lang=EN-GB>tenderness
or weakness, particularly in combination with these medicines. On rare
occasions these muscle disorders have been serious. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Symptoms of dizziness, lightheadedness, fainting
or sensation of abnormal heartbeats. Kaletra may cause changes in your heart
rhythm and the electrical activity of your heart. These changes may be seen on
an ECG (electrocardiogram).</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Other medicines and Kaletra</span></p>

<p class=EMEANormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=EMEANormal><b><span lang=EN-GB>Tell your doctor or pharmacist if you or
your child are taking, have recently taken or might take any other medicines. </span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antibiotics (e.g.&nbsp;rifabutin, rifampicin,
clarithromycin);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticancer medicines (e.g. abemaciclib, afatinib,
apalutamide, ceritinib, encorafenib, ibrutinib, venetoclax, most tyrosine
kinases inhibitors such as dasatinib and nilotinib, also vincristine and
vinblastine);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticoagulants (e.g. warfarin, rivaroxaban,
vorapaxar);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antidepressants (e.g. trazodone, bupropion);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti-epilepsy medicines (e.g. carbamazepine,
phenytoin, phenobarbital, lamotrigine and valproate);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>antifungals (e.g.&nbsp;ketoconazole, itraconazole,
voriconazole);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti&#8209;gout medicines (e.g. colchicine).
You must not take Kaletra with colchicine if you have kidney and/or liver
problems (see also <b>Do not take Kaletra</b> above);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti&#8209;tuberculosis medicine (bedaquiline,
delamanid);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antiviral medicine used to treat chronic
hepatitis C virus (HCV) infection in adults (e.g. glecaprevir/pibrentasvir, simeprevir
and sofosbuvir/velpatasvir/voxilaprevir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction medicines (e.g. sildenafil
and tadalafil);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fusidic acid used to treat long-term infections
of the bones and joints (e.g. osteomyelitis);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart medicines including:</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>digoxin;</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>calcium channel antagonists (e.g. felodipine,
nifedipine, nicardipine);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to correct heart rhythm
(e.g.&nbsp;bepridil, systemic lidocaine, quinidine);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>HIV CCR5-antagonist (e.g. maraviroc);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>HIV-1 integrase inhibitor (e.g. raltegravir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>medicines used to treat low blood platelet count
(e.g. fostamatinib);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>levothyroxine (used to treat thyroid problems);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to lower blood cholesterol (e.g.
atorvastatin, lovastatin, rosuvastatin or simvastatin); </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat asthma and other
lung-related problems such as chronic obstructive pulmonary disease (COPD)
(e.g. salmeterol);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat pulmonary </span>arterial
hypertension (high blood pressure in the pulmonary artery) <span lang=EN-GB>(e.g.
bosentan, riociguat, sildenafil, tadalafil);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines affecting the immune system (e.g.
cyclosporin, sirolimus (rapamycin), tacrolimus);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used for smoking cessation (e.g.
bupropion);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain-relieving medicines (e.g. fentanyl);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>morphine-like medicines (e.g. methadone);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>non-nucleoside reverse transcriptase inhibitors
(NNRTIs) (e.g. efavirenz, nevirapine);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>oral contraceptive or using a patch
contraceptive to prevent pregnancy (see section below titled <b>Contraceptives</b>);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>protease inhibitors (e.g. fosamprenavir, indinavir,
ritonavir, saquinavir, tipranavir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sedatives (e.g. midazolam administered by
injection);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>steroids (e.g.&nbsp;budesonide, dexamethasone,
fluticasone propionate, ethinyl oestradiol, triamcinolone).</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Read the list of medicines above Do not take Kaletra with any of
the following medicines</span></b><span lang=EN-GB> for information on
medicines that you must not take with Kaletra.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Tell your doctor or pharmacist if you or
your child are taking, have recently taken or might take any other medicines,
including medicines obtained without prescription.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Erectile dysfunction medicines (</span></b><b><span lang=EN-GB>avanafil,
vardenafil, sildenafil, tadalafil)</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not take Kaletra</span></b><span
lang=EN-GB> if you are currently taking avanafil or vardenafil.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You must not take Kaletra with sildenafil used
to treat pulmonary arterial hypertension </span>(high blood pressure in the
pulmonary artery) <span lang=EN-GB>(see also <b>Do not take Kaletra</b> section
above).</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you take sildenafil or tadalafil and Kaletra
together, you may be at risk of side effects such as low blood pressure,
passing out, visual changes and penile erection lasting more than 4 hours. If
an erection lasts longer than 4 hours, you should get medical help <b>immediately</b>
to avoid permanent damage to your penis. Your doctor can explain these
symptoms to you.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Contraceptives</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are currently using an oral contraceptive
or using a patch contraceptive to prevent pregnancy, you should use an
additional or different type of contraception (e.g. condom) as Kaletra may reduce
the effectiveness of oral and patch contraceptives.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra does not reduce the risk of passing HIV
to others. Appropriate precautions (e.g. use of a condom) should be taken to
prevent passing on the disease through sexual contact.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pregnancy and breast-feeding</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor <b>immediately</b> if you are
planning to have a baby, you are pregnant, think you may be pregnant or if you
are breast-feeding. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Breast-feeding mothers should not take Kaletra
unless specifically directed by the doctor. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is recommended that HIV-infected women do not
breast-feed their infants because there is a possibility that the baby can be
infected with HIV through your breast milk.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Driving or using machines</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
has not specifically been tested for its possible effects on the ability to
drive a car or operate machines. Do not drive a car or operate machinery if
you experience any side effects (e.g. nausea) that impact your ability to do so
safely. Instead, contact your doctor.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>3. How to take Kaletra</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:#D9D9D9'>

<p class=EMEABullet align=center style='margin-left:0in;text-align:center;
text-indent:0in;page-break-after:avoid;background:#D9D9D9;border:none;
padding:0in'><span lang=EN-GB style='color:black'>It is important that Kaletra
tablets are swallowed whole and not chewed, broken or crushed.</span></p>

</div>

<p class=EMEABullet style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Always
take this medicine exactly as your doctor has told you. Check with your doctor
or pharmacist if you are not sure how you should take your medicine.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>How much Kaletra should
be taken and when?</span></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Use in
adults</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The usual adult dose is 400&nbsp;mg/100&nbsp;mg
twice a day i.e. every 12 hours, in combination with other anti-HIV medicines.
Adult patients who have not previously taken other antiviral medicines can also
take Kaletra tablets once daily as an 800&nbsp;mg/200&nbsp;mg dose. Your
doctor will advise on the number of tablets to be taken. Adult patients who
have previously taken other antiviral medicines can take Kaletra tablets once
daily as an 800&nbsp;mg/200&nbsp;mg dose if their doctor decides it is
appropriate.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra must not be taken once daily with
efavirenz, nevirapine, </span><span lang=EN-GB>carbamazepine, phenobarbital and
phenytoin.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra tablets can be taken with or without
food.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Use in children</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For children, your doctor will decide the right
dose (number of tablets) based on the childs height and weight. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra tablets can be taken with or without
food.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
is also supplied as 100&nbsp;mg/25&nbsp;mg film-coated tablets. Kaletra oral
solution is available for patients who cannot take tablets.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child take more
Kaletra than you should</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you realise you have taken more Kaletra than
you were supposed to, contact your doctor right away. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you cannot contact your doctor, go to the hospital.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child forget to take
Kaletra</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><i><u><span
 style='text-decoration:none'>&nbsp;</span></u></i></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><i><u>If you are
taking Kaletra twice a day</u></i></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose within 6 hours of your normal
dosing time, take your missed dose as soon as possible, and then continue with
your normal dose at the regular time as prescribed by your doctor.</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'>&nbsp;</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose by more than 6 hours after your
normal dosing time, do not take the missed dose. Take the next dose as usual.
Do not take a double dose to make up for a forgotten dose.</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'>&nbsp;</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><i><u>If you are
taking Kaletra once a day</u></i></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose within 12 hours of your normal
dosing time, take your missed dose as soon as possible, and then continue with
your normal dose at the regular time as prescribed by your doctor.</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'>&nbsp;</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose by more than 12 hours after your
normal dosing time, do not take the missed dose. Take the next dose as usual.
Do not take a double dose to make up for a forgotten dose.</p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child stop taking
Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not stop or change the daily dose of Kaletra
without first consulting with your doctor.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra should always be taken every day to help
control your HIV infection, no matter how much better you feel. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Taking Kaletra as recommended should give you
the best chance of delaying the development of resistance to the product.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If a side effect is preventing you from taking
Kaletra as directed tell your doctor right away. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Always keep enough Kaletra on hand so you dont
run out. When you travel or need to stay in the hospital make sure you will
have enough Kaletra to last until you can get a new supply.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Continue to take this medicine until your doctor
tells you otherwise.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4. Possible side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Like all
medicines, Kaletra can cause side effects, although not everybody gets them.
It may be difficult to tell which side effects have been caused by Kaletra and
which may occur due to other medicines you take at the same time or by the
complications of the HIV infection. </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>During HIV therapy there may be an
increase in weight and in levels of blood lipids and glucose. This is partly
linked to restored health and life style, and in the case of blood lipids
sometimes to the HIV medicines themselves. Your doctor will test for these
changes.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>The
following side effects have been reported by patients who took this medicine.</span></b><span
lang=EN-GB> You should tell your doctor promptly about these or any other
symptoms. If the condition persists or worsens, seek medical attention.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Very common:</span></b><span
lang=EN-GB> may affect more than 1 in 10 people</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea; </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>upper respiratory tract infection.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Common:</span></b><span lang=EN-GB> may
affect up to 1 in 10 people</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the pancreas;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting, enlarged abdomen, pain in the lower
and upper stomach area, passing wind, indigestion, decreased appetite, reflux
from your stomach to your oesophagus which may cause pain;</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Tell your doctor</span></b><span lang=EN-GB>
if you experience nausea, vomiting or abdominal pain as these may be suggestive
of pancreatitis (inflammation of the pancreas).</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling or inflammation of the stomach,
intestines and colon;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased cholesterol levels in your blood,
increased triglycerides (a form of fat) levels in your blood, high blood
pressure;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased ability of the body to handle sugar
including diabetes mellitus, weight loss;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low number of red blood cells, low number of
white blood cells which are usually used to fight infection;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, eczema, accumulation of scales of greasy
skin;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness, anxiety, difficulty in sleeping;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling tired, lack of strength and energy,
headache including migraine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>haemorrhoids;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the liver including increased
liver enzymes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions including hives and
inflammation in the mouth;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lower respiratory tract infection;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>enlargement of the lymph nodes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impotence, abnormally heavy or extended
menstrual flow or a lack of menstruation;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle disorders such as weakness and spasms,
pain in the joints, muscles and back;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>damage to nerves of the peripheral nervous
system;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>night sweats, itching, rash including raised
bumps on the skin, infection of the skin, inflammation of skin or hair pores,
accumulation of fluid in the cells or tissues. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon:</span></b><span
lang=EN-GB> may affect up to 1 in 100 people </span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal dreams;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>loss or changed sense of taste;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an abnormality in your electrocardiogram (ECG)
called atrioventricular block;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>plaque building up inside your arteries which
could lead to heart attack and stroke;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels and capillaries;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the bile duct;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>uncontrolled shaking of the body;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>deep vein inflammation related to a blood clot;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dry mouth;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inability to control your bowels;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the first section of the small
intestine just after the stomach, wound or ulcer in the digestive tract,
bleeding from the intestinal tract or rectum;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red blood cells in the urine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>yellowing of the skin or whites of eyes
(jaundice);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fatty deposits in the liver, enlarged liver;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lack of functioning of the testes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a flare-up of symptoms related to an inactive
infection in your body (immune reconstitution);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased appetite;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormally high level of bilirubin (a pigment
produced from the breakdown of red blood cells) in the blood</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased sexual desire;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the kidney;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bone death caused by poor blood supply to the
area;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores or ulcerations, inflammation of the
stomach and intestine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breakdown of muscle fibres resulting in the
release of muscle fibre contents (myoglobin) into the bloodstream;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a sound in one ear or both ears, such as
buzzing, ringing or whistling;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tremor;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal closure of one of the valves (tricuspid
valve in your heart);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vertigo (spinning feeling);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>eye disorder, abnormal vision;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight gain.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Rare</span></b><span lang=EN-GB>: may
affect up to 1 in 1,000 people </span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe or lifethreatening skin rashes and
blisters (Stevens-Johnson syndrome and erythema multiforme).</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Not known: </span></b><span
lang=EN-GB style='font-size:11.0pt'>frequency<b> </b><span style='color:black'>cannot
be estimated from the available data</span></span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney stones.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>If any of the side effects gets serious,
or if you notice any side effects not listed in this leaflet, please inform
your doctor or pharmacist.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=EMEANormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=EMEANormal><span lang=EN-GB>If you get any side effects, talk to your
doctor or pharmacist. This includes any possible side effects not listed in
this leaflet. You can also report side effects directly via <span
style='background:lightgrey'>the national reporting system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a><span lang=EN-GB>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>5. How to store Kaletra</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use Kaletra after the expiry date which
is stated on the pack.</span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicinal product does not require any
special storage conditions.</span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine if you notice any discolouration.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>How should I dispose of any unused
Kaletra?</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Do
not throw away any medicines via wastewater. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>6. Contents
of the pack and other information</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>What Kaletra contains</span></b></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The active substances are lopinavir and
ritonavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>Each tablet of Kaletra contains
200&nbsp;mg of lopinavir and 50&nbsp;mg of ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>The
other ingredients are: </span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Tablet</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Copovidone,
sorbitan laurate, colloidal anhydrous silica, sodium stearyl fumarate<span
style='layout-grid-mode:line'>. </span></span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB style='layout-grid-mode:line'>Tablet
coating</span></b></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Hypromellose,
titanium dioxide, macrogols type 400 (polyethylene glycol 400), hydroxypropyl
cellulose, talc, colloidal anhydrous silica, macrogols type 3350 (polyethylene
glycol 3350), red ferric oxide E172, polysorbate 80.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB style='layout-grid-mode:line'>What
Kaletra looks like and contents of the pack</span></b></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
film-coated tablets are red debossed with [Abbott logo] and AL. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
film-coated tablets are supplied in packs containing 120 tablets (1 plastic bottle
of 120 tablets) and multipacks comprising 3 plastic bottles each containing 120
tablets (360 tablets). Blister multipacks containing 120 tablets (1 pack of
120 tablets or 3 packs each containing 40 tablets) are also available. </span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Not
all pack sizes may be marketed.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>Marketing
Authorisation Holder</span><span lang=EN-GB style='font-weight:normal'>: </span></p>

<p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie Deutschland
GmbH &amp; Co. KG, Knollstrasse, 67061 Ludwigshafen, Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Manufacturer</span></b><span
lang=EN-GB>:  </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp; Co. KG, Knollstrasse,
67061 Ludwigshafen, Germany</span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt;background:lightgrey'>Fournier Laboratories Ireland
Limited, Carrigtwohill Business Park, Anngrove, Carrigtwohill, Co. Cork,
 Ireland</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=FR-BE
  style='font-size:11.0pt'>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>AbbVie SA</span></p>
  <p class=MsoNormal style='line-height:13.0pt;page-break-after:avoid'><span
  lang=FR style='font-size:11.0pt'>Tl/Tel: +32 10 </span><span lang=FR
  style='font-size:11.0pt'>477811</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=LT
  style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=LV
  style='font-size:11.0pt'>AbbVie UAB </span></p>
  <p class=MsoNormal style='text-align:justify;page-break-after:avoid'><span
  lang=LV style='font-size:11.0pt'>Tel: +370 5 205 3023</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><b><span
  lang=BG style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid;text-autospace:none'><span
  lang=BG style='font-size:11.0pt'>&#1040;&#1073;&#1042;&#1080;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt;color:black'>&#1058;&#1077;&#1083;.</span><span
  lang=IT style='font-size:11.0pt;color:black'>: +359 2 90 30 430</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE
  style='font-size:11.0pt'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>AbbVie SA</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>Belgique/Belgien</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=FR
  style='font-size:11.0pt'>Tl/Tel: +32 10 477811</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>&#268;esk
  republika</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie s.r.o. </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +420 233 098
  111</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=HU style='font-size:11.0pt'>Magyarorszg</span></b></p>
  <p class=MsoNormal><span lang=HU style='font-size:11.0pt'>AbbVie Kft.</span></p>
  <p class=MsoNormal><span lang=HU style='font-size:11.0pt'>Tel.: +36 1 455
  8600</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:50.75pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.75pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +45 72
  30-20-28</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.75pt'>
  <p class=MsoNormal><b><span lang=MT style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal><span lang=FI style='font-size:11.0pt'>V.J.Salomone Pharma
  Limited </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +356
  22983201</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie Deutschland GmbH
  &amp; Co. KG</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: 00800 222843
  33 (gebhrenfrei)</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +49 (0) 611&nbsp;/&nbsp;1720-0</span></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie B.V.</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +31 (0)88 322
  2843</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>AbbVie O </span></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>Tel: +372 </span><span
  lang=EN-GB style='font-size:11.0pt'>623 1011</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NO-BOK style='font-size:11.0pt'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie AS</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +47 67 81
  80 00</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>AbbVie </span><span
  lang=EL style='font-size:11.0pt'>&#934;&#913;&#929;&#924;&#913;&#922;&#917;&#933;&#932;&#921;&#922;&#919;
  &#913;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&#932;&#951;&#955;:
  +30 </span><span lang=EN-GB style='font-size:11.0pt'>214 4165 555</span></p>
  <p class=MsoNormal><span lang=ES style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie GmbH </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +43 1 20589-0</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES style='font-size:11.0pt'>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>AbbVie Spain,
  S.L.U. </span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Tel: +34 9 1 384
  910</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>AbbVie Polska Sp. z
  o.o.</span></p>
  <p class=MsoNormal><span lang=ES style='font-size:11.0pt'>Tel.: +48 22 </span><span
  lang=PL style='font-size:11.0pt'>372 78 00 </span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:49.45pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>AbbVie</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tl: +33 (0)1 45 60
  13 00</span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span lang=PT style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>AbbVie, Lda. </span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +351 (0)21
  1908400</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:49.45pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=PT
  style='font-size:11.0pt'>Hrvatska </span></b></p>
  <p class=MsoNormal><span lang=HR style='font-size:11.0pt'>AbbVie d.o.o.</span></p>
  <p class=MsoNormal><span lang=HR style='font-size:11.0pt'>Tel: +385 (0)1 </span><span
  style='font-size:11.0pt'>5625 501</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>Romnia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>AbbVie
  S.R.L.</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>Tel: +40 21 529 30
  35</span></p>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie Limited </span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Tel: +353 (0)1
  4287900</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL style='font-size:11.0pt'>AbbVie
  Biofarmacevtska druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=SL style='font-size:11.0pt'>Tel: +386 (1)32 08
  060</span></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS style='font-size:11.0pt'>sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +354 535
  7000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK style='font-size:11.0pt'>Slovensk
  republika</span></b></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>AbbVie s.r.o.</span></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>Tel: +421 2 5050
  0777</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=PT style='font-size:
  11.0pt'>AbbVie S.r.l. </span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR style='font-size:
  11.0pt'>Tel: +39 06 928921</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie</span><span
  lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB
  style='font-size:11.0pt'>Oy</span><span lang=EN-GB style='font-size:11.0pt'> </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:11.0pt'>Puh/Tel: +358 (0)</span><span lang=EN-GB
  style='font-size:11.0pt'> 10 2411 200</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=EL
  style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=IT
  style='font-size:11.0pt'>Lifepharma (Z.A.M.) Ltd</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EL
  style='font-size:11.0pt'>&#932;&#951;&#955;: +357 22 34 74 40</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=SV
  style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=PT
  style='font-size:11.0pt'>AbbVie AB</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DA
  style='font-size:11.0pt'>Tel: +46 (0)8 684 44 600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=SV
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.35pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:44.35pt'>
  <p class=MsoNormal><b><span lang=LV style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>AbbVie SIA </span></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>Tel: +371 67605000</span></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:44.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>United Kingdom
  (Northern Ireland)</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie
  Deutschland GmbH &amp; Co. KG</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +44 (0)1628
  561090</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>This leaflet was last revised in:
{MM/YYYY}</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu.</span></p>

<p class=EMEANormal align=center style='text-align:center'><b><span lang=EN-GB>&nbsp;</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=EMEAHeadingLeaflet align=center style='margin:0in;text-align:center'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>Package leaflet:
Information for the user</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal align=center style='text-align:center'><b><span lang=EN-GB>Kaletra
100&nbsp;mg/25&nbsp;mg film&#8209;coated tablets</span></b></p>

<p class=EMEANormal align=center style='text-align:center'><span lang=EN-GB>lopinavir/ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Read all of this leaflet carefully
before you start taking this medicine because it contains important information
for you or your child.</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this leaflet. You may need to read it
again.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicine has been prescribed for you or
your child only. Do not pass it on to others. It may harm them, even if their
signs of illness are the same as yours.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side effects not listed in this
leaflet. See section 4.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>What is in this leaflet:</span></b></p>

<p class=EMEANormal><span lang=EN-GB>1. What Kaletra is and what it is
used for</span></p>

<p class=EMEANormal><span lang=EN-GB>2. What you need to know before you or
your child takes Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>3. How to take Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>4. Possible side effects</span></p>

<p class=EMEANormal><span lang=EN-GB>5. How to store Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>6. Contents of the pack and other information</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>1. What
Kaletra is and what it is used for</span></b></p>

<p class=MsoNormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor has prescribed Kaletra to help to
control your Human Immunodeficiency Virus (HIV) infection. Kaletra does this
by slowing down the spread of the infection in your body.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra is not a cure for HIV infection or AIDS.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra is used by children 2 years of age or
older, adolescents and adults who are infected with HIV, the virus which causes
AIDS. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra contains the active substances lopinavir
and ritonavir. Kaletra is an antiretroviral medicine. It belongs to a group
of medicines called protease inhibitors.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra is prescribed for use in combination
with other antiviral medicines. Your doctor will discuss with you and determine
which medicines are best for you.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>2. What
you need to know before you or your child takes Kaletra</span></b></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Do not take Kaletra</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you are allergic to lopinavir, ritonavir or
any of the other ingredients of Kaletra (see section 6); </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>if you have severe liver problems.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Do not take Kaletra with any of the following medicines:</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>astemizole or terfenadine (commonly used to
treat allergy symptoms  these medicines may be available without
prescription);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>midazolam taken orally (taken by mouth),
triazolam (used to relieve anxiety and/or trouble sleeping);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pimozide (used to treat schizophrenia);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>quetiapine (used to treat schizophrenia, bipolar
disorder and major depressive disorder);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lurasidone (used to treat depression);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ranolazine (used to treat chronic chest pain
[angina]);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>cisapride (used to relieve certain stomach
problems);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ergotamine, dihydroergotamine, ergonovine,
methylergonovine (used to treat headaches);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amiodarone, dronedarone (used to treat abnormal
heart beat);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lovastatin, simvastatin (used to lower blood
cholesterol);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lomitapide (used to lower blood cholesterol);</span></p>

<p class=EMEABullet style='margin-left:30.0pt;text-indent:-30.0pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>alfuzosin (used in men to treat symptoms of an
enlarged prostate (benign prostatic hyperplasia (BPH));</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fusidic acid (used to treat skin infections
caused by <i>Staphylococcus</i> bacteria such as impetigo and infected
dermatitis). Fusidic acid used to treat long-term infections of the bones and
joints may be taken under doctors supervision (see <b>Other medicines and
Kaletra</b> section);</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>colchicine (used to treat gout) if you have
kidney and/or liver problems (see the section on <b>Other medicines and Kaletra</b>);</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>elbasvir/grazoprevir (used to treat chronic
hepatitis C virus [HCV]);</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>ombitasvir/paritaprevir/ritonavir with or
without dasabuvir (used to treat chronic hepatitis C virus [HCV]);</span></p>

<p class=EMEABullet style='margin-left:30.05pt;text-indent:-30.05pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>neratinib (used to treat breast cancer);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>avanafil or vardenafil (used to treat erectile
dysfunction);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sildenafil used to treat pulmonary arterial
hypertension (high blood pressure in the pulmonary artery). Sildenafil used to
treat erectile dysfunction may be taken under doctors supervision (see <b>Other
medicines and Kaletra</b> section);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>products that contain St Johns wort (<i>Hypericum
perforatum</i>).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Read the list of medicines below under
Other medicines and Kaletra </span></b><span lang=EN-GB>for information on
certain other medicines which require special care.</span></p>

<p class=EMEANormal style='margin-left:30.0pt;text-indent:-30.0pt'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB>If you are currently taking any of these
medicines, ask your doctor about making necessary changes either in the treatment
for your other condition(s) or in your antiretroviral treatment. </span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Warnings and precautions</span></b></p>

<p class=EMEANormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=EMEANormal><span lang=EN-GB>Talk to your doctor or pharmacist before
taking Kaletra.</span></p>

<p class=EMEANormal><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEANormal><b><span lang=EN-GB>Important information</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>People taking Kaletra may still develop
infections or other illnesses associated with HIV disease and AIDS. It is
therefore important that you remain under the supervision of your doctor while
taking Kaletra. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>You can still pass on HIV when taking this medicine</span></b><span
lang=EN-GB>, although the risk is lowered by effective antiretroviral therapy.
Discuss with your doctor the precautions needed to avoid infecting other people.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-weight:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tell your doctor if you or your
child have/had</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Haemophilia</span></b><span lang=EN-GB> type
A and B as Kaletra might increase the risk of bleeding.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Diabetes</span></b><span lang=EN-GB> as
increased blood sugars has been reported in patients receiving Kaletra.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>A history of <b>liver problems</b> as patients
with a history of liver disease, including chronic hepatitis B or C are at
increased risk of severe and potentially fatal liver side effects.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><u><span lang=EN-GB
style='font-family:"Times New Roman",serif;font-weight:normal'><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Tell your doctor if you or your
child experience</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, vomiting, abdominal pain, difficulty
breathing and severe weakness of the muscles in the legs and arms as these
symptoms may indicate raised lactic acid levels.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Thirst, frequent urination, blurred vision or
weight loss as this may indicate raised sugar levels in the blood.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Nausea, vomiting, abdominal pain as large
increases in the amount of triglycerides (fats in the blood) have been
considered a risk factor for pancreatitis (inflammation of the pancreas) and
these symptoms may suggest this condition.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In some patients with advanced HIV infection and
a history of opportunistic infection, signs and symptoms of inflammation from
previous infections may occur soon after anti-HIV treatment is started. It is
believed that these symptoms are due to an improvement in the bodys immune response,
enabling the body to fight infections that may have been present with no
obvious symptoms. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>In addition to the opportunistic infections,
autoimmune disorders (a condition that occurs when the immune system attacks
healthy body tissue) may also occur after you start taking medicines for the treatment
of your HIV infection. Autoimmune disorders may occur many months after the
start of treatment. If you notice any symptoms of infection or other symptoms
such as muscle weakness, weakness beginning in the hands and feet and moving up
towards the trunk of the body, palpitations, tremor or hyperactivity, please
inform your doctor immediately to seek necessary treatment.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Joint stiffness, aches and pains </span></b><span
lang=EN-GB>(especially of the hip, knee and shoulder) and difficulty in
movement<b> </b>as some patients taking these medicines may develop a bone
disease called osteonecrosis (death of bone tissue caused by loss of blood
supply to the bone). The length of combination</span><span lang=EN-GB>
antiretroviral therapy, corticosteroid use, alcohol consumption, severe
immunosuppression (reduction in the activity of the immune system), higher body
mass index, among others, may be some of the many risk factors for developing
this disease. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Muscle pain, </span></b><span lang=EN-GB>tenderness
or weakness, particularly in combination with these medicines. On rare
occasions these muscle disorders have been serious. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Symptoms of dizziness, lightheadedness, fainting
or sensation of abnormal heartbeats. Kaletra may cause changes in your heart
rhythm and the electrical activity of your heart. These changes may be seen on
an ECG (electrocardiogram).</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Other medicines and Kaletra</span></p>

<p class=EMEANormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=EMEANormal><b><span lang=EN-GB>Tell your doctor or pharmacist if you or
your child are taking, have recently taken or might take any other medicines. </span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antibiotics (e.g.&nbsp;rifabutin, rifampicin,
clarithromycin);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticancer medicines (e.g. abemaciclib, afatinib,
apalutamide, </span>ceritinib<span lang=EN-GB>, encorafenib, ibrutinib, venetoclax,
most tyrosine kinases inhibitors such as dasatinib and nilotinib, also
vincristine and vinblastine);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anticoagulants (e.g. warfarin, rivaroxaban,
vorapaxar);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antidepressants (e.g. trazodone, bupropion);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti-epilepsy medicines (e.g. carbamazepine,
phenytoin, phenobarbital, lamotrigine and valproate);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>antifungals (e.g.&nbsp;ketoconazole, itraconazole,
voriconazole);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti&#8209;gout medicines (e.g. colchicine).
You must not take Kaletra with colchicine if you have kidney and/or liver
problems (see also <b>Do not take Kaletra</b> above);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>anti&#8209;tuberculosis medicine (bedaquiline,
delamanid);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antiviral medicine used to treat chronic
hepatitis C virus (HCV) infection in adults (e.g. glecaprevir/pibrentasvir, simeprevir
and sofosbuvir/velpatasvir/voxilaprevir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>erectile dysfunction medicines (e.g. sildenafil
and tadalafil);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fusidic acid used to treat long-term infections
of the bones and joints (e.g. osteomyelitis);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>heart medicines including:</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>digoxin;</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>calcium channel antagonists (e.g. felodipine,
nifedipine, nicardipine);</span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to correct heart rhythm
(e.g.&nbsp;bepridil, systemic lidocaine, quinidine);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>HIV CCR5-antagonist (e.g. maraviroc);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>HIV-1 integrase inhibitor (e.g. raltegravir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=PT-BR>medicines used to treat low blood platelet count
(e.g. fostamatinib);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>levothyroxine (used to treat thyroid problems);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to lower blood cholesterol (e.g.
atorvastatin, lovastatin, rosuvastatin or simvastatin); </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat asthma and other
lung-related problems such as chronic obstructive pulmonary disease (COPD)
(e.g. salmeterol);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used to treat pulmonary </span>arterial
hypertension (high blood pressure in the pulmonary artery) <span lang=EN-GB>(e.g.
bosentan, riociguat, sildenafil, tadalafil);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines affecting the immune system (e.g.
cyclosporin, sirolimus (rapamycin), tacrolimus);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>medicines used for smoking cessation (e.g.
bupropion);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pain-relieving medicines (e.g. fentanyl);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>morphine-like medicines (e.g. methadone);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>non-nucleoside reverse transcriptase inhibitors
(NNRTIs) (e.g. efavirenz, nevirapine);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>oral contraceptive or using a patch
contraceptive to prevent pregnancy (see section below titled <b>Contraceptives</b>);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=FR style='font-family:
Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=FR>protease inhibitors (e.g. fosamprenavir, indinavir,
ritonavir, saquinavir, tipranavir);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>sedatives (e.g. midazolam administered by
injection);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>steroids (e.g.&nbsp;budesonide, dexamethasone,
fluticasone propionate, ethinyl oestradiol, triamcinolone).</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Read the list of medicines above Do not take Kaletra with any of
the following medicines</span></b><span lang=EN-GB> for information on
medicines that you must not take with Kaletra.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>Tell your doctor or pharmacist if you or
your child are taking, have recently taken or might take any other medicines,
including medicines obtained without prescription.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Erectile dysfunction medicines (</span></b><b><span lang=EN-GB>avanafil</span></b><span
lang=EN-GB>,<b> vardenafil, sildenafil, tadalafil)</b></span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not take Kaletra</span></b><span
lang=EN-GB> if you are currently taking avanafil or vardenafil.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>You must not take Kaletra with sildenafil used
to treat pulmonary arterial hypertension </span>(high blood pressure in the
pulmonary artery) <span lang=EN-GB>(see also <b>Do not take Kaletra</b> section
above).</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you take sildenafil or tadalafil and Kaletra
together, you may be at risk of side effects such as low blood pressure,
passing out, visual changes and penile erection lasting more than 4 hours. If
an erection lasts longer than 4 hours, you should get medical help <b>immediately</b>
to avoid permanent damage to your penis. Your doctor can explain these
symptoms to you.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Contraceptives</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are currently using an oral contraceptive
or using a patch contraceptive to prevent pregnancy, you should use an additional
or different type of contraception (e.g. condom) as Kaletra may reduce the
effectiveness of oral and patch contraceptives.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra does not reduce the risk of passing HIV
to others. Appropriate precautions (e.g. use of a condom) should be taken to
prevent passing on the disease through sexual contact.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Pregnancy and breast-feeding</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Tell your doctor <b>immediately</b> if you are
planning to have a baby, you are pregnant, think you may be pregnant or if you
are breast-feeding. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Breast-feeding mothers should not take Kaletra
unless specifically directed by the doctor. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>It is recommended that HIV-infected women do not
breast-feed their infants because there is a possibility that the baby can be
infected with HIV through your breast milk.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>Driving or using machines</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
has not specifically been tested for its possible effects on the ability to
drive a car or operate machines. Do not drive a car or operate machinery if
you experience any side effects (e.g. nausea) that impact your ability to do so
safely. Instead, contact your doctor.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>3. How to take Kaletra</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt;
background:#D9D9D9'>

<p class=EMEABullet align=center style='margin-left:0in;text-align:center;
text-indent:0in;page-break-after:avoid;background:#D9D9D9;border:none;
padding:0in'><span lang=EN-GB style='color:black'>It is important that Kaletra
tablets are swallowed whole and not chewed, broken or crushed.</span></p>

</div>

<p class=EMEABullet style='margin-left:0in;text-indent:0in;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Always
take this medicine exactly as your doctor has told you. Check with your doctor
or pharmacist if you are not sure how you should take your medicine.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in;page-break-after:avoid'><span
lang=EN-GB style='font-family:"Times New Roman",serif'>How much Kaletra should
be taken and when?</span></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Use in
adults</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The usual adult dose is 400&nbsp;mg/100&nbsp;mg
twice a day i.e. every 12 hours, in combination with other anti-HIV medicines.
Adult patients who have not previously taken other antiviral medicines can also
take Kaletra tablets once daily as an 800&nbsp;mg/200&nbsp;mg dose. Your
doctor will advise on the number of tablets to be taken. Adult patients who
have previously taken other antiviral medicines can take Kaletra tablets once
daily as an 800&nbsp;mg/200&nbsp;mg dose if their doctor decides it is
appropriate. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra must not be taken once daily with
efavirenz, nevirapine, carbamazepine, phenobarbital and phenytoin.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra tablets can be taken with or without
food.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><b><span
lang=EN-GB>Use in children of 2 years of age and above</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>For children, your doctor will decide the right
dose (number of tablets) based on the childs height and weight. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra tablets can be taken with or without
food.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
is also supplied as 200&nbsp;mg/50&nbsp;mg film-coated tablets. Kaletra oral
solution is available for patients who cannot take tablets.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child take more
Kaletra than you should</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you realise you have taken more Kaletra than
you were supposed to, contact your doctor right away. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you cannot contact your doctor, go to the
hospital.</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child forget to take
Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><i><u>If you are taking
Kaletra twice a day</u></i></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose within 6 hours of your normal
dosing time, take your missed dose as soon as possible, and then continue with
your normal dose at the regular time as prescribed by your doctor.</p>

<p class=EMEABullet style='margin-left:28.35pt'>&nbsp;</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose by more than 6 hours after your
normal dosing time, do not take the missed dose. Take the next dose as usual.
Do not take a double dose to make up for a forgotten dose.</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'>&nbsp;</p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><i><u>If you are
taking Kaletra once a day</u></i></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose within 12 hours of your normal
dosing time, take your missed dose as soon as possible, and then continue with
your normal dose at the regular time as prescribed by your doctor.</p>

<p class=EMEABullet style='margin-left:28.35pt'>&nbsp;</p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'>-<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>If you notice you miss a dose by more than 12 hours after your
normal dosing time, do not take the missed dose. Take the next dose as usual.
Do not take a double dose to make up for a forgotten dose.</p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeadingLeaflet style='margin:0in'><span lang=EN-GB
style='font-family:"Times New Roman",serif'>If you or your child stop taking
Kaletra</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not stop or change the daily dose of Kaletra
without first consulting with your doctor.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kaletra should always be taken every day to help
control your HIV infection, no matter how much better you feel. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Taking Kaletra as recommended should give you
the best chance of delaying the development of resistance to the product.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If a side effect is preventing you from taking
Kaletra as directed tell your doctor right away. </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Always keep enough Kaletra on hand so you dont
run out. When you travel or need to stay in the hospital make sure you will
have enough Kaletra to last until you can get a new supply.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Continue to take this medicine until your doctor
tells you otherwise.</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>4. Possible side effects</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>Like all
medicines, Kaletra can cause side effects, although not everybody gets them.
It may be difficult to tell which side effects have been caused by Kaletra and
which may occur due to other medicines you take at the same time or by the
complications of the HIV infection. </span></p>

<p class=EMEANormal style='page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>During HIV therapy there may be an
increase in weight and in levels of blood lipids and glucose. This is partly
linked to restored health and life style, and in the case of blood lipids
sometimes to the HIV medicines themselves. Your doctor will test for these
changes.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>The
following side effects have been reported by patients who took this medicine.</span></b><span
lang=EN-GB> You should tell your doctor promptly about these or any other
symptoms. If the condition persists or worsens, seek medical attention.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Very common:</span></b><span
lang=EN-GB> may affect more than 1 in 10 people</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>diarrhoea; </span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>nausea;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>upper respiratory tract infection.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Common:</span></b><span lang=EN-GB> may
affect up to 1 in 10 people</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the pancreas;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span style='font-family:Symbol'><span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vomiting, enlarged abdomen, pain in the lower
and upper stomach area, passing wind, indigestion, decreased appetite, reflux
from your stomach to your oesophagus which may cause pain;</span><span
lang=EN-GB> </span></p>

<p class=EMEABullet style='margin-left:56.7pt'><span lang=EN-GB
style='font-family:Symbol'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Tell your doctor</span></b><span lang=EN-GB>
if you experience nausea, vomiting or abdominal pain as these may be suggestive
of pancreatitis (inflammation of the pancreas).</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>swelling or inflammation of the stomach,
intestines and colon;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased cholesterol levels in your blood,
increased triglycerides (a form of fat) levels in your blood, high blood
pressure;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased ability of the body to handle sugar
including diabetes mellitus, weight loss;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>low number of red blood cells, low number of
white blood cells which are usually used to fight infection;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>rash, eczema, accumulation of scales of greasy
skin;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dizziness, anxiety, difficulty in sleeping;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>feeling tired, lack of strength and energy,
headache including migraine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>haemorrhoids;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the liver including increased
liver enzymes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>allergic reactions including hives and
inflammation in the mouth;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lower respiratory tract infection;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>enlargement of the lymph nodes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>impotence, abnormally heavy or extended
menstrual flow or a lack of menstruation;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>muscle disorders such as weakness and spasms,
pain in the joints, muscles and back;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>damage to nerves of the peripheral nervous
system;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>night sweats, itching, rash including raised
bumps on the skin, infection of the skin, inflammation of skin or hair pores,
accumulation of fluid in the cells or tissues. </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal style='page-break-after:avoid'><b><span lang=EN-GB>Uncommon:</span></b><span
lang=EN-GB> may affect up to 1 in 100 people </span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal dreams;</span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>loss or changed sense of taste;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>hair loss;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an abnormality in your electrocardiogram (ECG) called
atrioventricular block;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>plaque building up inside your arteries which
could lead to heart attack and stroke;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of blood vessels and capillaries;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the bile duct;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>uncontrolled shaking of the body;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>constipation;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>deep vein inflammation related to a blood clot;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>dry mouth;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inability to control your bowels;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the first section of the small
intestine just after the stomach, wound or ulcer in the digestive tract,
bleeding from the intestinal tract or rectum;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>red blood cells in the urine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>yellowing of the skin or whites of eyes (jaundice);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fatty deposits in the liver, enlarged liver;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lack of functioning of the testes;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a flare-up of symptoms related to an inactive infection
in your body (immune reconstitution);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>increased appetite;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormally high level of bilirubin (a pigment
produced from the breakdown of red blood cells) in the blood</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decreased sexual desire;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>inflammation of the kidney;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>bone death caused by poor blood supply to the
area;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>mouth sores or ulcerations, inflammation of the
stomach and intestine;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney failure;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>breakdown of muscle fibres resulting in the
release of muscle fibre contents (myoglobin) into the bloodstream;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>a sound in one ear or both ears, such as
buzzing, ringing or whistling;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>tremor;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>abnormal closure of one of the valves (tricuspid
valve in your heart);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vertigo (spinning feeling);</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>eye disorder, abnormal vision;</span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>weight gain.</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Rare</span></b><span lang=EN-GB>: may
affect up to 1 in 1,000 people</span></p>

<p class=EMEANormal style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>severe or life&#8209;threatening skin rashes and
blisters (Stevens-Johnson syndrome and erythema multiforme).</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Not known: </span></b><span
lang=EN-GB style='font-size:11.0pt'>frequency<b> </b><span style='color:black'>cannot
be estimated from the available data</span></span></p>

<p class=EMEABullet style='margin-left:28.35pt'><span lang=EN-GB
style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>kidney stones.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>If any of the side effects gets serious,
or if you notice any side effects not listed in this leaflet, please inform
your doctor or pharmacist.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Reporting of side effects</span></b></p>

<p class=EMEANormal><b><u><span lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></b></p>

<p class=EMEANormal><span lang=EN-GB>If you get any side effects, talk to your
doctor or pharmacist. This includes any possible side effects not listed in
this leaflet. You can also report side effects directly via <span
style='background:lightgrey'>the national reporting system listed in </span></span><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
lang=EN-GB style='background:lightgrey'>Appendix V</span></a><span lang=EN-GB>.
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>5. How to store Kaletra</span></b></p>

<p class=MsoNormal style='page-break-after:avoid'><b><span lang=EN-GB
style='font-size:11.0pt'>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Keep this medicine out of the sight and reach of
children.</span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use Kaletra after the expiry date which
is stated on the pack.</span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>This medicinal product does not require any
special storage conditions.<b> </b></span></p>

<p class=EMEABullet style='margin-left:28.35pt;page-break-after:avoid'><span
lang=EN-GB style='font-family:Symbol'><span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not use this medicine if you notice any discolouration.</span></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>How should I dispose of any unused Kaletra?</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Do
not throw away any medicines via wastewater. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the
environment.</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>6. Contents
of the pack and other information</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>What Kaletra contains</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB>The active substances are lopinavir and
ritonavir.</span></p>

<p class=EMEANormal><span lang=EN-GB>Each tablet of Kaletra contains
100&nbsp;mg of lopinavir and 25&nbsp;mg of ritonavir</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>The other ingredients are: </span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Tablet</span></b></p>

<p class=EMEANormal><span lang=EN-GB>Colloidal anhydrous silica, copovidone,
sodium stearyl fumarate, sorbitan laurate<span style='layout-grid-mode:line'>. </span></span></p>

<p class=EMEANormal><b><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB style='layout-grid-mode:line'>Tablet coating</span></b></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>Polyvinyl
alcohol, talc, titanium dioxide, macrogols type 3350, red ferric oxide E172.</span></p>

<p class=EMEANormal><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB style='layout-grid-mode:line'>What
Kaletra looks like and contents of the pack</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></b></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
film-coated tablets are pale pink debossed with [Abbott logo] and AC. </span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEABullet style='margin-left:0in;text-indent:0in'><span lang=EN-GB>Kaletra
100&nbsp;mg/25&nbsp;mg film-coated tablets are supplied in plastic bottles containing
60 tablets. </span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span lang=EN-GB>Marketing
Authorisation Holder</span><span lang=EN-GB style='font-weight:normal'>: </span></p>

<p class=EMEAHeading2SPC style='margin:0in'><span style='font-family:"Times New Roman",serif;
font-weight:normal'>AbbVie Deutschland GmbH &amp; Co. KG, Knollstrasse, 67061
Ludwigshafen, Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>Manufacturer</span></b><span
lang=EN-GB>:  </span></p>

<p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
style='font-size:11.0pt'>AbbVie Deutschland GmbH &amp; Co. KG, Knollstrasse,
67061 Ludwigshafen, Germany</span></p>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><span lang=EN-GB>For any information about this medicine,
please contact the local representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=FR-BE style='font-size:11.0pt'>Belgi/Belgique/Belgien</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>AbbVie SA</span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR style='font-size:
  11.0pt'>Tl/Tel: +32 10 </span><span lang=FR style='font-size:11.0pt'>477811</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=LT style='font-size:11.0pt'>Lietuva</span></b></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>AbbVie UAB </span></p>
  <p class=MsoNormal style='text-align:justify'><span lang=LV style='font-size:
  11.0pt'>Tel: +370 5 205 3023</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=BG
  style='font-size:11.0pt'>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=BG
  style='font-size:11.0pt'>&#1040;&#1073;&#1042;&#1080;
  &#1045;&#1054;&#1054;&#1044;</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>&#1058;&#1077;&#1083;.</span><span
  lang=IT style='font-size:11.0pt;color:black'>: +359 2 90 30 430</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie SA</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Belgique/Belgien</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tl/Tel: +32 10
  477811</span></p>
  <p class=MsoNormal><span lang=HU style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=DE
  style='font-size:11.0pt'>&#268;esk republika</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>AbbVie s.r.o. </span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>Tel: +420 233 098 111</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=DE
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='page-break-after:avoid'><b><span lang=HU
  style='font-size:11.0pt'>Magyarorszg</span></b></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU
  style='font-size:11.0pt'>AbbVie Kft.</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=HU
  style='font-size:11.0pt'>Tel.: +36 1 455 8600</span></p>
  <p class=MsoNormal style='page-break-after:avoid'><span lang=EN-GB
  style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:50.75pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.75pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Danmark</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie A/S</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +45 72
  30-20-28</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.75pt'>
  <p class=MsoNormal><b><span lang=MT style='font-size:11.0pt'>Malta</span></b></p>
  <p class=MsoNormal><span lang=FI style='font-size:11.0pt'>V.J.Salomone Pharma
  Limited </span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +356
  22983201</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>Deutschland</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie Deutschland GmbH
  &amp; Co. KG</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: 00800 222843
  33 (gebhrenfrei)</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +49 (0)
  611&nbsp;/&nbsp;1720-0</span></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NL style='font-size:11.0pt'>Nederland</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie B.V.</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +31 (0)88 322
  2843</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ET style='font-size:11.0pt'>Eesti</span></b></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>AbbVie O </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=ET
  style='font-size:11.0pt'>Tel: +372 </span><span lang=EN-GB style='font-size:
  11.0pt'>623 1011</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=NO-BOK style='font-size:11.0pt'>Norge</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie AS</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tlf: +47 67 81
  80 00</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL style='font-size:11.0pt'>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal><span lang=ET style='font-size:11.0pt'>AbbVie </span><span
  lang=EL style='font-size:11.0pt'>&#934;&#913;&#929;&#924;&#913;&#922;&#917;&#933;&#932;&#921;&#922;&#919;
  &#913;.&#917;.</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&#932;&#951;&#955;:
  +30 </span><span lang=EN-GB style='font-size:11.0pt'>214 4165 555</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=DE style='font-size:11.0pt'>sterreich</span></b></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>AbbVie GmbH </span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>Tel: +43 1 20589-0</span></p>
  <p class=MsoNormal><span lang=DE style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=ES style='font-size:11.0pt'>Espaa</span></b></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>AbbVie Spain,
  S.L.U. </span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Tel: +34 9 1 384
  910</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=PL style='font-size:11.0pt'>Polska</span></b></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>AbbVie Polska Sp. z
  o.o.</span></p>
  <p class=MsoNormal><span lang=ES style='font-size:11.0pt'>Tel.: +48 22 </span><span
  lang=PL style='font-size:11.0pt'>372 78 00 </span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:49.45pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span lang=FR style='font-size:11.0pt'>France</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>AbbVie</span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tl: +33 (0)1 45 60
  13 00</span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span lang=PT style='font-size:11.0pt'>Portugal</span></b></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>AbbVie, Lda. </span></p>
  <p class=MsoNormal><span lang=FR style='font-size:11.0pt'>Tel: +351 (0)21
  1908400</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:49.45pt'>
  <td width=312 colspan=2 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal style='text-autospace:none'><b><span lang=PT
  style='font-size:11.0pt'>Hrvatska </span></b></p>
  <p class=MsoNormal><span lang=HR style='font-size:11.0pt'>AbbVie d.o.o.</span></p>
  <p class=MsoNormal><span lang=HR style='font-size:11.0pt'>Tel: +385 (0)1 </span><span
  style='font-size:11.0pt'>5625 501</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:49.45pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>Romnia</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt;color:black'>AbbVie
  S.R.L.</span></p>
  <p class=MsoNormal><span lang=PL style='font-size:11.0pt'>Tel: +40 21 529 30
  35</span></p>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>Ireland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie Limited </span></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>Tel: +353 (0)1
  4287900</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SL style='font-size:11.0pt'>Slovenija</span></b></p>
  <p class=MsoNormal><span lang=SL style='font-size:11.0pt'>AbbVie
  Biofarmacevtska druba d.o.o.</span></p>
  <p class=MsoNormal><span lang=SL style='font-size:11.0pt'>Tel: +386 (1)32 08
  060</span></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IS style='font-size:11.0pt'>sland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Vistor hf.</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +354 535
  7000</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SK style='font-size:11.0pt'>Slovensk
  republika</span></b></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>AbbVie s.r.o.</span></p>
  <p class=MsoNormal><span lang=SK style='font-size:11.0pt'>Tel: +421 2 5050
  0777</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=IT style='font-size:11.0pt'>Italia</span></b></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=PT style='font-size:
  11.0pt'>AbbVie S.r.l. </span></p>
  <p class=MsoNormal style='line-height:13.0pt'><span lang=FR style='font-size:
  11.0pt'>Tel: +39 06 928921</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span style='font-size:11.0pt'>Suomi/Finland</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie</span><span
  lang=EN-GB style='font-size:11.0pt'> </span><span lang=EN-GB
  style='font-size:11.0pt'>Oy</span><span lang=EN-GB style='font-size:11.0pt'> </span></p>
  <p class=MsoNormal style='text-autospace:none'><span lang=EN-GB
  style='font-size:11.0pt'>Puh/Tel: +358 (0)</span><span lang=EN-GB
  style='font-size:11.0pt'> 10 2411 200</span></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=EL style='font-size:11.0pt'>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal><span lang=IT style='font-size:11.0pt'>Lifepharma (Z.A.M.)
  Ltd</span></p>
  <p class=MsoNormal><span lang=EL style='font-size:11.0pt'>&#932;&#951;&#955;:
  +357 22 34 74 40</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal><b><span lang=SV style='font-size:11.0pt'>Sverige</span></b></p>
  <p class=MsoNormal><span lang=PT style='font-size:11.0pt'>AbbVie AB</span></p>
  <p class=MsoNormal><span lang=DA style='font-size:11.0pt'>Tel: +46 (0)8 684
  44 600</span></p>
  <p class=MsoNormal><span lang=SV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:44.35pt'>
  <td style='border:none;padding:0in 0in 0in 0in' width=2><p class='MsoNormal'>&nbsp;</td>
  <td width=310 valign=top style='width:232.2pt;padding:0in 5.4pt 0in 5.4pt;
  height:44.35pt'>
  <p class=MsoNormal><b><span lang=LV style='font-size:11.0pt'>Latvija</span></b></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>AbbVie SIA </span></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>Tel: +371 67605000</span></p>
  <p class=MsoNormal><span lang=LV style='font-size:11.0pt'>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt;
  height:44.35pt'>
  <p class=MsoNormal><b><span lang=EN-GB style='font-size:11.0pt'>United
  Kingdom (Northern Ireland)</span></b></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>AbbVie
  Deutschland GmbH &amp; Co. KG</span></p>
  <p class=MsoNormal><span lang=EN-GB style='font-size:11.0pt'>Tel: +44 (0)1628
  561090</span></p>
  </td>
 </tr>
 <tr height=0>
  <td width=2 style='border:none'></td>
  <td width=310 style='border:none'></td>
  <td width=312 style='border:none'></td>
 </tr>
</table>

<p class=EMEANormal><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEANormal><b><span lang=EN-GB>This leaflet was last revised in:
{MM/YYYY}</span></b></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=EMEANormal><span lang=EN-GB>Detailed information on this medicine is
available on the European Medicines Agency web site: http://www.ema.europa.eu.</span></p>

<p class=EMEANormal><b><span lang=EN-GB>&nbsp;</span></b></p>

</div>

</body>

</html>
